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Summary
This thesis is concerned with two different aspects of human embryonic stem cell 
research: legal and moral. These are not two distinct areas; the law cannot regulate this 
controversial area of science without the input of morality. There is not one moral 
viewpoint on the use of human embryos in scientific research and as such this thesis 
discusses several different moral viewpoints before moving on to consider how the law 
takes into account these wide ranging and diverse stances. The science of human 
embryonic stem cell research is discussed briefly so as to ensure that the reader 
comprehends the science that the law is seeking to regulate and over which there is so 
much ethical debate.
The majority of this thesis then considers the legal aspects of human embryonic stem cell 
research. The focus is upon the human embryo and human embryonic stem cell interface; 
how the legislation which governs human embryo research has been used to subsequently 
regulate human embryonic stem cell research. The examination of the legal aspects of 
human embryonic stem cell research starts with a historical chapter on how the legislation 
came into force. This is necessary so as to understand how and why we regulate human 
embryonic stem cell research as we do and what the legislation does, before moving onto 
the finer detail. The role of research ethics committees, the HFEA and the UK Stem Cell 
Bank in human embryonic stem cell research are all analysed in depth, problem areas 
highlighted and solutions suggested. An analytical discussion of the reform process 
which led to the Human Fertilisation and Embryology Act 2008 is the last step in the 
examination of the regulation of human embryonic stem cell research. Finally 
comparisons are made to the State of California, USA which was the first US state to 
permissively fund stem cell research.
The law stated is correct as of the 13th November 2008 when the Human Fertilisation and 
Embryology Act 2008 received Royal Assent.
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2001 Regulations -  Human Fertilisation and Embryology (research purposes) 
Regulations 2001 SI2001/188
Artificial gametes -  also known as in vitro derived gametes or pluripotent stem cell 
derived gametes. These are stem cells which have differentiated into gametes
Blastocyst -  Early human embryo
BBSRC - Biotechnology and Biological Sciences Research Council 
BMA -  British Medical Association
CIRM -  The California Institute for Regenerative Medicine (U.S. State funding body)
Clinical Trials Regulations - Medicines fo r  Human Use (Clinical Trials) Regulations 
2004
CNR -  Cell Nuclear Replacement, also known as SCNT and therapeutic cloning. The 
nucleus of a somatic cell is combined with an enucleated oocyte
Commons Amendments -  Human Fertilisation and Embryology Bill [HL] HL Bill 83, 
54/3
COREC -  Central Office for NHS Research Ethics Committees
Donaldson Report - Stem Cell Research: Medical Progress with Responsibility. A Report 
from  the Chief Medical Officer's Expert Group Reviewing the Potential o f  Developments 
in Stem Cell Research and Cell Nuclear Replacement to Benefit Human Health (2000) 
Department of Health
Draft Bill - Human Tissue and Embryos (Draft) Bill CM7087 Department of Health 
(2007)
Embryo -  product of a fertilised egg (either with sperm or by cell nuclear replacement) 
Enucleated oocyte -  an egg which has had its nucleus removed
EU Tissue and Cells Directive -  Directive 2004/23/EC o f the European Parliament and 
o f the Council o f  31 March 2004 on setting standards o f  quality and safety fo r  the 
donation, procurement, testing, processing, preservation, storage and distribution o f  
human tissue and cells [2004] OJ LI 02/48
EU Directive - EU Directive 2001/20/EC o f the European Parliament and the Council o f  
4 April 2001 on the approximation o f the laws, regulations and administrative provisions 
o f the Member States relating to the implementation o f  good clinical practice on the 
conduct o f  clinical trials on medicinal products fo r human use L121/34 OJEC
Extra-embryonic cells -  the cells which make up the trophoblast and the placenta
February Bill - Human Fertilisation and Embryology Bill [HL] HL Bill 70, 54/3
Fertilisation -  the fusion of egg and sperm to produce a blastocyst
GAfREC -  Governance Arrangements for NHS Research Ethics Committees
Gametes -  eggs and sperm
GIFT -  gamete intra-fallopian transfer
hESC -  human embryonic stem cell
HFEA -  The Human Fertilisation and Embryology Authority 
HFE Act -  The Human Fertilisation and Embryology Act 1990 
HFE Act 2008 — The Human Fertilisation and Embryology Act 2008 
HGAC -  Human Genetics Advisory Commission 
HTA -  The Human Tissue Authority 
HT Act -  The Human Tissue Act 2004
Human reproductive cloning -  the aim is the creation of a whole person through the use 
of the CNR technique and implanting the resulting embryo into a uterus, done to satisfy 
the reproductive desires of another person
Human therapeutic cloning -  creation of an embryo by the CNR technique for 
research/therapeutic purposes only
ICOC -  Independent Citizen’s Oversight Committee. Governing body of the CIRM (U.S. 
body)
ICSC -  Intra-cytoplasmic sperm injection
IPS Cells — induced pluripotent stem cells. Somatic cells are encouraged to differentiate 
into a stem cell like state
In vitro -  outside of the body
In vivo -  within the body
ii
In vitro derived gametes -  see artificial gametes 
IUI -  Intra-uterine insemination 
IVF -  In vitro fertilisation 
IVM -  in vitro maturation
January Bill -  Human Fertilisation and Embryology Bill [HL] HL Bill 25, 54/3
June Bill - Human Fertilisation and Embryology Bill [HL] HL Bill 120, 54/3
LREC - Local research ethics committee
MRC -  Medical Research Council
MREC -  Multi-centre research ethics committee
Multipotent -  capable of differentiating into limited cell types
New Bill - Human Fertilisation and Embryology Bill [HL] HL Bill 6, 54/3
NHS -  National Health Service
NIBSC - National Institute for Biological Standards and Control 
NIH -  The National Institute for Health (US body)
NPSA -  National Patient Safety Agency 
NREA -  National Research Ethics Adviser 
NRES -  National Research Ethics Service 
Oocyte -  human egg, female gamete
Parthenogenesis -  reproduction without the use of sperm, eggs divide and develop 
without the introduction o f sperm
Pluripotent -  capable of differentiating into almost any cell type, with the exception of 
the extra-embryonic cells
Primitive streak -  Normally occurs around the fourteenth day of development after 
creation of an embryo. The formation of the primitive streak signifies a unique genetic 
individual as it is the start of the spine and brain
Proposition 71 -  California Stem Cell Research and Cures Bond Act. Californian 
legislation authorising State funds to be spent on human stem cell research (US 
legislation)
RAFT -  Regulatory Authority for Fertility and Tissues 
RATE -  Regulatory Authority for Tissues and Embryos 
REC -  Research Ethics Committee
RCOG -  Royal College of Obstetricians and Gynaecologists
SCRO committee -  Stem Cell Research Oversight committee (US body)
SCNT -  Somatic Cell Nuclear Transfer. See CNR above
Somatic Cell -  adult cells, any cell that contains the full chromosome content
Sperm -  male gamete
Stem cell -  a cell capable of self-renewal and differentiation into another cell type
Stem cell line -  a collection o f stem cells which are self-renewing and genetically 
identical
Totipotent -  capable of differentiating into all cell types including extra-embryonic cells
Wamock Report -  Report o f  the Committee o f  Inquiry into Human Fertilisation and 
Embryology (1984) DHSS Cmnd 9314
UKECA -  United Kingdom Ethics Committee Authority
UKNSCN -  The UK National Stem Cell Network
UK Stem Cell Bank -  the body which stores and distributes human stem cell lines
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Introduction
Stem cell research is undoubtedly going to increase our knowledge about basic cell 
biology considerably, but this is not the benefit o f stem cell research that excites most 
people. The really exciting thing about stem cell research is in the therapeutic potential
o f stem cells.1
Embryonic stem cell research is perhaps the most controversial ethical issue o f  the new 
century. This is not surprising. It promises unprecedented potential benefits to human 
health but arguably comes at the expense o f violating the most fundamental moral virtue
-  the right to life.2
As can be seen from the above quotes human embryonic stem cell research is an area of 
science which could potentially revolutionise healthcare, but equally it is an area of 
science which raises complex ethical questions, ones which it is highly problematic if  not 
impossible to reach agreement upon. It is also an area of science for which it is difficult 
for the law to regulate.
Science
Adult stem cell research and therapies have been in existence for several decades, 
the most commonly known adult stem cell therapy being bone marrow transplants. 
However, human embryonic stem cell research is a relatively new area of research, albeit 
one which has grabbed the attention of scientists, the media and the public alike.
The science of human embryonic stem cell research has progressed at a 
phenomenal rate since 1981 when mouse embryonic stem cells were first isolated by Sir 
Professor Martin Evans working at Cambridge University and for which he was recently 
awarded the Nobel Prize for Medicine.
Work was initially carried out with animal studies and it was not until 1998 that 
the now famous Professor James Thomson at the University of Wisconsin reported the 
successful isolation of human embryonic stem cells.
Since 1998 human embryonic stem cell research has gathered pace, with 
developments reported almost daily. Human embryonic stem cell research is not an
1 Holm, S., Going to the Roots o f  the Stem Cell Controversy (2002) 16(6) Bioethics 493-507 at pg 496
2 Bagaric, M. and McConvill, J., — Embryonic Stem Cell Research: The Principal Ethical Issue — When 
Does Life Begin? (2003) 12 (1) Nott. L.J. 1 at pg 1
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isolated area of research; other developments made with human embryos have shaped the 
research paths taken. For example the birth of Dolly the sheep, the first cloned mammal, 
has allowed scientists to develop the cell nuclear replacement technique so as to then 
derive human embryonic stem cells, opening up the possibility of creating patient specific 
stem cells.
Human embryonic stem cell research is precisely that; research. Still in its infancy 
human embryonic stem cell research does have the potential to cure or create therapies 
for many diseases and conditions which affect the world’s population. Which disease will 
have a cure or therapy first is impossible to foresee although scientists are working on a 
vast and diverse range of illnesses from Parkinson’s to diabetes, sight loss to replacement 
heart cells. It is still likely to be a number of years before such research progresses to the 
clinical trials stage, let alone widespread medical applications, but if the research 
continues at the pace which it has done so far it must surely be only a matter of when, not 
if, embryonic stem cell therapies will be available. The science of human embryonic stem 
cell research is discussed in Chapter 1.
A particular property of human embryonic stem cells, their pluripotency, makes 
them so attractive scientifically. The significance of the pluripotent nature of human 
embryonic stem cells is that they have the potential to develop into almost any cell type 
of the human body, hence the potential capability to revolutionise healthcare. However it 
is the source of these pluripotent stem cells, the human embryo, which makes this 
research so ethically controversial.
Ethics
Human embryonic stem cell derivation normally involves the destruction of the 
human embryo (although note the work in the USA involving single cell biopsy of human 
embryos, although the embryos in question were left to perish).3 It is this destruction of 
the human embryo, or lack of fulfilling its potential to become a human being that upsets 
and perturbs many people.
As will be seen in Chapter 2, which discusses the ethics o f destructive embryo 
research, there is no clear moral dividing line on the status and respect which should be
3 Klimanskaya, I., et al. Human embryonic stem cell lines derivedfrom  single blastomeres 444 Nature 481 - 
485
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afforded to the human embryo. The range of opinions on the moral status of the human 
embryo is enormous, even those who claim to come from the same ethical standpoint will 
vary. For example, Gradualists may all recognise that the human embryo will gradually 
gain respect and status as it develops but may attach significance to different points of 
biological development, e.g. the formation of the primitive streak or quickening. I aim to 
discuss broadly some of the different ethical stances on the moral status of the human 
embryo whilst also recognising the diversity of those opinions.
The opponents of human embryonic stem cell research are vociferous in their 
opinions whilst those who may hold views which pertain to the middle ground or lean to 
the more liberal persuasion are not seen to be as vocal. This is particularly true when 
looking at the campaigns which were ongoing throughout the reform process of the 
Human Fertilisation and Embryology Act 1990 (for example, refer to the vocal campaign 
by Comment on Reproductive Ethics, which has a strong web presence as well as 
submitting evidence to a number of Government reports into the matter).4 Whilst 
opponents of human embryonic stem cell research may appear to be more vocal upon the 
matter, the supporters are not without a voice. The UK National Stem Cell Network 
(UKNSCN) was established in July 2006 to promote research and disseminate 
information and has submitted evidence to the Government on several occasions.5 The 
ethical issues are discussed in Chapter 2. Within the Chapter the five main moral 
viewpoints (Deontologist, Consequentalist, Liberal, Moderate and Gradualist) are 
examined to determine how each one would answer the questions ‘when does life begin 
to matter morally?’ and ‘Is an embryo a person?’ This examination of the moral status of 
the human embryo is then taken a step further by considering if the law respects and 
incorporates the diverse moral opinions surrounding the status of the human embryo.
Law
While the ethical debates may continue to rage, both academically and publicly, 
the legislation of the United Kingdom has taken a clear stance on the permissibility of 
human embryo research and human embryonic stem cell research. Embryo research and
4 Comment on Reproductive Ethics http://www.corethics.org/index.php (accessed 09/09/08)
5 About UKNSCN: Mission UKNSCN http://vyww.uknscn.org/aboutuknscn.html (accessed 13/10/08) 
UKNSCN Newsletter Issue 1, Autumn 2007
http://www.uknscn.org/downloads/pdfs/UKNSCNNewsletterIssuel .pdf ( accessed 13/10/08)
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human embryonic stem cell research are allowed within a defined set of limits, for 
specific research purposes, up to 14 days development of the embryo (post-creation) and 
only where the use of embryos is necessary and desirable. The interface between human 
embryo research and human embryonic stem cell research is an interesting one to 
examine; whilst the focus of this thesis is upon the regulation of human embryonic stem 
cells it is impossible to examine the regulation without reference to human embryo 
research, primarily due to the fact that the legislation which governs human embryo 
research has been subsequently used to largely regulate human embryonic stem cell 
research.
The path to statutory control was not a quick or easy one. Some eight years passed 
from the creation of the Wamock Committee until the passing of the Human Fertilisation 
and Embryology Act 1990. The road to legislation is discussed in Chapter 3.
Human embryonic stem cells were discovered eight years after the enactment of 
the Human Fertilisation and Embryology Act 1990. As such the legislation of the United 
Kingdom has been both amended and subjected to liberal interpretation by the judiciary 
to take into account the scientific developments so as to ensure that all research involving 
human embryos, regardless of the manner of their creation, is strictly regulated.
As the science has continued to progress rapidly the legislation needed to be 
revised and updated and the Human Fertilisation and Embryology Act 1990 has 
undergone reform. The path to new legislation has been long and arduous. The first five 
documents from 2004-2006 are discussed in Chapter 7. 2006-13th November 2008 is 
discussed in Chapter 8. As at the time of completing this thesis the discussion of the 
Human Fertilisation and Embryology Bill had just been concluded with the Human 
Fertilisation and Embryology Act 2008 receiving Royal Assent on the 13th November 
2008.6 The majority o f the provisions will come into force in October 2009.7
Scientists are not able to commence research as and when they see fit provided 
that they stay within the bounds of the legislation. Scientists must apply to the statutory 
regulator, the Human Fertilisation and Embryology Authority (HFEA), for a licence for
6 Hansard House o f  Lords, 13th November 2008, Royal Assent -  Human Fertilisation and Embryology Act 
2008, Volume 705, Column 832 http://www.publications.parliament.Uk/pa/ld200708/ldhansrd/text/81113- 
00Q8.htm#08111379000023 (accessed 20/11/08)
7 HFEA Chair welcomes Royal Assent o f  HFE Act (13/1/08) http://www.hfea.gov.uk/en/1746.html 
(accessed 20/11/08)
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such work and prior to that must normally seek and gain approval from a Research Ethics 
Committee. These two bodies are discussed in Chapters 4 and 5.
Equally whilst the Human Fertilisation and Embryology Act 1990 along with the 
HFEA and Research Ethics Committees may govern embryo research it does not control 
research upon the subsequently derived stem cell lines. This is the role of the UK Stem 
Cell Bank and is discussed in detail in Chapter 6.
Finally it should be remembered that, although the United Kingdom was the first 
country to bring into force permissive legislation on embryo research, it is not the only 
country which has done so. The final chapter of the thesis, Chapter 9, looks at the State o f 
California in the United States. California is an interesting place to compare to the United 
Kingdom as it was the first State to enact legislation which went against the Federal 
position of not providing funding for human embryonic stem cell research. Californian 
legislation is fascinating to compare to the UK legislation as there is far greater emphasis 
upon funding of human embryonic stem cell research, rather than strictly regulating it. 
The research for this final chapter was primarily undertaken during a five week trip to the 
University of California, Berkeley as a visiting scholar during May/June 2007.
This thesis aims to give the reader a comprehensive overview of the regulation o f 
human embryonic stem cell research in the United Kingdom, examining problems with 
that regulation and suggesting ways forward. While this thesis is very much concerned 
with the regulation of human embryonic stem cell research such a piece of work would 
not be complete without an explanation of the science involved as well as an examination 
of the ethical problems surrounding the moral status of the embryo.
The focus of this thesis is upon the interface between embryo research and human 
embryonic stem cell research. The legislation pertaining to embryos has been used to 
regulate the creation of, access to and research upon human embryonic stem cells. It is 
necessary to understand how the legislation which controls research upon embryos has 
also been used to regulate embryonic stem cells.
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Chapter 1 - The Science
Although this thesis is predominantly concerned with the legislation surrounding 
human embryonic stem cell research, it is important to understand the science which lies 
behind the need for legislation.
To understand human embryonic stem cell research it is necessary to explain 
certain scientific terms and processes. This chapter seeks to explain those processes in lay 
terms, to enable the reader to follow the scientific progress and developments and to 
understand the need for legislation to regulate this sensitive area of research.
Human embryonic stem cell research, within the United Kingdom, is permitted to 
be performed upon two different sources of embryos, those donated for research that are
o
surplus to fertility requirements, and those which are created specifically for research. 
Embryos which are donated after fertility treatment have been created by in vitro 
fertilisation. Embryos which are created specifically for research can either be created by 
in vitro fertilisation or by the cell nuclear replacement process.
Embryos created by in vitro fertilisation (IVF)
Embryos created by in vitro fertilisation (IVF) refer to human embryos which are 
created outside of the human body, within the laboratory. For the process of Intra- 
Cytoplasmic Sperm Injection (ICSI) sperm is mechanically inserted into an oocyte, and in 
IVF sperm is mixed with the oocyte, thereby replicating natural fertilisation within the 
laboratory.
The nucleus of human gametes, oocytes and sperm, contains 23 chromosomes 
each so that upon fertilisation the newly formed cell, the embryo, contains 46 
chromosomes, the exact number required for normal human development. The genetic 
makeup of the embryo comes from two different sources -  the two gamete providers.
IVF embryos used for research which have been donated after fertility treatment 
are often referred to as ‘spare’, ‘surplus’ or ‘supernumerary’ embryos.
8 Refer to Chapter 3 for a full discussion o f  the legislation which permits research upon these two sources 
o f  embryos
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Embryos created by cell nuclear replacement (CNR)
Embryos created by cell nuclear replacement (CNR) or somatic cell nuclear 
transfer (SCNT), as the process is also called, do not involve the use of sperm merely 
oocytes in their creation. In the process of cell nuclear replacement scientists take an 
oocyte and extract the nucleus which consists of 23 chromosomes. The oocyte is then 
referred to as an enucleated oocyte -  it is effectively an empty shell. Scientists then
17
extract the nucleus of a somatic cell, that is to say an adult cell o f any part of the body 
apart from gamete cells. The nucleus which is extracted contains 46 chromosomes. This 
nucleus is then inserted into the enucleated oocyte. The oocyte is given an electric shock 
to encourage the oocyte to then divide. As the nucleus which has been inserted into the 
oocyte contains 46 chromosomes it contains all the necessary genetic material for the 
oocyte to divide and develop as a normal embryo.
In this process the genetic makeup for the embryo is provided by only one donor, 
hence the resulting embryo is a genetic clone of the DNA provider. This process was first 
achieved in a mammal by Professor Ian Wilmut and his team working at the Roslin 
Institute in Scotland. The resulting mammal is the now famous Dolly the Sheep, born on 
the 5th July 1996.9 Dolly died on the 14th February 2003.10
Cloning - A life o f  Dolly Roslin Institute http://www.roslin.ac.uk/publidnterest/cloning.php (accessed 
19/02/08)
10 C lon in g -A  life o f  Dolly: D o lly ’s Final Illness Roslin Institute 
http://www.ri.bbsrc.ac.uk/publicInterest/DollvFinalIilness.php (accessed 22/07/08)
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This process is often referred to as cloning. Terminology for cloning includes 
human reproductive cloning, human therapeutic cloning, cell nuclear replacement and 
somatic cell nuclear transfer. Further explanation is found below.
«
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Human Reproductive Cloning
If scientists use the cell nuclear replacement technique to create an embryo, there 
is the (theoretical) possibility of implanting the embryo into a uterus. The embryo would 
then have the opportunity to develop to term. This is the process known as human 
reproductive cloning as the resulting child would be an exact genetic match to the person 
who donated the nucleus which was used to replace the nucleus taken from the oocyte. 
This process is theoretical within the UK as it is currently outlawed by the Human 
Reproductive Cloning Act 2001 as well as being theoretical in the scientific sense as it has 
not yet been achieved anywhere that we know of and been scientifically confirmed.
Whilst there is a general consensus that human reproductive cloning should not be 
performed we do not of course know that the clone which would be produced would be 
exactly the same as the ‘original’. For example, should Hitler’s DNA be used to produce 
a clone it is not 100% certain that the clone would also be sympathetic to the ideals 
promoted by Hitler and carry out atrocities similar to those of the Second World War. We 
do not know the effect of sociological factors, so whilst the clone may be a genetic clone, 
this does not necessarily mean that the clone will have the exact same personality as the 
‘original’, the clone would be subject to a different upbringing and experiences. The 
situation can be compared to genetic identical twins, whilst they may share the exact 
same genetic makeup, they are still two very different people.11
Human Therapeutic Cloning
If scientists create an embryo by cell nuclear replacement but do not implant the 
embryo into a uterus, the scientists may be able to perform research upon the embryo. 
The exact areas of permitted research are discussed in later chapters when considering the 
legislation regarding human embryos. The creation of embryos by the cell nuclear 
replacement technique for (limited) research purposes is permitted in the UK by the 
Human Fertilisation and Embryology Act 1990.
When research is performed upon embryos created by cell nuclear replacement 
this process is known as human therapeutic cloning. The reason for this is that the results
11 For an interesting discussion o f  this argument refer to Harris, J., Clones, Genes and Immortality: Ethics 
and the Genetic Revolution OUP (1998)
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of the research will hopefully have therapeutic benefit, not to the embryo upon which the 
research is performed due to the restrictions preventing implantation (as discussed in later 
chapters) but may have therapeutic benefit to already existing and future members of 
society.
Whilst the term ‘therapeutic cloning’ is used predominantly in the public press it 
is somewhat misleading. Scientists prefer the term ‘somatic cell nuclear transfer’ or ‘cell 
nuclear replacement’ to refer to the scientific process used to create these embryos as it is 
felt that ‘reproductive cloning’ and ‘therapeutic cloning’ are misleading phrases to use. 
The term ‘cell nuclear replacement’ is used throughout this thesis. The research which is 
being undertaken at this present time does not currently have any therapeutic benefits to 
society at large. Embryo research is still predominantly that, at the research stage. 
Benefits to be reaped from such research will hopefully appear sometime in the future, 
but until that happens, such research is purely research, not therapeutic.
The Primitive Streak
As will be seen in later chapters of this thesis, in the UK research is permitted 
upon human embryos up to the appearance of the primitive streak, this is taken to have 
occurred by the fourteenth day of development after fertilisation (if it has not already 
occurred by this date). The primitive streak is the point at which twinning can no longer 
occur as it is the point at which cells within the embryo group together to form a neural 
tube, this is the start of the spine and brain. It is at this point which it can be said that we 
have a unique individual. Prior to the primitive streak forming it is possible for the 
embryo to split into twins, triplets e tc .12 Equally, after division the embryo may 
recombine back into one embryo.13
The Blastocyst
From the point o f creation the embryo will go through several different 
developmental stages. The point at which stem cells are normally extracted is around five
12 For a useful discussion o f  the primitive streak refer to Report o f  the Committee o f  Inquiry into Human 
Fertilisation and Embryology, (the Wamock Report) Cmnd 9314
13 For an interesting discussion o f  this idea refer to Harris, J., Ch X  The Irredeemable Paradox o f  the 
Embryo in Enhancing Evolution (2007) Princeton University Press
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to six days after creation. At this point the embryo is referred to as a blastocyst and 
consists of around 150-200 cells with some cells having grouped together to form the 
inner cell mass which will go on to develop into the embryo.14 It is from the inner cell 
mass that the stem cells are extracted. The term ‘creation’ is used here rather than 
‘conception’ or ‘fertilisation’ due to the discovery of cell nuclear replacement and the 
ability to create human embryos by methods other than fertilisation.
Human Embryonic Stem Cells
The desire to extract stem cells from embryos is due to their huge potential to 
develop into almost any other cell o f the human body. Embryonic stem cells were first 
discovered in mice by Sir Professor Martin Evans in 1981, human embryonic stem cells 
were first successfully extracted by James Thomson of the University of Wisconsin in 
1998.15
There is great excitement surrounding human embryonic stem cells due to their 
pluripotency, which is their ability to develop into almost any cell and tissue of the 
human body. The discovery of these cells could have huge implications for how diseases 
and illnesses are treated medically. There is the potential to grow particular types of cells 
to be placed into the human body and replace those that are missing. Examples are brain 
nerve cells to treat Parkinson’s, pancreatic islet cells to treat diabetes and photoreceptor 
cells to treat diseases of the retina.16
If the human embryonic stem cells were to be extracted from cloned embryos 
there is also the possibility of creating patient specific stem cells for treatment. This 
would be done by using the patients DNA, for example by extracting the nucleus from a 
skin cell, and then implanting that nucleus into an enucleated oocyte. The resulting 
embryo would be a genetic match to the patient and so any stem cells which were 
extracted from the embryo would also be a genetic match to the patient. This could be 
very important where the risk of rejection is undesirable.
14 Korobkin, R with Munzer. S. R., Stem Cell Century: Law and Policy fo r  a Breakthrough Technology 
(2007) Yale University Press at pg 8
15 Refer to Evans, M.J. and Kauffman, M.H., Establishment in culture ofpluripotent cells from  mouse 
embryos (1981) 292 Nature 154 and Thomson, J., et al., Embryonic stem cell lines derived from  human 
blastocysts (1998) 282 Science 1145-47
16 For information on the photoreceptor work refer to Klassen, H and Reubinoff, B., Stem cells in a new 
light (2008) 26(2) Nature Biotechnology 187
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Pluripotent/Totipotent/Multipotent
As already mentioned the desire to create and derive human embryonic stem cells 
is due to their pluripotency. To say that a cell is pluripotent is to say that it has the ability, 
in the right conditions, to develop into almost any cell type or tissue of the human body. 
We say almost any cell type as pluripotent stem cells are unable to develop into the extra- 
embryonic cells, those that would form the placenta. Cells which can develop into any 
cell type of the human body including the extra-embryonic cells are known as totipotent 
stem cells.
In contrast cells which are known as multipotent stem cells have a far more 
limited capability to develop into other cell types. Generally adult stem cells will only be 
able to develop into the cell type for which they are programmed, for example bone 
marrow will produce only blood stem cells. The ability for self-renewal is highly 
important, particularly when the human body is consistently renewing and replacing 
many vital cells every second. However the usefulness of these multipotent stem cells is 
limited in terms of research for cell types outside of those for which the stem cells are 
programmed to produce.
Alternative Sources of Stem Cells
Adult stem cells are frequently referred to as an alternative to human embryonic 
stem cells. Most commonly referred to as a desirable alternative by the pro-life lobby 
these stem cells are generally not pluripotent, rather they are multipotent meaning that 
they do not have the potential to change into as many cell types as embryonic stem cells. 
It is for this reason that human embryonic stem cell research has progressed alongside the 
work being undertaken upon adult stem cells. However it must be noted that work is 
being undertaken to explore the possible pluripotency of adult stem cells, for example 
refer to the work of Catherine Verfaillie.17
Almost any stem cell which is not embryonic is defined as an adult stem cell; this 
includes cord blood stem cells, stem cells extracted from aborted foetuses, stem cells
17 Jiang Y, Jahagirdar BN, Reinhard RL, Schwartz RE, Keene CD, Ortiz XR, Reyes M, Lenvik T, Lund T, 
Blackstad M, Du J, Aldrich S, Lisberg A, Low, WC, Largaespada DA, Verfaillie CM., Pluripotency o f  
mesenchymal stem cells derived from  adult marrow (2002) 418 Nature 41-9
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extracted from bone marrow etc. The exception is induced pluripotent stem cells which 
appear to be a completely new type of stem cell.
Currently the majority of scientific research which involves the extraction of
human embryonic stem cells will destroy the embryo in the process of extraction. As the
science has progressed, and progressed rapidly (many advances having been made during
the writing of this thesis), alternative ways of creating embryos have come to light. Some 
have been pursued in a bid to overcome the controversy of using embryos for such 
research. Alternative ways of creating embryos include:
• Through the use of artificial gametes
• Parthenogenesis
• Entities created by tetraploid complementation
• In vitro maturation of oocytes (IVM)
• Chimeras
• Embryo biopsy
• Altered nuclear transfer
• Induced pluripotent stem cells
The possible use of artificial gametes for research and treatment is discussed 
elsewhere in this thesis in respect of the reform which the UK legislation is undergoing. 
For explanation artificial gametes are gametes from stem cells, i.e. stem cells have been 
extracted from embryos and have then been encouraged to develop into eggs or sperm. 
Whilst not yet achieved with human embryonic stem cells there has been success with 
mice resulting in live births.18 This could help some couples to overcome fertility 
problems whilst using their own genetic makeup. Artificial gametes is the term used 
throughout this thesis although the reader should be aware that they are also referred to as 
pluripotent stem cell derived gametes and in vitro derived gametes.19
18 Nayernia K, Nolte J, Michelmann HW, Lee JH, Rathsack K, Drusenheimer N, et al., (2006) In vitro- 
dijferentiated embryonic stem cells give rise to male gametes that can generate offspring mice Dev Cell
11:125-132 http://www.cell.com/developinental-cell/fulltext/S1534-5807(06100248-6 (accessed 15/06/09) 
Nicholl, H., Stem Cell Sperm Success 17th July 2006, Bionews 
http://bionews.org.uk/new.lasso?storvid=3107 (accessed 14/9/06)
19 Harvey, E., Scientists argue fo r  freedom  to develop sperm and eggs from  stem cells 21st April 2008, 
Bionews http://www.bionews.org.uk/new.lasso?storvid=3807 (accessed 22/04/08)
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Parthenogenesis is also referred to as a ‘virgin birth’. Parthenogenesis merely 
requires the use of oocytes which are encouraged to divide and multiply without the 
introduction of sperm or other genetic material. A relatively common phenomenon in the 
animal world, research into this method of reproduction for humans is being conducted.
Entities created by tetraploid complementation involve embryonic stem cells 
combining with helper cells to form an entirely new organism consisting o f both 
tetraploid and diploid cells. The tetraploid cells form the extraembryonic cells and tissues 
and as such the organism is incapable of implantation.20
The in vitro maturation of oocytes is used in conjunction with in vitro fertilisation 
or cell nuclear replacement. The maturation of oocytes in vitro allows the use of very 
immature oocytes to be used for research or fertility treatment. This is not really an 
alternative way of creating embryos; rather it is a method to help along the maturation of 
oocytes in preparation for fertilisation.
Chimeras and hybrid embryos have been in the UK news a lot recently due to the 
UK Government’s intention to specifically allow the creation of hybrid embryos for 
research purposes in the new legislation as well as stating that it is permitted under the 
current HFE Act. Chimeras or hybrids involve the use of animal gametes and human 
DNA to create embryos. Scientists are able to create hybrid embryos by using an animal 
egg, removing the nucleus and then inserting the nucleus from a human cell. This is the 
cell nuclear replacement technique but uses animal eggs rather than humans and has 
recently been achieved at Newcastle 21 The reason for scientists wishing to pursue this 
avenue for research is the severe shortage of good quality human eggs for research. By 
using animal eggs it overcomes the egg supply problem whilst ensuring that valuable 
research can continue. Chimera embryos in contrast use one human gamete and one 
animal gamete, e.g. human sperm and an animal egg. The resulting embryo would be half 
human and half animal. No licence has been issued for this type of work within the UK.
Whilst the researchers who have requested (and been granted) licences to 
undertake this work emphasise that any resulting embryos and stem cells will not be used 
in therapeutic treatments of humans (although this does not appear to have been banned
20 Denker, H-W., Potentiality o f  embryonic stem cells: an ethical problem even with alternative stem cell 
sources (2006) 32 J.Med. Ethics 665 at 669
21 H ybrid Embryos Statement Newcastle University, 1st April 2008
http://www.ncl.ac.uk/press.office/press.release/content.phtml?ref=1207065299 (accessed 18/04/08) H ybrid  
Embryos: FAQs Newcastle University, 1st April 2008
http://www.ncl.ac.uk/press.office/press.release/content.phtml7reiM207063854 (accessed 18/04/08)
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under the new legislation) there will undoubtedly be much debate as to whether these can 
be considered to be truly human.22 Also to be determined is the affect o f mitochondria 
and the influence that the animal mitochondria remaining in the cell will have upon the 
human DNA. One research centre has recently been granted a licence by the HFEA to 
undertake cell nuclear replacement with pig eggs but to also replace the pig mitochondria,
23apparently truly using the pig egg as a shell only.
Embryo biopsy or single cell biopsy is one possibility for extracting stem cells 
without the destruction of the embryo. One team in the US has shown that it is possible to 
extract a single cell from a developing embryo and to extract stem cells from that single 
cell.24
Altered nuclear transfer was suggested by William Hurlbut to the US Presidents 
Council on Bioethics as a solution to the ethical issues surrounding the human embryo. 
His suggestion was that scientists should alter the gametes before they fertilise, so that the 
resulting embryos are unable to develop beyond a few days as they cannot form the 
trophectoderm layer.25 Of note is that there are papers against this ‘solution’ showing that 
it is not a solution at all -  the resulting embryo is still a human embryo.
Induced pluripotent stem cells are perhaps one of the most exciting scientific 
advances since the news of the birth of Dolly the sheep. Developed by Shinya Yamanaka 
and his team at Kyoto University a method has been discovered whereby normal cells, 
such as a skin cell, have been reverted to a stem cell state, with properties very similar to 
that of embryonic stem cells.26 The ability to revert human skin cells to an embryonic like 
stem cell state was announced in November 2007. Currently these induced pluripotent 
stem cells (often referred to as IPS cells) are liable to cause cancers due to the use of 
retroviruses in the process and so are still at a very early stage of developmental research, 
they could not yet be used in clinical therapeutic applications in humans due to the risk of
22 Refer to the work currently being carried out at King’s College London and at the University o f  
Newcastle-Upon-Tyne Current Research Projects HFEA http://www.hfea.gov.uk/en/374.html (accessed 
03/03/08)
23 The generation o f  human embryonic stem cells by transferring a human cell into recipient p ig  eggs 
Clinical Sciences Research Institute, University o f  Warwick, 30th June 2008 HFEA 
http://www.hfea.gov.uk/en/1699.html (last accessed 28/07/08)
24 Chung. Y., et al., Human Embryonic Stem Cell Lines Generated without Embryo Destruction  (2008) 2(2) 
Cell Stem Cell 113-117
25 Refer to Alternative Sources o f  Human Pluripotent Stem Cells: A White Paper o f  the President’s Council 
o f  Bioethics (2005) The President’s Council on Bioethics
http://www.bioethics.gov/reports/white paper/altemative sources white paper.pdf (accessed 03/03/08)
26 Takahashi, K et al., Induction o f  Pluripotent Stem Cells from  Adult Human Fibroblasts by Defined  
Factors 131(5) Cell 861-872, 30th November 2007 (accessed 03/03/08)
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causing cancers. There is already research going on to overcome this problem with IPS 
cells.27
These IPS cells are a very interesting development as the creation o f these types 
of stem cells are not plagued with the ethical and moral dilemmas which surround human 
embryonic stem cell research. In respect of embryo research in the United Kingdom there 
could be an argument that the use of embryos for stem cell research is no longer 
‘desirable or necessary’ due to an ethically acceptable alternative source of stem cells in 
the form of these IPS cells. If that argument was successful then the HFEA would find it 
practically impossible to authorise any use of embryos for stem cell research where the 
use of IPS cells was a viable alternative. The HFEA is already taking into account the 
advances in the alternative methods of creating pluripotent stem cells.
Interestingly IPS cells appear to be a whole new category of stem cells, neither 
embryonic nor adult they fall outside o f statutory regulation and the control o f the UK 
Stem Cell Bank. The development and use of IPS cells alongside the more established 
adult and embryonic stem cell lines will be interesting to see.29
Conclusion
This chapter is designed to briefly introduce the reader to the terminology used in 
connection with human embryonic stem cell research. As has been discussed the area of 
stem cell research is a complex area scientifically with many different sources of stem 
cells available for such research. As will be shown in subsequent chapters the UK 
legislation has had to work hard to regulate this up and coming area of science; the 
scientific developments which have occurred over the last few years have affected how 
the legislation is interpreted, been amended and now reformed.
The progress in this area of science has been rapid, the impetus for research being 
the potential of stem cell science to revolutionise healthcare as we know it. The range of
27 Zhou, H., et al., Generation o f  Induced Pluripotent Stem Cells Using Recombinant Proteins (2009) 4(5) 
Cell Stem Cell 381-384
Cyranoski, D., Stem-cell therapies closer to clinic Nature News 28th May 2009 
http://www.nature.com/news/2009/090528/full/news.20Q9.525.html (accessed 15/06/09)
28 Refer to the HFEA Scientific and Clinical Advances Group Paper Alternatives to embryonic stem cells 
SCAG (02/08)04 http://hfea.gov.uk/docs/2008-02-21 SCAG paper - alternatives BS cells .p df(accessed 
05/07/08)
29 For a discussion o f  the effect o f  IPS cells upon human embryonic stem cell research refer to Hammond- 
Browning, N., Legal and Ethical Considerations o f  Induced Pluripotent Stem Cells (forthcoming) Medical 
Law Review
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illnesses, diseases and conditions which are being researched in conjunction with stem 
cells is enormous; this shows the potential of stem cells to not only help in one area but in 
all parts of the human body. Whilst there is huge pressure and expectation on the stem 
cell scientists to deliver the cures and therapies which are expected, the delivery date for 
these solutions is some what distant in the future.
Although progress has been rapid human embryonic stem cell research is still 
developmental, experimental and a work in progress. The therapeutic application of stem 
cell treatments may be futuristic at this moment in time, but the regulation of the research 
which is currently ongoing is vital, so as to retain public confidence and trust in human 
embryonic stem cell research. Later chapters look in detail at this regulation. The path to 
regulation has not been smooth, principally due to the disagreements over the protection 
and moral status to be afforded to the human embryo, the source of these valuable stem 
cells. The following chapter examines those different ethical arguments and considers 
how the legislation has respected and incorporated the diverse ethical opinions.
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Chapter 2 -  The Ethics of Embryo Research
Introduction
Whilst the physical developmental stages that the foetus undergoes during 
pregnancy are now well documented and agreed upon, it cannot be said that there is 
agreement as to the moral status which should be attached to the physical development of 
the foetus. Views vary from the one that life begins at the moment of conception and 
should be protected from then on to the opposite end of the spectrum that respect for life 
does not begin until some point after birth. In the middle there are those who believe that 
the foetus has a ‘special status’ but that does not mean it has the full status of a human 
being, rather, that protection increases as the foetus develops.
The ethics of embryo research, the moral status afforded to the embryo and the 
morality of destroying embryos for the benefit of others could easily be a complete PhD 
thesis by itself! What I seek to do in this chapter is to give a brief overview of some of 
the different ethical and religious positions before moving on to consider if the law 
incorporates and respects those diverse ethical opinions. Whilst I discuss the different 
ethical viewpoints as separate concepts this is not to say that these viewpoints stand 
alone, indeed it would be wrong to do so. The Deontological approach is often discussed 
in connection with the Conservative approach, whilst Utilitarianism and Liberalism often 
go hand in hand.
The second part of this chapter considers whether the law concerning embryo 
research and human embryonic stem cell research incorporates these diverse ethical 
opinions.
The Moral Status of the Embryo/Foetus30
The ethical, philosophical and religious arguments over the respect to be afforded 
to the embryo concern both the potentiality of the embryo and whether an embryo can be
301 do not profess to be an expert in Philosophy or Ethics, however what I attempt to do is give the reader a 
simplified overview o f the different ethical and religious approaches towards the moral status o f  the 
embryo and foetus
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considered to be a person. One example of a discussion o f the embryos potentiality can 
be found in Jeff McMahan’s detailed analysis of ‘Problems at the Margins o f  Life ’. 
McMahan discusses potential in terms of ‘identity-preserving potential’, whereby “...X  
has the potential to become Y only i f  X  and Y would be identical” and ‘nonidentity 
potential’ which is “ ...when X  has the non-identity potential to become Y (or a Y), Y will 
not, when it exists, be identical with X... ”31 McMahan concludes that “ ...the early fe tu s ’s 
potential to become a person is not identity-preserving but is only nonidentity potential. It 
therefore has no interest, and no time-relative interest, in becoming a person. ”32 This 
almost mathematical approach to potential is one way of looking at the issue, as 
previously mentioned there are several different approaches towards this question; the 
five main approaches are discussed below.
The Deontological approach
The most prominent Deontologist is Immanuel Kant (1724-1804) and his theories 
continue to generate great discussion and debate. Kant devised the Categorical Imperative 
which was designed to form the basis of all moral obligations. Kant formulated his 
Categorical Imperative in a number of ways but the one which is most relevant tells us to
Act in such a way that you always treat humanity, whether in your own person or 
in the person o f  any other, never simply as a means, but always at the same time 
as an end.33
As Mappes and DeGrazia note, “In Kant’s view, every person, by virtue o f  his or 
her humanity (i.e. rational nature) has an inherent dignity. All persons, as rational 
creatures, are entitled to respect, not only from others but from  themselves as well. ”34 It 
is this idea of respect for persons that is applied to the human embryo and which causes 
huge amounts of debate and division amongst commentators.
Some commentators may apply Kant’s Categorical Imperative to embryos to 
mean that we should never treat embryos as an end (i.e. use them for what they can 
provide), rather we should treat them as a means themselves. In this sense we should treat
31 McMahan, J., The Ethics o f  Killing: Problems at the Margins o f Life (2002) OUP at p304
32 Ibid. at p308
33 Translated by Paton, H.J., The Moral Law, (1964) Hutchinson & Co. (Publishers) Ltd at p32
34 Mappes.T.A. and DeGrazia.D., Biomedical Ethics (2006) McGraw-Hill 6th Ed. at p i8
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embryos as though they are persons, had full moral status and take all possible steps to 
protect them and help them fulfil their potential to become full human beings. If this 
approach was enshrined in legislation human embryo research including work to derive 
human embryonic stem cells, would be prohibited.
In contrast, some commentators may agree with Kant’s idea that we should never 
treat others merely as a means and yet still come to the conclusion that embryos may be 
researched upon and destroyed in the process. This is due to the issue of the respect to be 
afforded to people. As such it needs to be discussed what level of respect must be 
afforded and to whom -  are embryos people to whom we need to show respect?
Downie and Telfer expand upon the idea of respect for persons when they state
that:
...the meaning o f the injunction to treat and regard people not merely as a means 
hut also as ends is that we ought to treat them as valuable in themselves and not 
only as useful instruments...to respect a person as an end is to respect him for  
those features which make him what he is as a person and which, when 
developed, constitute his flourishing.35
But what are the features of persons that make this respect possible? Why do we 
treat persons as an end and never simply as a means? Gregory Vlastos discusses the idea 
of differentiating people due to their merits and achievements. Although we may accord 
additional respect (over and above what we may accord to ‘mere mortals’) to people due 
to particular merits which they display, Vlastos acknowledges that it is each individual’s 
‘human worth’ which justifies the expression that “...men are ‘ends in themselves’. ”36 It 
is the intrinsic value of people which we value and respect by never using people merely 
as a means. As Vlastos continues, “In all cases where human beings are capable o f  
enjoying the same goods, we feel that the intrinsic value o f  their enjoyment is the same. In 
just this sense we hold that (1) one m an’s well-being is as valuable as any other’s [and] 
(2) one m an’s freedom is as valuable as any others. ”37 His example o f giving assistance 
to the drowning man, irrespective of his merits, demonstrates how we believe we should 
each value our fellow man.38
35 Downie, R.S. & Telfer, E., Respect fo r  Persons (1969) George Allen and Unwin Ltd at pg 15
36 Vlastos, G., Human Worth, M erit and Equality in Feinberg, J., (Ed) M oral Concepts (1969) Oxford 
University Press pp. 141-152 at pg 147
37 Ibid. at pg 150
38 Ibid. at pg 147
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So for Vlastos it is the fact that we are human, the well-being and freedom to 
which we are entitled and the value which we have as humans which warrants the respect 
which should be given to each and every one of us.
Paton analyses the Kantian theory in terms of applying to rational beings. As he 
states “[Rational agents] alone can have an unconditioned and absolute value, it is
9)39wrong to use them simply as a means to an end whose value is only relative. ” Kant 
himself holds that the power to act in accordance with certain laws is a power which can 
only be found in rational beings and as such, “...every rational being, exists as an end in 
himself, not merely as a means fo r arbitrary use by this or that will, whether they are 
directed to himself or other rational beings, always be viewed at the same time as an
, „40end.
This concept of recognising rational beings as moral beings is further discussed 
by Patricia Clark who notes that “People should be treated as ends in themselves because 
we are all part o f a moral community: the Realm o f Ends. This is not a physical 
community but is a way o f  recognising all other people as moral beings. ”41
An extension of the rational beings argument is put forward by Downie and Telfer 
who discuss the specific features which differentiate people from other beings. They 
discuss why we take a certain attitude towards other people and go on to discuss why it is 
that we take the attitude that persons are valuable and so should be respected. The 
discussion which follows states that the respect that is due to persons is possible thanks to 
the human capacities of self-determination, rule making, minimal sensitivity and our 
possession of rational will. The possession of rational will, “the ability to govern one’s 
conduct by rules...to adopt rules which one holds to be binding on oneself and all 
rational beings ” and the ability to be self-determining are seen to give the intrinsic value 
to human personality.42
As Downie and Telfer themselves conclude:
... 'respect fo r  persons as ends ’ refers to an attitude ...ways o f  treating persons. To 
respect a person as an end is to value or cherish him fo r what he is -  and that is a
39 Paton, H.J., The Moral Law (1964) Hutchinson & Co. (Publishers) Ltd at pg 33
40 Ibid. at pg 95
41 Clark, P., An Outline o f  K an t’s Moral Theory Cardiff Uni versity Philosophy Handout
42 Downie, R.S. & Telfer, E., Respect fo r  Persons (1969) George Allen and Unwin Ltd at pg 21
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possessor o f a rational will, where ‘rational will ’ refers to the abilities to be self­
determining and rule-following...to respect such a person is to make his ends 
one’s own...and to take into account in all one’s dealings with him that he too is 
self-determining and rule-followingf3
Attfield discusses the concept that “...the well-being and flourishing o f  all 
morally considerable entities are o f intrinsic value. ”44 The development of certain 
essential capacities will contribute to the well-being and flourishing of moral entities. 
Essential capacities “ ...may be defined as essential capacities o f  a species, i f  and only i f  a 
species would forego its current identity in the absence o f any o f these capacities from  
most o f its members. ”45 Attfield notes that essential capacities of humans includes 
“...freedom, choice and responsibility. To this we can add that...human beings have 
essential capacities fo r  practical reasoning in general ...and for linguistic communication 
and perception, and probably fo r  skilled production and creativity. ”46 He further notes 
that a case is made for:
...the intrinsic value o f  self-determination (the ability to take decisions o f  our 
own), o f  the ability to devise rules, and o f being responsible for our beliefs, 
attitudes, and actions, all on the basis o f the intrinsic value o f  the development o f  
essential capacities47
It can be inferred from Attfield’s arguments that in the absence of all of these 
capacities a being cannot be recognised as human and as such makes respect for persons 
impossible and would equally allow the use of that being as merely a means to an end. It 
is the recognition of the essential capacities which makes respect possible and helps us to 
follow the Kantian maxim to never treat persons merely as a means but always as an end 
in themselves.48
If followers of Kant’s Categorical Imperative hold that respect for persons is only 
possible where persons possess capacities such as rational will and self-determination,
43 Ibid. at pg 37
44 Attfield, R., Value, Obligation and Meta-Ethics (1995) Value o f Inquiry Book Series at pg 45
45 Ibid. at pg 48
46 Ibid. at pg 51
47 Ibid. at pg 63
48 Note that a substantial part o f this section was submitted to the Philosophy Department o f  Cardiff 
University as a non-assessed essay as part o f the module Ethics: History and Theory. This module was 
studied as a non-registered student. My thanks to Professor Robin Attfield for his comments upon the essay
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they will hold that the human embryo is not a person and can therefore be researched 
upon and used to derive human embryonic stem cells.
The Utilitarian or Consequentalist approach
The Utilitarian or Consequentalist approach is so called as decisions are taken 
based upon an assessment of the consequences of the action. In assessing what action to 
take a person must assess all of the possible consequences of those actions and then 
choose the action which produces the greatest good or least amount of harm. The action 
itself which is to be undertaken is less relevant than the resulting consequence in the 
decision process. This contrasts to the Deontological approach whereby it is the action 
itself which determines the route taken, rather than the consequence of that action.
Applying this approach to the moral status of the embryo and the morality of 
embryo research, particularly where embryos are destroyed in the process, it can be seen 
that Utilitarians will, broadly speaking, support embryo research where the good 
consequences of that research (huge potential health benefits to others) will outweigh the 
bad consequence of the research upon the embryo (the destruction of the embryo).
This is an initially appealing approach to take towards embryo research for many 
people as it seems to value the maximum good being done with the least amount of harm. 
However, care needs to be taken when applying a strict Utilitarian approach; that is to say 
that the initial appeal of this approach to the average person may also be its hindrance in 
being accepted by more people. The application of the maxim ‘the maximum good with 
the least amount of harm’ could lead to situations whereby it was acceptable to kill and 
research upon very young children for the benefit of older siblings with proven records o f 
potential, for example. Most people would recognise that what needs to happen is a 
balancing of people’s rights and interests in deciding what action to take to obtain the 
greatest benefit. This would correspond more with the Gradualist viewpoint, as discussed 
below.
Authors who have taken a Utilitarian or Consequentalist approach at some point 
in their writings include R.M. Hare and Dame Mary Wamock, amongst others.
For Dame Mary Wamock there was no issue with taking a Utilitarian approach as 
the ‘harm’ done to the embryo for the ‘benefit’ of others was so small as to be irrelevant:
35
Embryos at the very early stages after fertilisation can themselves experience no 
pain...There can thus be no question o f balancing the pain o f  the embryo usedfor 
research against the pleasure or easement o f  pain experienced by infertile or by 
future unborn children. There is no contest....There could be nothing morally 
wrong about a procedure which produced manifest benefits to many, with no 
countervailing harms to anyone.49
Hare also agrees that the Utilitarian approach would be the best one to be 
enshrined in Law. By looking at the benefit which may be achieved through embryo 
research, including destructive embryo research, it would be possible to sanction embryo 
research. What is interesting to note is that Hare has taken account o f the implications of 
applying a Utilitarian approach to other forms of research, besides embryonic. 
Accordingly he makes the suggestion to “...grade the harms done by experimentation 
from zero in the case o f  sperms to a very high figure in case o f  (viable) infants (one that 
would forbid all but negligible harm), and balance these against the good expected from  
experiments. ”50
A strict Utilitarian approach towards the moral status of the human embryo may 
be the solution, it would permit the use of human embryos to derive stem cells; however 
if this approach is taken with the human embryo care will need to be taken in extending 
or applying this approach to other moral questions and situations.
The Conservative/Catholic approach
The Conservative approach is also the approach adopted by the Roman Catholic 
Church, although that is not to say that all those who hold a conservative position upon 
the moral status o f the embryo are also Catholics. The Conservative approach towards the 
human embryo is to hold that the embryo is a person from the moment of conception and 
as such deserves full protection from that moment onwards.
Pope John Paul II made it clear that in the Roman Catholic view human life 
begins from conception and as such it deserves respect and protection from that moment 
on:
49 Wamock, M. Baroness., The Enforcement o f  Morals in the Light o f  New Developments in Embryology 
(1986)39 C.L.P. 17 at p20
50 Hare. R.M., When Does Potentiality Count? A Comment on Lockwood { 1988) 2(3) Bioethics 214-226 at 
p224-5
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...the Church has always taught and continues to teach that the result o f  human 
procreation, from the first moment o f its existence, must be guaranteed that 
unconditional respect which is morally due to the human being in his or her 
totality and unity as body and spirit: “The human being is to be respected and 
treated as a person from the moment o f  conception; and therefore from that same 
moment his rights as a person must be recognized, among which in the first place 
is the inviolable right o f  every innocent human being to life. ”...51
This approach was repeated by the subsequent Pope. Pope Benedict XVI 
addressed a conference in Rome on stem cells where he reiterated the Church’s stance of 
“...full respect fo r  the human being from conception. ”52
There are a number of authors who have adopted this Conservative approach as 
the correct one to take in respect of the issue ‘when does life begin?’, ‘what respect must 
be afforded to the embryo?’ and ‘when and how must respect be shown to the embryo?’ 
A useful discussion of the Deontological and Consequentalist approaches towards the 
issue can be found in Bagaric and McConvill’s article, ‘Embryonic Stem Cell Research: 
The Principal Ethical Issue -  When Does Life Begin?’ What is interesting about this 
article is that after analysing the different approaches Bagaric and McConvill “...err on 
the side o f  conservatism. ”53 For these authors (and many others) “...the most coherent 
logical point at which life begins appears to be at conception. ”54 For Sikora “The 
obligation not to prevent the existence o f future generations is supported by what is 
perhaps a more fundamental question — that it is prima facie wrong to prevent the 
existence o f anyone with reasonable prospects for happiness. ”55
For most Conservatives, it is the potential of the embryo to develop into a full 
human person that requires them to treat the embryo in the same way as a person. The 
embryo is a full human being with potential, not a potential human being. The idea that 
we should treat others as we would want to be treated ourselves raises it head again here. 
The argument is that we would not have wanted to be aborted or researched upon
51 Pope John Paul II., The Unspeakable Crime o f  Abortion reproduced in Mappes.T.A. and DeGrazia.D., 
Biomedical Ethics, 6th Ed., (2006) McGraw-Hill at p457-459 at p459
52 Benedict, Pope XVI., Address o f  His Holiness Pope Benedict XVI to participants o f  the Symposium on 
the theme: Stem Cells: What Future fo r  Therapy? Scientific Aspects and Bioethical Problems 
Augustinianum Institute, Rome, Italy, 14-16 September 2006, reproduced in (2008) 41 Cell Prolif (Suppl. 
1) 4-6 at p5
53 Bagaric, M and McConvill, J., Embryonic Stem Cell Research: The Principal Ethical Issue — When Does 
Life Begin? (2003) 12(1) Nottingham Law Journal 1 at p l7
54 Ibid. at p i7
55 Sikora, R.I., Is it Wrong to Prevent the Existence o f Future Generations? in Sikora. R.I. and Barry. B. 
(Ed) Obligations to Future Generations (1978) Temple University Press at pi 12
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therefore we should not abort or research upon other embryos. The potentiality of the 
embryo protects its status.
If this approach was enshrined in the legislation, the human embryo would be 
granted full moral status from the moment of creation and as such work to derive stem 
cells would be prevented.
The Liberal Approach
At the opposite end of the moral spectrum to the Conservative or Catholic 
approach is the Liberal approach towards the human embryo. Many Liberals do not 
ascribe moral status to the human embryo or foetus until birth; a few may even delay 
attaching that moral status until sometime after birth. As Mappes and DeGrazia note 
" The liberal, o f  course, does not mean to deny that a fetus is biologically a human fetus. 
Rather, the claim is that the fetus is not human in any morally significant sense; that is, 
the fetus has no significant moral status. This point is often made in terms o f  
personhood. ”56 This is clearly stated by Schuklenk who notes that “There is an important 
distinction between membership o f  our species, on the one hand, and personhood on the 
other. ”57
Warren views sentience as being the thing which gives us intrinsic value and 
which makes us eligible for respect:
Sentience is the ultimate source o f  all moral rights; ...sentience is a necessary and 
sufficient condition fo r the possession o f moral rights. It does not follow from this 
that all sentient beings deserve to have their interests given equal weight in moral 
considerations. All people have equal moral rights, but it is only people who have 
full moral rights.58
Warren goes on to dismiss the Utilitarian approach that the goal of morality is to 
maximise happiness, rather in her opinion the “...aim o f morality should be to maximize 
the extent to which each actual... per son’s interests are promoted.”59 So for Warren (and 
others) the intrinsic value of potential people is not realised until they become conscious
56 Mappes. T. A. and DeGrazia. D., Biomedical Ethics, 6th Ed., (2006) McGraw-Hill at p450-451
57 Schuklenk, U., How not to win an ethical argument: Embryo stem cell research revisited  (2008) 22(2) 
Bioethics ii-iii at pii
58 Warren, M., Do Potential People Have Moral Rights? in Sikora. R.I. and Barry. B. (Ed) Obligations to 
Future Generations (1978) Temple University Press at p22 and 23
59 Ibid. at p24
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and we can then promote that person’s interests and recognise their intrinsic value. When 
exactly a person becomes conscious is another point which is open to debate, some would 
claim from conception (although this is not accepted by the majority of people), others at 
some point during gestation, alternatively it is upon birth or even it is contended at some 
point later in development after birth. The level of consciousness is also a point for 
debate, what type of consciousness is required so as to be considered a person? Whilst 
sentience is normally acquired during the foetal stages, self-consciousness is usually 
attained after birth, although at what point is open to debate.
In another article concerning the morality of abortion Warren discusses “...the 
traits which are most central to the concept o f personhood... ” and notes five traits: 
consciousness, reasoning, self-motivated activity, capacity to communicate and the 
presence of self-awareness.60 Whilst Warren notes that not all of these traits may be 
found in all humans what is important is that if a being lacks all of the above traits then 
they cannot be said to be a person in the moral sense. As such “...to ascribe fu ll moral 
rights to an entity which is not a person is as absurd as to ascribe moral obligations and 
responsibilities to such an entity. ”61 Harris has argued for allowing research upon human 
embryos up until the end of the third trimester as “Nine months development leaves the 
human embryo fa r  short o f  the emergence o f anything that could be called a person, fa r  
short o f an individual capable o f  valuing its own life or possessing any o f the capacities 
that would be required for such valuing. ”62
Shaw also takes a permissive, liberal stance towards embryo research, even going 
so far as to state that “Embryo experimentation and therapeutic cloning are...not merely 
permissible, but obligatory. ”63 For Shaw the arguments against embryo research do not 
withstand ethical analysis and as such the failure to undertake such research is a failure to 
help lessen future human suffering.64
Another Liberal approach, which is particularly relevant for pro-abortion 
arguments, is to take into account the relationship which the embryo has with the woman 
carrying the embryo. Most pro-abortionists would use this to show that the embryo’s
60 Warren, M., On the Moral and Legal Status o f  Abortion in Mappes.T.A. and DeGrazia.D., Biomedical 
Ethics, 6th Ed., (2006) McGraw-Hill at p457-466 at p461
61 Ibid. at p462
62 Harris, J., The Value o f  Life: An Introduction to Medical Ethics (1985) Routledge Publishing at p l29
63 Shaw, D.M., Moral Qualms, Future Persons, and Embryo Research (2008) 22(4) Bioethics 218-223 at 
p223
64 Ibid. at p222
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interests (if any) cannot override those of the woman who has full legal and moral rights. 
A different perspective upon the liberal view is to discuss the embryo’s relationship with 
the womb. This is most relevant for embryos created in the laboratory. One such 
commentator, Agar, uses the importance of the existence of a womb to distinguish 
between implanted and unimplanted embryos, to the extent that the absence of a 
functional relationship with a womb marks embryos morally suitable for human 
embryonic stem cell research.65 Holbrook also takes a similar approach in comparing the 
moral status of the implanted and unimplanted in vivo embryo, the frozen embryo and 
other in vitro embryos.66
As can be seen the Liberal approach can take many different forms, each 
commentator finding their own significant point which supports their view that embryos 
and foetuses are not to be accorded respect until birth or for some even later.
By not according moral status to the early human embryo, human embryonic stem 
cell derivation and research could be performed, possibly for any reason. Whilst this 
approach may be well argued for from an academic perspective, it does not sit so well 
with the more cautious majority of the general public.
The Gradualist/Moderate approach
For those who do not hold views at the opposite ends of the Conservative/Liberal 
spectrum there is a middle ground which is acceptable to many. Often referred to as the 
Gradualist approach this is the attitude which is enshrined in the Human Fertilisation and 
Embryology Act 1990 and has been continued in the new legislation, the Human 
Fertilisation and Embryology Act 2008 which received Royal Assent on the 13th 
November and comes into force in October 2009.
The Gradualist approach is to view the embryo with increasing respect as it passes 
through the developmental stages up until birth. The level o f respect which may be 
accorded to the embryo at each stage may vary from person to person but by the time the 
foetus is due to be bom nearly full respect is recognised, with full respect being granted 
upon birth.
65 Agar, N., Embryonic Potential and Stem Cells (2007) 21(4) Bioethics 198-207 at p i 99
66 Holbrook, D., All Embryos are Equal? Issues in Pre-Implantation Genetic Diagnosis, IVF Implantation, 
Embryonic Stem Cell Research and Therapeutic Cloning (2007) 21(1) International Journal o f  Applied 
Philosophy
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This Gradualist approach allows embryo research and embryonic stem cell 
research to happen but only up until a certain developmental point. The cut off point 
adopted by the legislation and generally agreed with by Gradualists is the formation of 
the primitive streak in the embryo, thereby signifying a unique genetic being (up until this 
point twinning is possible).
As already mentioned the Gradualist approach is not easily defined, some people 
would accord greater respect upon implantation, quickening, sentience, viability, 
moments before birth and any number of different stages in between.
An example of moral status being conferred upon implantation is the discussion 
by Cameron and Williamson. They do not argue that upon implantation respect is 
absolute, rather that upon implantation, as the potential to develop becomes a reality, so 
too does the embryo begin to acquire respect. As they state,
We believe that it is no longer possible to identify a single time (such as 
fertilisation) at which an embryo acquires respect as a future person. In view o f  
the new technologies, the process o f development o f  the individual can be 
regarded as beginning at implantation. This would clearly state that cells in 
culture that are not used fo r implantation and have not been manipulated to form  
an embryo, do not deserve respect.67
Lockwood however argues that it is potential plus identity that counts morally and 
as such brain development is the key to the attaching of moral status to the human 
embryo. Before the brain is ‘able to sustain distinctively mental processes’, which can be 
‘definitively ruled out during the first eight weeks from conception’ “one might perhaps 
conclude that there is no moral basis fo r conferring upon the human embryo or foetus 
any right to protection during those eight weeks. ”68
In contrast, Holm does not look to a particular point at which an embryo will 
begin to attain a greater moral status than previously, rather he argues that
...although human life is intrinsically valuable at all stages o f  life, it generally 
becomes more valuable during the development from fertilized egg to adult 
human being... On a gradualist analysis o f the moral status o f  the human being 
through its developmental stages, destroying embryos is always wrong to some
67 Cameron, C and Williamson, R., In the World o f  Dolly, when does a human embryo acquire respect?  
(2005) 31 J. Med. Ethics 215-220 at p218
68 Lockwood, M., Warnock versus Powell (andHarradine): When Does Potentiality Count? (1988) 2(3) 
Bioethics 187-213 at p208
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degree and cannot be done just fo r any kind o f  benefit. One great advantage o f  a 
gradualist analysis applied to stem cell research is that it can explain why 
destructive use o f embryos fo r stem cell production is less problematic than the 
destructive use o f fetuses, or infants.69
Warren also does not look for a particular point at which embryos gain moral 
status; rather she puts forward a multi-criterial analysis of moral status.70 In her opinion 
“Each o f the uni-criterial theories fail, not because it selects a criterion o f  moral status 
that has no validity, but because no single criterion can represent all o f  the relevant 
considerations. ”71 By applying Warren’s seven principles of moral status to embryos it 
can be seen that Warren’s Gradualist, multi-criterial approach permits embryo research.
As can be seen from just these few quotes the Gradualist approach is one which 
varies from person to person, one scientific point, such as the implantation of the embryo 
or the development of the brain, will hold different moral relevance for each person. The 
different moral relevance granted to the different scientific (and in some cases social) 
milestones by Gradualists can be at least partly explained by the fact that a Gradualist’s 
moral compass is dependent upon each individual’s moral upbringing and their 
understanding of the science.
The Gradualist approach of slowly granting increasing respect and moral status to 
the developing human embryo allows stem cell derivation, embryo research and 
embryonic stem cell research to occur as it is recognised that the human embryo has a 
moral status but that it is not absolute and solidified from the moment o f creation. As 
Holm notes the application of the Gradualist approach to human embryonic stem cell 
research does show why embryonic research is far less problematic than research upon 
foetuses, infants and beyond.
Conclusion
The ethical debate will continue and will absorb additional features, such as 
equity and access o f  patients in under-privileged societies to high technology and 
expensive health care. The fundamental question, over whether a six-day old
69 Holm, S., The Ethical Case against Stem Cell Research (2003) 12 Cambridge Quarterly o f  Healthcare 
Ethics 372-383 at p376
70 Warren, M.A., Moral Status: Obligations to Persons and Other Living Things (1997) OUP Chapter 6
71 Ibid  OUP at pgl76-7
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blastocyst embryo is a human entity or not, cannot be resolved when the 
arguments stem from different philosophical premises.72
What was once the miracle of having a child has become medicalised and more 
scientific. Science has proven that for life to occur we require gametes, egg and sperm 
and that it is the moment of conception when life in the scientific sense starts as the 
embryo has the potential to develop into a human being. O f course the various different 
philosophical and religious standpoints view this moment differently, for some the 
important point is identifying when the soul enters the body, for others it is reaching a 
point when the embryo no longer has the ‘potential’ to become a human, rather that it has 
the chance to be bom alive and survive.
The advent of cloning has shown that it is not necessary to have an egg and a 
sperm to create an embryo but that is a whole different argument about whether a cloned 
embryo is even a person! (And one which is discussed in many articles, for example refer
~T\to Cameron and Williamson.) The accepted position is that a cloned embryo can be 
regarded as a person, although not genetically unique, however neither are twins, triplets 
etc and we do not regard them as non-persons!
This has been a brief discussion of the different ethical viewpoints on the moral 
status of the embryo. What follows is a discussion of the legislation in England and 
Wales; does it incorporate these diverse ethical opinions?
Does the Law in England and Wales concerning embryo research 
incorporate diverse ethical opinions?
Introduction
The law in England and Wales concerning embryo research, the Human 
Fertilisation and Embryology Act 1990, is considered by many countries to be a model to 
be followed in outlining their own embryo research legislation.74 The HFE Act permits
72 Hearn, J., Stem cell frontiers: Science, ethics and regulation (2007) 15(1) Journal o f  Law and Medicine 
32-35 at p34
73 Cameron, C and Williamson, R., In the World o f  Dolly, when does a human embryo acquire respect?  
(2005) 31 J. Med. Ethics 215-220 at p218
74 Hereafter referred to as the HFE Act
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embryo research within a defined set of limits, thereby taking a controlled but permissive 
stance. The permitted research purposes are discussed in greater detail in Chapter 3.
Although the legislation carefully controls the research which is undertaken with 
human embryos, there are many opponents of embryo research who would like to see 
such research outlawed and as discussed above there are many different approaches 
towards the moral status of the human embryo. So how did the legislation come to take 
such a permissive stance in an area which still raises controversy and around which there 
is a vast range of diverse ethical opinions?
The Warnock Committee
To understand how the HFE Act came about it is necessary to go back to 1982 
when the Committee o f  Inquiry into Human Fertilisation and Embryology was 
established. Known as the Warnock Committee after its chairman, Dame Mary Warnock, 
the terms of reference of the Committee were:
To consider recent and potential developments in medicine and science related to 
human fertilisation and embryology; to consider what policies and safeguards 
should be applied, including consideration o f the social, ethical and legal 
implications o f  these developments; and to make recommendations.75
The Warnock Committee considered a wide range of issues relating to human 
fertilisation and embryology including surrogacy and artificial insemination. In respect of 
embryo research the Warnock Committee was asked to consider if human embryo 
research should be permitted.
A large amount o f evidence was submitted by those with an interest in the remit 
of the Committee and was considered by the members of the Warnock Committee in 
helping it to reach its conclusions. The evidence which was submitted to the Warnock 
Committee is held in the House of Commons Library. Nearly 300 organisations 
submitted evidence and there were nearly 700 submissions from the public, all o f which 
was taken into account by the Warnock Committee. Of course each organisation and
75 Report o f the Committee o f Inquiry into Human Fertilisation and Embryology (The Warnock Report)
(1984) DHSS Cmnd 9314 at Para 1.2
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member of public has their particular concern so not every piece of evidence discusses 
the embryo research element of the Warnock Inquiry.
Evidence submitted to Warnock
The author of this thesis has examined the evidence which was submitted to the 
Warnock Committee. The research at the time (September 2005) was concerned with 
another element of this PhD thesis and so this section is based upon the evidence from 
which either copies were made or relevant notes. This section is based upon a total of 94 
pieces of evidence which were submitted to the Warnock Committee prior to publication 
of the Report and it is from this information that the central ethical question in relation to 
human embryonic research is approached: ‘When does life begin to matter morally?’
The central ethical question relating to human embryo research is undoubtedly the 
problem concerning the moral status of the human embryo. However, upon examination 
of the evidence not all submissions are concerned with this ethical question.
Of the 94 pieces of evidence, 32 support embryo research, 35 are against embryo 
research, whilst the remaining 27 are either inconclusive or their opinion is unknown.
The ‘when does life begin?’ question is apparently of more concern to those 
groups who oppose embryo research upon the basis that the human embryo is a person 
from fertilisation, often referred to as the Conservative approach. For example refer to the 
comments made by the Catholic Bishops ’ Joint Committee on Bio-Ethical Issues, which 
state that:
...at the time o f  conception there comes into existence a new life. There is a union 
in which a living cell from the father fertilizes a living cell from the mother. That 
union, a transmission o f life, is the beginning o f new life.... Each such new life is 
the life not o f  a potential human being but o f a human being with potential.76
Evidence submitted by the University of Southampton Faculty of Law also point 
to fertilisation as ” ...being undoubtedly the starting point o f  meaningful life as we know
76 Written evidence to the Inquiry and Responses to the Report o f  Human Fertilisation and Embryology
(1985) DHSS House o f  Commons Library Dep 1497 In Vitro Fertilisation: Morality and Public Policy. 
Evidence submitted to the Government Committee o f  Inquiry into Human Fertilisation and Embryology 
(the Warnock Committee) by the Catholic Bishops’ Joint Committee on Bio-Ethical Issues, on behalf o f  the 
Catholic Bishops o f  Great Britain at Page 6, Paragraph 8
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it” and as such experimentation upon human embryos is “...wholly unacceptable and 
should be prohibited by law. ”
Additionally, the Nationwide Festival of Light, in its detailed consideration of the 
human embryo concludes that:
...the only humane ethical position...is to treat the human embryo at any and 
every stage o f its development with the respect due to human life at all later 
stages,...‘Human life’ must therefore refer to the human life from  
conception. ”75 [And as such] “ ...Deliberate destruction o f the embryo represents 
the taking o f ‘innocent ’ human life.79
Not all groups who oppose embryo research do so on the basis that the human 
embryo is a person from fertilisation and so deserving protection from that point 
onwards. Some oppose research on the basis that, although the embryo is not a person 
from fertilisation, the embryo has the potential to become a human being. Examples of 
this approach can be found in submissions from the Welsh National School of Medicine 
and from CHILD.
A different approach to the argument that the human embryo has the potential to 
become a human being can be found in the submission made by the Council o f Reform 
and Liberal Rabbis. The Council takes a Gradualist approach when it states that:
Not only is there a morally valid distinction between potential and actual human 
life, but the value o f the embryo itself may be deemed to increase gradually, from  
zero to “infinity”, between conception and birth.80
Whilst the Council recognises that the use of embryos for medical research would 
involve the destruction of potential human life they conclude that research could be 
justified provided that certain conditions are fulfilled:
(a) that the purpose o f the research is the prevention o f suffering; (b) that there is, 
additionally, a good prospect that the research may ultimately lead to the saving 
o f life; (c) that the research is only carried out during the very earliest stages o f  
the embryo ’s gestational life; (d) that the embryo is treated with the respect due to
77 Ibid. The University o f  Southampton, Faculty o f Law, 19th May 1983
78 Ibid. Nationwide Festival o f Light, February 1983, page 12
79 Ibid. Nationwide Festival o f  Light, February 1983, page 13
80 Ibid. Council o f Reform and Liberal Rabbis, 20th May 1983, Page ii
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that which, though not a human person, has the potential to become a human
81person.
Other groups oppose embryo research upon the basis that the embryo is incapable 
of consenting to the research, for example, the Joint Ethico-Medical Committee o f the 
Catholic Union of Great Britain and the Guild of Catholic Doctors note that:
Ethical clinical research is regulated by the informed consent o f  the volunteer. 
Experimentation on human embryos is, in our view, rendered unethical and 
unacceptable by the fact that they are not able to comply with the consent or 
volunteer principle.82
This approach is supported by the ‘The Responsible Society -  Family and Youth 
Concern’ group and the Royal College of General Practitioners. In contrast, the Episcopal 
Church, General Synod Committee for Social Responsibility discusses the issue of 
consent by the embryo for research to take place and at what point human life begins but 
concludes that all human material may be deemed to have an agent who could give or 
withhold consent for research.83
In contrast, the groups who favour embryo research do not appear to be as 
concerned with discussing the moral status of the embryo in reaching their conclusions.
However, it needs to be made clear that although there is a substantial number of 
groups who support embryo research, there is a clear desire to impose limits upon the 
research, the most often stated limit being that the research should only be undertaken 
where it will benefit the embryo itself, be reimplanted and have the opportunity to 
develop into a human being.
Examples of this approach can be found in submissions from The Presbyterian 
Church of Ireland, the United Free Church of Scotland and The Baptist Union of Great 
Britain and Ireland. The United Free Church of Scotland states that:
...eggs originally fertilized fo r  reimplantation into the mother (in excess o f  the 
number actually so used) may serve for experimentation so long as they could still 
be used as “spares” to achieve a successful pregnancy.84
81 Ibid. Council o f Reform and Liberal Rabbis, 20th May 1983, Page vii
82 Ibid. Joint Ethico-Medical Committee o f  the Catholic Union o f Great Britain and the Guild o f  Catholic 
Doctors, Page 7
83 Ibid. Episcopal Church, General Synod Committee for Social Responsibility, Paragraph 12
84 Ibid. United Free Church o f Scotland, Appendix B
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Not all groups support the implantation of human embryos after research has been 
conducted upon them. The committee of the Soroptimist International o f Colwyn Bay and 
District categorically states that:
The manipulation o f human embryos to be forbidden i f  there were any intention to 
implant the resulting embryo in the womb.
The National Association for the Childless (NI) is also in agreement with this 
approach to embryo research as the majority of the Association’s members
...felt that spare embryos...which would be destroyed anyway may be used fo r  
experiments provided that:- (a) the embryos are destroyed at an early stage and 
before they become recognisable human beings...86
Other groups support embryo research on the basis that there is potential to either 
help infertility and/or detect and prevent hereditary diseases. Taking a more 
Consequentalist approach generally these comments are made without the detailed 
consideration and reference to the moral status of the human embryo which can be found 
in the submissions made by groups opposing embryo research, for example refer to the 
submission made by the Department of Medicine, University of Leeds:
All agreed that research into the therapeutic aspects o f  human fertilisation, and 
particularly research into treatments for infertility and prevention o f clearly 
defined inherited disease should continue...
As to experimentation upon embryos the Department fe lt this should be strictly 
controlled by law unless the committee were able to decide at what gestational 
age a developing embryo takes on the rights o f a human being87
Overall, from the submissions which support embryo research there is a call for
strict guidelines to control the research being undertaken and that it should not be
permitted beyond a certain stage of development of the embryo. The exact stage at which
research should be permitted up until varies from submission to submission. Some agree
85 Ibid. Soroptimist International o f Colwyn Bay and District, Paragraph headed ‘Research on spare human 
embryos’
86 Ibid. National Association for the Childless (NI), 18th February 1983, Paragraph headed ‘Experimental 
Use o f  Human Embryos’
87 Ibid. Department o f Medicine, University o f  Leeds, 19th January 1983
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with the BMA and MRC guidelines which were in force at the time of the Warnock 
Inquiry and which recommended fourteen days development. Twenty-one days 
development is suggested (when the embryo differentiates) and up to the pre-implantation
oo
stage is also suggested.
As can be seen from the few different submissions which have been quoted from 
the range of opinions put forward by many varying groups and individuals is immense 
with each one taking a slightly different approach to the difficult ethical questions of 
‘when does life begin to matter morally?’ and ‘should we permit research upon human 
embryos’. It is also difficult to put each opinion into an ‘ethical category’, such as 
Consequentalism. As can be seen from the earlier discussion of the different ethical 
viewpoints, the groups are not clear cut and variations can be found within each ‘ethical 
category’.
So how did the Warnock Committee consider and take into account all o f these 
different ethical opinions concerning embryo research?
The Warnock Report
It is in Chapter 11 of the Warnock Report that we find the discussion concerning 
human embryos and research upon them. The Warnock Report first looks at the early 
development of the human embryo with a detailed but clear discussion of the stages of 
development from the scientific point of view. The Warnock Report then moves onto 
note that the question of when life or personhood begins receives many different 
responses and “...that the answers to such questions in fact are complex amalgams o f
89factual and moral judgements. ” However, the Warnock Committee does not provide 
definitive answers to these questions, as the Report states:
Instead o f trying to answer these questions directly we have therefore gone
straight to the question o f how it is right to treat the human embryo.90
88 Ibid. Refer to the Lothian Health Board (February 1983) for the twenty-one day suggestion and the 
University o f  Glasgow, Faculty o f  Medicine (15th February 1983) for the suggestion o f  not permitting 
research beyond the preimplantation stage, page 2
89 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Warnock Report) 
(1984) DHSS Cmnd 9314 at Para 11.9
90 Ibid. at Para 11.9
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The Warnock Committee notes the different views taken in relation to research 
upon human embryos, summarising in five paragraphs the range o f arguments both for 
and against the use of human embryos. These range from the view that the human 
embryo has the same status as a child or an adult due to its potential for human life, to the 
opposite end of the spectrum that the human embryo is merely a collection of cells which 
has no potential for development unless it implants into a uterus and therefore should be 
accorded no protected status. Further consideration of the legal position of the in vivo 
embryo leads to the conclusion that the in vitro embryo is not afforded the same legal 
status as a living child or adult.
The Warnock Committee then goes on to state that “The status o f  the embryo is a 
matter offundamental principle which should be enshrined in legislation. We recommend 
that the embryo o f  the human species should be afforded some protection in law. ”91 The 
Report goes on to state that although the embryo is to be afforded some protection in law 
this does not mean that it cannot be waived in certain circumstances, and as such the 
majority of the Committee felt that research should not be totally prohibited.92 Due to the 
special status which the Warnock Report accords to the human embryo conditions are 
attached to research being performed upon human embryos. These include the 
requirement that handling of embryos is only permitted under a licence, no human 
embryo may be kept alive or researched upon beyond fourteen days after fertilisation and 
that no embryo which has been used for research should be transferred to a woman.93 
Fourteen days development was chosen as the cut-off point for it is around this time that 
the primitive streak normally occurs in embryos and it is this point which marks the 
individual development of the embryo.94
The Warnock Report therefore does not answer explicitly the question of ‘when 
does life begin to matter morally?’ rather it considers all of the different ethical 
viewpoints which have been submitted to it and provides the human embryo with a 
special status without actually defining the moral status of the human embryo. However, 
it could be said that the Warnock Committee implicitly answer the ethical question -  by 
allowing research to be performed only within the first fourteen days of development the
91 Ibid. at Para 11.17
92 Ibid. at Para 11.18
93 Ibid. at Para 11.18 and 11.22
94 Ibid  at Para 11.22
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Wamock Committee accord a Gradualist status to the human embryo -  as the embryo 
develops it should receive better legal protection due to its increasing humanness.95
That the human embryo should be afforded some protection in law is agreed with 
by all members of the Committee, although the subsequent conclusion that this protection 
is not absolute and will therefore allow research in limited circumstances is not favoured 
by all members of the Committee. The majority o f the Wamock Committee were 
satisfied that research could go ahead although they did not want to “...see a situation in 
which human embryos are used frivolously or unnecessarily used in research but... the 
treatment o f  infertility ...could not have taken place without such research; and that 
continued research is essential, i f  advances in treatment and medical knowledge are to 
continue. ”96 The Report also notes that “ ...the research in question would be mainly fo r  
the alleviation o f  infertility and the prevention o f hereditary disease. ”97 By suggesting 
that research would be limited to reasons such as infertility the Wamock Committee was 
reinforcing not only the Gradualist status which it had implicitly accorded to the human 
embryo but also to the type of scientific research which was being done at the time of the 
Report and to what was perceived by the general public as an acceptable reason to use 
embryos. This opinion was not shared by all members of the Committee and three 
members of the Committee take the view that the special status of the human embryo is 
due to its potential for development and as such nothing should be done to prevent its 
implantation. In the view of these three members it is “ ...wrong to create something with 
the potential for becoming a human person and to deliberately destroy it. ”98
The Wamock Report has cleverly avoided answering definitively the fundamental 
ethical question concerning the moral status of the human embryo whilst at the same time 
reaching a position which would allow research to continue in limited circumstances, 
thereby appeasing those who favoured embryo research. By taking this approach the 
Wamock Committee effectively pays lip service to the moral arguments that the human 
embryo is a human being with potential and should be protected from fertilisation.
95 Thanks to John Coggon who highlighted the implicit answer approach
96 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Wamock Report) 
(1984) DHSS Cmnd 9314 at Para 11.18
97 Ibid. at Para 11.26
98 Ibid. at Expression o f Dissent B, Para 3
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As will be seen, the recommendations made by the Wamock Report were to form 
the basis of the legislation in the United Kingdom which governs human fertilisation and 
embryology.
Post-Warnock Report
The publication of the Wamock Report in July 1984 generated considerable 
public debate and controversy, in particular in relation to the provisions concerning 
embryo research. As such, the UK Government was not ready to enact legislation and a 
Consultation Paper was published in December 1986." Within the Consultation Paper it 
was stated that “The Government recognises that deeply-held moral beliefs help to 
determine attitudes towards the question o f embryo research.. .” and accordingly took a 
position of neutrality during Parliamentary debates and allowed M P’s to take a free vote 
on this issue.100 The position of neutrality was further reflected in the fact that the 
Consultation Paper stated that alternative sets of draft clauses would be presented to 
Parliament -  one which would give effect to the Wamock Recommendations, the other 
would prohibit all research except that which was intended to benefit the embryo.101
The Consultation Paper summarised the different ethical approaches taken 
towards the human embryo and research upon it. The arguments in favour of research are 
framed under the heading ‘Suggested benefits of research’ whilst the opposing side is 
found under the heading ‘Arguments against research’. Although the Government stated 
that it was taking a position of neutrality, the way that the ethical arguments in favour of 
research are framed, in relation to possible scientific advances, seemed to weight the 
Consultation Paper towards allowing embryo research.
The 1987 White Paper, Human Fertilisation and Embryology: A Framework fo r  
Legislation, continued to recognise the ongoing debate surrounding the status of the 
human embryo although at this point in the legislative process the ethical arguments both 
for and against embryo research are summarised in two paragraphs.102 The recognition of 
what was now seen to be the two opposing arguments concerning embryo research is
99 Legislation on Human Fertility Services and Embryo Research, A Consultation Paper (1986) DHSS 
CM46
100 Ibid. at Para 57
101 Ibid. at Para 59
102 Human Fertilisation and Embryology: A Framework fo r  Legislation (1987) DHSS Cm259 at Para’s 28 
and 32
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found in the alternative draft clauses, one permitting research (within defined limits) and 
the other prohibiting it.
The later Human Fertilisation and Embryology Bill [H.L.] contains clauses which 
would allow human embryo research if passed in Parliament but o f course does not 
contain any further reference to the ethical arguments on the status o f the human embryo. 
The point of Consultation Documents and White Papers is that the ethical arguments and 
opposing views can be aired and discussed before the draft legislation is brought forth for 
debate. The fact that members of Parliament had a free vote on the Bill shows that there 
was still considerable ongoing public and parliamentary debate concerning this issue.
Finally, the Human Fertilisation and Embryology Act was enacted in 1990. The 
parliamentary free vote resulted in embryo research being permitted in limited 
circumstances as recommended in the Wamock Report.
The Human Fertilisation and Embryology Act 1990
The HFE Act brought into force the recommendations made by the majority o f the 
Wamock Committee -  to allow embryo research for specified research purposes and that 
the research could not continue beyond the fourteenth day of development of the embryo, 
or the appearance of the primitive streak, which ever occurs first.
By following the recommendations of the Wamock Report the HFE Act 
effectively still leaves open the question of the moral status of the human embryo. The 
legislation does not accord a moral status of the embryo; rather it implies a gradual status, 
it protects the embryo in certain circumstances, through the prohibition of certain 
activities and preventing research past fourteen days development.
One senior legal academic, Douglas J. Cuisine, recognised back in 1983 that it 
would be possible for the law to legislate on the matter of embryo research without 
defining the moral status of the human embryo. As he stated:
It is possible fo r  the law to say what ought or ought not to happen to these
embryos without actually defining their status...103
103 Douglas J. Cuisine, Senior Lecturer in Law, University o f Aberdeen, 18th March 1983, Written evidence 
to the Inquiry and Responses to the Report o f  Human Fertilisation and Embryology (1985) DHSS House o f  
Commons Library Dep 1497
53
Whether this is the correct approach to take towards such a profound ethical 
dilemma is of course open to debate. However, when read in light of other UK 
legislation, namely the Abortion Act 1967, the approach taken towards embryo research 
in the HFE Act is the most sensible approach to take. The situation would have been 
somewhat bizarre if embryos created through natural fertilisation were not protected and 
could be aborted, whilst embryos created by in vitro fertilisation were protected by 
legislation and had a right to implantation.
While the legislation veers away from definitively deciding the ethical questions, 
the HFE Act can undoubtedly be seen to be a victory for those who supported research, 
although the groups who favoured research only where the embryo would be implanted 
subsequently may not have been as happy with the resulting legislation.
Post-HFE Act 1990 -  Reform
Although the legislation took the approach of saying what research could be 
performed on human embryos, without explicit reference to the moral status of the 
embryo, the debate has continued to rage. The HFE Act has now undergone reform, due 
partly to the advances which have been made in the area of human embryo research.
Numerous documents relating to the reformation of the HFE Act have been 
published. The first was the House of Commons Science and Technology Committee 
Report, Human Reproductive Technologies and the Law, published in March 2005. This 
Report came about due to the Government’s lacklustre response to the Science 
Committee that it was keeping this area of law ‘under review’.
The Science Committee looks at the status of the human embryo in Chapter 3 o f its 
report. It recognises that there are three principal views on the status of the embryo:
a) That the embryo is a human life and therefore is entitled to conferral o f fu ll 
human rights;
b) That the development o f personhood is a gradual process but that the embryo is 
entitled to some protection; and
c) That the embryo is no more than a collection o f cells, albeit with the potential to 
develop into a human being.104
104 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1 at Chapter 3, paragraph 24
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Upon brief consideration of each of these positions, the Committee recognises that the 
Wamock Report adopted the Gradualist approach and that this remains valuable in 
today’s society. As the Report goes onto state:
...we believe that it represents the most ethically sound and pragmatic solution 
and one which permits in vitro fertilisation and embryo research within certain 
constraints set out in the legislation.105
Although the Science Committee expressly accepted that “At the heart o f  any 
review o f assisted reproduction legislation is the fundamental question o f  the status to be 
accorded to the human embryo” the Committee goes on to deal with this fundamental 
ethical question very briefly within its report.106 This is possibly because society is today 
generally accepting of embryo research within the defined limits set by the legislation.
In the response to the Science Committee Report the UK Government noted the 
Committee’s support of the Gradualist approach and responded by stating that it had 
“ ...no plans to bring forward proposals that would alter the legal status o f  the human 
embryo. ” 107 The Government was clear in its response that the ethical questions 
surrounding the status of the human embryo were not open for debate again.
Whilst the Science Committee was seeking and hearing evidence for its report, the 
Department of Health also announced its own review of the HFE Act, although it waited 
for the Science Committee Report to be published first to help inform its own review. 
The Department of Health undertook a public consultation on many different aspects of 
the HFE Act. Although the consultation was concerned with many aspects o f the 
legislation the Consultation document makes it very clear that the status of the embryo is 
not up for discussion. Within the introduction of the Consultation document it states that:
While many o f the [Science] Committee’s recommendations call fo r  changes to 
the law, the Committee considered that the basic foundations o f  the HFE Act 
remain sound. This included the approach taken in the Warnock Report to the 
status o f  the human embryo...108
105 Ibid. at Chapter 3, paragraph 28
106 Ibid. at Chapter 3, paragraph 24
107 Human Reproductive Technologies and the Law: Government Response to the Report from the House o f  
Commons Science and Technology Committee (2005) CM6641 at Para 2
108 Review o f  the Human Fertilisation and Embryology Act 1990: A Public Consultation (2005) Department 
o f Health at Para 1.10
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The Government does not intend that the review o f  the HFE Act will open up 
those fundamental aspects o f the legislation which are widely accepted in our 
society or which have been recently debated and conclusively resolved in 
Parliament. These include the creation and use o f  embryos fo r  research...109
Therefore, the Consultation document made it very clear that as far as the 
Government was concerned the ethical issue on the status of the human embryo was 
resolved and not up for discussion.
In December 2006 the Government published its White Paper with proposals for 
revised legislation.110 Within the White Paper it was reiterated that the status o f the 
human embryo as ascribed to it in the HFE Act was not to be altered -  the special status 
of the human embryo was actually described as one of the bedrocks o f the existing legal 
scheme.111
Since the White Paper a Draft Bill was published for consultation (May 2007) 
followed by the Bill itself in November 2007.112 Whilst the Bill was subjected to several 
amendments one provision which was not the subject of great debate was the retention of 
the fourteen day limit for research upon the embryo. The Bill and now the Human 
Fertilisation and Embryology Act 2008 has continued the Gradualist approach of the 
HFE Act 1990 by allowing research for a limited number of reasons and for a limited 
time period, hence respect for the embryo increases as it develops. As will be seen in the 
later discussion of the research purposes in the new Act, these have been expanded due to 
the changing social consensus of when it is acceptable to use human embryos for research 
as well as due to the scientific advances made since the Wamock Committee considered 
the issues in the early 1980’s although it is important to note that the frivolous use of 
embryos is still not permitted.
It was therefore clear that the Government intended that new legislation regulating 
human embryos was to continue the Gradualist approach adopted by the Wamock 
Committee in 1984 and which has formed the basis of the UK legislation for the past 18 
years.
109 Ibid. at Para 1.13
110 Review o f  the Human Fertilisation and Embryology Act: Proposals fo r  revised legislation (including 
establishment o f  the Regulatory Authority fo r  Tissue and Embryos) (2006) Department o f  Health CM 6989
111 Ibid. Foreword
112 Human Tissue and Embryos (Draft) Bill (2007) Department o f Health CM7087 http ://www. official- 
documents.gov.uk/document/cm70/7087/7087.pdf (last accessed 05/07/08)
Human Fertilisation and Embryology Bill [HLJ HL Bill 6, 54/3
http://www.publications.Darliament.uk/pa/ld200708/ldbills/006/2008006.pdfnast accessed 9/11/07)
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Conclusion
In considering the law which regulates embryo research in England and Wales it 
is clear that it does not respect diverse ethical opinions on the status of the human 
embryo. It would be impossible for the law to regulate a situation as delicate and 
sensitive as embryo research and respect all of the diverse opinions which surround this 
issue.
The ethical debate concerning the status of the human embryo occurred to its 
fullest extent in the 1980’s -  first in evidence considered by the Wamock Report, then in 
debates concerning the subsequent Consultation, White Paper and Bill. However, upon 
enactment of the HFE Act the position has become very clear -  the law respects and 
incorporates the ethical opinion of those who agree with embryo research in limited 
circumstances -  where the research is for a specified purpose and the embryo is not 
implanted after research has been performed. Limits upon the type of research which can 
be performed as well as the imposition of a time limit have appeared in the legislation 
due to the recognition that the human embryo has a special status; whilst this status is not 
absolute this does not signify that the human embryo can be used for frivolous matters. 
The continuation of this approach will no doubt persistently frustrate those with opposing 
ethical standpoints although it is hard to see why the law would change its current 
protective stance towards human embryos. The majority o f the public appear content with 
the current regulatory scheme and without more overwhelming support the chances of 
overturning this legal position in the future are remote.
In considering all of the different ethical opinions, and the variations within each 
category it is difficult to see how the legislation could ever find a position which would 
be acceptable to all. At first sight, the debate surrounding human embryo research 
appears to divide people, moving people to take one of two extremes with only a few 
taking the middle ground. What is interesting to note though is that the UK legislation has 
followed the middle ground and has not allowed itself to be led by those with extreme 
views on the moral status of the embryo. Holm sums up the position succinctly:
...no country currently has legislation that is consistent with any philosophically 
respectable view o f the moral status o f  the embryo, and it is worth noting that no 
country has legislation that is consistent with either o f  the two polar opposites,
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i.e. that the embryo has fu ll moral status, or that it has none at all... What is 
therefore likely to happen is a slow, incremental movement, probably towards a 
more liberal regulation o f ES cell research.113
113 Holm, S., Embryonic stem cell research and the moral status o f human embryos (2005) Reproductive 
Medicine Online Vol 10, Supp. 1 63-67 at p67
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Chapter 3 - The United Kingdom and the Path to Regulation
Introduction
The birth of Louise Brown in 1978, the first so-called ‘test-tube baby’, brought 
into the public forum the new reproductive technologies which up until that point were 
relatively unknown and unheard of. Following the ‘miracle’ birth o f Louise Brown 
concerns were voiced about the ethics and legality of such technologies and questions 
were raised over their regulation. In response to these concerns the Government 
established the Committee of Inquiry into Human Fertilisation and Embryology in July 
1982. This Committee was headed by Mary Wamock (now Dame Mary Wamock) and 
the report which ensued, the Report o f the Committee o f Inquiry into Human Fertilisation 
and Embryology, is now commonly referred to as the Wamock Report.114
Within the sphere of Medical Law the Wamock Report is perhaps one of the 
clearest reports to read and yet it also had the most far reaching implications. It formed 
the backbone of what was to eventually become the Human Fertilisation and Embryology 
Act 1990 as well as the later Human Fertilisation and Embryology Act 2008 and has since 
been considered to be the starting point of all the United Kingdom’s legislation on human 
fertilisation and embryology.
There is a very strong interface between embryo research and human embryonic 
stem cell research. Human embryonic stem cells were unheard of in 1978 when Louise 
Brown was bom; yet the legislation which came about as a result of the successful use o f 
IVF has since been applied to and shaped the research being done with human embryonic 
stem cells. As such it is vital to understand the legislation pertaining to human embryo 
research; in analysing the current legal standpoint of the United Kingdom towards human 
embryonic stem cell research it is vital to first consider both the content and the impact of 
the Wamock Report.
114 And will continue to be referred to as such throughout this work
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The Warnock Report
As Mary Wamock notes in her presentation of the Report, the Committee o f  
Inquiry into Human Fertilisation and Embryology was established in July 1982 “...to  
examine the social, ethical and legal implications o f  recent, and potential developments 
in the fie ld  o f  human assisted reproduction F us The terms of reference expand upon this 
statement:
To consider recent and potential developments in medicine and science related to 
human fertilisation and embryology; to consider what policies and safeguards 
should be applied, including consideration o f the social, ethical and legal 
implications o f  these developments; and to make recommendations.116
The Committee continued to clarify what the scope of the Inquiry was to be.117 In 
summary the scope of the Inquiry was to clarify two particular words -  ‘embryology’ and 
‘potential’ within the context of the new assisted reproductive technologies. The 
members o f the Committee recognised that the pace at which science was progressing 
would make it difficult to predict the effects science would have on the future. Therefore 
they took the approach o f reacting to what they knew and what they could foresee.118 As 
will be seen later this has implications in the debate surrounding the legality o f human 
cloning and human embryonic stem cell research.
The Wamock Report covered a wide array of issues ranging from surrogacy and 
artificial insemination to the storage o f human gametes and embryos. The principal areas 
of the Wamock Report which are of concern in relation to human embryonic stem cell 
research are Chapters 11, 12 and 13. These cover respectively Human Embryos and 
Research, Possible Future Developments in Research, and Regulating Infertility Services 
and Research. Chapter 13 of the Wamock Report is discussed in Chapter 5 o f this thesis 
-  the Human Fertilisation and Embryology Authority.
115 Report o f  the Committee o f  Inquiry into Human Fertilisation and Em bryology (The Warnock Report) 
(1984) DHSS Cmnd 9314 at Pg iv
116 Ibid. at Para 1.2
117 Ibid. at Para’s 1.3-1.5
118 Ibid. at Para 1.5
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Chapter 11 -  Human Embryos and Research
Prior to the Wamock Report no single body had been asked to consider the 
question whether human embryo research should be allowed. This was the question 
which the Committee was asked to consider and in order to answer it the Committee had 
to look at the early stages of human embryonic development.119
Paragraphs 11.2 to 11.7 clearly explain the early stages of human embryonic 
development and the Committee defined the point of fertilisation as being when “...the 
egg and sperm unite to become a single cell.”120 Once the Committee explained the early 
development of human embryos they continued on to consider the arguments both for and 
against the use of human embryos in research. This acceptance of when and how 
fertilisation occurs and how human embryos come into existence would in the future have 
far reaching implications for research involving embryos created by cell nuclear 
replacement (cloning). O f course it is to be borne in mind when reading the Wamock 
Report that it was written in 1984 when the concept of cloning was seen as somewhat 
futuristic and highly unlikely along with the fact that the cell nuclear replacement 
technique was not known about. That is not to say that the Wamock Committee did not 
consider cloning at all, in fact it was examined at Paragraph 12.11. O f note though is that 
the common day concept o f cloning, of replacing the nucleus of an unfertilised egg, is not 
mentioned. The method of cloning which was examined was the division of an embryo at 
a very early stage of development to produce identical twins, rather than producing a 
cloned embryo of someone who already (or has already) existed.
Note however that the concept o f cloning through cell nuclear replacement was 
brought to the attention of the Wamock Committee, albeit in relation to animals and 
through using a fertilised egg (rather than an unfertilised egg which the process now 
uses).
There are two methods o f  producing clones, genetically identical individuals, in 
animals. The first involves the destruction o f the nucleus in a fertilised egg and its 
replacement with a diploid nucleus from an individual selected fo r  cloning. This is 
the type o f  cloning which gives rise to the science-fiction spectre o f  unlimited 
clones o f  purpose-selected individuals. The technique has been applied to
119 Ibid. at Para 11.1
120 Ibid. at Para 11.2
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amphibians but, among other complications, successful development o f  the 
embryo requires the serial transfer o f  a diploid nucleus which has been obtained 
from  an embryonic source. In our present state o f  knowledge about embryology 
and the control o f  differentiation, this cannot be regarded as a feasible procedure 
fo r  man in the foreseeable future.121
Although the ethics of human embryo research and how the Wamock Committee 
considered the different ethical opinions has been discussed in the previous chapter, 
mention needs to be made briefly of these issues here.
The problem for many people was, and still is, the fact that the development of in 
vitro fertilisation has led to the creation of human embryos which may have no chance of 
being transferred to a uterus and therefore not have a chance to implant and develop. The 
Wamock Report clearly summarises the principal arguments against the use of human 
embryos in research:
Put simply, the main argument is that the use o f human embryos fo r  research is 
morally wrong because o f  the very fac t that they are human...The human embryo 
is seen as having the same status as a child or an adult, by virtue o f  its potential 
fo r  human life.12
The Wamock Report also raises the point that many people fear that scientists are 
tampering with the creation o f human life, that they are ‘playing God’. However this fear 
was probably adequately addressed in the Committee’s consideration o f the introduction 
of a new statutory licensing authority (which is discussed in Chapter 5 o f this thesis).
In contrast the Committee acknowledges that the views in support of the use of 
human embryos in research differ when considering the reasons why such research is 
supported. These range from the view that human embryos are not human persons and 
therefore do not need protecting (the Liberal approach) to the more popularly held view 
that human embryos are entitled to some protection but that respect cannot be absolute 
(the Gradualist approach). The respect which the human embryo deserves must be 
weighed against the potential benefits which could be obtained through such research (the 
Consequentalist approach). It is also noted that human embryos cannot always be
121 Comments o f  the Royal College o f  Pathologists, Feb 1983, pg 1 Written evidence to the Inquiry and  
Responses to the Report o f  Human Fertilisation and Embryology (1985) DHSS House o f  Commons Library 
Dep 1497
122 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Warnock Report)
(1984) DHSS Cmnd 9314 at Para 11.11
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substituted for animal cells thereby requiring the use of human embryos in some
123situations.
Possibly the most important part of the Wamock Report is the discussion by the 
Committee of the legal status of the human embryo. The succinct discussion o f the legal 
status of the human embryo clearly explains that the human embryo has no legal status; it 
is not protected by the law. Notwithstanding this, the Committee does note that there is 
some protection for human embryos in vivo which can be found in the Offences Against 
the Person Act 1861 read in conjunction with the Abortion Act 1967, Infant Life 
Preservation Act 1929 and Congenital Disabilities (Civil Liability) Act 1976.124
The Committee concluded that the human embryo should be afforded a special 
status and that human embryo research should not occur where animal products could be 
used. Although the Committee recommended that the human embryo should be given 
some protection in law the members recognised that this did not mean that research 
should be totally prohibited. However, the research which did occur should be stringently 
monitored and have strict controls due to the special status of the human embryo. 
Consequently the Committee recommended that research and handling of human 
embryos should only be permitted under licence and that unauthorised use should 
constitute a criminal offence.125 This is the Gradualist approach which has been discussed 
in greater detail in the preceding Chapter.
Whilst the majority o f the Committee agreed with the recommendation that 
research should be permitted upon human embryos it was agreed that it was necessary to 
impose a time limit upon keeping human embryos alive in vitro. A time limit was needed 
due to the recognition that the human embryo had a special status, even if this was not 
absolute. It was recognised that it would be the job of the proposed statutory licensing 
body to not only ensure that other research material was not available (principally animal 
materials) but to also limit the length o f time for which an embryo could be kept alive in 
vitro. Although the Committee recognised that “...the timing o f  the different stages o f  
development is critical... ”, they also recognised that “ ...biologically there is no one 
single identifiable stage in the development o f  the embryo beyond which the in vitro
123 Ibid. at Para 11.15
124 Ibid. at Para 11.16
125 Ibid. at Para 11.18
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embryo should not be kept a live”126 However, the Committee had to take a precise 
decision in order to allay public fears.
Various time limits were proposed by the groups who submitted evidence. The 
majority o f groups who agreed with research and proposed a time limit agreed with the 
Medical Research Council recommendation of fourteen days.127 In contrast other groups 
went as far as suggesting that twenty-one days would be an appropriate time limit, prior 
to organogenesis.128 In the end the Committee’s view was to use the development o f the 
primitive streak as the appropriate marker, this normally develops about fifteen days after 
fertilisation, and as such “This marks the beginning o f  individual development o f  the 
embryo” 129 Consequently the Committee recommended that no live human embryo 
(which will not be transferred to a woman) is to be allowed to develop beyond fourteen 
days after fertilisation. This does not include any time when the embryo is frozen. It was 
also recommended that embryos which have been used for research should not be 
transferred into a woman and that it was to be a criminal offence to use embryos beyond 
fourteen days growth.
There was further conflict from the groups who submitted evidence as to the 
source of human embryos for research, where such research was to be permitted. The 
conflict was between ‘spare’ embryos, i.e. those embryos which had been created for use 
in fertility treatments but which were no longer needed for treatment purposes, and those 
embryos which could be created specifically for research purposes. One statement which 
summarises the general opinion is:
“Spare” embryos should be used and not wasted (assuming the ‘parents’ have 
consented) but they should not be created specifically fo r  any purpose other than 
to conceive a child.130
126 Ibid. at Para 11.19
127 For example refer to the Welsh National School o f  Medicine, 20th April 1983 Written evidence to the 
Inquiry and Responses to the Report o f  Human Fertilisation and Embryology (1985) DHSS House o f  
Commons Library Dep 1497
128 Ibid. Refer to the Lothian Health Board, February 1983 and The Royal College o f  Physicians o f  
Edinburgh, January 1983
129 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Warnock Report) 
(1984) DHSS Cmnd 9314 at Para 11.22
130 Evidence submitted by CHILD to the Warnock Committee on the 24th February 1983 Written evidence 
to the Inquiry and Responses to the Report o f  Human Fertilisation and Embryology (1985) DHSS House o f  
Commons Library Dep 1497
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The Committee finally concluded that the issue was one for legislation to decide 
rather than the proposed statutory licensing body and subsequently recommended that, 
irrespective of the source of embryos, research should not be permitted after the 
fourteenth day of fertilisation.131
This was of relevance to human embryonic stem cell research; if the Warnock 
Committee had taken a firm stance against creating embryos specifically for research this 
may have dramatically slowed human embryonic stem cell research. In some research 
projects there is a need to derive stem cells from embryos which display specific traits, 
e.g. cystic fibrosis. If there were no ‘spare’ embryos available for research which showed 
this particular trait then the research would happen falteringly as and when ‘spare’ 
embryos were found that could be used.
Chapter 12 - Possible Future Developments in Research
It has already been noted above that the common day concept of cloning 
involving cell nuclear replacement was not considered by the Committee under their 
discussion of cloning. However, they did consider the concept of what they termed 
‘virgin birth’ under the paragraph on Parthenogenesis.132 This term describes the 
reproductive process whereby a gamete develops into a new individual without 
fertilisation although the consideration o f such a technique appears to involve the 
stimulation of growth through the application o f some substances, rather than the genetic 
manipulation of a gamete. Either way the Committee did “...not believe that such a 
development will take place in the foreseeable future .”133
Although the development of a gamete into a human embryo has not been 
successful through applying stimulating products (although parthenogenesis has been 
used to stimulate the division of unfertilised eggs134) it has been successful through the 
genetic manipulation of a gamete. This is the process of nucleus substitution and
131 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Warnock Report) 
(1984) DHSS Cmnd 9314 at Para 11.30
132 Ibid. at Para 12.10
133 Ibid. at Para 12.10
134 Advanced Cell Technology reports world’s first human embryo clone - Cibelli, J.B., Lanza, R.P. and 
West, M.D. with Ezzell, C. The First Human Cloned Embryo 24th Nov 2001, Scientific American 
286(1 ):44-51, 2002 http://www.sciam.com/article.cfm?articleID=0008B8F9-AC62-1C75-
9B 81809EC588EF21 &catID=4 (accessed 6th June 2005) Reported by the BBC Controversy over human 
embryo clone 26th November 2001: http://news.bbc.co.Uk/l/hi/sci/tech/1676234.stm (last accessed 6th June 
2005)
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principally this has been done through the replacement of the nucleus of an unfertilised 
egg with the nucleus of a cell taken from another cell (not necessarily from a fertilised 
egg). This is the current concept of cloning. The process was first successfully achieved 
in mammals by the Roslin Institute in Edinburgh with the announcement o f the birth of 
the now world famous Dolly the Sheep in 1996.135 This was a mere twelve years after the 
Warnock Committee had firmly stated that they could not see such a development in the 
foreseeable future. The process has also been successfully recreated in human embryos. 
The first claim of success in cloning a human embryo was from The Advanced Cell 
Technology Company based in the United States. They reported their work in Scientific 
American.136 However this first reported attempt at producing a human embryo clone 
received a note o f caution from Dr Wilmut at the Roslin Institute as the clone did not 
develop past the six cell stage.137 Since that first reported attempt there have been 
subsequent reports o f successful attempts to clone human embryos. These include the 
first UK success which was achieved by Newcastle University scientists in conjunction 
with the Newcastle Centre for Life.138
The final point to note in relation to Chapter 12 of the Warnock Report is that the 
Committee considered the possibility o f nucleus substitution. This is the process 
described above. The Committee considered the process in relation to fertilised eggs 
whereas today we know that the process can be performed with unfertilised eggs. What is 
important here is that although the Committee felt that “...nucleus substitution would 
raise more fundamental questions...” they do not note in the Report what those 
fundamental questions would be or consider whether this is something which could in 
reality happen.139 They recognised the possibility of producing clones in this way could 
lead to the production of “.. .immunologically identical replacement organs by growing
135 Cloning - A life o f  Dolly Roslin Institute, http://www.roslin.ac.uk/publicInterest/cloning.php (accessed 
19/02/08)
136 Cibelli, J.B., Lanza. R.P. and West. M.D with Ezzell, C. The First Human Cloned Embryo 24th 
November 2001 Scientific American 286(1):44-51, 2002
http://www.sciam.com/article.cfm?articleID=0008B8F9-AC62-lC75-9B81809EC588EF21 (accessed 6th 
June 2005)
137 Dr Wilmut quoted in the BBC news report Controversy over Human Embryo Clone 21st November 
2001 http://news.bbc.co.Uk/l/hi/sci/tech/1676234.stm (accessed 6th June 2005)
138 Stojkovic. M., Stojkovic. P., Leary. C., Armstrong. L., Herbert. M., Nesbitt. M., Lako. M., Murdoch. A. 
Derivation o f  a human blastocyst after heterologous nuclear transfer to donated oocytes. (2005) 11(2) 
Reproductive Biomedicine Online 226-231
http://www.rbmonline.com/4DCGI/Article/Detail738%091%09=%201872%09 (Extract accessed 6th June 
2005, full article accessed 2nd February 2007)
139 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Warnock Report) 
(1984) DHSS Cmnd 9314 at Para 12.14
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the organ in an embryo in which the nucleus had been replaced by one taken from  the 
person fo r  whom the replacement organ is intended.”140
The fact that the Warnock Committee considered that nucleus substitution would 
raise ‘fundamental questions’ is particularly interesting in light of the later acceptance by 
both the Courts and the Government of the inclusion of the cell nuclear replacement 
technique within the statutory definition (for further discussion of this matter see below). 
Whilst various reports and a subsequent court decision considered that cell nuclear 
replacement embryos were included in the legislation, there was not a great deal of debate 
about the fundamental issues of including such embryos, possibly due to the fact that the 
use of cell nuclear replacement embryos in conjunction with stem cell research could 
provide cures for many illnesses and diseases.
Although the Warnock Report recommended that human embryos should be 
permitted to be used in research (subject to strict controls) there was sufficient dissent 
within the membership of the Committee to warrant the inclusion of ‘Expression o f  
Dissent: B. Use o f  Human Embryos in Research \  The inclusion of this expression of 
dissent by three members of the Committee accurately reflects the current day attitudes of 
society towards the use of human embryos in research.
The dissenting members o f the Committee, Madeline Carriline, Professor John 
Marshall and Jean Walker, all agreed with the other Committee members that the human 
embryo had a special status but then departed from the majority thinking as to what this 
special status actually signified. They recognised that the question “When does life 
begin?” is not an accurate phrasing o f the moral question facing most people when 
deciding upon the use of human embryos in research. They rephrased the question to read 
“At what stage o f  development should the status o f a person be accorded to an embryo o f  
the human species?”XAX However the dissenting members did not believe that the special 
status of the human embryo and the protection which it is to be afforded by the law 
depends on the decision as to when it becomes a person. They recognise that the human 
embryo has a special status due to its potentiality; the “...potentialfor development to a 
stage at which everyone would accord it the status o f  a human person.5,142 The dissenting 
members firmly believed that it was “...wrong to create something with the potential fo r
140 Ibid. at Para 12.14
141 Ibid. at Para 2, Expression o f  Dissent: B. Use o f  Human Embryos in Research
142 Ibid. at Para 3, Expression o f  Dissent: B. Use o f  Human Embryos in Research
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becoming a human person and then deliberately destroy it.”143 They continued on to state 
that whilst they supported the creation of human embryos with the aim of implanting 
them, thereby being permitted to attempt to fulfil their potentiality, they were firmly 
against using ‘spare’ embryos or deliberately created embryos in experimentation and 
research. As they succinctly state, “Because embryos have the potential to become human 
persons neither the relief o f  infertility nor the advance o f knowledge justifies their 
deliberate destruction.” 144 This reflected many opinions of the time and continues to 
reflect many modem day opinions and criticisms of the United Kingdom’s stance on 
human embryo research.
Finally it should be noted that although the majority of the Committee agreed that 
research should be permitted on human embryos there was a further expression of dissent 
concerning creating embryos specifically for the purposes of research. ‘Expression o f  
Dissent: C. Use o f  Human Embryos in Research ’ was signed by four members of the 
Committee who, although they agreed with permitting research on human embryos, 
expressly disagreed that “research should be permitted on embryos brought into existence 
specifically fo r  that purpose or coming into existence as a result o f  other research.”145
Since this Expression o f Dissent various figures have been reported on the 
number of embryos created specifically for research. Between 1991 and 1998 only 118 
embryos were created specifically for research (compared to 48,444 which were created 
for other reasons and donated to research). A further reference to the number of embryos 
created specifically for research is found in the House of Commons. Dawn Primarolo, on 
the 3rd December 2007, stated that only 2 embryos had been created specifically for 
research since 1999.146 This figure is obviously incorrect when compared with the more 
recent and reliable figures available from the HFEA which show that between 2005 and 
early 2007 a total of 429 embryos were created specifically for research. This figure 
represents 5% of the total number o f embryos used in research.147 Whilst these relatively 
low numbers will of course not appease those completely against creating embryos 
specifically for research, it is hoped that it would at least ease some people’s concerns
143 Ibid. at Para 3, Expression o f  Dissent: B. Use o f  Human Embryos in Research
144 Ibid. at Para 7, Expression o f  Dissent: B. Use o f  Human Embryos in Research
145 Ibid. at Expression o f  Dissent: C. Use o f  Human Embryos in Research
146 Hansard -  House o f  Commons, Written Answers, 3rd December 2007, Human Embryo Experiments, 
Volume 468, Column 1005W
147 Figure 4 Human Embryo Research in the UK 2006/2007  HFEA
http://www.hfea.gov.uk/docs/HFEA Human-Embrvo-Research-06-07.pdf (accessed 16/06/09)
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over embryos being consistently used as a means to an end. It is noted that these figures 
are not completely up to date; however a recent request for the latest data from the HFEA 
has not received a response.148
Post-Warnock
Legislation on Human Fertility Services and Embryo Research: A 
Consultation Paper
Whilst the Warnock Report was generally well received by the Government it was 
felt that further consultation was needed. It took some two and a half years for the 
Government to publish its consultation paper, Legislation on Human Fertility Services 
and Embryo Research}*9 As the Consultation Paper notes the publication of the Warnock 
Report and the introduction o f three Private Members Bills to prohibit embryo research 
had all generated “ .. .considerable debate both on the principle o f  allowing any such 
research and the definition o f  circumstances in which it might be permissible.”150 In 
addition the Government recognised that “...the range and complexity o f  the issues 
raised by the Warnock Report and the strength and diversity o f  opinion expressed make it 
desirable that there should be a further period fo r  consultation before any legislation is 
drafted.11,151
O f particular relevance to this thesis are paragraphs 45-60 of the Consultation 
Paper which are concerned with the issue of research involving human embryos. To 
ensure that the proposals were fully debated the Government had taken care in framing 
the proposals to take into account the diversity of views.
The suggested benefits of continued controlled research include:
a) Improving the treatment o f  infertility:
b) Gaining further knowledge about factors leading to congenital disease:
c) Developing more effective form s o f  contraception:
d) Detecting gene or chromosome abnormalities before implantation.152
148 Personal electronic communication to the HFEA 24th October 2008
149 Legislation on Human Fertility Services and Embryo Research: A Consultation Paper (1986) DHSS 
Cm46
150 Ibid. at Para 45
151 Ibid. at Para 4
152 Ibid. at Para 48
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It is also noted that those who support embryo research do not generally accept the 
proposition that embryos should have the same full human status as a child from the 
moment of conception.153
In contrast the principal argument against embryo research is noted as “...embryos 
from the point o f  conception have the same human status as that o f  a child or an 
adult.”154 Therefore it is improper to conduct research upon them which will lead to their 
eventual destruction. “The embryo should be seen as fully human because o f its potential 
fo r  human life, the right to life being the most fundamental o f  all human 
rights.. .destruction o f  an embryo is tantamount to murder.. .”155
It is also suggested that research should only be carried out on an embryo where it 
could benefit from the research, in the sense that the research would enhance the potential 
of the embryo for development to a possible birth.156
A further argument against human embryo research is that the introduction of a 
fourteen day rule would not result in any worthwhile research on hereditary diseases as 
the embryo would not have developed sufficiently in this period. There are also fears that 
many scientists would later argue to raise the cut-off point. Additionally it is argued that 
most research could easily be carried out in animal studies.
The Consultation Paper also recognises that there are many who do not clearly fall 
into the pro- or anti- groups, as some would allow limited research and believe that it 
ought to be controlled. Others have endorsed the view that ‘spare’ embryos could be used 
for research but that scientists should not be allowed to create embryos specifically for 
research. The majority appear to agree with the fourteen day limit although some felt that 
this should be reviewed in the future.
What does come out of this Consultation Paper is that the majority of respondents 
to the Warnock Report did want regulation as the lack of statutory controls was a deeply 
unsatisfactory situation to be in. O f course the diversity of views on the subject matter 
results in a diversity of opinions as to what rules exactly the regulation should impose.
The approach taken by the Government towards legislation on embryo research is 
a position of neutrality. It proposed in the Consultation Paper to offer to Parliament
153 Ibid. at Para 51
154 Ibid. at Para 52
155 Ibid. at Para 52
156 Ibid. at Para 53
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alternative sets o f draft clauses. One would follow the recommendations of the Warnock 
Report whilst the other would prohibit all research which was not intended to benefit the 
individual embryo. The idea of proposing alternative clauses is to allow a full debate and 
a free vote on the contentious issue of permitting human embryo research.157
Human Fertilisation and Embryology: A Framework for Legislation158
The consultation period for the paper Legislation on Human Fertility Services and 
Embryo Research ended in June 1987 and the Government published the White Paper, 
Human Fertilisation and Embryology: A Framework for Legislation in November of that 
same year.
In the opening paragraphs of the White Paper the need to define an embryo was 
recognised. It states that the
Government proposes that legislation should apply to embryos created in vitro 
(i.e. by mixing sperm and eggs together in a dish), from  the point at which 
fertilisation is completed. The start o f cell division would be taken to be proof that 
the process o f  fertilisation has ended}59
This is interesting to note as the moment or process of fertilisation was not 
defined in the White Paper, and if the moment or process of fertilisation had not been 
specifically referred to in the final legislation it could have saved the time and effort 
involved in the Quintavalle cases which disputed whether cell nuclear replacement 
embryos fell into the remit of the Human Fertilisation and Embryology Authority. The 
case is discussed below.
The discussion of embryo research can be found in paragraphs 28 to 42 o f the 
White Paper where it is considered that “77ze key distinction in the debate surrounding 
embryo research appears to be between the use o f  an embryo with the intention o f  
achieving...a successful pregnancy ...and its use for other reasons (e.g. improvement o f  
knowledge about disease).”160 In light of this conflict over the use o f human embryos in 
research the Government formulated two alternative draft clauses:
157 Ibid. at Para 58-60
158 Human Fertilisation and Embryology: A Framework fo r  Legislation (1987) DHSS Cm259
159 Ibid. at Para 7
160 Ibid. at Para 29
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Prohibiting research:
It will be a criminal offence to carry out any procedures on a human embryo 
other than those aimed at preparing the embryo fo r  transfer to the uterus o f  a 
woman; or those carried out to ascertain the suitability o f  that embryo fo r  the 
intended transfer.
Permitting research:
Except as part o f  a project specifically licensed by the SLA, it will be a criminal 
offence to carry out any procedures on a human embryo other than those aimed at 
preparing the embryo fo r  transfer to the uterus o f  a woman or those carried out to 
ascertain the suitability o f  that embryo for the intended transfer.161
In the same paragraph it also assures that the provisions would not make it an 
offence to store embryos with the intention of using them for future transfer to a woman, 
nor would it be illegal to allow embryos to perish where they are not to be transferred (for 
example because an abnormality had been detected).
Concerning the time limit on the use of embryos in research it was recognised that 
this would obviously only be needed if  Parliament subsequently voted to permit research 
on human embryos but that the recommendation of an upper time limit was needed 
should this eventuality occur. The proposed time limit in the Warnock Report is 
documented in the White Paper as being the most controversial recommendation to come 
from the Warnock Committee. At the date o f the White Paper it was stated that no human 
embryo had been kept alive in vitro for more than eight or nine days but equally it 
recognised that this time period could be extended in the near future.162 Whilst it 
recognised that Parliament would take its own view the Government decided to accept 
the Warnock Report recommendation and that if research was permitted “the Government 
...proposes that the Authority will not be able to give a licence fo r  the use o f  embryos 
beyond fourteen days or after the appearance o f  the primitive streak, whichever is the 
earlier.”163 It continues on, “The period will be measured as fourteen completed days 
from  the time at which egg and sperm are placed together fo r  fertilisation (excluding 
periods o f  storage in an arrested state o f  development) .”164
161 Ibid. at Para 30
162 Ibid. at Para 31
163 Ibid. at Para 33
164 Ibid. at Para 34
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The White Paper goes further than the earlier Consultation Document as it 
suggests that certain areas of research should be expressly prohibited due to public 
concerns about possible future developments involving human embryos. Whilst the 
Warnock Report considered any such developments to fall within the remit of the 
proposed statutory licensing authority, who would issue guidelines on those areas which 
it considered ethically unacceptable and should not be licensed, the Government 
proposed that legislation should specifically prohibit such activities but with the ability of 
Parliament to make exceptions to these prohibitions if  new developments were 
appropriate. The areas which it suggests should be prohibited are the genetic 
manipulation o f the embryo, the creation of hybrids, and trans-species fertilisation.165
In relation to the proposed prohibitions what is interesting to note at this stage is 
that paragraphs 37 and 38 o f the White Paper specifically state that the practice of “...the 
artificial creation o f human beings with pre-determined characteristics through 
modification o f  an early embryo’s genetic structure” and “producing artificially two or 
more genetically identical individuals by nucleus substitution (sometimes known as 
cloning)n would be prohibited by the Bill and make such practices a criminal offence. It 
also notes that no such work involving cloning is known to be carried out at present 
although it might theoretically be achieved.
The second specific prohibition involving the artificial production of two or more 
genetically identical individuals by nucleus substitution was not carried through to the 
Bill or the resulting Act. As will be seen the Act prohibited cloning in the form as it was 
known at the time (the replacement o f a nucleus of a cell of an embryo). It did not 
prohibit nucleus substitution of a single cell, which it would appear that it could have 
done by prohibiting the artificial creation of genetically identical individuals through 
nucleus substitution.
Human Fertilisation and Embryology Bill [H.L.1
Two years on from the White Paper Human Fertilisation and Embryology: A 
Framework fo r  Legislation, the Government published its Human Fertilisation and 
Embryology Bill}66
165 Ibid. at Para 36-42
166 Human Fertilisation and Embryology Bill [H.L] (1989)
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The first point to note is that the Bill continues the definition of an embryo as 
espoused in the earlier White Paper. The definition of an embryo is found in Clause 1 
subsection 1 where it states that:
References in this Act to an embryo, except where otherwise stated, are to a live
human embryo where fertilisation is complete and, fo r  this purpose, fertilisation
is not complete until the appearance o f a two cell zygote.
So again it leaves the ambiguity as to the exact process of fertilisation and what 
this involves for legal as well as scientific purposes. At the time of drafting the Bill it was 
not foreseen that this would cause a problem in the future, however as will be seen from 
the later discussion this particular definition of an embryo was to prove problematic. 
Although the definition is very similar to that found in the White Paper there is one 
noticeable difference; the White Paper specifically referred to ‘embryos created in vitro 
i.e. by mixing sperm and eggs together in a dish’ whereas the Bill refers to ‘live human 
embryos where fertilisation is complete’. The more direct reference to fertilisation and 
the removal o f ‘embryos created in vitro’ was to lead to a Court challenge which could 
have altered the path o f human embryonic stem cell research (see below for a discussion 
of the case).
The Human Fertilisation and Embryology Bill expanded upon the proposed 
activities which it was felt should be specifically prohibited by legislation. The activities 
governed by the proposed Act are covered in Clause 3 of the Human Fertilisation and 
Embryology Bill'.
Clause 3(1) No person shall-
(a) bring about the creation o f  an embryo, or
(b) keep or use an embryo,
except in pursuance o f  a licence.
(2) No person shall place in a woman —
(a) a live embryo other than a human embryo, or
(b) any live gametes other than human gametes.
(3) A licence cannot authorise -
(a) keeping or using an embryo after the appearance o f the primitive streak,
(b) placing an embryo in any other species o f  animal,
(c) keeping or using an embryo in any circumstances in which regulations 
prohibits its keeping or use, or
(d) replacing a nucleus o f  a cell o f  an embryo with a nucleus taken from  a cell o f  
any person, embryo or subsequent development o f  an embryo.
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(4) For the purposes o f  subsection (3)(a) above, the appearance o f  the primitive 
streak is to be taken to have appeared in an embryo not later than the end o f  the 
period o f  14 days beginning from  the day when the gametes are mixed, not counting 
any time during which the embryo is stored.
It appears that Clause 3(3)(d) o f the Human Fertilisation and Embryology Bill 
specifically prohibits cloning. However, it merely prohibits the replacing of a nucleus o f a 
cell of an embryo -  i.e. where fertilisation is complete. It does not appear to foresee the 
replacing of the nucleus o f an egg with the nucleus from another cell. It has therefore not 
continued the prohibition of nucleus substitution mentioned in the White Paper (as 
discussed above). This has implications in relation to human embryonic stem cell 
research which will be discussed later on.
It should also be noted that Clause 3(4) continues the Warnock Report 
recommendation of imposing a maximum fourteen day time limit on research.
As with the Warnock Report the Human Fertilisation and Embryology Bill 
continues to discuss many other areas such as surrogacy and the powers of the proposed 
Statutory Licensing Authority. What is of relevance to this work however is Schedule 2 
of the Human Fertilisation and Embryology Bill which discusses activities for which 
licences may be granted by the Statutory Licensing Authority.
The main provisions of Schedule 2 which concern us are those contained in 
Paragraph 3:
Schedule 2, Paragraph 3 — Licences fo r  research 
3(1) A licence under this paragraph may authorise any o f  the following -
(a) bringing about the creation o f  embryos in vitro, and
(b) keeping or using embryos,
fo r  the purposes o f  a project o f  research specified in the licence.
(2) A licence under this paragraph cannot authorise any activity unless it appears to 
the Authority to be necessary or desirable fo r  the purpose o f—
(a) promoting advances in the treatment o f  infertility,
(b) increasing knowledge about the causes o f  congenital disease,
(c) increasing knowledge about the causes o f  miscarriages,
(d) developing more effective techniques o f contraception, or
(e) developing methods fo r  detecting the presence o f  gene or chromosome 
abnormalities in embryos before implantation,
or more generally fo r  the purpose o f  increasing knowledge about the creation and
development o f  embryos and enabling such knowledge to be applied.
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(3) A licence under this paragraph cannot authorise altering the genetic structure 
o f any cell while it forms part o f  an embryo, except in such circumstances ( if any) 
as may be specified in or determined in pursuance o f  regulations.
(5) No licence under this paragraph shall be granted unless the Authority is 
satisfied that any proposed use o f  embryos is necessary fo r  the purposes o f  the 
research.
O f particular interest here is sub-paragraph 3 which specifically prohibits the 
‘altering o f  the genetic structure o f  any cell whilst it forms part o f  an embryo\ Again, in 
relation to cloning and human embryonic stem cell research, it would seem that the 
replacement o f the nucleus of an egg falls outside the remit of the Human Fertilisation 
and Embryology Bill. It does not prohibit human embryonic stem cell research as such, 
merely not seeming to cover human embryonic stem cell research which involves cloned 
embryos.
Human Fertilisation and Embryology Act 1990
The Human Fertilisation and Embryology Act 1990 was enacted on the 1st 
November 1990.167 There were no substantial changes made to the Human Fertilisation 
and Embryology Bill although that is not to say that the HFE Act had a smooth passage 
through Parliament. As can be seen from Hansard the provisions concerning human 
embryo research were the most contentious o f all of the provisions.
The fundamental issue o f  conscience in the Bill relates to whether embryo 
research should be allowed within closely defined limits or prohibited altogether. 
That topic has occupied most o f  the time o f the House on Second Reading.
The relevant provisions discussed above in the Human Fertilisation and 
Embryology Bill were all enacted more or less as formulated in the Bill. However the 
definition of an embryo was expanded upon to include ‘an egg in the process o f  
fertilisation ’, and so now reads as thus:
Section 1(1) In this Act, except where otherwise stated -
167 Hereafter referred to as the HFE Act
168 Sir Geoffrey Howe, 2nd April 1990, Hansard  HC Volume 170, Column 986
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(a) embryo means a live human embryo where fertilisation is complete, 
and
(b) references to an embryo include an egg in the process o f  fertilisation, 
and, fo r  this purpose, fertilisation is not complete until the appearance o f  
a two cell zygote.
This was probably introduced as a means of providing protection to eggs which 
had not yet reached the appearance o f the two cell zygote. Additionally, further statutory 
protection was provided by Section 3(3)(a) which prohibits ‘keeping or using an embryo 
after the appearance o f the primitive streak’. According to Section 3(4) of the HFE Act 
“...the primitive streak is to be taken to have appeared in an embryo not later than the 
end o f  the period o f  14 days... ” This section prevents scientists from (legally) working on 
embryos which have developed past this point. Whilst the majority of the public now 
favours embryo research it appears that it is the strict controls which are applied to 
scientists working with embryos that have increased public confidence and acceptance of 
such work.169 For the purpose o f human embryonic stem cell research, stem cells are 
normally extracted at around five to six days development, at which point the embryos 
are destroyed. Therefore, in respect o f human embryonic stem cell research, the fourteen 
day limit is adequate as it does not hinder embryonic stem derivation and subsequent 
research.
Schedule 2, Clause 3(3) of the Human Fertilisation and Embryology Bill became 
Schedule 2, Paragraph 3, sub-paragraph 4 in the HFE Act but continues to prohibit the 
alteration o f the genetic structure o f any cell whilst it forms part of an embryo; this does 
not prohibit the cell nuclear replacement technique which was developed a few years 
after the enactment of the HFE Act, however, it equally does not specifically include the 
process of cell nuclear replacement as a method of creating embryos for research. When 
read in conjunction with the definition of an embryo contained in section 1(1) it can be 
seen, admittedly with hindsight, that these definitions and the resulting grey area in 
relation to the cell nuclear replacement technique would later be challenged in the Courts, 
and as discussed below, was challenged as such a mere eleven years after enactment.
169 Refer to the 2003 MORI poll which found that around 56% o f  people are supportive o f  the use o f  human 
embryos for research into treatments for serious diseases and fertility but not for most other types o f  
research. Seven In Ten M embers O f The Public Support The Use O f Embryos For M edical Reasons MORI 
Poll 8th April 2003 http://www.ipsos-mori.com/content/seven-in-ten-members-of-the-public-support-the- 
use.ashx (last accessed 4/11/08)
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The HFE Act placed onto a legislative footing, for the first time, five permitted 
areas o f research involving human embryos. A licence must first be obtained from the 
statutory licensing authority set up under the HFE Act -  the Human Fertilisation and 
Embryology Authority (HFEA). The HFEA may give a licence to create, keep or use 
embryos and permit research where it is desirable or necessary for a specified purpose. 
The permitted areas of research are contained in Schedule 2, paragraph 3(2):
(a) promoting advances in the treatment o f  infertility,
(b) increasing knowledge about the causes o f  congenital disease,
(c) increasing knowledge about the causes o f  miscarriages,
(d) developing more effective techniques o f  contraception, or
(e) developing methods fo r detecting the presence o f  gene or chromosome
abnormalities in embryos before implantation,
or fo r  such other purposes as may be specified in regulations.
The limitation o f embryo research to these permitted purposes carried through the 
approach adopted by the Warnock Committee; the human embryo has a special status that 
is not absolute but also cannot be overridden for any frivolous reason. The above 
permitted research purposes were also those which were being looked into by the 
scientific community and were deemed to be acceptable, non-frivolous reasons for 
overriding the moral status of the human embryo.
The Act continues on to state that:
Purposes may only be so specified with a view to the authorisation o f  projects o f
research which increase knowledge about the creation and development o f
embryos, or about disease, or enable such knowledge to be applied.170
At the time of enactment human embryonic stem cell research was not conceived 
of. The first stem cells had been extracted from mice in 1981 by Sir Professor Martin 
Evans at Cambridge but it was not until 1998 that the first human embryonic stem cells 
were successfully extracted by James Thomson at the University o f Wisconsin. Upon 
inspection o f the permitted purposes for human embryo research it becomes apparent that 
the majority of human embryonic stem cell research would not have been permitted under 
the original five permitted purposes. Importantly, the Government had added to the Act 
the proviso that other purposes could be specified in regulations at a later date, if  it was
170 Schedule 2, Paragraph 3(3) HFE Act 1990
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felt that further purposes were needed. This was vital in allowing human embryonic stem 
cell research and, as will be seen later in this work, regulations were indeed used to 
permit such research to be licensed by the HFEA. As will be seen, the use of regulations 
to extend the permitted research purposes is an excellent example of the legislation 
governing embryo research being used to allow the derivation of stem cells and 
subsequent research.
1990 Onwards
The HFE Act is seen by many countries to be a progressive and liberal piece of 
legislation and elements o f the Act have been used as a framework for legislation 
elsewhere.171 The provisions of the Act apparently worked in harmony with scientists for 
a number o f years allowing them to progress with important research whilst also 
maintaining a system of checks and balances.
The birth o f Dolly the Sheep in 1996, which was announced in 1997, re-sparked 
both public and academic interest in the regulation of scientists and their research. Dolly 
the Sheep was the product of the work of Dr Ian Wilmut and his team at the Roslin 
Institute in Scotland. She was produced after 277 attempts to create and grow a clone 
through the cell nuclear replacement technique. As the first ever successful production of 
a mammal clone this raised in the public mind the fear that scientists could and would 
produce a human clone in the near future. Initially the public fears were unfounded as it 
was thought that cloning fell into the remit o f the HFE Act, as seen by the Governments 
assertion as such in June 1999, and would therefore be prohibited.172
171 Examples include Belgium, Canada and Spain. Refer to Stem Cell Policy: World Stem Cell M ap for a 
map showing the policies o f  different countries http://www.mbbnet.umn.edu/scmap.html (accessed 
23/11/08)
172 Government Response to the Report by the Human Genetics Advisory Commission and the Human 
Fertilisation and Embryology Authority on Cloning Issues in Reproduction, Science and Medicine 
1999/0383 Department o f  Health
http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/PressReleasesNotices/fs/en?CONTENT ID 
=4025446&chk=0zNabK (accessed 05/07/08)
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Human Genetics Advisory Commission Paper -  Cloning Issues in
Reproduction, Science and Medicine
Following the scientific breakthrough of Dolly the Sheep, the Human Genetics 
Advisory Commission and Human Fertilisation and Embryology Authority held a 
consultation exercise on cloning. This was due to the national, as well as international, 
concern that the technology used to clone Dolly could be applied to human beings. The 
paper was a comprehensive overview o f the legal, ethical and scientific situation in 1998. 
It discussed the two different methods of cloning -  embryo splitting and nuclear 
replacement.
Whilst not specifically referring to human embryonic stem cell research the paper 
was of relevance due to the desire to extract stem cells from cloned embryos, allowing for 
the creation of stem cells which are a genetic match to patients who had donated the 
genetic material to create the clones in the first place.
O f particular relevance here is Section 5: Legal Framework. As the paper states:
The nuclear substitution o f  an embryo, or any cell whilst it form s part o f  an 
embryo is expressly prohibited by the HFE Act. Embryo splitting and nuclear 
replacement o f  eggs are not expressly prohibited, but as both involve the use or 
creation o f  embryos outside the body, they fa ll within the HFE Act and therefore 
come under the jurisdiction o f the HFEA.m
As can be seen it was accepted by the relevant bodies that embryos created by cell 
nuclear replacement fell within the remit of the HFE Act. This view was subsequently 
confirmed in the Donaldson Report, Stem Cell Research: Medical Progress with 
Responsibility, and accepted by the Government in their response to that report.
173 HGAC Paper Cloning Issues in Reproduction, Science and Medicine (1998) Department o f  Health 
http://www.advisorybodies.doh.gov.uk/hgac/papers/papers c.htm (last accessed 13/08/08)
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Stem Cell Research: Medical Progress with Responsibility. A Report
from the Chief Medical Officer’s Expert Group Reviewing the Potential 
of Developments in Stem Cell Research and Cell Nuclear Replacement 
to Benefit Human Health174
The Expert Group was set up by the Government following the publication of the 
joint report from the Human Genetics Advisory Commission and the HFEA Cloning
175Issues in Reproduction, Science and Medicine. The Report which ensued, Stem Cell 
Research: Medical Progress with Responsibility. A Report from  the Chief Medical 
Officer’s Expert Group Reviewing the Potential o f  Developments in Stem Cell Research 
and Cell Nuclear Replacement to Benefit Human Health (hereafter referred to as the 
Donaldson Report due to the presiding Chief Medical Officer Professor Liam Donaldson) 
provides a comprehensive analysis o f the issues involved in stem cell research and cell 
nuclear replacement.
The Expert Group was asked “ .../o undertake an assessment o f  the anticipated 
benefits o f  new areas o f  research using human embryos, the risks and the alternatives 
and, in the light o f  that assessment, to advise whether these new areas o f  research should
1 7  f\  •be p e r m i t t e d The Donaldson Report provided a wide-ranging overview of the then 
current situation (in the year 2000) concerning the potential benefits of stem cell research 
along with the ethical and legal considerations which had to be taken into account. The 
ethical considerations are dealt with elsewhere in this work.
The Expert Group was concerned with determining if  it would be acceptable to 
increase the number of research purposes permitted at the time under the HFE Act. In 
consideration of this the Expert Group had to deliberate whether embryos created by cell 
nuclear replacement were controlled by the HFE Act. Continuing the stance taken by the 
Human Genetics Advisory Commission and the HFEA the Expert Group obviously 
considered that embryos created by cell nuclear replacement did fall under the control of 
the HFE Act. This stance can be seen from the following extracts from the Report:
174 (2000) Department o f  Health
175 Stem Cell Research: M edical Progress with Responsibility. A Report from  the C hief M edical O fficer’s 
Expert Group Reviewing the Potential o f  Developments in Stem Cell Research and Cell Nuclear 
Replacement to Benefit Human Health (2000) Department o f  Health at Chapter 1.1
176 Ibid. Executive Summary, point 1
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Research involving the creation o f  an embryo by cell nuclear replacement is not 
prohibited under the 1990 Act provided it is fo r  one o f  the existing specified 
research purposes. In such circumstances, the HFEA would consider each 
application fo r  a research licence on its merits and would need to be satisfied that 
the creation o f  an embryo by cell nuclear replacement was necessary fo r  the 
purposes o f  the research.177
Provided that the necessity o f  using embryos created by cell nuclear replacement 
is clearly demonstrated...with proper consent o f  the donors and under the 
regulatory control o f  the Human Fertilisation and Embryology Authority, the
/  7RExpert Group was willing to support it.
Chapter 3 of the Donaldson Report which discusses the legal considerations, also 
continues in this vein. Whilst discussing embryos created in vitro it does not distinguish 
between those created in the ‘normal’ manner, i.e. through the process of fertilisation 
using eggs and sperm, to those created by cell nuclear replacement involving merely 
eggs. The Expert Group then makes the recommendation that:
Recommendation 1:
Research using embryos (whether created by in vitro fertilisation or cell nuclear 
replacement) to increase understanding about human disease and disorders and 
their cell-based treatments should be permitted, subject to the controls in the
170Human Fertilisation and Embryology Act 1990.
It is apparent throughout the Donaldson Report that the Expert Group was of the 
opinion that embryos created by cell nuclear replacement were governed by the HFE Act 
and consequently the research regulations and prohibitions applied accordingly.
The discussion of cell nuclear replacement embryos and the applicability of the 
HFE Act are important to human embryonic stem cell research as the desire is to extract 
stem cells from an embryo which is a genetic match to a patient, permitting the extracted 
stem cells to be used in treatment of the patient without the risk of rejection. O f note 
though is the discussion in the Donaldson Report of the research purposes permitted 
under the HFE Act. Whilst the use of cell nuclear replacement embryos for human 
embryonic stem cell research is important to scientists, the research can equally be 
undertaken with embryos created by in vitro fertilisation. What needs to be considered is,
177 Ibid. Executive Summary, point 14
178 Ibid. Executive Summary, point 28
179 Ibid. Recommendation 1 at Chapter 5.10
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if human embryonic stem cell research (with either in vitro fertilisation or cell nuclear 
replacement embryos) could actually take place, was it permitted under the research 
purposes as found in the HFE A ctl As discussed earlier, upon inspection of the five 
permitted areas of research it could be said that human embryonic stem cell research was 
not permitted under the HFE Act. However, the Donaldson Report does not agree with 
that analysis, it states that:
Research involving the use o f  embryos to extract stem cells is permitted currently
under the 1990 Act provided that the research is fo r  one o f  five specified
purposes.180
It is somewhat difficult to see how the extraction of human embryonic stem cells 
is necessary or desirable for the purposes of either promoting advances in the treatment of 
infertility, increasing knowledge about the causes of congenital disease or miscarriages, 
helping to develop more effective techniques of contraception or helping to develop 
methods for detecting the presence o f gene or chromosome abnormalities in embryos 
before implantation. Human embryonic stem cell research occurs as scientists and 
researchers wish to use the extracted stem cells in patients, not to fulfil one of the 
purposes as laid out in the HFE Act. The Donaldson Report does note that a research 
licence for one research project had been granted at the time of writing which fell into the 
permitted research purposes. So it seems that some research projects involving human 
embryonic stem cell research would fall into the five research purposes. However, the 
Donaldson Report goes on to state that the creation or use o f embryos for research to 
improve the understanding of, or the treatment of, non-congenital diseases could not be 
authorised under the HFE Act although affirmative regulations could be used to extend 
the permitted research purposes.181 This was recommended by the Expert Group within 
their discussion o f Recommendation 1 of the Report. 182 As discussed later the 
Government did make use of these affirmative Regulations to extend the permitted 
research purposes.
180 Ibid. at Chapter 3.9
181 Ibid. at Chapter 3.12
182 Ibid. at Chapter 5.10
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Government Response to the Recommendations Made in the Chief
Medical Officer’s Expert Group Report “Stem Cell Research: Medical 
Progress with Responsibility”183
It is clear in the Government’s response to the Donaldson Report that the 
Government agreed with the Expert Group’s conclusion that embryos created by cell 
nuclear replacement were also subject to the regulation found in the HFE Act. The 
Government accepted in full the Expert Group recommendations and expanded upon its 
position in relation to each recommendation.
In considering the research purposes contained within the HFE Act the 
Government thought that it would be appropriate to extend the research purposes due to 
the potential medical benefits which could arise from research to extract human 
embryonic stem cells from very early embryos. As such the Government stated that:
...the Government accepts that such an extension should be made to allow fo r  
research to increase understanding about human disease and disorders and their 
cell-based treatments.184
It therefore seems clear that although some human embryonic stem cell research 
could be undertaken as it would fall within the original five permitted research purposes, 
there was a need to extend the research purposes to allow further human embryonic stem 
cell research to occur. This corresponded with the position adopted by Warnock that there 
should be some limits upon the type of research being performed; equally it corresponded 
with the social consensus which had changed over the decade as to what it was 
permissible to use human embryos for. In this manner the special moral status o f the 
human embryo was still recognised, as was the fact that the moral status of the human 
embryo is not absolute. As will be seen in the later discussion, the decision to extend the 
research purposes to allow and use human embryonic research to investigate human 
disease and disorders, rather than limiting the research to fertility and the embryo itself, 
would be somewhat controversial.
183 (2000) Department o f  Health CM 4833
184 Government Response to the Recommendations M ade in the Chief M edical O fficer’s Expert Group 
Report “Stem Cell Research: M edical Progress with Responsibility” (2000) Department o f  Health CM 
4833 at pg 3, Recommendation 1, point 2
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Continuing the discussion of Recommendation 1 in relation to cell nuclear 
replacement embryos, the Government commented that:
The Report explains that research using embryos created by cell nuclear 
replacement has unique potential benefits in terms o f understanding how to 
produce compatible tissue fo r  treatment and how adult cells might in future be 
reprogrammed...we have assessed carefully the scientific and ethical case 
presented in the Report and conclude that such research should be allowed, but 
only under the very stringent safeguards set by the 1990 Act.185
Again this is supporting the commonly held opinion o f the time that the HFE Act 
regulated all embryos, regardless of how they were created. However, this was soon put 
into doubt with the judicial review action initiated by Bruno Quintavalle, director of the 
Pro-Life Alliance; this was in direct response to the Donaldson Report.
Quintavalle
The Quintavalle cases challenged the definition of a human embryo and whether 
embryos created by cell nuclear replacement fell into the legislative definition. Why is 
this case so important? Because the extraction o f stem cells from cell nuclear replacement 
embryos is considered to be the Holy Grail o f science. Whilst stem cell research could 
have continued with embryos produced by in vitro fertilisation, the desire was, and still 
is, to extract stem cells that are a genetic match to a patient which can be achieved by 
extracting stem cells from cloned embryos. I f  the Courts had decided that embryos 
created by cell nuclear replacement were not included in the legislative definition the 
search for the Holy Grail could not have continued in the United Kingdom.
In 2004 this process was claimed to have been achieved by a Korean scientist, 
Hwang Woo-Suk, and was heralded as a major breakthrough and huge step forward for 
stem cell research.186 Hwang has subsequently been discredited and stepped down from 
his posts as his work was proven to be fraudulent, so the Holy Grail is still being sought.
There are two main points to the Pro-Life Alliance case. First they contested 
whether an embryo created by cell nuclear replacement fell within the definition of an
185 Ibid. at pg 3, Recommendation 1, point 3
186 Hwang, W-S e t al., Evidence o f  a Pluripotent Human Embryonic Stem Cell Line D erived from  a Cloned  
Blastocyst (2004) 303 (5664) Science 1669-1674 (Retracted)
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‘embryo’ under section 1(1) of the HFE Act and secondly, in the alternative, that if such 
an embryo did fall into the definition then section 3(3)(d) of the HFE Act renders cell 
nuclear replacement unlawful.
At first sight it seems strange that the Pro-Life Alliance would be the instigators 
of this case. The Pro-Life Alliance is a group which is opposed to human cloning. If their 
argument that embryos created by cell nuclear replacement did not fall into the remit of 
the HFE Act was correct, then this would leave their creation, and subsequent research 
upon them, unregulated. However, upon closer inspection the purpose of the Pro-Life 
Alliance in bringing this case was obvious. As Herring notes, “The Alliance hoped that i f  
its arguments were accepted by the courts, then Parliament would be compelled to 
address the subject, leading, they anticipated, to a complete legislative ban on all forms 
o f cloning.nX%1
The High Court
The case was first heard by Judge Crane in the Queens Bench Division.188 The 
central issue hinged upon the definition of an embryo in the HFE Act which reads as:
Meaning o f  “embryo ”, “gamete ” and associated expressions 
1(1) In this Act, except where otherwise stated -
(a) embryo means a live human embryo where fertilisation is complete, and (b) 
references to an embryo include an egg in the process o f  fertilisation, and, fo r  this 
purpose, fertilisation is not complete until the appearance o f  a two cell zygote.
The Pro-Life Alliance contended that as an ‘embryo’ created by cell nuclear 
replacement was not the product o f fertilisation it could not therefore be ‘an embryo 
where fertilisation is complete’ thereby not falling into the Section 1(1) definition. In 
contrast the defendant, the Secretary of State for Health, argued for a purposive 
construction of the statute:
It argues that the essential concept is ‘a live human embryo’. The subsection 
should be read as i f  the words were, in effect, ‘a live human embryo where [ if  it is 
produced by fertilisation] fertilisation is complete.,189
187 Herring, J and Dr Chau, P-L., Cloning in the House o f  Lords. (2003) 33 Fam LJ 663 at p663
188 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2001] 4 All ER 1013
189 Ibid. at Para 45, Pg 1021
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Prior to the legal challenge by the Pro-Life Alliance, the Government had stated 
that ‘embryos’ produced by cell nuclear replacement fell into the remit of the HFE Act 
and Judge Crane noted that this viewpoint had been reiterated in several authoritative 
Government Reports, including the Donaldson Report and the Government response to 
that Report.190
Although the Government had previously asserted that ‘embryos’ created by cell 
nuclear replacement were within the remit of the HFE Act Judge Crane felt unable to 
agree. Although reluctant to leave ‘embryos’ created by cell nuclear replacement outside 
of regulation he stated, “/  decline any invitation to attempt to rewrite any o f  the sections 
o f the 1990 Act to make them apply by analogy to organisms produced by CNR.”m
... With some reluctance, since it would leave organisms produced by CNR outside 
the statutory and licensing framework, I  have come to the conclusion that to insert 
these words would involve an impermissible rewriting and extension o f the 
definition.192
The reading of the Act given by Judge Crane is by all accounts the most sensible, 
logical and literal interpretation to take. It is widely accepted that ‘embryos’ created by 
cell nuclear replacement do not involve fertilisation in the normal accepted sense and 
logically this means that they are outside of the regulation of the HFE Act. 
Understandably this caused considerable concern and the Government was swift to react 
with the Human Reproductive Cloning Bill (discussed in detail later on) which came into 
force on the 4th December 2001. Whilst not outlawing the process of cell nuclear 
replacement per se it prohibited the placing of such an embryo created other than by 
fertilisation into a woman. As this legislation did not prevent the creation o f embryos by
190 Stem Cell Research: M edical Progress with Responsibility. A Report from  the C hief M edical Officer’s 
Expert Group Reviewing the Potential o f  Developments in Stem Cell Research and Cell Nuclear 
Replacement to Benefit Human Heath (2000) Department o f  Health. For example see Para 14, Chapter 3.3 
and Recommendations 1 and 2
Government Response to the Recommendations M ade in the Chief M edical O fficer’s Expert Group Report 
“Stem cell Research: M edical Progress with Responsibility” (2000) Department o f  Health CM 4833. See 
response to Recommendations 1 and 2
191 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2001] 4 All ER 1013 at Para 61, pg 
1024
192 Ibid. at Para 62, pg 1024
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cell nuclear replacement in the first place it was vital for the issue to be resolved by the 
courts whether such embryos were within the remit of the HFEA.
The Court of Appeal
The case soon found its way to the Court of Appeal193 where the Secretary o f State 
for Health challenged Judge Crane’s decision under four heads:
(1) unforeseen scientific developments can carry with them the necessity to strain 
statutory language; (2) the purpose o f  the legislation is o f  prime importance; (3) 
no countervailing considerations conflict with a purposive construction; (4) 
incoherence o f  other parts o f  the 1990 Act is no bar to a purposive construction o f  
s i  ( l) .194
In view of the first argument the Court o f Appeal found that Lord Wilberforce’s 
authoritative dissenting speech in Royal College o f  Nursing o f  the UK v Dept o f  Health 
and Social Security [1981] 1 All ER 545 at 564-565 provided guidance as to how to deal 
with unforeseen scientific developments. Lord Phillips of Worth Matravers MR then 
phrased the relevant question as
...the court has to ask, not what would Parliament have enacted i f  it had foreseen 
the creation o f  embryos by CNR, but, do such embryos fa ll plainly within the 
genus covered by the legislation and will the clear purpose o f the legislation be 
defeated i f  the extension is not made?195
According to the Master o f the Rolls, the purposive interpretation made by the 
Court of Appeal is further also supported by Human Rights Act 1998.196
In considering the genus o f an embryo created by cell nuclear replacement the 
Master of the Rolls considered that “...it is this capacity to develop into a human being 
that is the significant factor and it is one that is shared by both types o f  embryo?’191 
When linking the genus covered by the legislation to the clear purpose of the legislation 
the honourable judge continued on to state that,
193 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2002] 2 All ER 625
194 Ibid. at Para 22, pg 632
195 Ibid. at Para 27, pg 633
196 Ibid. at Para 27, pg 633
197 Ibid. at Para 34, pg 634
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To the question o f  whether it is necessary to bring embryos created CNR within 
the regulatory regime created by the 1990 Act in order to give effect to the 
intention o f Parliament, there can be only one answer. It is essential. There is no 
factor that takes embryos created by CNR outside the need, recognised by 
Parliament, to control the creation and use o f  human organisms.198
As the Court of Appeal notes the HFE Act was designed to bring the creation and 
use of embryos within a regulatory regime which would control and restrict the permitted 
activities.199 It is principally for this reason that the Court of Appeal felt that they had to 
interpret the legislation to include embryos created by cell nuclear replacement; otherwise 
the regulatory regime set up by Government would fail. This was reiterated by Lord 
Justice Buxton who stated that
...the purpose o f  the legislation was to protect and to make provision in respect o f  
embryos, they being seen as a form  o f life particularly deserving o f  protection and 
control; and to bring dealing with such form s o f  life within the control o f  the 
newly set up Human Fertilisation and Embryology Authority. That purpose 
should extend, and there is no reason why it should not extend, to embryos 
created by CNR as to embryos created by what I  would call orthodox 
fertilisation.200
The final two arguments submitted by the defendant against Judge Crane’s 
decision were briefly considered by the Master of the Rolls who felt that there were no 
countervailing considerations which would conflict with a purposive construction of the 
Act and the small amount of incoherence in the Act, as some sections would not apply to 
embryos created by cell nuclear replacement, was not significant.
Concerning the second point before him, Lord Phillips of Worth Matravers MR 
considered the argument that if  embryos created by cell nuclear replacement were within 
the definition of an embryo in the HFE Act then the process was prohibited under section 
3(3)(d) of that Act.
Section 3(3)(d) of the Act states that:
3 (3) A licence cannot authorise -
(d) replacing a nucleus o f  a cell o f  an embryo with a nucleus taken from  a cell o f  
any person, embryo or subsequent development o f  an embryo.
198 Ibid. at Para 38, pg 635
199 Ibid. at Para 36, pg 635
200 Ibid. at Para 56, pg 638
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The argument was quickly dismissed as the learned judge could “...see no basis
fo r  arguing that an unfertilised egg, prior to the insertion o f  the nucleus under the cell
nuclear replacement process, is required to be treated under the Act as i f  it is an
embryo.”201 The section in question was designed to prohibit genetic manipulation o f an
embryo already in existence and so outlawed the process of cloning as known in 1990. In
the process of cell nuclear replacement there is no embryo until after the oocyte has had
its nucleus replaced with the nucleus of another cell containing the full set of
chromosomes. Therefore the Court o f Appeal felt unable to apply section 3(3)(d) to
embryos created by cell nuclear replacement.
The Court of Appeal decision has since been severely criticised both academically
and, later legally, in the House of Lords. Herring and Chau provide a clear discussion of
the problems with the approach taken by the Court of Appeal which include a shift in
interpretation from ascertaining the will o f Parliament at the time of enacting the
legislation to “...how would Parliament have wanted the courts to interpret the
202 •legislation given the situation the court is now faced  with? ” As Herring and Chau note 
if the Court o f Appeal had considered Parliament’s will at the time of enactment it was 
“...unlikely that Parliament intended cloning to be regulated in the same way as other
)>203embryos created using medical assistance. ”
The House of Lords
The House of Lords heard the case over a year after the Court of Appeal.204 The 
outcome is the same as that o f the Court of Appeal although the reliance of the Court of 
Appeal upon the Human Rights Act 1998 to support their purposive construction is 
criticised and rejected by the House of Lords.
Lord Bingham of Comhill correctly states that:
The basic task o f  the court is to ascertain and give effect to the true meaning o f  
what Parliament has said in the enactment to be construed....The court’s task,
201 Ibid. at Para 51, pg 637
202 Herring, J and Dr Chau, P-L., Case Commentary: Are Cloned Embryos Embryos? -  The Queen on the 
Application o f  Quintavalle v The Secretary o f  State fo r  Health (2002) 14 CFLQ 315 at pg 322
203 Ib id  at pg 321
204 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2003] 2 All ER 113
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within the permissible bounds o f  interpretation, is to give effect to Parliament’s 
purpose. So the controversial provisions should be read in the context o f  the 
statute as a whole, and the statute as a whole should be read in the historical
205context o f  the situation which led to its enactment.
Lord Bingham of Comhill continued on to explain that he could see no 
inconsistency between the rule that statutory language retains the meaning that it had at 
the time of enactment and the rule that a statute is always speaking. This is particularly 
relevant where legislation concerns fast moving scientific technology. The House o f 
Lords approved Lord Wilberforce’s speech in Royal College o f  Nursing o f  the UK v Dept 
o f Health and Social Security [1981] 1 All ER 545 at 564-565 where it was stated that 
when a case involves fast-moving or new technology a court can consider if  the new state 
of affairs falls within the “ ...same genus offacts as those to which the expressed policy 
has been formulated. ”206
The House of Lords obviously felt that it would go against the clear purpose of 
Parliament if embryos created by cell nuclear replacement were left outside the scope of 
the legislation. This is reiterated by all o f the Law Lords at some point, for example see:
Lord Bingham of Cornhill:
Can Parliament have been intending to distinguish between live human embryos 
produced by fertilisation o f  a female egg and live human embryos produced 
without such fertilisation? The answer must certainly be negative, since 
Parliament was unaware that the latter alternative was physically possible.... this 
was an act passed fo r  the protection o f live human embryos created outside the 
human body. The essential thrust o f  s i  (l)(a) was directed to such embryos, not to 
the manner o f  their creation, which Parliament (entirely understandably on the 
then current state o f  scientific knowledge) took fo r  granted.207
While it is impermissible to ask what Parliament would have done i f  the facts had 
been before it, there is one important question which may permissibly be asked: it 
is whether Parliament, faced  with the taxing task o f  enacting a legislative solution 
to the difficult religious, moral and scientific issues mentioned above, could 
rationally have intended to leave live human embryos created by CNR outside the
205 Ibid. at Para 8, pg 118
206 Royal College o f  Nursing o f  the UK v Department o f  Health and Social Security [1981] 1 All ER 545 at 
564-565 as reproduced in the House o f  Lords decision o f R (on the application o f  Quintavalle) v Secretary 
o f  State fo r  Health [2003] 2 All ER 113
207 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2003] 2 All ER 113 at Para 14, pg 
120
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scope o f  regulation had it known o f  them as a scientific possibility. There is only 
one possible answer to this question and it is negative.208
Lord Steyn:
...there is not a hint o f  a rational explanation why an embryo produced otherwise 
than by fertilisation should not have the same status as an embryo created by 
fertilisation. It is a classic case where the new scientific development falls within 
what Lord Wilberforce called ‘the same genus o f  facts ’ and in any event there is a 
clear legislative purpose which can only be fulfilled i f  an extensive interpretation 
is adopted.209
Lord Millett takes a simpler approach to the interpretation of Section 1(1) of the 
HFE Act. What is clear from his judgment is that he does not believe that the phrase 
‘where fertilisation is complete’ adds anything to the definition of an embryo, rather it is 
the fact that is it ‘live’ and ‘human’ which is of relevance when considering what an 
embryo is and the protection to be afforded to it.
The purpose o f  the opening words o f  the paragraph is not to define the word 
‘embryo ’ but rather to limit it to an embryo which is (i) live and (ii) human. These 
are the essential characteristics which an embryo must possess i f  it is to be given 
statutory protection. The important point is that these characteristics are 
concerned with what an embryo is, not how it is produced.210
The concluding words o f  the paragraph ( ‘where fertilisation is complete )  have a 
different function. They do not describe the essential characteristics o f  an embryo, 
and do not form  part o f  the definition o f the word ‘embryo They merely indicate 
the stage o f  development which an embryo must reach before it qualifies fo r  
protection.211
For the House o f Lords the function o f a purposive construction o f Section 1(1) 
was to give effect to Parliament’s intention of regulating the creation, use and storage of 
human embryos, and this, they felt applied irrespective of how the embryos were created. 
This was a contentious point as Parliament had deliberately taken steps to outlaw cloning,
albeit in the form known at the time of drafting the statute. As noted earlier this
prohibition is found in section 3(3)(d) of the HFE Act. The House of Lords did not 
consider that this section prohibited the creation of embryos by cell nuclear replacement
208 Ibid. at Para 15, pg 120-121
209 Ibid. at Para 26, pg 126
210 Ibid. at Para 45, pg 129
211 Ibid. at Para 46, pg 129
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as it specifically prohibited the genetic manipulation of an already existing embryo, 
clearly not including the process of cell nuclear replacement which does not involve an 
embryo, only an oocyte.
However, if  the Law Lords were willing to include embryos created by cell nuclear 
replacement into the definition of an embryo in section 1(1) it is no stretch o f the 
imagination that they could equally have found that the creation of embryos by cell 
nuclear replacement was prohibited by section 3(3)(d). In Royal College o f Nursing o f the 
UK v Department o f  Health and Social Security212 Lord Wilberforce stated that:
...when a new state o f  affairs, or a fresh set o ffacts bearing on policy, comes into 
existence, the courts have to consider whether they fa ll within the parliamentary 
intention. They may be held to do so, i f  they fa ll within the same genus o f facts as 
those to which the expressed policy has been formulated. They may also be held to 
do so i f  there can be detected a clear purpose in the legislation which can only be 
fulfilled i f  the extension is m ade213
The Law Lords could have utilised Lord Wilberforce’s dictum in interpreting 
section 3(3)(d) if  they had been willing to interpret the technique of creating embryos by 
cell nuclear replacement as falling into the same genus o f the technique described in the 
legislation. Parliamentary intention had clearly been to prohibit cloning, albeit in the form 
known at the time of drafting, and as such it could be argued that the legislation should 
have been interpreted to include the new scientific technique. In considering section 
3(3)(d) the Court concerned itself with the ‘genus of facts’ rather than the purpose of the 
legislation. If  it had considered the purpose of section 3(3)(d) it may not have been so 
willing to interpret the section as not applying to embryos created by cell nuclear 
replacement.
It should also be noted that the Government had specifically mentioned nucleus 
substitution as a method desirable of prohibition although this was not carried through to 
the HFE A c t214 Parliament had clearly tried to ban cloning at the time o f enactment, why 
not include today’s current process? O f course the issue here was that if  the Law Lords
212 [1981] 1 All ER 545
213 Royal College o f  Nursing o f  the UK  v Department o f  Health and Social Security [1981] 1 All ER 545 at 
564-565
214 White Paper Human Fertilisation and Embryology: A Framework fo r  Legislation  (1987) DHSS Cm 259 
See paragraphs 37 and 38 and comments made about these provisions under the relevant heading o f  this
had applied Lord Wilberforce’s dictum to the issue at hand, the result would have been 
the complete prohibition of all types of cloning, not just reproductive cloning. The 
Government had clearly stated that human reproductive cloning was undesirable and had 
taken steps to outlaw it prior to the House of Lords judgment. In contrast, therapeutic 
cloning was being strongly endorsed by the Government.215 Lord Millett summarised 
succinctly the position of both Parliament and the House of Lords in relation to this 
provision:
O f course Parliament did not positively intend to prohibit CNR, the possibility o f  
which it did not foresee. It might or might not have prohibited it i f  it had done so. 
But such considerations are irrelevant. Even i f  Parliament had intended to 
prohibit CNR it fa iled  to do so. The court cannot give effect to Parliament’s 
intention i f  the legislative text does not permit it. The only question is whether 
CNR falls within the statutory language. It manifestly does not.216
This statement by Lord Millett at first sight appears to underline the point that the 
House of Lords were not in a position to strain the language of the legislation so as to be 
able to include cell nuclear replacement embryos within the section 3(3)(d) definition. 
However, it is the Court that decides if the text permits them to give effect to the 
intention o f Parliament, not the text constraining the Court. It is simply a question of how 
far the text can be strained to reach the desired outcome. What becomes apparent upon 
reading the judgments is that the House of Lords wanted to give effect to the current 
Government’s clearly stated aims and desires of permitting research upon cell nuclear 
replacement embryos whilst prohibiting human reproductive cloning. Therefore the 
House o f Lords strained the parts of the language of the text they thought appropriate to 
give effect to the Parliamentary intention of 2003, rather than looking to the 
Parliamentary intention o f 1990.
As the law stands today stem cell research and therapeutic cloning is governed by 
the HFE Act and the governing body the HFEA. Whilst the cases brought by the Pro-Life 
Alliance created for a brief while the legal lacuna that embryos created by cell nuclear
215 Refer to Government Response to the Recommendations Made in the Chief M edical O fficer’s Expert 
Group Report “Stem cell Research: M edical Progress with Responsibility” (2000) Department o f  Health 
CM 4833
216 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2003] 2 All ER 113 at Para 51, pg 
130
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replacement were not regulated by the HFEA, this has since been rectified by the House 
of Lords decision.
Criticisms
Overall, Judge Crane in the High Court should be praised for his logical and clear 
interpretation of the legislation. The literal interpretation which he applied gives effect to 
parliamentary intention at the time of enactment, that embryos created by fertilisation 
should be regulated. Although this literal interpretation would mean that there was no 
governing body regulating embryos created by cell nuclear replacement the legislation 
should have been left to the Government to alter as appropriate to include cell nuclear 
replacement embryos if that was desired.
Whilst it was necessary for the case to continue to the Court of Appeal and House 
of Lords the interim knee jerk reaction by the Government of enacting the Human 
Reproductive Cloning Act 2001 only helped to confuse the situation further -  not 
outlawing the creation of such embryos but merely prohibiting the placing of such 
embryos within a woman’s body. The situation apparently being that anyone was free to 
create cell nuclear replacement embryos for research without regulation provided that 
they did not subsequently attempt to implant them.
The HFE Act is the most contentious piece of legislation currently in existence in 
the UK. The Government’s action of implementing the Human Reproductive Cloning Act 
2001 can be criticised for being poorly thought out. Nonetheless the Government wanted 
to review the entirety o f the HFE Act so it could be forgiven for taking what could be 
seen as an interim step whilst preparing for a thorough review and debate over new 
legislation.
While it was contested that embryos created by cell nuclear replacement were 
outside the remit o f the HFE Act I believe that the situation created by Judge Crane’s 
decision in the High Court was not as disastrous as first thought, although it is recognised 
that embryos created by cell nuclear replacement would have been left outside of 
statutory regulation.
If Judge Crane’s decision had been followed by the higher courts, cell nuclear 
replacement embryos would have been left outside of the statutory definition as contained 
in section 1(1) of the HFE Act and no licence would have been needed from the HFEA to
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create such embryos. There is only a need for a licence from the HFEA for research upon 
embryos, not oocytes.217 Whilst a licence would have been needed from the HFEA if a 
researcher was intending to store the oocytes it was most likely that fresh oocytes would 
be used in the process.218 It was therefore clear that if cell nuclear replacement embryos 
were left out of the statutory definition they were also outside of the HFEA’s powers.
Whilst the Human Reproductive Cloning Act 2001 had specifically outlawed the 
implantation of any embryos created other than by fertilisation it did not outlaw the 
creation of cell nuclear replacement embryos. The question which needed to be 
considered was how easily would researchers have been able to obtain the necessary 
oocytes to create cell nuclear replacement embryos? Where the researchers needed to use 
oocytes from NHS patients or NHS facilities to carry out the research they would have 
needed to obtain research ethics committee approval prior to starting such work (for more 
detail about NHS research ethics committees refer to Chapter 4). There would have been 
a very slim chance that a research ethics committee would give ethics approval to such 
work precisely due to the ethical issues involved and the clear Governmental opposition 
to such work. If an NHS research ethics committee had approved a project involving the 
creation of cell nuclear replacement embryos the researcher would then have been able to 
approach egg donors for consent to use their oocytes in such research. What were the 
chances that egg donors would have agreed to donate in such circumstances? The number 
of egg donors is relatively small and it is thought that only a tiny percentage of any of 
those donors would have agreed to give consent to their oocytes being used to create cell 
nuclear replacement embryos. The situation would be very similar even where a 
researcher did not need NHS research ethics committee approval, due to not using NHS 
patients or facilities, a very small number of oocytes, if any, would have been donated to 
research. The success rates o f creating cell nuclear replacement embryos were also very 
low and far less likely to be successful with the tiny number of oocytes which may have 
been available.
Although following Judge Crane’s decision in the High Court would have left cell 
nuclear replacement embryos outside o f statutory control, from the discussion above, it is 
clear that the number of such embryos being created would have been tiny, if any.
217 Sch 2, Para 3(1) HFE Act 1990
218 Storage licence for gametes or embryos is required under Sch 2, Para 2(1) HFE Act 1990
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Researchers would also have been unlikely to be able to keep the embryos beyond a few 
days growth and were legally prohibited from implanting them into a woman.
The Government had worked fast in enacting the Human Reproductive Cloning 
Act 2001 and, if  it so desired, it could have enacted a similar piece o f legislation which 
specifically stated that embryos created by cell nuclear replacement and all other methods 
were to be within the remit of the HFEA. This would have been another piece of interim 
legislation until such time as the review and reform of the HFE Act was completed. 
Finally note that regulations could not have been used for this purpose as the HFE Act did 
not provide regulation making powers in such a situation as this, and so primary 
legislation would have been needed as was the case with the Human Reproductive 
Cloning Act 2001.
The practical implications of leaving cell nuclear replacement embryos outside of 
the statutory definition was very much overlooked in the Courts reasoning and by the 
Government at the time of enacting the Human Reproductive Cloning Act 2001. In light 
o f this it could be said that the concern expressed, and subsequent reaction, at the time 
was overblown and possibly disproportionate. In considering the important role which 
research ethics committees and donors themselves play in research projects it is hard to 
understand why this aspect was not taken into consideration by those involved in the 
public debates, legislative drafting and court cases.
A final criticism of the Court of Appeal and House of Lords approach to the 
problem laid before them is that not only did they take a very liberal purposive 
interpretation as to the definition of an embryo; they were not consistent in their 
legislative interpretations.
Whilst the judges took a very liberal purposive approach to interpreting the 
definition of an embryo contained in s l(l)(a) to include embryos created by cell nuclear 
replacement they took a literal approach to their interpretation of s3(3)(d) of the Act. 
Undoubtedly the literal approach would have been the correct approach to take to both 
sections; the statutory language could not be strained to include the modem day process 
of cloning. When the Government had obviously taken steps to include in the statute a 
prohibition concerning the process o f cloning as known about in 1990, it seems 
somewhat bizarre that the Judges would then liberally interpret s l(l)(a) to include cloned 
embryos, thereby allowing their creation and research upon them. Whilst the approach 
taken by the Judges towards sections 1 and 3(3)(d) does appear strange and inconsistent
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from a statutory interpretation point of view, it is understandable as the Judges did not 
want cloned embryos to be outside o f statutory control. However, if  the Judges had taken 
a closer look at the implications of Judge Crane’s decision in the High Court, they may 
not have been so ready to take different statutory interpretative approaches to the two 
sections of the Act.
Brazier had earlier applied a literal interpretation to both sections 1 and 3(3)(d) 
which resulted, in her reasoning, to cell nuclear replacement embryos falling out of the 
legislative definition and as such outside of the remit of the HFEA.219 Brazier correctly 
stated that a licence is required from the HFEA to create an embryo, and as such 
contended that the creation of a cell nuclear replacement embryo took it outside of the 
HFE Act requirements to obtain a licence as it did not involve fertilisation (as defined in 
section 1).
I would submit that the learned judges could have followed Judge Crane’s 
decision in the High Court without endangering too much the workings of the HFEA and 
related legislation. The Government could then have either enacted interim legislation 
regarding cell nuclear replacement embryos in research or taken its time reviewing the 
Act, allowing for a full, free and frank discussion and vote on the issues involved.
Conclusions following Quintavalle
It is appropriate at this point to draw some conclusions for the future. The 
Government will undoubtedly face future challenges over its human fertilisation and 
embryology legislation. It would be advisable for the Government to relax and allow the 
HFEA to take the lead in regulating difficult issues. As can be seen from previous 
decisions the HFEA takes a reasoned and practical approach to the issues placed before 
it.220
The Government has very recently finished reviewing and reforming the HFE Act 
and one of the most difficult issues to resolve was the definition of an embryo in the new 
legislation.221 The Quintavalle cases should have helped the Government to relax when
219 Brazier, M., Regulating the Reproductive Business? (1999) 7 Med. L. Rev. 166 at pi 89
220 For example refer to the situation over which the Hashmi family sought guidance, support and 
regulation from the HFEA
221 Refer to Review o f  the Human Fertilisation and Embryology Act: A Public Consultation Department o f  
Health (2005) and to Human Reproductive Technologies and the Law Fifth Report o f  the Session 2004-05  
House o f  Commons Science and Technology Committee Report HC 7-1
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framing the new legal definition of an embryo as the decisions o f the higher courts 
demonstrated that they were willing to stretch the genus of an embryo to include embryos 
created by methods unforeseen at the time of enactment. This is particularly relevant in 
the light of the possibility of creating embryos directly from stem cells.222 As will be seen 
in Chapters 7 and 8 the Government took a broad definitional approach towards the 
human embryo which could help to prevent legal challenges, yet in respect o f hybrid 
embryos the Government again took a precise scientific approach which may lead to a 
situation such as occurred in Quintavalle.
The challenge by Quintavalle was inevitable, as was the outcome in the House of 
Lords; however, the reasoning to reach the desired position is neither consistent nor well 
thought out. Additionally, the reaction by the Government of enacting the Human 
Reproductive Cloning Act 2001 can be viewed as a purely interim action whilst the 
legislation is under review. In light of the ongoing experiments to create artificial 
gametes and wombs it is to be hoped that the Government does not again fall into the trap 
of enacting legislation which will need to be strained unduly by the Courts to achieve the 
desired end.
The Human Fertilisation and Embryology (Research Purposes) 
Regulations 2001, SI 2001/188
The Human Fertilisation and Embryology (Research Purposes) Regulations 2001 
were introduced by the Government following the recommendations made in the 
Donaldson Report. Prior to these regulations coming into force there were five permitted 
areas o f research within the HFE Act. The regulations added an additional three further 
research purposes for which the HFEA could grant a licence. The regulations state that:
Section 2. - (1) The Authority may issue a licence fo r  research under paragraph
3 o f  Schedule 2 to the Act fo r  any o f the purposes specified in the following
paragraph.
(2) A licence may be issued fo r  the purposes o f  -
222 For a full discussion o f  the possibilities o f  creating embryos from stem cells refer to Holm, S., Who 
should control the use o f  human embryonic stem cell lines: A defence o f  the donors ’ ability to control 
(2006) Vol 3 (1-2) Journal o f  Bioethical Inquiry pg 55-68
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(a) increasing knowledge about the development o f  embryos;
(b) increasing knowledge about serious disease, or
(c) enabling any such knowledge to be applied in developing treatments fo r  
serious disease.
These regulations were primarily introduced to permit stem cell research and 
therapeutic cloning which potentially could lead to enormous scientific advancements in 
cell-based treatments for a wide range of diseases and illnesses including Parkinson’s 
disease and Alzheimer’s.
The new Regulations were controversial as for the first time they allowed research 
upon embryos which would not directly benefit the embryos themselves or the provision 
of fertility services (for example, note that whilst many would not consider developing 
methods for the testing of gene abnormalities to be a benefit to the embryo, as the vast 
majority of such embryos will be discarded, there are some people who may prefer to 
know and prepare for an embryo which is affected by such an abnormality rather than go
223through amniocentesis and a possible miscarriage at a later date). These were the limits 
which were discussed as far back as the early 1980’s in the Wamock Report; they were 
linked to the science which was in progress at the time as well as the social consensus.
Whilst the majority o f society has developed its views upon the acceptable uses of 
embryos, these regulations were still seen to be controversial. For example, note the 
opinion of the All-Party Parliamentary Pro-Life Group which stated that:
We consider that the regulations allow “pure” research on human embryos, 
without reference to clinical goals, fo r  the first time.224
The use o f affirmative regulations to introduce these three further research 
purposes has been criticised as it has been argued that the research purposes should have 
been introduced by way o f an Act o f Parliament, thus allowing detailed and thorough 
debate of the appropriateness and desirability of the extended research purposes.225 
However, the flexibility of regulations allows the Government to keep legislation up to 
date without undergoing a thorough review and consultation period; making the process
223 Discussed with Professor Emily Jackson and Professor Aurora Plomer, 21st May 2009
224 Stem Cell Research: Report from  the Select Committee: Evidence House o f  Lords Select Committee, HL 
Paper 83(ii) Session 2001-02, pg 213, Para 1.3
225 Plomer, A., Beyond the HFE Act 1990: The Regulation o f  Stem Cell Research in the UK  [2002] 10 Med. 
L. Rev. 132
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quicker and allowing the Government to respond faster to a particular legislative need. In 
response to the question as to why secondary legislation was being used to introduce the 
three research purposes, Yvette Cooper, the Under-Secretary o f State for Health in 2000, 
stated that:
This is secondary legislation because Parliament considered the issue in detail in 
1990, and set out a power in the Human Fertilisation and Embryology Act 1990 
to extend the purposes o f  research in this way ...Parliament clearly decided at that 
time to give power to its successors to extend the purposes o f  research through 
regulations.226
As Yvette Cooper stated the Regulations permitted exactly what they were 
allowed to under Schedule 2, paragraph 3(3) o f the HFE Act i.e. ‘increase knowledge 
about the creation and development of embryos, or about disease, or enable such 
knowledge to be applied’. Although the HFE Act had laid out the circumstances in which 
it would be acceptable to use regulations to extend the permitted research purposes the 
new regulations did go further than was possibly anticipated when the regulation making 
power was put into the HFE Act in 1990. The regulation making powers were provided to 
extend the purposes for which research could be performed on embryos, not products of 
the embryos. The issue of using embryos to derive stem cells, to use those stem cells in 
research and for developing treatments was not debated in Parliament in 1990.
Human embryonic stem cell research is a controversial area of research and it is 
argued that the permission for such research to be undertaken should have been debated 
further in Parliament. Although it seems unfair to say that there was not detailed 
discussion o f these Regulations. In the House o f Commons alone there were in fact two 
five hour debates held on Friday 17th November and Friday 15th December 2000 followed 
by a further debate o f nearly three and a half hours before voting on the Regulations on 
the 19th December 2000. This is an extraordinary amount of debate for a statutory
227instrument.
Although generally welcomed, there have been a number o f criticisms made of 
the Regulations. The House of Lords Select Committee was asked to review the 
Regulations in its report on stem cell research. It noted that there was a diversity o f views 
towards the Regulations ranging from those who were opposed to research o f any kind on
226 Hansard  HC 19th December 2000, Volume 360, Column 212
227 Ibid. as noted by Yvette Cooper on the 19th December
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embryos, those who felt that the Regulations raised new ethical issues in so far as the 
original purposes for research were restricted to reproductive research whereas the new 
Regulations are far more widely drawn, and finally, those who felt that there were no new
778issues arising from the introduction o f these Regulations.
This diversity o f views can be seen in the Hansard reports o f the debates which 
took place before the introduction of the 2001 Regulations, and again in the split o f 366 
votes for and 174 votes against the 2001 Regulations in the House of Commons (for 
further detail of the House o f Lords Select Committee discussion of the 2001 Regulations 
see below).
The 2001 Regulations were a significant step further than the original research 
purposes as they acknowledged that there were other people now involved in the 
processes for which human embryos were being used. For example, there are the people 
who provide genetic material to create embryos by cell nuclear replacement, the scientists 
who are making disease models using embryonic stem cells and the involvement of 
bodies besides the HFEA, including amongst others the Medical Research Council and 
the Stem Cell Bank. The resulting stem cell lines are also outside of the control of the 
HFEA and other statutory control although no attempt has been made to bring human 
embryonic stem cell lines within statutory control as of yet. The original research 
purposes as contained within the HFE Act were limited to reproductive uses as that was 
the original and accepted use o f human embryos when the debate occurred to its fullest in 
the early 1980’s. The 2001 Regulations shows the interface between embryo research and 
stem cells and how the evolving social consensus allowed human fertilisation and 
embryology legislation to be extended to cover a product o f embryo research, human 
embryonic stem cells.
The Human Reproductive Cloning Act 2001
As previously mentioned the Government promptly enacted the Human 
Reproductive Cloning Act 2001 after Judge Crane’s decision in the High Court in 
Quintavalle. The Human Reproductive Cloning Act 2001 states that:
228 House o f  Lords Select Committee on Stem Cell Research - Report Session 2001-02, HL Paper 83(i) refer 
to Chapter 5.3 and 5.4
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1 The Offence
(1) A person who places in a woman a human embryo which has been created 
otherwise than by fertilisation is guilty o f  an offence.
(2) A person who is guilty o f  the offence is liable on conviction on indictment to 
imprisonment fo r  a term not exceeding 10 years or a fine or both.
The Human Reproductive Cloning Bill was introduced prior to Judge Crane’s 
decision in R (on the application o f Quintavalle) v Secretary o f  State fo r  Health [2001] 4 
All ER 1013. However, the outcome of that case forced the Government to act fast and it 
enacted the Human Reproductive Cloning Act 2001 barely a month after the High Court 
decision. This was criticised by many as it was seen as a ‘knee-jerk’ reaction to the Court 
case and it was felt by some that it would have been better to wait for the appeal and also 
an anticipated report from the House of Lords Select Committee on stem cell research.229
The Human Reproductive Cloning Act 2001 can be both praised and criticised. 
The subject matter o f the Act is without question -  it makes it a criminal offence to place 
in a woman a human embryo which has been created otherwise than by fertilisation. It is 
also very clever as it avoids defining the term ‘embryo’ and ‘fertilisation’ which could 
lend itself to the need for further legislation later down the line. Additionally as Grubb 
notes, “ ...the wording avoids an even greater definitional problem. The 1990 Act covers 
embryos produced ‘by fertilisation’; the 2001 Act covers all others, i.e. those produced 
‘otherwise than by fertilisation ’.”230 This should mean that there is no loop-hole in the 
legislation, thereby covering all future techniques of creating embryos which may 
presently be seen as impossible or even unheard of.
Another beneficial point to the Act is that it avoids “...the pit-fall o f  introducing 
ambiguity into the existing legislative framework governing stem cell research.”231 The 
legislative framework which is in place seems to appease the majority of people 
(although it is recognised that the pro-life lobby will never be content until all forms of 
research upon embryos is outlawed) as it allows potentially beneficial research to 
continue, to the delight of scientists and the public alike, whilst prohibiting human 
reproductive cloning. With the decision in the House of Lords that embryos created by
229 The Human Reproductive Cloning Bill [H .L.] Research Paper 01/104, refer to page 21 for comments on 
the timing o f  the Bill. Available at http://www.parliament.uk/commons/lib/research/rp2001/rp01-104.pdf 
(last accessed 13/08/08)
230 Grubb, A., Commentary: Reproductive Cloning in the UK, The Human Reproductive Cloning A ct 2001 
(2002) 10 Med L Rev 327 at pg 328
231 Wood, Dr P and Good, Dr J., Human Reproductive Cloning -  Nipped in the Bud? (2001) 151 NLJ 1760 
at pg 1762
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cell nuclear replacement are governed by the HFE Act and with the corresponding 
Human Reproductive Cloning Act 2001 this allows valuable research to continue using 
the therapeutic cloning technique but allays most people’s fears by criminalising human 
reproductive cloning.
There are however a number of issues which the Act does not address. Some of 
these are raised in the House of Commons Research Paper 01/104:
Members voiced concerns that the Bill does not go fa r  enough. It does not 
prohibit implantation o f  cloned embryos into animals, not does it prevent creation 
o f hybrid clones ie the placing o f human DNA in animal eggs. The prospect was 
also raised that embryos cloned in the UK could be exported fo r implantation
232elsewhere.
Additionally, the Human Reproductive Cloning Act 2001 only prohibits the 
placing of an embryo created otherwise than by fertilisation into a woman. It does not 
prevent the implantation of such an embryo into an artificial uterus or even into a man. 
The possibility of artificial uteri is no longer the work of science fiction and could 
become a workable possibility in the future.233 After all, it was a mere six years after the 
enactment of the HFE Act that Dr Wilmut successfully produced the first clone, in a 
manner not envisaged at the time of enactment. The final problem which has been noted 
is that it may in the future be possible for a scientist to create a clump of cells from 
manipulated sperm and eggs which is not an embryo but which could grow and provide 
replacement tissues or organs for therapeutic purposes. It may be that the legislation does 
not prohibit the insertion of such a clump of cells into a woman.234
Furthermore, with the recent news that in work involving mice, where gametes 
were created from mouse embryonic stem cells which were then fertilised and produced 
seven baby mice, it needs to be questioned if the United Kingdom legislation covers such
232 The Human Reproductive Cloning Bill [H .L.] Research Paper 01/104, page 21. Available at 
http://www.parliament.uk/commons/lib/research/rp2001/rpO 1 -104.pdf (last accessed 13/08/08)
233 Note the work o f  Dr Hung-Ching Liu o f  Cornell University’s Centre for Reproductive Medicine and 
Infertility who is developing an artificial womb which would allow embryos to grow outside o f  the body. 
McKie, R., Men redundant? Now we d o n ’t need women either The Observer, 10th February 2002, 
http://observer.guardian.co.Uk/international/storv/0.6903.648024.00.html (accessed 27/10/06)
Also note the apparent lack o f  scientific papers published on this topic, references to Dr Liu’s work appear 
to be mainly by the press and web references, although the lack o f  scientific papers is by no means 
evidence that the work is not being undertaken.
234 See Herring, J and Dr Chau, P-L., Case Commentary: Are Cloned Embryos Embryos? -  The Queen on 
the Application o f  Quintavalle v The Secretary o f  State fo r  Health (2002) 14 (3) CFLQ 315 at 324
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artificial gametes and subsequent development.235 It would appear that currently the 
Human Reproductive Cloning Act 2001 would prohibit the implantation o f an embryo 
created from artificial gametes provided that it was considered that the embryo had been 
created otherwise than by fertilisation. However, it is likely that the Courts would 
consider an embryo created by fertilisation involving one or two artificial gametes as ‘a 
live human embryo where fertilisation is complete’ thereby falling into the remit o f the 
HFE Act and could be implanted (for further discussion of the reproductive use of 
artificial gametes refer to the chapters 7 and 8). If  however, you could produce enough 
artificial sperm to perform artificial insemination in vivo, it is unclear where that 
procedure would be regulated 236 With ongoing scientific work in this area, the creation 
and use o f artificial gametes is an issue which will need to be addressed by the 
Government soon.
So whilst the Human Reproductive Cloning Act 2001 does what it says, prohibit 
human reproductive cloning, it can be said that it only currently prohibits it. It is 
foreseeable that scientists could develop alternative methods for nurturing embryos 
through to birth without the assistance of a woman’s uterus.
House of Lords Select Committee Report on Stem Cell Research, 
Session 2001-2002, HL Paper 83(i)
The call upon the Government to establish a Select Committee to report on the 
issues connected with human cloning and stem cell research was proposed by Lord 
Walton o f Detchant during the debate of the Human Fertilisation and Embryology 
(Research Purposes) Regulations, and was passed without contention.237 The remit of the 
House of Lords Select Committee on Stem Cell Research was “to consider and report on 
the issues connected with human cloning and stem cell research arising from  the Human 
Fertilisation and Embryology (Research Purposes) Regulations.”238 The resulting report
235 Nayernia K, Nolte J, Michelmann HW, Lee JH, Rathsack K, Drusenheimer N, et al., (2006) In vitro- 
differentiated embryonic stem cells give rise to male gametes that can generate offspring mice Dev Cell 
11:125-132 http://www.cell.eom/developmental-cell/flilltext/S 1534-5807(06100248-6 (accessed 15/06/09) 
Nicholl, H., Stem Cell Sperm Success 17th July 2006, Bionews 
http://bionews.org.uk/new.lasso?storvid=3107 (accessed 14/9/06)
236 Thanks to Soren Holm for his input on this point.
237 House o f  Lords Select Committee on Stem Cell Research  - Report Session 2001-02, HL Paper 83(i) at 
Para 1.12
238 Ibid. at Para 1.15
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was published on the 13th February 2002 and provides a comprehensive overview o f the 
important aspects of human cloning and stem cell research including not only the status 
of the early embryo but also the potential advantages, limitations and commercial 
interests of human cloning and stem cell research.
The House of Lords Select Committee reviewed the stance taken by the Wamock 
Committee towards the status of the early embryo. It noted that the basic ethical 
arguments had not changed substantially since they were considered by Wamock and 
whilst considering those arguments the Select Committee found that “ Unless early 
embryos have an unconditional claim to protection, therefore, it would be wrong to rule 
out research involving them fo r such a purpose.” The Committee is clear that it agrees 
with the conclusion reached by the majority of the Wamock Committee concerning the 
status of the early human embryo and for which there was considerable public support.
Accordingly, the Select Committee also considered the fourteen day limit to 
research upon human embryos which was proposed by Wamock and subsequently carried 
through into legislation. As the Select Committee notes, the fourteen day limit seems to 
have been widely accepted and that research carried out under licence from the HFEA 
has also attracted little criticism from those who accept research upon early embryos. 
Additionally, the Select Committee received no evidence to suggest that a different limit 
would be appropriate if research were to continue. Therefore, the fourteen day limit was 
advocated as remaining the limit for research on early embryos.240
The 2001 Regulations
The Human Fertilisation and Embryology (Research Purposes) Regulations 2001 
extended the research purposes permitted under the HFE Act. The Select Committee 
considered that embryos created by cell nuclear replacement fell into the remit of the 
HFE Act and the 2001 Regulations (although at the time of the House of Lords Select 
Committee Report it was noted that an appeal in Quintavalle was pending in the House of 
Lords which could have altered this position, in time it was established that the outcome 
of the House of Lords did not affect this opinion). The Select Committee considered that 
although the method of creation varied between embryos created by IVF and embryos
239 Ibid. at Para 4.17
240 Ibid. at Para 4.22
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created by cell nuclear replacement, there was no ethical difference in their use for 
research purposes up to the fourteen day limit. However, as with embryos created by IVF 
the Select Committee recommended that embryos should not be created by cell nuclear 
replacement for research purposes unless there “...is a demonstrable and exceptional 
need which cannot be met by the use o f  surplus embryos.”241
The Select Committee is critical of the 2001 Regulations noting that the new 
research purposes are a step further than the 1990 research purposes (as discussed 
earlier):
The purposes in the 1990 Act are all related, one way or another, to reproductive 
medicine, whereas applications under the Regulations will be fo r  research 
relevant to a range o f  serious diseases and fo r  fundamental research that 
underlies it.242
The House of Lords Select Committee raised two issues in relation to the drafting 
of the 2001 Regulations. The first concerned the use of the term ‘serious disease’. 
‘Serious disease’ is not defined in the Regulations and whilst the Select Committee 
recognised that it would be somewhat difficult to frame an exhaustive list it did 
recommend that the Department o f Health or the HFEA issue non-statutory guidance on 
the matter.243 Clearer guidance would be useful, particularly as the term does not even 
make clear for whom the disease should be serious -  the individual or society more 
generally.
The second issue of concern for the Select Committee was the application of the 
2001 Regulations to basic research. As the Select Committee noted, stem cell research 
was and still is at an early stage and a great deal of basic research will need to be 
conducted before a stage of applied research is reached. There is a question mark whether 
basic research to understand how cells behave falls into the research purposes of 
increasing knowledge about the development of embryos, or about serious disease, or 
applying knowledge to the development of treatments. This again shows how legislation 
designed to deal with embryos has been used and interpreted to apply to cells, going 
further than envisaged at the time o f enactment.
Upon questioning, the HFEA replied that it had received counsel that:
241 Ibid. at Para 5.14
242 Ibid. at Para 8.3
243 Ibid. at Para 8.8
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...where an application is directed at understanding how human stem cells behave 
and differentiate, such research “may be appropriately described” as being 
concerned with increasing knowledge about the development o f  an embryo 
(purpose (a) in the Regulations)...where such basic research moves beyond 
purpose (a), consideration will need to be given to whether it fa lls under purpose 
(b) (increasing knowledge about serious disease) or (c) (development o f  
treatments fo r  serious disease)244
An alternative approach is to consider “...whether the legislative policy was 
judged to encompass basic research on human embryos (at any rate where such research 
is a necessary precursor to the development o f  therapies fo r  serious diseases)245
The Select Committee did not express an authoritative view as to which was the 
correct approach to take but did note that it would be somewhat perverse if the 2001 
Regulations recognised the development of treatments for serious disease but not 
implicitly incorporate basic research.246 At any rate the Select Committee recommended 
(at Paragraph 8.15) that when the Government introduced new legislation, basic research, 
as a precursor to the development of cell-based therapies, should be expressly provided 
for.
Government Response to the House of Lords Select Committee Report 
on Stem Cell Research CM 5561
The Government Response to the House of Lords Select Committee Report on 
Stem Cell Research was supportive and agreed extensively with the majority of the 
recommendations made. The Government in its response went on to say that “...the 
Government believes that the existing controls over embryo research in the 1990 Act and 
by ethics committees are sufficiently robust to allow the HFEA to oversee this aspect o f  
embryology.”241
244 Ibid. at Para 8.11
245 Ibid. at Para 8.14
246 Ibid. at Para 8.15
247 Government Response to the House o f  Lords Select Committee on Stem Cell Research (2002) 
Department o f  Health CM 5561 at Para 5.14, pg 11
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O f note though is the Government’s response to the recommendations made by 
the Select Committee in relation to the 2001 Regulations -  the definition of ‘serious 
disease’ and applying the Regulations to basic research.
The recommendation to consider drawing up guidance as to what constitutes 
‘serious disease’ was rejected by the Government, noting that the Health Ministers in 
both Houses did not believe that guidance would be helpful or practical. As every licence 
application is dealt with by the HFEA the Government states that such a list would be 
unnecessary.248 The Government’s response did not answer the question raised by the 
Select Committee of whether ‘serious disease’ applies to the individual or to society at 
large and the Government’s intention of reviewing the situation “as and when the number 
o f research applications increase ” was unsatisfactory. The HFEA was effectively left in 
the situation of regulating embryo research but of also devising policy without adequate 
guidance from Government. This could lead to legal challenges in the future by groups 
who may contest that the HFEA has overstepped its role and remit.
Finally the Government’s response to the query as to whether the 2001 
Regulations permitted basic research was unequivocal:
The Government agrees with the Committee that basic research as well as applied 
research should be allowed under the Regulations. The Government is confident 
that the research purposes laid down in the 1990 Act and amended by the 2001 
Regulations will cover the type o f research described by the Committee.249
We will keep this aspect under review but at present have no reason to believe 
that legislation will be requiredfor the foreseeable future.250
Although the Government agreed to keep the situation under review it was clear
that it did not believe that explicit legislation would be needed to cover basic research.
Whilst it would be bizarre if the current legislation permitted applied research but not the 
preliminary basic research, it can be said that basic research is by no means explicitly 
covered by the legislative research purposes. As will be seen when the Government 
reviewed and reformed the legislation it sought to cover this issue in greater detail, so as 
to avoid future legal challenges and to satisfy the many who held the opinion that basic 
research was not covered by the legislation as it stood.
248 Ibid. at Para 8.8, pg 15
249 Ibid. at Para 5.4, pg 11
250 Ibid. at Para 8.15, pg 15
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Conclusion
The journey from non-regulation to full statutory control o f the human 
fertilisation and embryology services within the United Kingdom has been a lengthy and 
detailed process which has considered many controversial and morally divisive areas.
The resulting legislation, the HFE Act, is regarded by many as providing a 
comprehensive, yet workable, framework for regulating the use, creation and storage of 
human embryos and gametes and has been the basis for legislation in other jurisdictions. 
The HFE Act in conjunction with the Human Reproductive Cloning Act 2001 and the 
2001 Regulations regulates and controls research upon human embryos which may be 
used to extract human embryonic stem cells.
Although not without its legal challenges and definitional problems, the 
legislation has worked well over the years in maintaining and building public confidence 
in an area of science which, although it could potentially provide us with cures for many 
diseases, is plagued by moral outrage and misinformation. The one area where the 
legislation falls down is in the regulation o f the stem cells post-extraction. This was noted 
in the Donaldson Report and currently leaves stem cells outside of statutory control. This 
problem area is discussed in further detail later in Chapter 6 of this thesis. It is not 
surprising that human embryonic stem cells are outside of statutory control, after all, the 
legislation designed to govern human embryos was not intended to apply to stem cells. 
Using human embryo legislation to govern stem cells is a whole new ball game and one 
which the legislation has generally adapted well to even though this situation was 
unheard o f and unforeseen in the 1980’s when the legislation was being formulated, 
drawn up and debated upon.
The HFEA has also been successful in implementing the controls found in the 
Statutes although the application and licensing process is not without its faults and will be 
looked at in greater detail elsewhere in this thesis.
The road to statutory control was neither smooth nor quick, however, once 
reached the legislation has successfully regulated this controversial area o f science.
Chapter 7 continues the legislative story; the intervening Chapters look at the 
current licensing and research processes and as such discuss the role o f research ethics 
committees, the HFEA and the UK Stem Cell Bank.
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Chapter 4 - Research Ethics Committees
A research project involving human embryos has three bureaucratic obstacles it 
must overcome before it can proceed. It must have an HFEA licence, it must 
satisfy a local ethics committee and it must have funding.251
When a researcher is considering seeking research ethics committee approval 
prior to commencement of a research project he will have to decide which of the three 
different research ethics committees he must approach - the local research ethics 
committee, multi-centre research ethics committee or the in-house ethics committee. The 
HFEA requires that each research project is referred to a properly constituted ethics 
committee for ethical approval prior to the HFEA giving approval for a research licence. 
This requirement was previously to be found in the HFEA Code of Practice but following 
the publication of the 7th edition the requirement is now to be found only in the Guidance 
notes on completing all research licence applications.252
It should be noted that the need for research ethics committee approval prior to 
applying to the HFEA for a research licence is a requirement that the HFEA has 
introduced. Within the HFE Act 1990 (and now the HFE Act 2008) there is no legal 
provision stipulating the need for research ethics committee approval for a research 
licence. There is only a legal requirement to obtain research ethics committee approval 
where work involves NHS patients or takes place in an NHS hospital (as discussed 
below). The bodies involved with embryo research and human embryonic stem cell 
research more specifically, have invented and imposed this additional level of control. It 
should be noted that it is not only the HFEA which requires research ethics committee 
approval but also the funding bodies. Interestingly one recent research licence application 
from the University o f Newcastle upon Tyne to the HFEA for work involving the 
derivation of embryonic stem cell lines from hybrid embryos was successfully applied for
251 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05 House o f  Commons 
Science and Technology Committee HC 7-1 at Para 330, Pg 145
252 Confirmed in private correspondence with the HFEA 15/11/07; Regulation o f  Research on Human 
Embryos, HFEA at Section 14, page 13,
http://www.hfea.gov.uk/docs/2006 Guidance Notes for All Research Licence Applications.pdf 
(accessed 8/01/08) previously found in HFEA 6th Code o f  Practice, Para 10.6 
http://212.49.193.187/cps/rde/xbcr/SID-3F57D79B-525847C4/hfea/Code_of Practice Sixth Edition - 
final.pdf (accessed 5/5/06)
How to apply fo r  a research licence, HFEA
http://www.hfea.gov.uk/Research/Howtoapplvforaresearchlicence (accessed 5/5/06)
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without research ethics committee approval. The research group was able to show that 
they would be using existing cell lines, therefore not involving NHS patients or 
facilities.253
Research ethics committees now fall under the remit of the newly formed 
National Research Ethics Service (NRES) which is discussed later.
The Declaration of Helsinki
The Declaration of Helsinki has been the cornerstone of biomedical research since 
its inception in 1964. It has been revised and amended several times since 1964, most 
recently in 2000.254 It was not until the 1975 version of the Declaration of Helsinki that 
research ethics committees were mentioned as being a vital aspect of biomedical research 
involving human subjects although they were not referred to specifically as research 
ethics committees. The 1975 version stated that:
The design and performance o f each experimental procedure involving human 
subjects should be clearly formulated in an experimental protocol which should 
be transmitted to a specially appointed independent committee fo r  consideration, 
comment, and guidance.255
This section of the Declaration of Helsinki was expanded in 1996 and again in 
2000. The relevant section now reads as:
The design and performance o f  each experimental procedure involving human 
subjects should be clearly formulated in an experimental protocol. This protocol 
should be submitted fo r  consideration, comment, guidance, and where 
appropriate, approval to a specially appointed ethical review committee, which 
must be independent o f  the investigator, the sponsor or any other kind o f undue 
influence...2 6
253 Derivation o f  Embryonic Stem cell Lines from  Interspecies Embryos produced by Somatic Cell Nuclear 
Transfer (R0179) University o f  Newcastle Upon Tyne, Centre for Stem Cell Biology & Developmental 
genetics, Institute o f  Human Genetics http://www.hfea.gov.uk/1580.html (accessed 2/7/09) Confirmed in 
personal communication with Professor Emily Jackson 3rd July 2009, member o f  the HFEA
254 See the World Medical Association website for the full text and dates o f  amendments 
http: //w w w .wma. net/e/pol i cv/b3. htm (accessed 10/8/06)
255 Paragraph 2, Declaration o f  Helsinki (1975) available in the Bulletin o f  Medical Ethics (1999) Issue 
150, pg 14
256 Paragraph 13, Declaration o f  Helsinki (2000) http://www.wma.net/e/policv/b3.htm (accessed 10/8/06)
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As can be seen there was a very soft law requirement to have ethics committees 
from 1975 onwards for biomedical research involving human subjects. The committees 
existed informally in the UK until 1991 when, as will be seen in the discussion below, the 
NHS formally constituted research ethics committees.
NHS Research Ethics Review
NHS research ethics review consists of Local Research Ethics Committees and 
Multi-Centre Research Ethics Committees. The development, functioning and problems 
of both are discussed along with reform which has occurred recently.
Local Research Ethics Committees
Local Research Ethics Committees were established in 1991 and must be 
approached for research ethics approval prior to the start o f research where the project 
will involve the use o f human subjects within the NHS.257 Specifically the local research 
ethics committee must be consulted about any research proposal involving:
NHS patients ...including those treated under contracts with private sector 
providers
Fetal material and IVF involving NHS patients
The recently dead in NHS premises
Access to the records ofpast or present NHS patients
The use o f  or potential access to, NHS premises or facilities258
Additionally, the local research ethics committee may also be approached to 
advise on the ethics of studies which does not involve NHS patients, records or 
premises.259 It is important to note that NHS research ethics committees must always be 
approached when NHS patients or facilities are involved in the human embryonic stem 
cell research project, and can be approached when NHS resources are not involved. 
However, the HFEA and relevant funding bodies will normally require research ethics 
committee approval regardless o f whether it is NHS or private resources which are going
257 Local Research Ethics Committees (1991) Department o f  Health, HSG (91 )5
258 Ibid. at Para 1.3
259 Ibid. at Para 1.6
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to be used. The attempt to impose this additional level o f ethical control is not necessarily 
of beneficial use in human embryonic stem cell research projects and is discussed further 
below.
Research ethics committees have been described as acting “...as an independent 
safeguard sitting between the researcher and the potential participant.”260 Their purpose 
is to consider the ethics of proposed research projects which will involve human 
subjects.261
Composition
Local research ethics committees should have between eight and twelve members, 
of both sexes, from a wide age range. Members must be drawn from different 
backgrounds (scientific and lay membership is compulsory) allowing for a broad range of 
experience and expertise and can be appointed for between three and five years, with the 
appointment permitted to be renewed but only two terms of office should be served 
consecutively.262 Additionally, the local research ethics committee is permitted to seek 
the advice o f specialist referees to cover any aspect of a research proposal which lies
' j f / i
beyond the expertise of the existing members. This is very important as research is 
becoming increasingly varied and specialised, the chances of having a member with the 
requisite knowledge on the local research ethics committee may become more remote.
Multi-Centre Research Ethics Committees
In 1991 the Department of Health Guidance noted that where research was 
proposed to be undertaken in more than one geographical area, each local research ethics 
committee was free to take its own decision when considering a proposal. To eliminate 
unnecessary delay and to help conformity in criteria in reaching decisions, one local 
research ethics committee should be nominated to consider the issue on behalf of all the 
local research ethics committees.264
260 Pattinson, S., M edical Law and Ethics (2006) Sweet & Maxwell, at p362
261 Local Research Ethics Committees (1991) Department o f Health, HSG (91) 5 at Para 1.1
262 Ibid. at Para’s 2.4 -  2.5 and 2.10
263 Ibid. at Para 2.10
264 Ibid. at Para 2.18
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Whilst the decision to allow one local research ethics committee to take the lead 
in considering a research proposal which would be performed in more than one area was 
in itself a reasonable one to take, it was not one that worked well. The delay and 
duplication of work involved in multi-area research lead to the creation o f multi-centre 
research ethics committees in July 1997.
Multi-centre research ethics committees will advise on research proposals which 
will be carried out in five or more local research ethics committees’ geographical 
boundaries. Once an application for a research proposal has been approved by the multi­
centre research ethics committee it is then sent to the local research ethics committee in 
every area which will be involved. The local research ethics committee then has an
O f \ f \opportunity to accept or reject the proposal for local reasons.
The idea of the multi-centre research ethics committees was to allow research 
proposals to be dealt with efficiently and on an equal criteria basis. In reality, the dual 
level approach to research proposals meant that many proposals were subject to 
enormous amounts of duplication, in terms of both work and time, to resubmit 
applications to all the relevant local research ethics committees after approval by the
9 A7multi-centre research ethics committee.
Research Governance Framework for Health and Social Care and 
Governance Arrangements for NHS Research Ethics Committees
The first edition of the Research Governance Framework fo r  Health and Social 
Care was published by the Department o f Health in 2001.268 This was closely followed 
by the Governance Arrangements fo r  NHS Research Ethics Committee269 
As Jackson notes:
265 Ethics Committee Review o f  Multi-Centre Research  (1997) Department o f Health, HSG (97) 23
266 Ibid. at Para 3
267 For example refer to Middle et al., Ethics approval fo r  a national postal survey: recent experience, 
(1995) 311 BMJ 659 which identified personnel, time and expense as some o f  the problems in obtaining 
approval for a relatively simple postal survey on birth weight o f children born in 1988
268 Research Governance Framework fo r  Health and Social Care, 1st edition published in 2001, 2nd edition 
published in 2005, Department o f  Health. The 2005 edition will be referred to throughout this work and can 
be accessed at:
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicvAndGuidance/DH 4108 
962 (last accessed 10/01/08)
269 Governance Arrangements fo r  NHS Research Ethics Committee (2001) Department o f  Health 
http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicvAndGuidance/Publications 
PolicyAndGuidanceArticle/fs/en?CONTENT ID=4005727&chk::=CNcpvR (last accessed 10/01/08)
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The new governance arrangements fo r  research in the UK were...partly a 
response to the recognition that the procedures and powers o f  ethics committees 
were offering a fa r  too fragmented, inconsistent and ineffective system fo r  
ensuring that high quality and ethically sound research is carried out in the 
UK.270
Research Governance Framework for Health and Social Care
The Research Governance Framework fo r Health and Social Care applies to all 
research undertaken in or by the Department of Health and the NHS but is equally offered 
as a model for the governance of research outside o f the NHS.271
Participants
The Research Governance Framework notes that the primary consideration in any 
research study must be “The dignity, rights, safety and well-being o f  participants.”212 In 
relation to human embryonic stem cell research it can be questioned if research involving 
human embryos can ever be considered to be within the ‘well-being of the participants’ 
particularly as the embryos will not be subsequently implanted, denying them the 
opportunity and potential to develop normally. However, research ethics committees do 
not consider human embryos as ‘participants’ to a research study, participants are defined 
in the Research Governance Framework as:
Patient, service, user, carer, relative o f  the deceased, professional carer, other 
employee, or member o f  the public, who consents to take part in a study.273
Clearly embryos are not considered to be research participants within the 
guidelines laid down in the Research Governance Framework, rather it is the donors of 
the gametes used to create the embryos which are to be used in the subsequent research 
who would be classed as the participants, and provided that their interests are protected
270 Jackson, E., M edical Law: Text, Cases and M aterials (2006) OUP at p480
271 Research Governance Framework fo r  Health and Social Care, 2nd ed (2005) Department o f  Health at 
Para 1.2, 1.5 and 3.12.3. Hereafter referred to as the Research Governance Framework
272 Ibid. at Para 2.2.1
273 Ibid. Box C: A to Z o f  the main people and organisations involved in a health or social care research 
study, Pg 22
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and informed consent is acquired, there is no dilemma in applying the purpose of 
protecting subjects in the Research Governance Framework to human embryonic stem 
cell research.
At Paragraph 2.3.4 the Research Governance Framework notes that special 
regulations govern the use of human embryos of which further information can be found 
in the Annex. Upon investigation, the Annex merely refers the reader to additional 
legislation and guidance (which has been discussed elsewhere in this work) without 
further explanation. It does not explain the role played by research ethics committees in 
licensing the use, storage or research of human embryos. This seems to muddy the waters 
in relation to obtaining research ethics committee approval prior to seeking a licence from 
the HFEA and although there is an element of co-operation between the two bodies (as 
required by the Research Governance Framework) it is not clear what exactly the role of 
each body is.274
Progress Reports
Research ethics committees have a number of responsibilities which they are 
required to fulfil; they must be independent and impartial when undertaking ethical 
review of the proposed research placed before them; they are not to provide legal advice 
as it is the researchers and health and social care organisations who have the 
responsibility not to break the law; and they are required to keep the progress of approved 
research studies under review.275 The progress reports provided by the researcher to the 
relevant research ethics committee allows the committee to review its advice on the 
ethical acceptability of the study and, if needs be, to alter the advice given.276
Again the Research Governance Framework can be criticised for being vague in 
its guidance. Whilst progress reports provide a useful tool to keep checks upon the 
research project, there is no information provided as to the regularity with which these 
reports should be submitted; additionally data could easily be omitted from the progress 
report, thus not allowing the research ethics committee to properly review the project 
being undertaken. Although the idea of progress reports is a good one it appears to be
274 Ibid. at Para 1.14
275 Ibid. at Para 3.12.4, 3.12.6-8
276Ibid. at Para 3.12.8
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relatively easy to overcome the burden of submission and concern about possible 
variation or revocation of the approval given to the project.
The lack of guidance specifically relating to human embryos once more confuses 
the situation for both the scientist and the interested observer. As will be seen, the HFEA 
makes it a requirement of any research licence that the person leading the research 
submits regular progress reports to the HFEA for review, allowing for variation or 
revocation of the licence. At first sight it would then appear that a scientist undertaking 
human embryonic stem cell research would have to submit two progress reports, one to 
the relevant research ethics committee and another to the HFEA.
Whilst the same progress report may be suitable to submit both times, thereby 
negating any additional administration, it does not alleviate the risk o f the two bodies 
disagreeing over the research project once it is underway. For example, a research ethics 
committee may consider the number of embryos used in such a project as unethical and 
excessive and may wish to move to vary the advice given to prohibit exceeding a 
specified number of embryos. In contrast, the HFEA may be able to compare the number 
of embryos used to previous research projects and find that the numbers used are 
perfectly acceptable. Who is to take priority? It would appear that the HFEA would take 
priority as the body which actually gives the legal approval for the research project to go 
ahead; the research ethics committee merely gives the ethical approval before the 
scientific merits (and legal implications) are considered by the Licensing Committee of 
the HFEA. It is another complication to the area of ethical review prior to HFEA 
approval.
It does not appear that a research ethics committee has ever withdrawn its 
favourable ethical opinion for a research project involving human embryonic stem 
cells.277 Although withdrawal o f ethical approval has not yet happened this could of 
course occur in the future. As the Central Office for Research Ethics Committees 
(COREC, now superseded by NRES) acknowledges, a research ethics committee could 
unilaterally withdraw its opinion as it is independent of the HFEA, but that the research 
ethics committee may refer its concerns to the HFEA and seeks its advice.278 
Additionally, the HFEA has also confirmed that were a research ethics committee to
277 Confirmed by COREC, personal communication 14th August 2006
278 Thanks to COREC for clarifying this issue, personal communication 14th August 2006
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withdraw its approval for a research project, the licence holder could not continue
279working with only HFEA approval.
If an NHS research ethics committee withdrew its approval for a research project 
involving human embryonic stem cell research, and the HFEA did not withdraw its 
approval (although unlikely given the HFEA response mentioned above), it is likely that 
the NHS Trust body in whose jurisdiction the research project is being undertaken would 
refuse to allow the research to continue. Although it would seem that the HFEA would 
take priority concerning the approval of the research project, public opinion would 
require the NHS institution to halt the research whilst the conflict between the opinion of 
the research ethics committee and the HFEA are resolved. If the scientists involved 
attempted to continue their research within the NHS institution they would be subject to 
their employer’s sanctions, not the sanctions of the research ethics committee. The 
research ethics committee does not have any powers to prevent a researcher from 
continuing with his work in the situation where research ethics committee approval has 
been withdrawn.
In contrast, the situation is less clear when dealing with a research ethics 
committee which has withdrawn approval for a research project being undertaken in a 
private institution. It would appear that if the private institution is happy for the research 
to continue with only the approval of the HFEA then there would be no potential 
sanctions from the employer for the researchers involved. If, however, the private 
institution preferred to halt the work the researchers would be subject to any sanctions 
their employer saw fit if  they continued their work without the full support of their 
employer.
Governance Arrangements for NHS Research Ethics Committees
The Governance Arrangements fo r  NHS Research Ethics Committees replaces the 
previous guidance found in HSG (91)5 and HSG (97) 23 which originally established 
Local Research Ethics Committees and Multi-Centre Research Ethics Committees.280 The 
Governance Arrangements were introduced following the Research Governance
279 Personal communication from Dr Richard Martin, Head o f  Information, HFEA, 9th November 2006
280 Governance Arrangements fo r  NHS Research Ethics Committee (2001) Department o f  Health at 
Preface, Para 7 Hereafter referred to as the Governance Arrangements
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• 281Framework which identified a need for review of research ethics committees. 
Additionally significant changes were required following the EU Directive 2001/20/EC 
which put, for the first time, ethical review of clinical trials upon a statutory footing. The 
European Directive has since been adopted in the UK through the Medicines fo r  Human 
Use (Clinical Trials) Regulations 2004.
The purpose o f the Governance Arrangements is to provide a:
...standards framework fo r the process o f  review o f the ethics o f  all proposals fo r  
research in the NHS and Social Care which is efficient, effective and timely, and 
which will command public confidence.282
Role and Remit
The Governance Arrangements repeats the primary consideration of the Research 
Governance Framework by stating that the purpose of a research ethics committee in 
reviewing a proposal for a research project is ‘Vo protect the dignity, rights, safety and
J O  5
well-being o f all actual or potential research participants. ” Research ethics 
committees should seek to balance the interests of all those people involved including the 
participants, the researchers and the concerned communities, although the research 
participants should always take priority. Again human embryos are not considered to be 
research participants according to the definition contained in the Governance 
Arrangements Glossary:
Participants:- patients, users, relatives o f the deceased, professional carers or 
members o f  the public agreeing to take part in the study.284
The Governance Arrangements gives further detail as to what particular types of 
research will always require ethical advice from a research ethics committee, including 
research which involves fe ta l material and IVF involving NHS patients’.2*5 Embryo 
research is not specifically mentioned in paragraph 3.1 as requiring ethical advice from 
an NHS research ethics committee, however it does state that:
281 Ibid. at Preface, Para 3
282 Ibid. at Preface, Para 6
283 Ibid. at Para 2.2
284 Ibid. at Para 11.3
285 Ibid. at Para 3.1(d)
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Certain types o f  research specified under the Human Fertilisation and 
Embryology Act 1990, may not proceed without a licence from  the Human 
Fertilisation and Embryology Authority, from whom further information may be 
obtained. Research Ethics Committee approval is also required. (See Section 
B). ”286
Upon closer inspection of the Governance Arrangements it is obvious that there is 
no Section B, effectively making ethical review of embryo research (and human 
embryonic stem cell research) a circular process -  the HFEA requires research ethics 
committee approval prior to considering the application for a licence to perform embryo 
research, the Governance Arrangements notes that further information may be obtained 
from the HFEA. The HFEA only states that research ethics committee approval is 
required, it does not provide any further information. It would be thought that information 
should be obtainable from both the research ethics committee from whom approval is 
being sought, and from the HFEA. What appears to occur here is that each body is 
passing the buck and no solid information seems to be accessible.
To whom an interested party may apply to for guidance over the ethical review of 
human embryonic stem cell research suddenly becomes very unclear. This is a major flaw 
with the Governance Arrangements. Whilst designed to provide clear guidance on 
research ethics committees, in relation to human embryonic stem cell research, in many 
respects it actually serves the opposite, in confusing who to apply to for ethical review, 
and the process to be followed.
Whilst the guidance is unclear and confusing this may be mitigated by the fact 
that the numbers o f researchers involved in human embryonic stem cell research is very 
low. Any confusion will be quickly resolved as the researchers build up their expertise in 
dealing with the appropriate research ethics committee.
286 Ibid. at Para 3 .9 ’
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Membership and Composition
The membership of a research ethics committee must be such that it can ensure 
that “...tasks can be executed free from bias and influence that could affect their 
independence in reaching their decision.”
Members are normally appointed for five years and may be reappointed although 
it is preferred that a member does not sit on a specific research ethics committee for more 
than two consecutive terms.288 Whilst the maximum number of members is set at 18, the
7 0 Q
minimum number required to constitute a quorum at a meeting is seven. The reason for 
this is that it is recognised that members will also hold other positions and so may be 
unable to attend all meetings, although attendance at a minimum of two thirds of all 
scheduled meetings is expected.290
The membership is expected to be diverse with a broad range of experience and 
expertise whilst also reflecting the wider community with members from across the age 
groups and the sexes.291 Importantly the requirement that there is a mixture o f lay and 
expert members is carried through from the 1991 Local Research Ethics Committee 
Guidance. There is an additional requirement that at least three members are independent 
of any organisation where research under ethical review is likely to take place.292
Crucially the ability of the research ethics committee to seek expert advice has 
also been carried across from the 1991 Local Research Ethics Committee Guidance. The 
Governance Arrangements permits the Chair and Administrator to “...seek the advice o f  
specialist referees on any relevant aspects o f a specific research proposal that lie beyond 
the expertise o f  the members.” In relation to human embryonic stem cell research this 
is very important; it is unlikely that a research ethics committee will have the relevant 
expert knowledge amongst its members to deal with an application for ethical review. 
Human embryonic stem cell research is an up and coming area o f science with still a 
relatively small number o f people claiming to have expert knowledge of the subject;
287 Ibid. at Para 5.1
288 Ibid. at Para 5.10
289 Ibid. at Para 6.1 and 6.11
290 Ibid. at Para 5.5
291 Ibid. at Para 6.1 and 6.2
292 Ibid. at Para 6.3
293 Ibid. at Para 6.10
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scientific, ethical or legal. Additionally, the Governance Arrangements has extended 
greatly the range of specialist referees who may be referred to for advice:
These referees may be specialists in ethical aspects, specific diseases or
methodologies, or they may be representatives o f  communities, patients, or
. r . 294special interest groups.
This has greatly expanded the potential number of specialist referees who may be 
approached for advice concerning human embryonic stem cell research. Whilst it may be 
scientists who are currently carrying out the work, potentially many patients may be 
affected by the outcomes of such research and the author of this thesis believes that it is 
important that special interest groups could be approached for advice on this significant 
matter. Although these special interest groups may be approached, it is unclear how 
regularly they are in fact approached, although COREC has advised that they are 
consulted where appropriate.295 O f course, the research ethics committee may want to 
approach groups with opposing ethical perspectives which would allow the research 
ethics committee to come to a balanced decision.
Progress Reports
As indicated in the Research Governance Framework the research ethics 
committee can request progress reports from research projects which it has approved. The 
Governance Framework gives further guidance as to the regularity of such progress 
reports. At the time of approval the research ethics committee should indicate any 
progress reports which it will require ‘from time to time ’ along with a final report to be 
submitted within three months of completing the research project.296
The Governance Arrangements call upon the research ethics committee to require 
as a minimum an annual report from the researchers at which point the research ethics
907committee will reconsider its opinion. The research ethics committee is at liberty to
294 Ibid. at Para 6.10
295 Thanks to COREC for clarifying the use o f special interest groups, personal communication, 14th August 
2006
296 Governance Arrangements fo r  NHS Research Ethics Committee (2001) Department o f  Health at Para 
7.26
297 Ibid. at Para 7.27
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request more frequent reports and conduct interim review where it is considered that the
298degree of risk requires it.
The Governance Arrangements are to be commended for finally providing some 
guidance over the progress reports, although the guidance does not go far enough; upon 
closer inspection it can be seen to be as lacking as the guidance in the Research 
Governance Framework. There is no indication of what the research ethics committee 
should demand to see in the progress reports, what information the researchers are 
obliged to provide, or how and why the research ethics committee should review its 
approval. Again there is apparent cross-over between the HFEA and research ethics 
committees in requiring progress reports to be submitted to two bodies. This double 
reporting requirement arises due to the fact that research ethics committees do not treat 
human embryonic stem cell research as a special case and do not take into account the 
fact that progress reports will be required by another body which is fully capable of 
overseeing the work being undertaken. It can also be questioned what is the usefulness 
and necessity of these progress reports in light of the following information from the 
Governance Arrangements:
Other than by means o f these required progress reports, the REC has no 
responsibility fo r  pro-active monitoring o f research, the accountability fo r  which 
lies with the host NHS institution, but the REC may wish to be reassured o f  the 
process fo r  such monitoring in certain specific cases.299
If a research ethics committee has no responsibility for monitoring of research, 
why require the researcher to submit a progress report to the research ethics committee? 
The important point here is that the research ethics committee has no responsibility for 
the pro-active monitoring of research, therefore the committee is not required to 
undertake physical inspection of the work being undertaken, or to actively seek problems 
with the research project.
If the research ethics committee has no responsibility for pro-active monitoring of 
research, the usefulness of the progress reports can be questioned. How much information 
is a researcher actually going to provide within the progress reports? Would it not be 
preferable to submit the report to the NHS institution which is accountable for the
298 Ibid. at Para 7.27
299 Ibid. at Para 7.33
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research being undertaken? Concerning human embryonic stem cell research the HFEA 
could step into the position of the NHS institution.
Whilst the majority of human embryonic stem cell research projects may involve 
an NHS institution, possibly due to the use of premises or access to NHS patients, and so 
there would be an accountable NHS institution, there may be a few projects which are 
privately funded and so would not report to an NHS institution. The Governance 
Arrangements has made it clear that NHS research ethics committees can be approached 
by bodies outside of the Department of Health or NHS. With the HFEA requirement that 
research ethics committee approval must be sought prior to an application to the 
Licensing Committee of the HFEA it seems somewhat strange that a privately funded 
human embryonic stem cell research project may need to submit progress reports to an 
NHS research ethics committee which does not and is not accountable for the monitoring 
of the research, in addition to the progress reports required to be submitted to the HFEA.
The Central Office for NHS Research Ethics Committees (COREC) and 
the United Kingdom Ethics Committee Authority (UKECA)
The Central Office for NHS Research Ethics Committees was established in 
2000.300 Its role is to provide
...help and leadership fo r  RECs and the REC system by co-ordinating the 
development o f  operational and infrastructure arrangements in support o f  their 
work. This includes implementing standards to ensure national consistency, 
providing training fo r  REC members and co-ordinators, identifying IT  solutions 
fo r  procedural management and establishing regional Offices fo r  Research Ethics 
Committees (ORECs) to manage local RECs.301
So COREC was designed to improve and coordinate the organisation of research 
ethics committees in the United Kingdom.
On the 1st April 2005 COREC became the responsibility of the National Patient 
Safety Agency but continued in its role of overseeing national research ethics
302committees. COREC is designed to help research ethics committees, to speed up
300 Hereafter referred to as COREC
301 COREC website, About Us http://www.corec.org.uk/public/about/about.htm (accessed 3/7/06)
302 Hereafter referred to as the NPSA
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applications and to ease the administrative burden imposed by the application process. 
With the introduction of Standard Operating Procedures and the reduction in the number 
of research ethics committees it does appear that COREC is slowly winning the battle to 
establish a centralised and coherent research ethics committee system. The number o f 
local research ethics committees has dropped from 197 in 2002 to 155 in April 2004 as
303local research ethics committees have merged.
In May 2004 the Medicines fo r  Human Use (Clinical Trials) Regulations came 
into force in the United Kingdom which implemented EU Directive 2001/20/EC
The Clinical Trials Regulations are concerned with clinical trials involving 
medicines for human use. Human embryonic stem cell research has not yet reached the 
clinical trials stage of its research process so the Clinical Trials Regulations will be 
mentioned only briefly here (if and when human embryonic stem cell research reaches 
the clinical trials stage it is envisaged that the Regulations will still be applicable 
although this of course is not certain).
Whilst the EU Directive and the Clinical Trials Regulations apply only to clinical 
trials of medicinal products for human use and not all projects requiring research ethics 
committee approval, COREC has agreed that the benefits introduced by the new law will 
be applied to the whole national research ethics committee system.
There is now a common system fo r  application to research ethics committee’s 
across the whole o f  the UK, with ethics committees working to one set o f  standard 
operating procedures, using standard paperwork and the same application form  
fo r  all NHS research ethics committees.30
A new United Kingdom Ethics Committee Authority has been established under 
Regulation 5 of the Clinical Trials Regulations.306 The UKECA is responsible for 
establishing, recognising and monitoring research ethics committees which review 
clinical trials applications.307 COREC worked with the UKECA in providing advice on 
the procedure for recognising research ethics committees capable o f dealing with such
303 Central Office for Research Ethics Committee’s (COREC) Annual Report, June 2004, at 1.5 and 4.4
304 E U  Directive 2001/20/EC o f  the European Parliament and the Council o f  4 April 2001 on the 
approximation o f  the laws, regulations and administrative provisions o f  the Member States relating to the 
implementation o f  good  clinical practice on the conduct o f  clinical trials on medicinal products fo r  human 
use L121/34 OJEC Hereafter referred to as the Clinical Trials Regulations and the EU Directive
305 Central Office for Research Ethics Committee’s (COREC) Annual Report, June 2004, at Para 3
306 Hereafter referred to as the UKECA
307 M edicines fo r  Human Use (Clinical Trials) Regulations 2004, Reg 5(1)
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applications. The criteria for recognition are contained in COREC’s 2004 Annual 
Report.308
The role o f the UKECA was originally envisaged as overseeing clinical trials 
research ethics committees but the framework introduced by the Clinical Trials 
Regulations along with the work done by the UKECA in conjunction with COREC now 
applies nationally to all research ethics committees.
COREC has recently been incorporated into the National Research Ethics Service 
(NRES) and is discussed below. COREC (now NRES) and the UKECA are mentioned 
briefly here due to the role that they play in governing and overseeing research ethics 
committees who review applications for human embryonic stem cell research. The 
UKECA will play a greater role in the future when human embryonic stem cell research 
reaches the stage of clinical trials. O f note at this point is that although the UKECA 
appears to have been established, as it is referred to by NRES, there is a serious lack of 
information about it, no information can currently be located as to membership, remit or 
powers. It appears that the UKECA is a body in name only; it is NRES which carries out 
its functions. A personal request for information from COREC makes it clear that the 
membership of the UKECA is made up of the health ministers from England, Scotland 
and Wales together with the Department of Health and Personal Social Services in 
Northern Ireland.309 Whilst the ministers would not carry out the functions of UKECA 
personally, and therefore it is likely that NRES is the body which carries out those 
functions, this is not entirely clear from the information which is available. It is to be 
hoped that the lack of information freely available online will be rectified.
Report of the Ad Hoc Advisory Group on the Operation of NHS 
Research Ethics Committees
A Department of Health Advisory Group was asked to report on the operation of 
NHS Research Ethics Committees and on the interface with other research approval
310 •processes. The Advisory Group recognised that there are many problems with research 
ethics committees including lack of co-ordination and support, differing application
308 Central Office for Research Ethics Committee’s (COREC) Annual Report, June 2004, at Para 3.2
309 Personal communication from COREC 14th August 2006
310 Report o f  the A d  Hoc Advisory Group on the Operation o f  NHS Research Ethics Committees (2005) 
Department o f  Health at Pg 1 http://www.dh.gov.Uk/assetRoot/04/l 1/24/17/04112417.pdf
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processes, schedules and approaches to research issues.311 This is a particular problem for 
human embryonic stem cell research applications. If a researcher becomes accustomed to 
one set of procedures, processes and forms but then moves to a different area governed 
by a different research ethics committee the researcher may need to learn a whole new set 
of procedures and forms.
The Advisory Group considered the ‘perceived problems’ with research ethics 
committees. These were:
• The remit of research ethics committee’s
• Scientific and ethical review
• The operating system
• The application form
• Repeated requests for information
• Issues with workload and capacity
• Constitution and membership issues
• Inconsistency of decisions by research ethics committee’s, and
i n
• Challenges for members and administrators
Of note here is the issue of scientific and ethical review. Many perceive research 
ethics committees as dealing principally with clinical trials and many applicants felt that 
research ethics committees had not understood their research.313 Importantly the Report 
of the Advisory Group notes that research ethics committees are designed to deal with the 
ethical issues, not the scientific issues. Adequate scientific review should have been 
undertaken prior to application to the relevant research ethics committee. The Report of 
the Advisory Group notes that “...Where peer review has taken place, the RECs should 
accept this in all but exceptional cases; i f  it has not taken place, the RECs should be able 
to refer the application, fo r  scientific review purposes only, to a Scientific Officer based 
in COREC.”314 This then forms the basis of one of the recommendations made by the 
Advisory Group:
311 Ibid. at Para 1.1
312 Ibid. at Para 3.1-3.9
313 Ibid. at Para 3.2
314 Ibid. at Para 3.2
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RECs should not reach decisions based on scientific review. In the unusual situation 
o f a REC having reservations about the quality o f  the science proposed, they should 
be able to refer to COREC fo r  scientific guidance.315
It seems a sensible suggestion that appropriate scientific review should occur prior to 
application to a research ethics committee. In terms of human embryonic stem cell 
research this does not occur to the extent which appears to be required in the Report of 
the Advisory Group. Whilst there is scientific review prior to the application going to the 
research ethics committee there is not peer review as seems to be required by the 
Advisory Group. The Advisory Group seems to advocate peer review, whereby the 
application is sent out to others for review prior to submission to a research ethics 
committee. The current system does not seem to be sufficient for the Advisory Group.
Currently NHS Trusts have a committee which will consider and sign off the 
scientific merits o f a research proposal before it goes to the research ethics committee. 
Therefore the research proposal does not receive external peer review of its scientific 
merits but does get looked at by an appropriate committee before the ethics of the project 
are considered.316 The external peer review of the scientific aspects of the application 
would occur after approval by the research ethics committee. As will be seen the HFEA 
sends all applications to perform human embryonic stem cell research out for peer review 
prior to granting a licence.
The United Kingdom is in need of a coherent and cohesive research ethics committee 
approval system. There does not appear to be any focus upon the workings of research 
ethics committees with the HFEA or other bodies. Within the Report o f the Advisory 
Group there is comment made that human research does occur outside of the NHS, 
particularly in relation to the Human Tissue Act and the Mental Capacity Bill, but the 
Report is a very general look at how research ethics committees function. The Report of 
the Advisory Group may form the basis for an overhaul of the current research ethics 
committee system but does not provide any useful guidance to scientists conducting 
human embryonic stem cell research who wish to seek information about how in the 
future they are likely to proceed with an application.
315 Ibid. Recommendation 2
316 Thanks to Soren Holm for clarifying this point
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Implementing the recommendations of the Ad Hoc Advisory Group• 
consultation
In June 2005 the Ad Hoc Advisory Group on the Operation of NHS Research 
Ethics Committees made a total of nine recommendations; COREC under the control of 
the National Patient Safety Agency, wasted no time in bringing out an implementation
• • 317plan for those recommendations and as such initiated a public consultation period. This 
public consultation closed on Friday 21st April 2006, and the implementation plan was 
published in August 2006 (to be discussed below).
Concerning Recommendation 2 the Consultation Document notes that the 
Governance Arrangements are already quite specific that scientific review is outside of 
the scope of research ethics committees. It notes however that,
...research ethics committees can he drawn into the science when apparently 
inadequate design affects the ethical judgement. ...they do need evidence o f  the 
quality o f  the science in order to reassure themselves that the study has the 
potential to deliver benefits that justify risks, and that the design is ethically
318appropriate.
The Consultation Document proposes a ‘triage’ system designed to filter out 
applications which are of a poor scientific quality or design prior to the research ethics
T1 Qcommittee reviewing the application. Research Ethics Advisers (a new post to be 
created under the Consultation Document) would advise applicants to withdraw their 
application and re-submit with better evidence of scientific review or a better explanation. 
Research Ethics Advisers, we are told, would be able to provide this advice based upon 
their experience o f the type of evidence research ethics committees require and would 
also be able to make enquiries on behalf of the research ethics committee where there was 
uncertainty over the scientific validity of a proposal.320
This system would seem to be suitable for an application for research ethics 
committee review of a project involving human embryonic stem cell research. The
317 Implementing the recommendations o f  the Ad Hoc Advisory Group: consultation (2006) COREC 
http://www.corec.org.uk/consultation/ImplementationPlanConsultation.pdfHereafter referred to as the 
Consultation Document
318 Ibid. at page 9, Recommendation 2
319 Ibid. for further details o f  the ‘triage’ system refer to Section 4.1.2 and 4.1.3
320 Ibid. at page 10, Recommendation 2
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Consultation Document clarifies how the system will work and potentially shorten the 
period o f time currently involved in applying to a research ethics committee to only then 
discover that the material provided is inadequate. If a person was able to review 
applications at an early stage this would help to save time for all involved, helping to stop 
going back and forth between the researcher and the committee which may seek further 
evidence before consideration of the ethics of the research project.
Whilst an application for human embryonic stem cell research would then proceed 
to the Licensing Committee o f the HFEA for scientific approval and hopefully the all 
important licence required to conduct such research, it is known that the level of scientific 
review required by the research ethics committee is less onerous than that required by the 
HFEA. Having said that, if the amount of scientific evidence required to be provided to 
the research ethics committee was the same as that to be provided to the HFEA, this 
would cut down on essentially making two distinct applications for the researcher. In that 
situation it could then be questioned the usefulness of two committees reviewing the 
same scientific evidence. What seems to come out of the Consultation Document is that 
there will in fact be scientific review of a research proposal by a Research Ethics Adviser 
before the application makes its way to the research ethics committee for ethical 
consideration. An application for human embryonic stem cell research would then be 
scientifically reviewed again by the HFEA prior to obtaining a licence.
Upon reflection what may actually occur under this proposed plan is that a 
Research Ethics Adviser would review the research application to check that there is 
enough appropriate scientific evidence for the research ethics committee to base its 
decision upon. Once approved by the research ethics committee the application would 
then proceed to the Licensing Committee o f the HFEA for thorough scientific review, 
including two peer reviewers, before approval for the application went ahead.
Building on improvement: Implementing the recommendations of the 
Report o f  the Ad Hoc Advisory Group on the Operation o f NHS Research 
Ethics Committees
Following the Consultation Document, an Implementation Plan was published in 
August 2006, titled ‘Building on Improvement: Implementing the recommendations of
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the Report o f  the Ad Hoc Advisory Group on the Operation o f  NHS Research Ethics 
Committees.,321 The Implementation Plan discussed in detail how the recommendations 
made in the Governance Arrangements document would be brought into force.
Although Recommendation 2 of the Governance Arrangements recommended 
that ‘RECs should not reach decisions based on scientific review ’ and is quite specific 
that scientific review is outside the remit of research ethics committees, the 
Implementation Plan reiterates the point that “RECs can be drawn into the science when 
apparently inadequate design affects the ethical judgement. ” 322 As such the 
Implementation Plan continues the idea of Research Ethics Advisers although these are 
now referred to as National Research Ethics Advisers and will be able to form an 
executive sub-committee of at least two members (including a lay member).323 As the 
introduction to the Implementation Plan notes there was some concern about individuals 
making decisions on applications and the solution appears to be the new executive sub­
committee.324 The National Research Ethics Advisers will screen applications which are 
submitted to a research ethics committee. The screening is designed to identify 
applications which:
1. fa ll outside the remit o f  NHS RECs;
2. are patently o f  poor scientific quality or are poorly presented;
3. apparently present no ethical issues;
4. are studies that are complex, or involve potentially unfamiliar research methods 
(for complex studies committees may benefit from further advice to facilitate their 
review -  the research ethics service will arrange fo r  experts to provide such 
advice).325
Where the studies do not involve physical interventions and the ethical dimensions 
are minimal, the executive sub-committee o f National Research Ethics Advisers is able to
\m)f\issue a favourable opinion. Where the study involves more ethical issues then the 
National Research Ethics Advisers “ ...must refer applications to fu ll committee review as 
only fu ll ethics committees will be able to reject applications. ”321
321 (2006) COREC http://www.corec.org.uk/consultation/ImplementationPlan.pdf (accessed January 2007) 
Hereafter referred to as the Implementation Plan
322 Ibid. Recommendation 2, Page 4
323 Ibid. at Para 2.1.5, page 10-11
324 Ibid. at Page 1
325 Ibid. at Para 2.1.5, page 10
326 Ibid. at Para 2.1.5, page 11
327 Ibid. at Para 2.1.5, page 11
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Importantly for human embryonic stem cell research the research ethics committee is 
able to call upon expert advice when dealing with complex or unfamiliar research 
methods (see above). This is important as the research ethics committee may need to 
understand the scientific processes involved in greater detail before being able to consider 
the ethical issues. Whilst thorough scientific review is carried out by the HFEA the 
importance attached to sufficient peer review prior to application to the research ethics 
committee should not be underestimated.
The timescale for the implementation of these recommendations is not stated as it is 
noted that a pilot scheme will need to be undertaken first.328 What can be stated is that 
even though the introduction of National Research Ethics Advisers will likely reduce the 
number o f meetings involving the full membership of research ethics committees due to 
the National Research Ethics Advisers dealing with a large number of non-contentious 
applications, any application involving human embryonic stem cell research will 
undoubtedly require the full research ethics committee to consider the application due to 
the contentious ethical issues which arise from using human embryos and human 
embryonic stem cells (and/or tissue in light of the possibilities of chimera/hybrid 
embryos) in research.
The National Research Ethics Service
Following the publication of ‘Building on Improvement ’ COREC has since been 
incorporated into another body. The National Research Ethics Service (hereafter referred 
to as NRES) was launched on the 1st April 2007 and incorporated COREC and research 
ethics committees in England.329 In respect of Wales, Northern Ireland and Scotland a 
transitional period is currently taking place involving the Regional Offices for Research 
Ethics Committees during which NRES has shadow structures in place. 330 The 
establishment of NRES forms part of the process of implementing the recommendations 
made in the Implementation Plan.331
328 Ibid. at Para 2.1.6, page 11
329 About us NRES http://www.nres.npsa.nhs.uk/aboutus (accessed 10/01/08)
330 NRES sta ff— Regional Offices fo r  Research Ethics Committees NRES 
http://www.nres.npsa.nhs.uk/contacts/nres-staff-regional-offices/ (accessed 11/01/08)
331 Developing NRES NRES http://www.nres.npsa.nhs.uk/aboutus/developing-nres/ (accessed 10/1/08)
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Although COREC has been incorporated into NRES the UKECA still exists and 
“...is responsible fo r  the committees within NRES (and some independent committees) 
that are recognised to review Clinical Trials o f  Investigational Medicinal Products 
(CTIMPs) P332 Available information about the UKECA is still limited (September 2008) 
and the information gleaned comes from other reputable websites.
According to the NRES website the mission of NRES is to "...protect the rights, 
safety, dignity and well-being o f  research participants, whilst facilitating and promoting
2 2 5ethical research. ” In order to do this NRES is:
• Providing ethical guidance and management support to Research Ethics 
Committees in England
• Delivering a quality assurance framework fo r  the Research Ethics Service
• Working with colleagues in the UK to maintain a UK-wide framework
• Working with colleagues in the wider regulatory environment to streamline the 
processes334
The suggestion of introducing National Research Ethics Advisors does not yet appear 
to have been implemented (according to information available online) although NRES is 
currently undertaking pilot projects for ‘Early Provision o f Advice ’ and ‘Fast Track 
Review’ and once the results of these projects are assimilated, the introduction of 
National Research Ethics Advisors may happen. It is not clear exactly how these pilot 
projects have been designed and so the use of advisors may be one factor.335
In-House Ethical Review
As mentioned at the start o f this chapter when a researcher seeks research ethics 
committee approval prior to commencement o f a research project he will need to 
approach one o f the three different research ethics committees. The NRES will send out 
the application to the appropriate research ethics committee.336 Local and Multi-Centre
332 Development o f  the research ethics service in the t/A'NRES 
http://www.nres.npsa.nhs.uk/aboutus/historv/ (accessed 10/1/08)
333 About us NRES http://www.nres.npsa.nhs.uk/aboutus (accessed 10/01/08)
334 Ibid.
335 For a brief discussion o f  the pilot projects refer to Developing NRES, Pilot Screening NRES 
http://www.nres.npsa.nhs.uk/aboutus/developing-nres/ (accessed 10/1/08)
336 Guidance fo r  applicants to the National Research Ethics Service NRES (2007) 
http://www.nres.npsa.nhs.uk/EasvSiteWeb/GatewavLink.aspx7alkU330 (accessed 23/11/08)
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research ethics committees have already been discussed above. In-house ethical review 
occurs when the researcher is working outside o f the NHS.
As the HFEA states in its Guidance notes on completing all research licence 
applications research centres outside of the NHS may refer research projects to the local 
research ethics committee or may set up their own committee. These in-house committees 
are expected to be independent and have five members as a minimum. Additionally the 
Chairman of the committee is expected to be independent of the research centre and no 
more than one third of the committee members are expected to be employed by or have a 
financial interest in the research centre.337 Whilst membership of the in-house committee 
should be approved by the HFEA, information about the creation and operation o f a 
research ethics committee can be obtained from the Department of Health.338
External funding and research ethics committee approval
NHS research ethics committees must be approached for ethics approval where 
the research proposes to use NHS patients, data or facilities and in-house ethics 
committees may be created where the research project is privately funded or alternatively 
approach an NHS research ethics committee where that is preferred. Additionally, NHS 
research ethics committee approval may be a prerequisite to obtaining outside sources o f 
funding.
The Medical Research Council provides funding for stem cell research and has 
specific guidance for research involving human stem cells. In this guidance it is stated 
that:
All research aimed at deriving stem cell lines must be approved by a Local
Research Ethics Committee.339
337 Regulation o f  Research on Human Embryos HFEA at Section 14, page 13, 
http://www.hfea.gov.uk/docs/2006 Guidance Notes for All Research Licence Applications.pdf 
accessed 8/01/08,
338 Ibid. at Section 14, page 13. Guidance has been discussed above concerning NHS research ethics 
committees
339 Medical Research Council, Research Involving Human Stem Cells: Supplementary Terms and  
Conditions to be applied to new and extant MRC Grants, MRC Unit Programmes and M RC Training 
Awards from  1/08/2003 http://www.mrc.ac.uk/pdf-terms conditions stem cells.pdf (accessed 03/08/06)
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This statement encompasses all types of stem cell research, not just embryonic. 
The Medical Research Council requirement to approach a local research ethics committee 
will ensure that a large proportion of ‘privately funded, non-NHS resourced’ human 
embryonic stem cell research will go through local research ethics committee approval. 
This is an additional level o f scrutiny added by the funding body regardless o f who is 
funding the work and the resources being used.
The Biotechnology and Biological Sciences Research Council (hereafter referred 
to as the BBSRC) in contrast does not have guidelines relating specifically to human 
embryonic stem cell research (or stem cell research more generally) but does have the 
requirement that:
I f  research involves human subjects, genetically modified organisms, or any other 
sensitive or dangerous materials, work must not commence until approval has 
been received from  the appropriate Local Ethical Committee or appropriate 
authority.340
The guidance from the BBSRC is slightly ambiguous here. Within the NHS the 
appropriate authority would be the local research ethics committee; as mentioned 
previously, NHS research ethics committees can also be approached by private bodies for 
ethical approval. However, the BBSRC has taken the step of stating that approval must be 
“ ...received from the appropriate Local Ethical Committee or appropriate authority, 
(emphasis added). ” It is unclear what other body may be an appropriate authority for 
human embryonic stem cell research besides an ethical committee which the BBSRC 
have specifically mentioned in their guidance. It is likely that ‘appropriate authority’ has 
been included as the BBSRC covers more than just research with human subjects; it also 
covers research with ‘non-human’ subjects. ‘Non-human’ subjects have different 
appropriate authorities from which to seek ethical approval but may be too numerous to 
mention in the guidance.
As can be seen, two of the principal bodies which fund human embryonic stem 
cell research require local research ethics committee approval. This strengthens the 
position of local research ethics committees and also the need to reform and clarity the
340 BBSRC Research Grants Guide, Version 6.20, May 2006 at Para 4.13 
http://www.bbsrc.ac.uk/funding/research/grants booklet.pdf (Accessed 4/7/06)
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exact role which NHS research ethics committees play in considering and granting ethical 
approval for research projects involving human embryonic stem cell research.
Conclusion
The development of research ethics committees has undoubtedly been an 
important step in ensuring the safety and wellbeing of participants in medical research 
whilst helping the scientists to proceed with their important work. Research ethics 
committees have also played a role in helping to increase public confidence in the 
medical research work that is being undertaken.341 This additional level of scrutiny has 
also largely been imposed by the HFEA and the funding bodies (particularly where non- 
NHS resources are involved) in a bid to increase public confidence in the research which 
is being performed.
In relation to human embryonic stem cell research the guidance which is provided 
about research ethics committees seems to be confusing and contradictory. The role o f 
the research ethics committees in giving ethical approval to a research project for human 
embryonic stem cell research appears to be merely rubber stamping the detailed scientific 
review, and it could be said part of the ethical review too, is actually undertaken by the 
HFEA.342
One commentator has noted that “Effectively, the HFEA partially “contracts out” 
the regulatory requirement o f  ethical scrutiny.” 343 I agree with this statement as the 
HFEA still performs some ethical review (as will be seen in the next chapter) but find 
that the current procedure does not in reality form a sound basis for ethically reviewing 
human embryonic stem cell research projects. The system is in desperate need o f review 
and reform to clarify the exact role which research ethics committees play in giving 
ethical review to research projects involving human embryonic stem cell research and the 
use of progress reports once approval has been granted.
341 Although note the recent public concern over ethics committees following the adverse reactions o f  six 
men in March 2006 involved in a drugs trial involving the TGN1412 drug given to them by medical 
research company Parexel, working on behalf o f  German manufacturer TeGenero Drug trials need ‘better 
cover’ 18th April 2006, BBC http://news.bbc.co.Uk/l/hi/england/london/4918080.stm (Accessed AH 106)
342 This point is discussed further in Chapter 5
343 Morgan, R., The Regulation o f Human Embryonic Stem Cell Research in the United Kingdom  (2005) 
PhD Thesis, Cardiff Law School at Page 259
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Ideally, the establishment of a central research ethics committee which deals 
solely with research project applications to undertake human embryonic stem cell 
research would help to resolve the confusion and conflict which exists. One central 
research ethics committee for stem cell research is a possibility as there are such a small 
number o f research projects being undertaken with stem cells. A central stem cell 
research ethics committee would have the expertise to deal with the ethical issues 
surrounding not only human embryonic stem cell research but also stem cell research 
more generally if it was felt that a completely centralised research ethics committee was 
needed. The central stem cell research ethics committee could be attached to the UK 
Stem Cell Bank. It could then be approached for ethical approval prior to application to 
the HFEA to undertake research on human embryos which involves the extraction of 
human embryonic stem cell lines; it could also be a requirement to approach the central 
stem cell research ethics committee to undertake research on stem cell lines held at the 
UK Stem Cell Bank.
With the introduction of a central stem cell research ethics committee a single set 
of criteria could then be used in assessing research projects involving human embryonic 
stem cell research ensuring that all applications are dealt with on an equal footing. As 
Morgan has noted, “I f  the public is to have confidence that ES cell research is soundly 
regulated in terms o f ethical review, it is right that there ought to be a single set o f  ethical 
criteria consistently applied. ”344 The current system of using various research ethics 
committees to look at research projects wishing to undertake human embryonic stem cell 
research results in the application of different ethical criteria by each research ethics 
committee as well as different forms and procedures.
In composing this central stem cell research ethics committee it would be 
important to carry through many o f the principles already applicable to NHS research 
ethics committees, such as independence and expertise of members, a diversity of ages 
and sex, and both lay and expert representation. Specialist interest groups, such as patient 
groups or pro-life groups, may also wish to be involved. The inclusion o f specialist 
interest groups would not necessarily hinder human embryonic stem cell research, 
although, broadly speaking, pro-life groups would take an anti-embryo research stance,
344 Ibid. at Page 302
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they could still give a valuable contribution, particularly in considering if  the work could 
and should be done using adult stem cells rather than embryonic.
The central stem cell research ethics committee could then work directly with the 
HFEA (and Human Tissue Authority where relevant) in establishing one coherent system 
for ethical and scientific review of research projects. In addition, the use o f and 
submission of progress reports could be simplified. The progress report is an important 
element of the process of ongoing review once a proposal has been approved. If there was 
a central stem cell research ethics committee working in conjunction with the HFEA, 
progress reports could be submitted jointly to both bodies and be considered and 
discussed jointly, looking at both the ethical and the scientific aspects.
The establishment o f a central stem cell research ethics committee working with 
the HFEA and the Human Tissue Authority would provide a cohesive system which it is 
proposed would have the remit to control research involving the derivation, culture, 
storage, research and clinical trials of human embryonic stem cells.
It is a pity that the Government has not taken the opportunity provided by the 
establishment o f Ad Hoc Advisory Group on the Operation of NHS Research Ethics 
Committee to move towards establishing such a body. On reflection this is perhaps not 
surprising, in 2002 the House of Lords Select Committee suggested establishing just such 
a body, similar to the Gene Therapy Advisory Commission:
The Committee invites the Department o f  Health to consider either establishing a 
similar body [to the GTACJ with oversight o f  clinical studies involving stem cells, 
or extending the membership and remit o f  GTAC to achieve the same ends.345
However, the Government Response to that Report was not fully supportive of 
this recommendation:
The Select Committee makes an interesting suggestion in respect to clinical 
studies. We are pleased that the report recognises and endorses the important 
role played by the Gene Therapy Advisory Committee in overseeing gene therapy 
research. However, the comparison to gene therapy reveals a number o f  key 
differences with stem cells.
345 House o f  Lords Select Committee on Stem Cell Research: Report Session 2001-02 HL Paper 83(i) at 
Para 8.23
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Unlike adult stem cell transplantation, the clinical use o f  cells derived from  ES 
cells would be a new development. The Government will consider whether any 
further oversight o f  such clinical trials involving embryonic stem cells is desirable 
and will discuss this further with interested parties including regulatory agencies 
such as the MCA and Medical Devices Agency, industry, the Human Genetics 
Commission and other interested groups.346
It does not appear from the literature that the Government has considered further 
the oversight of clinical trials involving human embryonic stem cells. This is something 
which must be done promptly. Whilst human embryonic stem cell research is just that, 
still at the research stage, it is surely only a matter of time until scientists develop the use 
of stem cells to the clinical trials stage. It would be better to consider the situation now 
rather than making a knee jerk reaction which may not help to resolve the issue for 
anyone involved.
346 Government Response to the House o f  Lords Select Committee on Stem Cell Research  CM 5561 at 
Paragraph 8.23, pg 16-17
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Chapter 5 - Human Fertilisation and Embryology Authority
The Human Fertilisation and Embryology Authority was established in 1991 
following the enactment of the Human Fertilisation and Embryology Act 1990.341 Before 
the introduction of the HFEA, treatments for human infertility were already in existence 
and being used daily and scientists were performing research upon human gametes and 
embryos. In this chapter I shall discuss the situation concerning regulation prior to 1990, 
the role o f the HFEA and licensing of human embryonic stem cell research.
There is a need to examine the licensing and regulation of research upon human 
embryos as the body involved, the HFEA, is now involved in licensing the derivation of 
stem cells from embryos. The HFEA was not originally established to regulate such a 
process but due to the scientific advances which have been made as well as the 
interpretation and amendment of the legislation to include embryonic stem cell research 
the HFEA is now central to the process of human embryonic stem cell research.
Pre-1990
Following the birth of Louise Brown in 1978 and the subsequent media interest in 
the possibilities now open to infertile couples, the Government decided to undertake a 
review of human fertilisation and embryology. However, the Committee o f  Inquiry into 
Human Fertilisation and Embryology was not established until July 1982 and the 
Committee did not report until 1984. It was then a further six years before the Human 
Fertilisation and Embryology Authority was established under the HFE Act. Although it 
was 13 years between the birth of Louise Brown and the establishment of a statutory 
licensing body, the area of human fertilisation and embryology was not left completely 
unregulated. The Medical Research Council took an important interim step in helping to 
regulate this controversial area of research and treatment.
347 Hereafter referred to as the HFEA and the HFE Act respectively
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The Medical Research Council
The Medical Research Council originally had taken little interest in in vitro 
fertilisation but following the birth of the first IVF child in 1978 and the continuing work 
in both the UK and abroad, the Medical Research Council set up an Advisory Group in 
1979 to review the ethical aspects of research related to in vitro fertilisation and embryo 
transfer in humans.348 The Advisory Group considered a number of matters and made 
five recommendations to the Medical Research Council which were accepted:
i) Scientifically sound research involving in vitro fertilization, both
between human gametes and between human and non-human gametes 
where there is no intention to transfer the embryo to the uterus, should, 
on ethical grounds, be allowed to proceed i f  the aim o f  the research is 
clearly defined and acceptable -  fo r  example to obtain information 
about the process o f  reproduction relevant to clinical problems such as 
contraception or the differential diagnosis and treatment o f  infertility.
ii) Informed consent to the research should be obtained in every case from  
the donor o f both ovum and sperm; sperm from sperm banks should 
therefore not be used unless collected and preserved specifically fo r  this 
purpose.
iii) Human in vitro fertilization with subsequent embryo transfer should 
now be regarded as a therapeutic procedure covered by the normal 
ethics o f  the doctor/patient relationship. The role o f  the MRC should be 
to maximize opportunities presenting themselves to make the procedure 
safer and more successful, and coincidentally to increase knowledge o f  
human reproductive processes.
iv) The Health Departments should be advised to set up a confidential 
register to record the number o f embryo transfers undertaken and the 
number o f  subsequent pregnancies, and should consider the advisability 
and practicality o f  monitoring the resulting offspring.
v) The Advisory Group should meet again to examine the ethics o f  
particular studies involving in vitro fertilization and embryo transfer i f  
and when this proved desirable, and should possibly be reconvened to 
reconsider the general issues in about five years ’ time.249
In 1982, two years earlier than expected, the Advisory Group was reconvened to 
provide the Council with information to form the basis of Council policy in this area. The 
terms of reference of the advisory group were:
348 Gunning, J and English, V., Human In Vitro Fertilization (2002) Ashgate at pg 15
349 From Minutes o f  the MRC Advisory Group to review policy on research in in vitro fertilization  and  
embryo transfer in humans March 1979 Reproduced in Gunning, J and English, V., Human In Vitro 
Fertilization (2002) Ashgate at pg 15
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to consider recent and potential developments in research related to human
fertilisation and embryology, and to advise the council on these and on the ethical
grounds they should take into account in considering research proposals in these
350areas.
The Advisory Group considered a wider range of treatment options and uses of 
research than had been considered three years earlier due to the rapid advances which 
were being made. Amongst the issues considered was the use of genetic manipulation in 
conjunction with in vitro fertilisation to overcome genetic disorders, the source of 
embryos for research, and at what stages of embryo development research was 
acceptable.351
Following the recommendations made by the Advisory Group the Medical 
Research Council issued guidelines that organisations which were supported by the 
Council should follow.
The guidelines are stated as:
i) permitting scientific research into the processes and products o f  in vitro 
fertilisation where the research is related to clinical problems and that no 
embryo which has been researched upon must be transferred to the uterus
ii) Requiring informed consent from the donor’s o f  gametes fo r  research as 
well as requiring approval from the appropriate ethics committees
iii) Embryos which had been created fo r  therapeutic purposes but which were 
no longer required could be used in research where informed consent had 
been obtained
iv) Embryos should not be stored after the implantation stage and only be 
stored fo r  specific research uses
v) Animal studies must be carried out before assuming that freezing and 
storage o f  embryos does not cause harm to the conceptus
vi) Valuable interspecies fertilisation should be supported although fertilised  
ova should not be permitted to develop beyond the cleavage stage.352
The Royal College of Obstetricians and Gynaecologists (RCOG) and the British 
Medical Association also produced similar reports and guidelines on human in vitro
350 Research related to human fertilisation and embryology: Statement by the M edical Research Council 
(1982) 285 BMJ 1480
351 For further detail o f the issues discussed by the Advisory Group refer to Gunning, J and English, V., 
Human In Vitro Fertilization (2002) Ashgate at pg 22-25
352 Research related to human fertilisation and embryology: Statement by the M edical Research Council 
(1982) 285 BMJ 1480
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fertilisation in 1983 and it seemed that the preferred approach in the United Kingdom was
353professional self-regulation rather than legislation.
Whilst not establishing a licensing authority per se the Medical Research Council 
effectively established themselves as a voluntary oversight body. The Guidelines may not 
have had the force of law but as with most guidelines would have been persuasive 
authority, particularly as anyone wishing to seek funding from the Medical Research 
Council would have had to comply with them. At this time the Medical Research Council 
was the principal source of funding for research, guaranteeing high rates o f compliance 
within the scientific community, additionally the sections of the scientific community 
which were not funded by the Medical Research Council wanted to be seen as 
responsible and so voluntarily followed the standards established.
What becomes clear though is that prior to the establishment of the HFEA there 
were no statutory licensing authorities regulating human fertilisation and embryology, 
neither treatment nor research. The Medical Research Council and the other organisations 
guidelines were important though as they showed the willingness of the relevant 
organisations to be guided by good practice and that they were seeking such regulation.
The fact that the Council had an Advisory Group and saw the need to formulate 
policy in relation to research relating to human fertilisation and embryology shows that 
the Council was receiving requests for funding for such research and that it was felt that 
regulation was needed in this area at least until further formal regulation was provided by 
the Government.
The Warnock Report Recommendations
The Report from the Committee o f Inquiry into Human Fertilisation and 
Embryology recommended the creation of a statutory licensing authority to regulate 
research into human reproduction and embryology and to control the infertility services 
which the Committee had recommended for regulation.354 The Warnock Report discussed
353 Report o f  the RCOG Ethics Committee on in vitro fertilization and embryo replacement or transfer 
RCOG, London (1983), Interim Report on human fertilization and embryo replacement and transfer British 
Medical Association Working Group on in vitro fertilization (1983) 286 BMJ 1594-1595
354 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (1984) DHSS Cmnd 9314 
at Para 13.3. Hereafter referred to as the Warnock Report
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the statutory licensing authority in general terms, seeing it as the role o f the drafters of 
legislation to give substance and form to their recommendations.
Concerning the membership of the statutory licensing authority the Warnock 
Report noted the importance of lay membership of a body which would primarily be 
concerned with medical and scientific matters. This was considered important to help 
protect the public interest which would be affected by the potentially far reaching 
decisions the authority would have to take in the future.355 The Committee went further 
than was possibly anticipated by not only recommending substantial lay membership but 
also a lay chairman.
The Warnock Committee concluded that the authority would have two distinct 
functions, one advisory and the other executive.356 In performing its advisory function 
there would be two main interested parties; the Government and the scientists working 
within the field. The advice would of course vary between offering advice to Government 
on issues as they arose, to providing guidance on good clinical practice. As part of its 
responsibility in protecting the public interest, an annual report to Parliament was also
357recommended which would be publicly available.
The executive function of the authority would involve granting licences to those 
wishing to offer infertility services and licences to researchers wishing to work with 
human embryos and gametes. Regular inspections to ensure compliance with licences and 
licensing conditions would be carried out by an inspectorate.358
The Warnock Report notes that it does not want to set out the criteria for granting 
a licence but prefers to discuss further some of the controls it would like to see put into 
force.359 O f note for this work is the control desired in relation to research licences. The 
Warnock Report recognises the sensitivity of research upon human gametes and embryos 
and seeks tight control upon research licences by recommending that licences are granted 
to an individual or institution for a specific project, with a named licence holder who 
would have overall responsibility for the project. The objectives of the research must be 
clearly identified with reasons why the research cannot be carried out without human 
embryos. The source, number o f embryos and duration of the project must also be clearly
355 Ibid. at Para 13.4
356 Ibid. at Para 13.5
357 Ibid. at Para 13.5
358 Ibid. at Para 13.6
359 Ibid. at Para 13.6
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stated along with approval from a local research ethics committee responsible for the 
institution in which the research will be carried out. Importantly, the Warnock Report 
states that the statutory licensing authority must not be responsible for the funding of
360such research projects; this could lead to a conflict o f interests if this was permitted.
The statutory licensing authority could be viewed as the most important element 
of the Warnock Report as without it, human fertilisation and embryology could not be 
regulated. This was recognised by the Warnock Committee:
...by far the most urgent is the recommendation that a statutory body should be 
established, within whose powers would fa ll the licensing and monitoring o f  
provision fo r  infertility treatment and o f  research on the human embryo. None o f  
our other recommendations can have any practical impact until such a body is set
361up.
The Voluntary Licensing Authority
As seen above, the Warnock Report recommended the creation of a statutory 
licensing authority to regulate research into human reproduction and embryology and to 
control the infertility services which the Committee had recommended for regulation.362 
The Government sought comments on the Warnock Report and the Advisory Group of 
the Medical Research Council met again to discuss the recommendations. The 
establishment of a statutory licensing authority was well received by the Advisory Group 
and subsequently proposed “...that some interim arrangement might be instituted until 
such time as the Warnock provisions could be implemented.”363
The Councils of the Medical Research Council and the RCOG agreed to establish 
an interim licensing authority with members nominated by both groups. At the time of 
establishment in March 1985 it was thought that the statutory licensing authority would 
be enacted within a couple o f years and as such “...the main tasks o f the Voluntary 
Licensing Authority would be to register and approve centres undertaking IVF and to 
consider and approve proposals fo r  research in preparation fo r  handing over to a 
statutory authority. ”364
360 Ibid. Refer to Paragraphs 13.10 to 13.12
361 Ibid. at Para 13.14
362 Ibid. at Para 13.3
363 Gunning, J and English, V., Human In Vitro Fertilization (2002) Ashgate at pg 41
364 Ibid. at pg 44-45
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It was not until 1991 that the statutory licensing authority was established and 
during this six year period the Voluntary Licensing Authority worked with the centres 
providing infertility services and undertaking research to establish appropriate guidelines 
and licensing procedures. The lack of statutory footing for the Voluntary Licensing 
Authority worked to its favour as it was able to adapt and alter its guidelines as the 
science developed or if it became apparent that it had made an erroneous decision it could 
change its view.
The Interim Licensing Authority
Following the Consultation document in 1986 ‘Legislation on Human Infertility 
Services and Embryo Research ’265 and the White Paper in 1987 ‘Human Fertilisation and 
Embryology: A Framework fo r Legislation’ it was expected that the Human 
Fertilisation and Embryology Bill would soon be introduced to Parliament. However, this 
did not occur immediately and following a reduction in funding from the RCOG and the 
cramped conditions provided to the Voluntary Licensing Authority, which had intended 
to be in existence for only two years, the Voluntary Licensing Authority sought 
assistance from the Government. This was eventually granted in December 1988 to the 
tune of £45,000. In order to reflect the recognition now given to the Voluntary Licensing 
Authority it chose to change its name in May 1989 to the Interim Licensing Authority fo r  
Human Fertilisation and Embryology261
The Interim Licensing Authority continued the work of licensing centres engaged 
in providing infertility services and/or undertaking research, it was also consulted on 
developments in science, law and policy both in the United Kingdom and abroad.
From a Voluntary to a Statutory Licensing Authority
Although the Recommendation from the Warnock Report that a Statutory 
Licensing Authority should be established to oversee human fertilisation and embryology 
was made in 1984, it was not actually established until the 1st August 1991. During this 
period the Interim Licensing Authority worked to establish and ensure adherence to its
365 (1986) DHSS Cm46
366 (1987) DHSS Cm 259
367 Gunning, J and English, V., Human In Vitro Fertilization (2002) Ashgate at pg 87-88
151
guidelines. Upon the enactment of the HFE Act the Interim Licensing Authority did not 
automatically cease to exist, for a brief period it worked with the new Statutory Licensing 
Authority to hand over its activities.
The Statutory Licensing Authority, i.e. the HFEA, and the Interim Licensing 
Authority worked side by side for a total of nine months. A few o f the Interim Licensing 
Authority members became members of the HFEA allowing the new Authority to draw 
upon their experience. Members of the HFEA also attended inspection visits by the 
Interim Licensing Authority to gain an understanding of how the inspection procedure 
had been set up. The HFEA did however return to discuss many of the issues already 
considered in depth by the Interim Licensing Authority in order to formulate its own 
policies in light of the new legislation.
The Interim Licensing Authority continued to consider applications for services 
and research up to the cut off date of 31st July 1991. The legislation had made provision 
for any services being offered or research being undertaken prior to the 31st July 1991 to 
continue until the HFEA had considered the licence application or up to the 31st July 
1992, whichever was sooner. This meant that the Interim Licensing Authority received a 
relatively large number of applications by centres rushing to get the Interim Licensing 
Authority approval before the HFEA took over.368
Overall the work of the Interim Licensing Authority can be considered to be a 
success; it helped to establish guidelines for clinics to follow in an innovative and fast 
developing area of science whilst helping to increase public confidence in the work being 
undertaken at the clinics. It also established licensing procedures and good working 
practices which the HFEA continued in its new statutory setting.
368 For a full discussion o f the changeover period between the Interim Licensing Authority and the Human 
Fertilisation and Embryology Authority please refer to Gunning, J and English, V., Human In Vitro 
Fertilization  (2002) Ashgate Chapter 7
Post-1990
The Human Fertilisation and Embryology Authority
The HFE Act which was enacted on the 1st November 1990 covers a wide and 
diverse area relating to human fertilisation and embryology, including surrogacy, embryo 
research and the statutory licensing authority. The HFE Act has been in force for 18 years 
with what can be considered a great deal of success. However, as with most legislation it 
has been subject to various legal challenges, along with the statutory licensing authority 
which it established, for example refer to R (on the application o f Quintavalle) v 
Secretary o f  State fo r  Health369 and R (on the application o f Quintavalle) v Human 
Fertilisation and Embryology Authority?10
The Human Fertilisation and Embryology Authority
The Human Fertilisation and Embryology Authority was formally established in 
August 1991, nearly a year after the enactment of the HFE Act 1990. The principal tasks 
of the HFEA are to:
• License and monitor clinics that carry out in vitro fertilisation (IVF) and donor 
insemination
• License and monitor research centres undertaking human embryo research
• Regulate the storage of gametes and embryos371
• Keep under review information about embryos and any subsequent development 
of embryos and about the provision of treatment services governed by this Act, 
and to advise the Secretary of State.. .about those matters,
• Publicise services provided to the public by the Authority or provided in 
pursuance of licences,
369 R (on the application o f Quintavalle) v Secretary o f State fo r  Health [2001] 4 All ER 1013, [2002] 2 All 
ER 625, [2003] 2 All ER 113 -  progression through the High Court, Court o f  Appeal and House o f  Lords
370 R (on the application o f  Quintavalle) v Human Fertilisation and Embryology Authority [2002] EWHC 
2785, [2003] EWCA Civ 667, [2005] UKHL 28
371 About the HFEA HFEA http://www.hfea.gov.uk/AboutHFEA (accessed 2/5/06)
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• Provide, to such extent as it considers appropriate, advice and information for 
persons to whom licences apply or who are receiving treatment services or 
providing gametes or embryos for use for the purposes o f activities governed by
' i n ' )
the Act, or may wish to do so...
As can be seen the HFEA was set up to deal with human embryos, subsequently the 
remit has been interpreted to include processes which involve human embryos (the 
derivation of embryonic stem cells) but do not strictly involve research upon human 
embryos or the provision of fertility services.
Composition
In accordance with the HFE Act the HFEA is composed of a chairman, deputy 
chairman and such other members as the Secretary of State appoints.373 All members are 
appointed by the Secretary of State and can hold the position for up to three years at a 
time.374 Currently there are 19 members of the HFEA including the Chair, Professor Lisa 
Jardine CBE who was appointed on the 1st April 2008.375 The previous Chair, Miss 
Shirley Harrison was appointed on the 1st January 2007 and her predecessor Dame Suzi 
Leather was appointed in March 2002.376 Like Shirley Harrison and Dame Leather, 
Professor Jardine is a lay person and all previous chairmen have been lay people, 
complying with the recommendations of Warnock which were carried through to the 
HFE Act?11 The balance of medics, scientists and lay people as members of the HFEA is 
directly referred to in Schedule 1 of the HFE Act. The importance of lay representation 
within committees which principally deal with scientific matters should not be 
underestimated. Lay representation increases public confidence concerning the control of
372 Section 8 (a)-(c) HFE Act 1990
373 Section 5 HFE Act 1990
374 Schedule 1, part 4(1) and 5(2) HFE Act 1990
375 New Chair appointedfor HFEA HFEA Press release, 23rd January 2008 
http://www.hfea.gov.uk/en/1641 .html (accessed 26/06/08)
376 http://www.hfea.gov.uk/AboutHFEA/HFEAMenibers (accessed 2/5/06)
377 Schedule 1, part 4 (3) HFE Act 1990
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scientists in an area that has been seen to be ‘playing God’ and occasionally making
T7Rclaims which abhor the majority of people.
Committees
The HFE Act permits the HFEA to “...maintain one or more committees to 
discharge the Authority’s functions relating to the grant, variation, suspension and 
revocation o f licences,...” as well as permitting the HFEA to “...provide fo r  the 
discharge o f  any o f its other functions by committees or by members or employees o f  the 
Authority.”379
This has resulted in the establishment of the Licensing Committee, the Ethics and 
Law Committee (ELC) and the Scientific and Clinical Advances Group (SCAG).
The Licensing Committee
The Licensing Committee is responsible for the grant, variation, suspension and 
revocation of licences. In accordance with Section 11 of the HFE Act essentially a licence 
is required for treatment services, storage and research upon human gametes and 
embryos. Any activity which involves creating an embryo outside of the human body, 
whether for treatment or research, requires a licence. There is currently one Research 
Licence Committee and three Treatment Licence Committees; in October 2009 when the 
Human Fertilisation and Embryology Act 2008 comes into force there will be only one of 
each. Additionally there will be an Executive Licensing Panel.381 The Executive 
Licensing Panel will consist o f a Chair and two members drawn from a pool of six and is 
designed to turn around applications faster than is currently achieved by the HFEA.382 
The Executive Licensing Panel will consider all initial licence applications except 
research licence applications and must refer any applications which are considered to be 
‘novel, complex or potentially controversial’ to the Licence Committee for
378 For example refer to the cloning claims made the company Clonaid backed by the French-based Raelian 
Sect: Cloned baby met with doubt BBC 27th December 2002 http://news.bbc.co.Uk/l/hi/health/2608655.stm  
(accessed 2/5/06)
379 Section 9(1) and (2) HFE Act 1990
380 Section 3(1) HFE Act 1990
381 Authority Paper on The Executive Licensing Panel HFEA (18th March 2009) Annex A: New Licensing 
Scheme Under the HFE Act 1990 as amended at Para 5(ii) 
http://www.hfea.gov.uk/docs/AM Item 5 March 09.pd f (accessed 6/7/09)
382 Ibid. at Para 4
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consideration. 383 Although the Executive Licensing Panel will not consider initial 
research licence applications it may consider applications to renew research licences 
although the Chair o f the Research Licence Committee must be made aware of all 
renewal applications and can require the renewal to be considered by the Research 
Licence Committee, rather than the Executive Licensing Panel, where appropriate.384
It is a requirement of law to approach the Licensing Committee to obtain a licence 
prior to commencing activities controlled by the Act. The Licensing Committee will not 
automatically grant a licence, a thorough review of the proposed research is undertaken. 
Additionally, as noted in Section 3(3) of the HFE Act, certain activities cannot be 
authorised by the Licensing Committee, these include keeping or using an embryo after 
the appearance of the primitive streak, placing an embryo in an animal and the genetic 
manipulation of an embryo.
Additionally, as discussed in Chapter 4 and below, Local Research Ethics 
Committee approval must be sought and obtained prior to submitting an application to the 
Licensing Committee of the HFEA.385 The HFEA generally requires this of all research 
licence applications even though it is only a legal requirement where the research 
involves the use of NHS patients or facilities (see previous chapter for further discussion 
of this requirement). One recent application from the University of Newcastle Upon Tyne 
received a research licence without research ethics committee approval as the applicants 
were able to show that they would be working with already existing stem cell lines and as 
such did not need further ethical approval.386
Permitted areas of research
In the UK, scientists are not allowed to do any type of research that they desire 
within the first 14 days of development of an embryo -  the legislation strictly controls the 
permitted areas of research. As mentioned in earlier chapters, research upon embryos
383 Ibid. at Para 6.1 and Annex B, Para 5
384 Ibid. at Annex B, Para 5 and 6
385 Regulation o f  Research on Human Embryos HFEA, Section 14, page 13 
http://www.hfea.Rov.uk/docs/2006 Guidance Notes for All Research Licence Applications.pdf 
(accessed 08/01/08)
386 Derivation o f  Embryonic Stem cell Lines from  Interspecies Embryos produced by Somatic Cell Nuclear 
Transfer (R0179) Newcastle-Upon-Tyne, Centre for Stem Cell Biology & Developmental Genetics,
Institute o f  Human Genetics http://www.hfea.Rov.uk/l 580.html Confirmed in personal communication with 
Professor Emily Jackson, 3rd July 2009, member o f  the HFEA
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was limited to respect the special status of the human embryo, permitting limited research
which accorded with the social consensus and not allowing embryos to be used for
frivolous reasons. The areas permitted to be licensed are expanded upon in Schedule 2 of 
the HFE Act. Of principal concern for this work is Schedule 2, paragraph 3 which deals 
with licences for research. Licences may authorise the creation of embryos in vitro and 
keeping or using those embryos for the purposes of a project of research specified in the 
licence. Research may be authorised by licence where it is
.. .necessary or desirable for the purpose of:
(a) promoting advances in the treatment o f infertility,
(b) increasing knowledge about the causes o f  congenital disease,
(c) increasing knowledge about the causes o f  miscarriages,
(d) developing more effective techniques o f contraception, or
(e) developing methods for detecting the presence o f  gene or chromosome
abnormalities in embryos before implantation,
or for such other purposes as may be specified in regulations .388
The proviso of allowing other purposes to be devised in regulations was very 
important for human embryonic stem cell research. Under the original purposes contained 
in the legislation, the HFEA could not grant a licence for human embryonic stem cell 
research where the purpose of the research did not fall clearly into one o f the five 
permitted research purposes. The use of regulations allowed the UK Government to 
introduce further research purposes, specifically to allow human embryonic stem cell 
research to go ahead. The list of permitted research purposes was extended in 2001 by the 
Human Fertilisation and Embryology (Research Purposes) Regulations?*9 A licence can 
now also be granted where the purpose of the research is to:
(a) increasing knowledge about the development o f  embryos;
(b) increasing knowledge about serious disease, or
(c) enabling any such knowledge to be applied in developing treatments fo r
serious disease.39°
387 Schedule 2, paragraph 3(1) HFE Act 1990 Note that by referring to embryos ‘created in vitro’ these 
refers to all embryos created outside o f the human body, regardless o f the method o f  creation.
388 Schedule 2, paragraph 3(2) HFE Act 1990
389 SI 2001/188, hereafter referred to as the 2001 Regulations
390 Section 2(2) Human Fertilisation and Embryology (Research Purposes) Regulations 2001, SI 2001/188
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These regulations are somewhat controversial as they allow for the first time 
research upon embryos which would not directly benefit the embryos themselves or the 
provision of fertility services. It has also been queried whether the 2001 Regulations
• 391permit basic research to be undertaken to help improve the techniques used.
The flexibility of regulations allows the Government to keep legislation up to date 
without undergoing a thorough review and consultation period; however, there have been 
criticisms of the use of regulations to introduce such a fundamental aspect to the 
legislation. Human embryonic stem cell research is a controversial area o f research and it 
is argued that the permission for such research to be undertaken should have been 
debated further in Parliament. However, one could disagree that the use of regulations 
was inappropriate for the introduction of these further research purposes. In the House of 
Commons alone the regulations were debated for nearly fourteen hours in total, a vast 
amount of time for a statutory instrument.
Note that Schedule 2, Paragraph 3 authorises “ ...the creation o f  embryos in v itro” 
This would appear to refer to the creation of embryos outside o f the human body rather 
than the creation of embryos by in vitro fertilisation, thereby including embryos created 
by the cell nuclear replacement technique and any other technique. This is an important 
distinction to make as even though section 1 (l)(a) of the HFE Act has been interpreted to 
include embryos created by cell nuclear replacement, Schedule 2, Paragraph 3 
exclusively deals with embryos being created for research licences. If it specifically 
stated that a research licence could authorise the creation of embryos by in vitro 
fertilisation this would exclude embryos created by cell nuclear replacement or any other 
method from being used in research projects. This is particularly important for human 
embryonic stem cell research. Often, in research projects involving the derivation of 
embryonic stem cells, there is a need to derive those stem cells from embryos created in a 
particular manner. For example, there may be a need to derive patient specific stem cells 
which is only possible with the use of cell nuclear replacement embryos.
The research licence cannot be granted unless the HFEA is satisfied that any 
proposed use of embryos is necessary for the purposes of the research.392 This may 
appease somewhat those who are uncomfortable with the thought that ‘potential’ human
391 House o f  Lords Select Committee on Stem Cell Research: Report Session 2001-02 HL Paper 83(i) at 
Para 8.14-8.15
392 Schedule 2, paragraph 3(6) HFE Act 1990
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beings are used in research unnecessarily. Additionally, there is the requirement that ‘Wo 
embryo appropriated fo r the purposes o f  any project o f  research shall be kept or used 
otherwise than for the purposes o f  such a project”393 Again, this helps to alleviate and 
negate the fears of the public of ‘Frankenstein’ babies being bom after research has been 
performed at an early stage of embryonic development and which may affect subsequent 
growth. Also, by limiting the type of research upon human embryos, this helps to 
reinforce the Gradualist status which is implied by the HFE Act and the enforcement of 
the fourteen day rule. The limitation upon research conforms to the social consensus of 
not outlawing embryo research but also not allowing it to occur without any limits or 
protection.
Applicable to all types of licences is the requirement that the premises where the 
treatment, storage or research is being undertaken is specified in the licence along with 
the name of the person under whose supervision the activities will be performed.394 This 
is in accordance with the recommendations made by the Wamock Committee.
The ‘Person Responsible’
The person who must supervise the activities authorised by a licence is referred to 
in the HFE Act as the ‘person responsible’. The ‘person responsible’ is under a duty to 
ensure that the other people who will participate in the activity permitted by the licence 
are suitably qualified by training and experience, that the proper equipment is used, 
proper arrangements are made for keeping and disposing of gametes and embryos, that 
suitable practices are used and that the conditions of the licence are complied with.395 The 
Licensing Committee may revoke or vary the terms of a licence if it is satisfied that the 
‘person responsible’ has failed to, or is unable to, discharge his duties as described under 
section 17, as described, no longer has the character required for the supervision o f the 
activities in the licence or that the person responsible dies or is convicted o f a criminal 
offence.396
It could be said that the ‘person responsible’ has an onerous duty in ensuring that 
the conditions of the licence are complied with, after all they are unlikely to be on site
393 Section 15(4) HFE Act 1990
394 Section 12(a) and Schedule 2, paragraph 4 HFE Act 1990
395 Section 17(l)(a)-(e) HFE Act 1990
396 Section 18(l)(c), 18(2)(a)-(b) HFE Act 1990
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every minute of every day supervising in minute detail. However, when dealing with such 
sensitive material, both physically and morally, someone needs to be responsible to 
ensure compliance with the licence conditions. The fact that the Licensing Committee can 
revoke a licence if the ‘person responsible’ is not capable o f fulfilling his duties as 
defined in Section 17 demonstrates the seriousness with which the Licensing Committee 
deals with the treatment, storage and research of human gametes and embryos.
To date, there has been only one criminal prosecution o f a ‘person responsible’. 
The case was first heard at Southampton Crown Court (unreported) where a ‘person 
responsible’ had been prosecuted for keeping an embryo except in pursuance of a licence, 
contrary to sections 3(1 )(b) and 41(2)(a) of the HFE Act. The judge directed the jury to 
return a verdict of not guilty as he ruled that there was no case to answer. He held that as 
a matter of law the defendant was not a ‘keeper’ o f the embryos.397 The case was referred 
by the Attorney General to the Court of Appeal, Criminal Division for their opinion.
The ‘person responsible’ in this particular situation was not the person who had 
been dealing directly with the embryos in question; an embryologist had in fact been the 
person who had dealt with the embryos incorrectly. However, the question remained for 
the opinion of the Court of Appeal:
Is the ‘person responsible ’ as defined by the Human Fertilisation and Embryology 
Act 1990 a person who as a matter o f law ‘keeps’ the embryos at the assisted 
conception unit at which he is named in the licence as being the ‘person 
responsible ’?398
The Court of Appeal regards the HFE Act as providing two different mechanisms 
for dealing with non-compliance with the conditions of a licence. The first is a regulatory 
mechanism; section 18 of the HFE Act provides for the revocation or variation o f a 
licence where the ‘person responsible’ fails to discharge his supervisory duties. The 
second is criminal sanctions relating to specific activities as specified in Section 41 of the 
HFE Act. Although the Court of Appeal recognises that these two methods o f control are 
not ‘mutually exclusive’, it is equally recognised that the activity which triggers the 
regulatory mechanism will not necessarily also attract the attention of the criminal law.399
397 Facts as summarised by the Court o f Appeal in Attorney G eneral’s reference (No 2 o f 2003) [2004] 
EWCA Crim 785, Para’s 5 & 6
398 Ibid. at Para 9
399 Ibid. at Para’s 13 & 14
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...regulatory mechanisms and criminal sanctions are not mutually exclusive. 
Criminal activity may bring the regulatory mechanisms into operation. Equally 
however, it does not follow that activity which infringes the licence conditions, 
and may trigger the regulatory mechanisms, necessarily attracts the sanctions o f  
the criminal law.400
The Court of Appeal answered the question put before them with a resounding 
‘No’.401 This would seem fairest to the ‘person responsible’; it would be inequitable if a 
‘person responsible’ had fulfilled their duties under Section 17 o f the HFE Act, in 
ensuring that the fellow researchers are suitably qualified and trained, and that suitable 
practices are used, for the ‘person responsible’ to then be found criminally liable for 
actions undertaken by those persons whom he had deemed appropriate to work on the 
licence project. Whilst there must be someone responsible for the work being undertaken, 
criminal sanctions are too extreme in this type of situation, whereby the ‘person 
responsible’ is not working directly with the material which is governed by the licence.
While it is sensible to have someone responsible for matters such as ensuring that 
the proper equipment is used, staff are suitably qualified and proper storage arrangements 
are in place, it does seem inequitable for this person to be held criminally liable for the 
actions of others when that person has done all that has been required of them. Rather, it 
would be more appropriate for the person who has performed the breach to be personally 
held liable.
Applying for a research licence
The cost of applying for a research licence is kept to a minimum due to 
Department of Health subsidisation of the HFEA. Licence fees are set at £500 and 
increase to £750 where the project involves the derivation of human embryonic stem cell 
lines; this is due to the complexity of regulating such projects 402
For individual research projects the HFEA has the power to grant research 
licences for up to three years and these can be renewed. Upon receipt of a completed 
application the HFEA aims to process licence applications within four months and
400 Ibid. at Para 14
401 Ibid. at Para 23
402 HFEA Research Licence Fees HFEA Research News http://www.hfea.gov.uk/Research/Researchnews 
(accessed 5/5/06)
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requires local research ethics approval to have been sought prior to application.403 The 
Chairman of the local research ethics committee is required to sign the completed 
application form to show that approval has been sought and obtained prior to application 
to the HFEA 404 This is considered very important by the HFEA and has been imposed 
beyond what was required under the HFE Act. The role of the research ethics committee 
has been discussed in Chapter 4 of this thesis.
The requirement of seeking local research ethics committee approval prior to 
applying for a licence from the HFEA can be criticised as it effectively places the person 
applying for the licence under a double burden; the proposed research has to pass through 
the approval of two research committees. There are effectively two review procedures 
prior to the grant of a licence; the local research ethics committee and the Licensing 
Committee of the HFEA.
The two committees are designed to consider two different aspects of a research 
proposal involving human embryonic stem cell research. The local research ethics 
committee is designed to deal with the ethical issues, the Licensing Committee is 
designed to deal with the scientific and legal issues. Whilst the Licensing Committee of 
the HFEA does not reconsider the ethics of the research as such, it does consider if the 
research requires human embryos to fulfil its aims and objectives, this is an ethical 
consideration.
Local research ethics committees are permitted to seek the advice of specialist 
referees to cover any aspect of a research proposal which lies beyond the expertise of the 
members of the committee.405 It can be questioned if a local research ethics committee 
which seeks expert advice from someone in the field o f human embryonic stem cell 
research will receive anything more than scientific advice, the exception possibly being if 
the expert advises that the research can be undertaken with adult stem cells, similar to the 
considerations which must be fulfilled by peer reviewers of the HFEA.
403 How to apply fo r  a research licence HFEA
http://www.hfea.gov.uk/Research/HowtoaDplvforaresearchlicence (accessed 5/5/06)
404 Regulation o f  Research on Human Embryos HFEA Section 15, page 14
http://www.hfea.gov.uk/docs/2006 Guidance Notes for All Research Licence Applications.pdf 
(accessed 08/01/08)
405 Governance Arrangements fo r  NHS Research Ethics Committee (2001) Department o f  Health at Para 
6.10
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Peer Review
Upon the introduction of the 2001 Regulations expanding the areas of research, 
the HFEA refined its licensing process. Applicants who wish to investigate human 
embryonic stem cell research have to justify the use of embryonic stem cells rather than 
adult stem cells, provide detailed information on the fate of the stem cells throughout the 
research project, and place a sample of all cell lines in the UK Stem Cell Bank.406 
Furthermore, additional peer reviewers with expertise in the field have been recruited and 
six monthly progress reports are required to be made after the licence has been granted 
(see below for further discussion of the progress reports) 407
The recruitment of peer reviewers with expertise in the field o f stem cell research 
is important as all research licence applications are sent out to at least two peer reviewers 
to report on the merits o f the proposed project. The report from the peer reviewers is then 
submitted to the Licence Committee to assist in determining if a licence should be 
granted or renewed.408
The peer review is very detailed requiring consideration of:
• Whether the research fulfils at least one o f the categories fo r  which embryo 
research is permitted
• The importance o f the research in the field
• Whether research has been done before
• Whether the research requires human embryos to fulfil its aims and objectives
• Whether the research requires the numbers and types o f  embryos outlined in the 
application
• The suitability o f  the methods
• The length o f  the study
• The applicant’s qualifications
• Meets the requirements o f  the HFEA Code o f  Practice including ethical 
approval and patient informationm
The consideration of the project and whether the work has been done previously is 
vital, as it prevents duplication of work, time and resources. This provision along with the
406 Regulation o f  Research on Human Embryos HFEA Section 11 
http://www.hfea.gov.uk/cps/rde/xbcr/SID-3F57D79B- 
17AF5458/hfea/Licensing the use o f  Human Embrvos.pdf (accessed 5/5/06)
407 Ibid. at Section 13
408 Ibid. at Section 22 Personal communication from Dr Richard Martin, Head o f  Information, HFEA, 9th 
November 2006
409 Ibid. at Section 12
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provisions to consider the need to use human embryos and the quantities of embryos 
proposed to be used in the project helps to control the work being done and to avoid the 
unnecessary use of human embryos. While the public of the United Kingdom are 
generally supportive of the work being done in the field o f human embryonic stem cell 
research, there are still many who are completely opposed to the use o f human embryos 
in this way and others who are uncomfortable with using embryos unnecessarily.
Progress Reports
These progress reports again emphasise the importance which is attached to 
human embryos; the HFEA does not want to be perceived to be a body which does not 
consider the ethical implications of the research which it licences. In contrast the HFEA 
can be commended for taking a role which is both permissive of such research whilst also 
being protective of the research subject.
The progress reports are submitted to the HFEA once the research project is 
underway and allow the HFEA to oversee the research being undertaken, including the 
number of embryos used and if this is appropriate. For research projects which involve 
the derivation of human embryonic stem cell lines, there is the requirement to submit 
progress reports every six months from the date the licence was granted.410
The content of the progress report is quite detailed and, from a lay persons 
outlook, would take a considerable amount of time to complete properly. In actuality the 
level of detail required does not appear to be onerous; in fact it may help the ‘person 
responsible’, who is required to complete the progress report, to consider the research 
which has already been undertaken and the direction in which it is heading. This may 
prevent researchers from straying too far from the original licence as they will need to 
reconsider the licence boundaries whilst completing the progress report form.
An important section, particularly from a lay perspective, is Section 6 o f the 
HFEA Research Progress Report.411 Section 6 concerns the usage o f material i.e. the 
gametes and/or embryos which are being used in the research project. The HFEA requires
410 HFEA letter to all Persons Responsible 26th July 2006 CE(06)04 HFEA 
http://www.hfea.gov.uk/cps/rde/xchg/SID-3F57D79B-3AD90B09/hfea/hs.xsl/1361.html (accessed  
16/10/06)
411 HFEA Research Progress Report can be downloaded from http://www.hfea.gov.uk/cps/rde/xbcr/SlD- 
3F57D79B-BB56E384/hfea/2005 Research Progress Report 2 .p d f(accessed 12/01/07)
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the researcher to reveal the number of embryos and/or eggs which they have used, to 
explain why the numbers are substantially different from those estimated in the original 
research proposal (if applicable) and to estimate the number o f eggs and/or embryos 
which will be used in the following twelve months. The number o f eggs and/or embryos 
being used in the research project is foreseen as the principal reason for the HFEA 
varying or revoking a research licence. The other main reason for varying or revoking a 
licence would be if a researcher has deviated so far from the original research proposal as 
to be considered unacceptable by the HFEA. The advantage with a central body 
overseeing embryo research is that it will quickly gain experience in such research 
projects and be able to gauge the acceptable number of eggs and/or embryos to be used in 
such research projects.
The numbers of eggs and/or embryos used in a research project is one o f the areas 
which can be foreseen as causing conflict between the HFEA and the research ethics 
committee which gave ethical approval to the research project in the first instance. As 
discussed in the previous Chapter, research ethics committees also require progress 
reports once a project is underway and may withdraw their approval at any point during a 
research project. If a research ethics committee receives a progress report and concludes 
that the numbers of eggs and/or embryos used is unacceptable, it may withdraw its ethical 
approval. In contrast, the HFEA may be happy for the research project to continue due to 
its previous experiences with embryo research projects. Where there is conflict 
concerning approval for an ongoing research project the HFEA is clear that the licence 
holder is not able to work with only HFEA approval, research ethics committee approval 
is necessary.412
Donor Consent
When obtaining a licence to perform human embryonic stem cell research, there 
are additional requirements imposed when obtaining consent from patients to use their 
gametes or embryos in the proposed research. The HFEA requires that patients are to be 
informed that:
412 Personal communication from Dr Richard Martin, Head o f  Information, HFEA, 9th November 2006
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i. any stem cells lines created may continue indefinitely and be used in many 
different research projects;
ii. that once an embryo has been used in the project o f  research the donors have 
no control over any future use o f the embryonic cells and any stem cell lines 
derived;
iii. that cell lines may be used for commercial purposes, but that the donor will 
not benefit financially from this; and
iv. that any cell lines derived, or discoveries made usin$* them, could be patented, 
but that the donor will not benefit financially from this.
The consent requirements to donate human gametes or embryos for embryonic 
stem cell research are far stricter than those which must be fulfilled when donating 
gametes or embryos for use in fertility treatment. The principle reason for this appears to 
be for copyright and patent reasons; any possible discoveries which may be made, 
potentially, have great financial rewards, besides the health benefits. The scientists, or 
rather the companies that they work for, will not want the donors of human material to 
have a claim over the financial rewards. The fact that this consideration forms part o f the 
consent requirements protects all parties involved; the donors, by making them aware of 
the possible consequences arising from their donation, and the companies, by protecting 
their financial investment from future legal challenges.
The UK Stem Cell Bank
The HFEA imposes as a requirement of a research licence permitting human 
embryonic stem cell research that a sample of all embryonic stem cell lines is to be 
placed in the UK Stem Cell Bank.414 This is an important step in allowing access for 
other researchers, ensuring that a minimum number of embryos are used in research, as 
well as providing information on the success of creating stem cell lines from human 
embryos. The role of the UK Stem Cell Bank is discussed further in Chapter 6 of this 
thesis.
413 Regulation o f  Research on Human Embryos HFEA Section 15 
http://www.hfea.gov.uk/cps/rde/xbcr/SID-3F57D79B-
17AF5458/hfea/Licensing the use o f  Human Embrvos.pdf (accessed 5/5/06)
414 Ibid. at Section 11
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Diagram: The Application Process for a Research Licence for Human
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This can be compared to the HFEA ‘Decision Tree for Application for a Research 
Licence’ found in the HFEA document ‘Regulation of Research on Human Embryos’ 
http://www.hfea.gov.uk/docs/2006 Guidance Notes for All Research Licence Applica 
tions.pdf Reproduced at Appendix A.
Conclusion
Overall the composition and workings o f the HFEA provide a structured and 
coherent basis for the licensing of research on human embryos. Within this system, 
licensing for human embryonic stem cell research can be found. The combination of 
requiring each licence to have a ‘person responsible’, peer review and research ethics 
committee approval of each application, along with progress reports of projects 
underway, all help to ensure that the research undertaken is worthwhile, within the 
permitted areas of research and is not needlessly experimenting upon embryos. This is 
important from a moral, as well as legal, aspect as the public confidence is retained in the 
research being done.
The HFEA takes its role as regulator and licensor seriously. When a research 
application falls within their remit but there are issues of public policy to consider, the 
HFEA will act to deal with those policy issues prior to considering such a research 
application. An example of this is the HFEA public consultation of the public during 
2007 on the issue of research using human cells and animal eggs (known as ‘hybrid’ or 
‘cybrid’ embryos).415 The transparency of the workings of the HFEA has helped to 
increase public confidence in the HFEA, vital for a body dealing with such sensitive 
materials.
415 HFEA Update, Spring 2007 Pg 2 http://www.hfea.gov.uk/docs/Update3.pdf (accessed 14/03/07)
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Chapter 6 - The UK Stem Cell Bank
Introduction
As work on human embryonic stem cells gathered pace a need was identified for a 
central place to deposit stem cell lines which had been created. This resulted in the 
establishment of the UK Stem Cell Bank, the first such bank in the world.
This chapter seeks to look at the process by which the UK Stem Cell Bank came 
about, the composition of the Bank, the role that it plays in regulating stem cell research 
and its future role in bringing about and regulating clinical applications o f stem cell 
therapies.
Pre-UK Stem Cell Bank 
The Donaldson Report
The Donaldson Report, Stem Cell Research: Medical Progress with
Responsibility, was published in June 2000.416 The terms of reference were broad, 
considering many different aspects of human embryonic stem cell research. In the context 
of this Chapter of this thesis the relevant term of reference of the Donaldson Report was 
“to advise on whether any additional regulation o f the use o f  embryonic cell lines (such 
as stem cells) is required. ”417
In light of this consideration the Donaldson Report noted that subsequent research 
involving cultures of stem cells fell outside of the remit of the HFEA, and although the 
Report did not think that further scrutiny of individual research proposals involving stem 
cell lines was necessary, it was desired that progress of research was to be monitored, 
assessed and to highlight any unforeseen concerns.418
As such, the Donaldson Report recommended that:
416 Stem Cell Research: Medical Progress with Responsibility. A Report from  the C hief M edical O fficer’s 
Expert Group Reviewing the Potential o f  Developments in Stem Cell Research and Cell Nuclear 
Replacement to Benefit Human Health (2000) Department o f Health
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicvAndGuidance/DH 4065 
084 (last accessed 15/08/08) Hereafter referred to as the Donaldson Report
417 Ibid. at Annex A, pg 49
418 Ibid. at Para 4.34, pg 42
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The Research Councils should be encouraged to establish a programme fo r  stem 
cell research and to consider the feasibility o f  establishing collections o f  stem 
cells for research use.419
This recommendation of “establishing collections o f  stem cells fo r  research use” 
was to lead to the establishment of the UK Stem Cell Bank.
Government Response to Donaldson
The Government response to the recommendation made by the Donaldson Report 
was unequivocal in its acceptance. Not only did the Government call upon the Research 
Councils to establish a programme for stem cell research involving all sources o f stem 
cells, but it also called upon the Research Councils to consider the feasibility of 
establishing collections of stem cells for research “...to avoid the need fo r  researchers to 
continually create new cell lines or to import cell lines...”420 As will be seen the 
acceptance by the Government of the need for a central collection of stem cells would 
quickly hurry along the creation of the UK Stem Cell Bank.
The House of Lords Select Committee on Stem Cell Research
By the time that the House of Lords Select Committee on Stem Cell Research 
reported in February 2002, the Department of Health had already asked the Medical 
Research Council to take the lead in establishing an embryonic stem cell bank.421 As the 
Select Committee reports
The Department o f  Health proposes that rules governing what can be deposited in 
and withdrawn from the bank should be established by a steering committee. 
Among the matters the rules would cover would be knowledge o f  the source o f  the 
stem cells, obtaining the consent o f  the donor, and establishing a fu ll history o f  
their storage and handling under good laboratory conditions.422
419 Ibid. Recommendation 9, pg 48
420 Government Response to the Recommendations Made in the Chief M edical O fficer’s Expert Group 
Report “Stem Cell Research: M edical Progress with Responsibility” (2000) Department o f  Health Cm 
4833 Recommendation 9, point 13, pg 6
421 House o f Lords Select Committee on Stem Cell Research: Report Session 2001-02 HL Paper 83(i) at 
Para 8.26
422 Ibid  at Para 8.26
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The Select Committee considered the issue of oversight o f embryonic stem cell 
lines once they have been derived from embryos as a pressing matter.423 This is 
understandable as although once the stem cells have been derived from an embryo and 
they no longer form part of an embryo, some parties would still attain a special status to 
the material. The regulation of human embryonic stem cells is an issue which needs to be 
resolved as they are not covered by the Human Tissue Act 2004 or the HFE Act but the 
oversight of such sensitive material is important. This matter is discussed below.
The Select Committee recommended steps which would take the role of the Bank 
further than that proposed by the Department of Health. The Select Committee 
recommended that the Bank should include embryonic stem cell lines which have been 
generated abroad and are of the appropriate standard to be deposited with the Bank, and 
to facilitate the distribution of embryonic stem cell lines to researchers abroad operating 
under approved ethical guidelines.424 Additionally the Select Committee recommended 
that the Bank should be open to the deposit of adult stem cell lines should it become 
possible to generate adult stem cell lines in the future.425
The Select Committee therefore endorsed the Department of Health proposal to 
create a Stem Cell Bank overseen by a steering committee. The Select Committee then 
goes further and for the first time we see the recommendation that the HFEA should 
make it a condition of granting a research licence that any embryonic stem cell lines 
which are created during human embryo research should be deposited with the Stem Cell 
Bank. The Select Committee goes on to also recommend that the HFEA checks with the 
Stem Cell Bank that there are no existing stem cell lines which could be used for the 
research.426 This final part of the recommendation will take some time to come into force, 
as the creation of stem cell lines is a difficult process, it will be several years before there 
are sufficient numbers of stem cell lines deposited with the Stem Cell Bank which may be 
suitable for research. However, this is a wise recommendation to make, further enforcing 
the stated desire of the Select Committee and Department of Health to obviate the need to 
destroy excessive numbers of embryos for research.427
423 Ibid. at Para 8.24
424 Ibid. at Para 8.27
425 Ib id  at Para 8.28
426 Ibid. at Para 8.29
427 Ibid. at Para 8.24
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The Government Response to the House of Lords Select Committee
Report
The Government Response to the House of Lords Select Committee Report on
• 428Stem Cell Research was almost entirely agreeable of the recommendations made. In 
light of the recommendations made by the Select Committee in relation to the UK Stem 
Cell Bank the Government was greatly supportive. The Government noted in its response 
that the Medical Research Council was already making progress in establishing a Stem 
Cell Bank. It also noted that the Research Councils had already indicated that the award 
of grants and funding for stem cell research would have the added requirement of 
banking cells with the Stem Cell Bank. All of this shows that the Stem Cell Bank had 
good support from its inception.
The EU Tissue and Cells Directive
The need for the UK Stem Cell Bank had also arisen due to the EU Tissue and 
Cells Directive. Directive 2004/23/EC covers tissues and cells intended for human 
application, not research using such material.429 As Morgan notes, “Whilst the current 
state o f art does not extend to clinical applications o f ES cell lines, the fie ld  is geared 
toward achieving such outcomes. ”430 Each Member State is obliged by the EU Tissue 
and Cells Directive to designate a ‘competent authority’ to implement the requirements of 
the Directive. Matters which must be complied with include, amongst others, the 
supervision of human tissue and cell procurement, accreditation of tissue establishments 
or cell preparation processes, the organisation of inspections of tissue establishments and 
the regulation of the import and export of human tissues and cells.431
428 Government Response to the House o f  Lords Select Committee Report on Stem Cell Research (2002) 
Department o f Health Cmnd 5561
429 Directive 2004/23/EC o f  the European Parliament and o f the Council o f  31 March 2004 on setting 
standards o f quality and safety fo r  the donation, procurement, testing, processing, preservation, storage 
and distribution o f human tissue and cells, [2004] OJ LI 02/48 at Paragraphs 10 and 11. Hereafter referred 
to as the EU Tissue and Cell Directive
430 Morgan. R., A lack o f foresight? Jurisdictional uncertainties in the regulatory interface between the 
HFEA, the UK Stem Cell Bank and beyond  27(3) Legal Studies 511 at p526
431 Directive 2004/23/EC o f  the European Parliament and o f the Council o f  31 March 2004 on setting  
standards o f quality and safety fo r  the donation, procurement, testing, processing, preservation, storage 
and distribution o f  human tissue and cells, [2004] OJ LI 02/48 Articles 5, 6, 7 and 9
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The UK Stem Cell Bank, as discussed below, is considered to be the ‘competent 
authority’ in respect of the donation, procurement, storage, testing, processing, 
preservation and distribution of human embryonic stem cell lines which are to be used in 
clinical trials. If the UK Stem Cell Bank was not considered to be the ‘competent 
authority’ then the UK Government would need to set up yet another body to be involved 
in the regulation of human embryonic stem cell lines.
Not all countries have taken the step of designating a ‘competent authority’ to 
deal specifically with human embryonic stem cells. It should be noted that within the UK 
the Human Tissue Authority and the HFEA are both ‘competent authorities’ for the 
purposes of the Directive, but further steps were taken in respect of human embryonic 
stem cells by recognising the authority of the UK Stem Cell Bank.
Many of the other EU countries have designated their Ministry o f Health as the 
‘competent authority’, for example, the Czech Republic, Latvia and Slovakia. Other 
countries recognise the bodies which deal with transplantation as the ‘competent 
authority’, such as Bulgaria, Italy and Spain. It appears that apart from the United 
Kingdom only Poland has a Centre that deals with both tissues and cells, the National 
Centre of Tissues and Cell Banking.432
The UK Stem Cell Bank
Establishment
As mentioned above the Medical Research Council was asked by the Department 
of Health to take the lead in co-ordinating the establishment of a UK Stem Cell Bank 433 
The Medical Research Council set up a National Stem Cell Bank Advisory Committee to 
oversee a tendering process for the UK Stem Cell Bank. It was agreed that the Bank 
should be sited in an independent national laboratory to avoid conflicts o f interest. The 
National Stem Cell Bank Advisory Committee had to consider all o f the submitted 
tenders and generate a rank order list for the Medical Research Council to take a funding
432 For the list o f competent authorities refer to Meeting o f  Competent Authorities on Tissues and Cells, 8th 
February 2007, Summary Report, Annex I, European Commission
http://ec.europa.eu/health/ph threats/human substance/documents/ev 20070208 mi en.pdf (accessed 
06/08/08)
433 Code o f  Practice o f  the UK Stem Cell Bank, Consultation Document Aug 2003, Section 3.1, p i 1
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decision in July 2002. The National Stem Cell Bank Advisory Committee was to form the 
Steering Committee for the Bank once it was established.434
On the 9th September 2002 the Medical Research Council announced that the 
National Institute for Biological Standards and Control had been appointed to set up the 
UK Stem Cell Bank.435 The Medical Research Council and the Biotechnology and 
Biological Sciences Research Council were to share the costs o f the UK Stem Cell Bank, 
75% and 25% respectively.436
The first embryonic stem cell lines were deposited at the UK Stem Cell Bank on 
the 19th May 2004, the same day that the Bank was officially opened by the Health 
Minister Lord Warner. The two stem cell lines were created by researchers working 
separately at King’s College London and the Centre for Life in Newcastle.437
At the time of announcing the launch of the UK Stem Cell Bank the Medical 
Research Council also laid out the management structure of the Bank; this consists o f the 
Steering Committee to oversee the activities of the Bank and to establish the Codes of 
Practice for the Bank, a local Management Committee which will report directly to the 
Steering Committee, and the Joint Clinical and User Liaison Committees to discuss the 
use of the Bank and issues relating to the generation of stem cell lines for banking and 
clinical application.438 Each of these committees is discussed in further detail below.
434 House o f  Lords report on stem cell research Medical Research Council 
http://www.mrc.ac.uk/index/strategy-strategv/strategy-science strategy/strategy-
strategy implementation/strategy-govemment spending review initiatives/strategy-stem cells/strategy- 
house o f lords stem cell report.htm (accessed 3/8/06)
435 UK stem cell bank launched Medical Research Council 
http://www.mrc.ac.uk/index/strategy-strategv/strategy-science strategy/strategy-
strategy implementation/strategy-government spending review initiatives/strategy-stem cells/strategy- 
stem cell bank launched.htm (accessed 3/8/06) Hereafter referred to as the NIBSC
436 Hereafter referred to as the BBSRC
437 First stem cell lines to be deposited as UK Stem Cell Bank officially opens today  Medical Research 
Council
http://www.mrc.ac.uk/public-interest/public-news centre/public-press office/public- 
press releases 2004/public-19 may 2004.htm (accessed 3/8/06)
438 UK stem cell bank launched Medical Research Council
http://www.mrc.ac.uk/pm/index/strategy-strategv/strategy-science strategy/strategy-
strategy implementation/strategy-govemment spending review initiatives/strategy-stem cells/strategy-
stem cell bank launched.htm (accessed 3/8/06)
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Remit of the UK Stem Cell Bank
As the first Code of Practice of the UK Stem Cell Bank states:
The UK Stem Cell Bank has been charged with providing ethically sourced, 
quality controlled adult, fetal and embryonic stem cell lines fo r  research and fo r  
the development o f therapies by the national and international research 
community ...In order to fulfil this remit the Bank must adhere to good practice 
standards in terms o f validating, screening, processing, storing, providing and 
delivering stem cell lines to users.429
Importantly it must be noted by the reader that the UK Stem Cell Bank does not 
deal solely with embryonic stem cell lines, it is designed to also bank adult and foetal 
stem cell lines. The Code of Practice governing the UK Stem Cell Bank covers the 
banking of all o f these sources of stem cell lines, whether they are derived from living or 
dead human tissue.440 It should also be noted that the UK Stem Cell Bank deals with stem 
cell lines, not individual stem cells. Stem cell lines consist of genetically identical cells.
The UK Stem Cell Bank does not yet (as of November 2008) deal with adult stem 
cell lines although it is authorised by its remit to do so 441 It could be questioned if there 
is a need to have a Bank for adult stem cell lines. Adult stem cells have been known 
about, researched upon and used in medical therapies for far longer than embryonic stem 
cells, and without the need for a central bank. Although adult stem cell research has been 
around for a long time the ability of the UK Stem Cell Bank to bank adult stem cell lines 
should not be underestimated. Whilst adult stem cells have been used in treatments for 
some time, adult stem cell lines are still at an early stage o f research and treatment. 
Should researchers wish to bank their cell lines with the UK Stem Cell Bank this should 
be permitted, the central storing and distribution of cell lines, regardless o f their source, 
should help researchers to share their resources and to aid research.
The aim of the UK Stem Cell Bank to provide ‘ethically sourced, quality 
controlled stem cell lines for research and the development of therapies’ should be 
welcomed by the majority of commentators. By banking human stem cell lines this
439 Code o f  Practice o f  the UK Stem Cell Bank, Consultation Document Aug 2003, Section 1.1, p7
440 Ibid. at Section 1.2, p7
441 Catalogue Overview  UK Stem Cell Bank http://www.ukstemcellbank.org.uk/catalogue.html (accessed 
17/09/08)
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should reduce the use of human tissue in research, embryonic and non-embryonic, 
facilitate access for researchers and scientists to high quality stem cell lines and enable 
different researchers to work on identical material.442
Due to the different sources of the stem cell lines which will be deposited with the 
UK Stem Cell Bank, the Code o f Practice fo r  the use o f  Human Stem Cell Lines 
recognises that there are two pieces of legislation which govern the establishment of 
human stem cell lines -  the Human Tissue Act 2004 and the Human Fertilisation and 
Embryology Act 1990.44S The Code of Practice does however note that established cell 
lines as well as those created outside of the human body are outside o f the remit o f the 
Human Tissue Act 2004, this is discussed further below 444
Governance of the UK Stem Cell Bank
UK Stem Cell Bank Steering Committee445
The Steering Committee is the overarching body of the UK Stem Cell Bank, it 
oversees the activities of the Bank and the use of stem cell lines in the UK. Its terms of 
reference are:
• To develop and monitor implementation o f a code ofpractice fo r  the Bank andfor  
the use o f stem cell lines
• To review on a case by case basis all applications to deposit and access 
embryonic stem cell lines
• To monitor all applications to deposit and access fetal and adult stem cell lines
• To ensure that strategies are in place to manage risk
• To address issues reported by the local Management Committee fo r  the Bank
• To consider issues identified by the User and Clinical Liaison Committees
• To report at least annually to the Medical Research Council
• To brief Health and Science Ministers annually and advise them on request or as 
the need arises446
442 Recognised in the Code o f  Practice fo r  the use o f  Human Stem Cell Lines Version 3, August 2006, 
Section 5
http://www.ukstemcellbank.org.uk/documents/Code%20of%20Practice%20for%20the%20Use%20of%20 
Human%20Stem%20Cell%20Lines.pdf (accessed 30/04/08)
443 Ibid. at Section 3
444 Ibid. at Section 3.1
445 Hereafter referred to as the Steering Committee
446 UK Stem Cell Bank Steering Committee Medical Research Council
http://www.mrc.ac.uk/PolicvGuidance/EthicsAndGovemance/StemCells/SteeringCommittee/index.htm  
(last accessed 17/09/08)
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The Steering Committee is chaired by Lord Patel and consists of 14 members all with 
different expertise and interests in stem cell research. The current (as of October 2008) 
committee consists of a bioethicist, two lay members (one o f whom is also a solicitor), 
four stem cell experts, a theologian and ethicist, a lawyer, a tissue banking expert, a 
sociologist, a tissue engineer and a patient contact along with the Chairman who is a 
medical doctor.447
There are also a number of observers and Research Council representatives involved 
with the Steering Committee, this is due to the leading role which the Steering Committee 
plays liasing with the regional Health Departments, the Human Fertilisation and 
Embryology Authority, the Medicines and Healthcare products Regulatory Agency and 
the Research Council funders. ”448
The variety of people involved should help to ensure that decisions are reached 
equitably upon consideration of all the relevant issues. It can be assumed (although not 
known for certain) that the members of the Steering Committee will all be advocates of 
human embryonic stem cell research. Of course, with the UK Stem Cell Bank also 
dealing with adult and foetal stem cells, it is not as much of a necessity as could be said 
(and has been criticised) about the membership of the HFEA.
The Stem Cell Bank Management Committee449
The Management Committee of the UK Stem Cell Bank was established by the 
National Institute for Biological Standards and Control (NIBSC) to deal with the day to 
day issues relating to the Bank. The Management Committee reports to the Steering 
Committee.450 As expected the Management Committee has a broad remit, the terms of 
reference are:
447 Steering Committee Membership
http://www.rnrc.ac.uk/PolicvGuidance/EthicsAndGovemance/StemCells/SteeringCommittee/index.htm 
(accessed 2/10/07)
448 Steering Committee fo r  the UK Stem Cell Bank andfor the use o f  Stem Cell Lines, F irst Annual Report, 
March 2004, pg 2 Available at Governance o f the UK stem cell bank and the use o f  stem cell lines 
Medical Research Council http://www.mrc.ac.uk/index/strategy-strategv/strategy-science strategy/strateav- 
strategy implementation/strategv-govemment spending review initiatives/strategy-stem cells/strategy- 
stem cell govemance.htm (accessed 3/8/06)
449 Hereafter referred to as the Management Committee
450 Governance o f the UK stem cell bank and the use o f stem cell lines Medical Research Council
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• Oversee the establishment, management and development o f  the UK Stem Cell 
Bank.
• Approve and monitor implementation o f financial strategies fo r  the Bank and fo r  
Bank projects.
• Approve work plans fo r  the Bank and fo r Bank projects and monitor progress.
• Approve regimes for testing, quality control etc; also certificates o f  analysis and 
supporting data.
• Oversee the Bank’s R&D activities and ensure that Bank s ta ff keep up to date 
with new stem cell developments and products.
• Ensure compliance with the Steering Committee’s Code o f  Practice fo r  the Bank 
and other relevant national regulatory and legal requirements and guidelines.
• Oversee implementation o f Steering Committee decisions on applications for  
deposition/accession o f stem cell lines.
• Develop marketing and customer liaison strategies.
• Develop a communications strategy fo r  the Bank that interfaces with the overall 
stem cell communications strategies o f the MRC and the BBSRC.
• Develop a long-term plan for the scientific andfinancial development o f  the Bank.
• Put in place and oversee a comprehensive risk management strategy.
• Approve the Bank’s annual report and accounts fo r  submission to the Steering 
Committee.
• Report to the Steering Committee.451
The Management Committee is effectively the Committee which deals with the day 
to day and long term planning of the Stem Cell Bank, ensuring that procedures are in 
place and that the Code of Practice is complied with. This contrasts with the Steering 
Committee which assesses each application as well as addressing issues raised by the 
various committees of the Stem Cell Bank.
The UK Stem Cell Bank Joint Clinical and User Liaison Committee452
The terms of reference of the Joint Committee are to:
• Discuss issues relating to the use o f the UK Stem Cell Bank by the scientific 
community
• Bring relevant issues and concerns to the attention o f the Steering Committee fo r  
the UK Stem Cell Bank andfor the Use o f Stem Cell Lines453
http://www.mrc.ac.uk/index/strategv-strategv/strategy-science strategy/strategy-
strategy implementation/strategy-government spending review initiatives/strategy-stem cells/strategy- 
stem cell govemance.htm (accessed 3/8/06)
451 UK Stem Cell Bank Management Committee Medical Research Council
http://www.mrc.ac.uk/PolicvGuidance/EthicsAndGovemance/StemCells/ManagementCommittee/index.ht
m (accessed 30/04/08)
452 Hereafter referred to as the Joint Committee
453 UK Stem Cell Bank Joint Clinical and User Liaison Committee Medical Research Council
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The membership of the Joint Committee is currently (as o f September 2008) made up 
of 78 people who are all working or involved in stem cell research to one degree or 
another.454 This should not be surprising as the purpose of the group is to discuss issues 
relating to the use of the UK Stem Cell Bank by the scientific community. It is therefore 
logical that the Joint Committee is dominated by scientists and clinicians working in the 
field of stem cells and related areas. The range of experience of stem cells and of clinical 
application of therapies (whether adult/embryonic/foetal stem cells or other therapies) 
will ensure that there will be in depth and appropriate discussion of the issues which will 
arise in relation to the generation of stem cell therapies for clinical applications. Many of 
the members will be able to bring to the table their experience of past clinical applications 
of new therapies, which could help to ensure that some of the stumbling blocks that may 
have been faced in the past by those developing new therapies are avoided or at least 
negated as much as possible.
Originally this committee was set up as two separate committees -  the Stem Cell User 
Liaison Committee and the Stem Cell Clinical Liaison Committee. The Clinical Liaison 
Committee had slightly different terms of reference to those now found for the Joint 
Committee.
The terms of reference for the Stem Cell Clinical Liaison Committee were:
• To discuss clinical issues relating to the generation o f stem cell lines fo r  banking
• To discuss issues relating to the generation o f  stem cell therapies fo r  clinical 
application
• To bring relevant issues and concerns to the attention o f  the Steering Committee 
fo r  the UK Stem Cell Bank andfor the Use o f Stem Cell Lines455
The two committees were merged to form the Joint Committee in 2003. The decision 
to merge the two committees was taken as the remits of each committee were similar.456
http://www.rnrc.ac.uk/PolicvGuidance/EthicsAndGovemance/StemCells/UserLiaisonCommittee/index.htm  
(accessed 30/04/08)
454 Ibid.
455 Stem Cell User and Clinical Liaison Committees: Stem Cell User Liaison Committee Medical Research 
Council
http://www.mrc.ac.uk/index/strategv-strategv/strategv-science_strategv/strategy-
strategy implementation/strategy-govemment spending review initiatives/strategy-stem cells/strategy- 
stem cell governance/strategy-user and clinical liaison committees.htm (accessed 3/8/06)
456 Personal communication with the MRC 6th May 2008
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Human Fertilisation and Embryology Authority
The UK Stem Cell Bank works with the HFEA to govern and control access to 
human embryonic stem cells. The HFEA makes it a requirement o f all licences which it 
grants that any human embryonic stem cell lines which are created are to be offered to the 
UK Stem Cell Bank for deposit.457 Other scientists can then access the stem cell lines 
which are held at the UK Stem Cell Bank.
The HFEA plays an important role is ensuring that any human embryonic stem 
cell lines which are created are deposited in the UK Stem Cell Bank. O f course not all 
lines which are offered to the UK Stem Cell Bank are viable for deposit and storage but it 
is the role of the UK Stem Cell Bank to verify the viability of the cell lines, not the 
researchers who created them.
If a researcher does not offer his stem cell lines to the UK Stem Cell Bank for 
deposit he will be breaking a condition of his licence and therefore the HFEA is able to 
vary, suspend or revoke his licence.
Legislation governing the establishment of human stem cell lines
As discussed in detail elsewhere in this thesis the HFE Act as amended by the 
2001 Regulations sets out the permitted research purposes for which a research licence 
may be granted by the HFEA. Additionally for research which involves the derivation of 
human embryonic stem cell lines the HFEA makes it a requirement of all such research 
licences that the resulting stem cell lines are offered to the UK Stem Cell Bank for 
deposit.
What is vital to note here is that once embryonic stem cells have been extracted 
they are no longer subject to the controls contained in the HFE Act. This is recognised by 
the UK Stem Cell Bank in its Code of Practice.458
457 Regulation o f  Research on Human Embryos HFEA Section 11 
http ://www.hfea. eov.uk/cps/rde/xbcr/SID-3 F5 7D79B- 
17AF5458/hfea/Licensine the use o f  Human Embrvos.pdf (accessed 5/5/06)
458 Code o f  Practice fo r  the use o f  Human Stem Cell Lines August 2006, Version 3 at Section 3.2, pg 8 
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Initially it could be thought that the extracted embryonic stem cell lines would be 
governed by the Human Tissue Act 2004, however, upon examination of the Act it 
quickly becomes apparent that human embryonic stem cell lines are actually outside of 
statutory regulation. Section 53 of the Human Tissue Act states that the ‘relevant 
material’ which is covered by the Act ‘ ...means material, other than gametes, which 
consists o f  or includes human cells, [and that] references to relevant material from  a 
human body do not include - embryos outside the human body... ’ The Act continues in 
Section 54(7) to state that ‘For the purposes o f this Act, material shall not be regarded as 
from a human body i f  it is created outside the human body. ’
Therefore as embryos for research are created outside of the human body they do 
not fall into the remit of the Human Tissue Authority (this is as expected as they are 
governed by the HFEA). Equally as human embryonic stem cells are also created outside 
of the human body, as they are extracted from embryos which are created outside of the 
human body, they are also outside of the remit of the Human Tissue Authority. This is 
also recognised by the UK Stem Cell Bank Code of Practice which notes that 
“Established cell lines as well as any other human material created outside the human 
body are excludedfrom the [Human Tissue] Act. ”459
Whilst the regulation of human embryonic stem cell lines is outside statutory 
regulation this does not lead to the conclusion that they are unregulated. The UK Stem 
Cell Bank notes that “The conservation and use o f  human embryonic stem cells and cell 
lines is the responsibility o f the Steering Committee. ”460 Human embryonic stem cell 
lines effectively become the responsibility of the UK Stem Cell Bank before they are 
even created. Due to the requirement which the HFEA places upon all researchers 
applying for a licence to create embryos for the derivation of embryonic stem cell lines to 
place those resulting lines into the care of the UK Stem Cell Bank, the Bank effectively 
becomes aware of all embryonic stem cell lines which should be offered to it once a 
licence has been issued by the HFEA. Of course there is no guarantee that the scientists 
will be able to derive stem cell lines but once created they must be sent to the Bank for 
processing. The Bank then controls all access to those stem cell lines banked with it and 
as such controls the research which occurs upon those lines.
http://www.ukstemcellbank.org.uk/documents/Code%20of%20Practice%20for%20the%20Use%20of%20 
Human%20Stem%20Cell%20Lines.pdf (accessed 2/10/07)
459 Ibid. at Section 3.1, pg 7
460 Ibid. at Section 3.2, pg 6
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In this manner the Bank will also help to control the route to clinical applications 
of stem cell research. It will control it in the sense that it will direct the type of research 
which is permitted and as such in what areas developments and progress is made towards 
clinical applications. Note that the UK Stem Cell Bank does not require research ethics 
committee approval for research which involves established human embryonic stem cell 
lines but that once a researcher is to commence clinical trials o f stem cell derived 
therapeutic products research ethics committee approval must be sought first.461
The UK Stem Cell Bank makes it clear in the Code o f  Practice fo r  the use o f  
Human Stem Cell Lines that the research projects in which human embryonic stem cell 
lines may be used must have “...justified and valuable purposes that reflect the 
requirements o f  the HFEA Regulations. ”462 The Code of Practice clarifies the permitted 
research areas, these are:
(a) research which increases the knowledge about the development o f  embryos or 
has the long term goal o f  helping to increase knowledge about serious 
diseases and their treatment...
(b) basic cell research which underpins these aims...
(c) development o f cell based therapies for clinical trials in respect o f  serious 
human diseases.463
So as “...to ensure compliance with the appropriate regulations and 
permissions... ” the UK Stem Cell Bank also has the right to seek periodic independent 
audit of the research which is being carried out, by both UK based and overseas 
researchers 464
The fact that the UK Stem Cell Bank is following the aims of Parliament in the 
research which it allows access to human embryonic stem cell lines for can only be seen 
as a good thing, even though “It must be noted that this extra level o f  regulation is 
entirely an innovation o f the UK Stem Cell Bank Steering Committee. ”465 Theoretically, 
without any statutory regulation relating directly to derived human embryonic stem cells 
the UK Stem Cell Bank is free to draw up its own areas of permitted research. This would 
probably be counter-productive to public confidence in an area which is already
461 Ibid. at Section 8.1.3, pg 13
462 Ibid. at Section 8.1.1, pg 12
463 Ibid. at Section 8.1.1, pg 12
464 Code o f Practice o f  the UK Stem Cell Bank, Consultation Document, Aug 2003 at Section 13.2, pg 29
465 Morgan. R., A lack o f foresight? Jurisdictional uncertainties in the regulatory interface between the 
HFEA, the UK Stem Cell Bank and beyond 27(3) Legal Studies 511 at p523
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confusing to the average lay person. Whilst the majority o f people would probably be of 
the opinion that the embryonic stem cell lines are merely cells, there could still be some 
who would like to see additional protection for embryonic stem cell lines as they may be 
viewed as an extension of the embryo. This is recognised by Morgan who notes that “I f  
ES cell lines derived under an HFEA licence were used fo r  purposes outside those listed 
in para 3(2) o f  Sch 2 and the 2001 Regulations, then the original embryo would 
effectively have been used for purposes which do not outweigh its due respect. ”466 By 
adhering to the purposes laid out in the 2001 Regulations and the discussions made in 
Parliament and in the Donaldson Committee the UK Stem Cell Bank is helping to 
increase public confidence in the type of work which is being carried out on human 
embryonic stem cells.
By following the aims of Parliament in respect o f embryo research the UK Stem 
Cell Bank is adding extra levels of protection which will help to stop researchers from 
circumnavigating the permitted research purposes as laid out in the HFE Act and 
effectively prevent the frivolous use of embryos. For example it would not be desirable to 
allow human embryonic stem cell lines to be used for testing cosmetics as this would go 
beyond the purposes which Parliament debated and decided were acceptable reasons for 
which to override the special status which has been accorded to the human embryo. The 
UK Stem Cell Bank’s acceptance and enforcement of the permitted research purposes as 
devised by Parliament implies that there is a morally sound basis for restricting research 
upon embryos and products derived from embryos. As discussed in earlier chapters there 
is a morally sound basis to this approach; the Wamock Committee recognised that the 
human embryo had a special status but that it was not absolute. The special moral status 
accorded to the human embryo could be overridden but that it must be subject to strict 
controls, this Gradualist status has formed the backbone to the legislation governing 
human embryo research and it is logical that products derived from embryos, in this case 
embryonic stem cells, should also be subject to some controls.
466 Ibid. at p525
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Foreign Stem Cell Lines
Import of Stem Cell Lines
Obviously human embryonic stem cell lines are not only generated within the UK 
and there may be occasions when a researcher wishes to access and use stem cell lines 
which have been derived abroad. The UK Stem Cell Bank recognises that this situation 
will arise and accordingly requires that “all researchers wishing to work with human 
embryonic stem cell lines (whether accessed from the Bank, from  other sources in the UK 
or overseas) should inform the Steering Committee... ”,46? The Steering Committee o f the 
Stem Cell Bank oversees all research involving human embryonic stem cell lines, 
regardless of where the cell lines have been sourced from.468
The Steering Committee of the Bank “needs to satisfy itself that the research 
fulfils the criteria in section 8.1.1 ...and that the human embryonic stem cell lines have 
been ethically sourced with fully informed and free donor consent. ”469 In satisfying itself 
that these criteria have been fulfilled the Steering Committee will refer to the information 
provided by the researcher on the application form to ‘Import human embryonic stem cell 
line(s) into the UK.,470 The information required to be provided includes clarification that 
informed consent has been given in line with UK guidelines. This requirement could be 
considered to be onerous or difficult, particularly as each country has its own consent 
guidelines, not all of which may reach the UK standards, in which case the Steering 
Committee may refuse to give consent to import the stem cell line.
It is interesting to note that the UK Stem Cell Bank accepts that stem cell lines 
from certain countries will reach the required standards for consent. For example any 
stem cell lines which are to be imported from the United States NIH Human Embryonic 
Stem Cell Registry are generally accepted by the UK Stem Cell Bank. However even this 
source of stem cell lines has had questions raised about its consent procedures (and is 
discussed in further detail in Chapter 9). Although the UK Stem Cell Bank is satisfied
467 Code o f Practice fo r  the use o f  Human Stem Cell Lines August 2006, Version 3 at Section 8.3, page 14 
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http://www.ukstemcellbank.org.uk/documents/Code%20oP/o20Practice%20for%20the%20Use%20oP/o20 
Human%20Stem%20Cell%20Lines.pdf (accessed 6/05/08)
468 Ibid. at Section 8.3, page 14
469 Ibid. at Section 8.3, page 14
470 Ibid. Found in the Appendix
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that the majority of stem cell lines from the NIH are ethically sourced, so far the UK 
Stem Cell Bank has accessioned some stem cell lines from the NIH Human Embryonic 
Stem Cell Registry but has not yet banked or distributed those stem cell lines to UK 
researchers.471
Whilst the Code of Practice of the Bank requires all researchers to apply to the 
Bank to import foreign stem cell lines, this is an informal control, or as Morgan states, 
“...the UK Stem Cell Bank does not have the power to force compliance with its 
authorisation policy. ”472 Although the control of the UK Stem Cell Bank over the import 
of stem cell lines appears to be informal it cannot be said that it is not without force. 
Should a researcher import stem cell lines without the consent of the Steering Committee 
then the Committee will write to the researcher’s superior informing them that the Bank’s 
Code of Practice has not been complied with.473 At this point it would be up to the 
researcher’s superior to take appropriate action to either ensure compliance with the Code 
of Practice, or possibly choose to ignore the advice given by the Steering Committee. 
This would be unlikely when considered in light of the fact that many funding bodies in 
the UK support the work of the UK Stem Cell Bank. Additional control to ensure 
compliance with the Code of Practice can be found through this funding mechanism. 
Funding bodies “ ...could make it a precondition offunding an ES cell project that import 
o f ES cell lines is subject to bank approval...Nevertheless, purely private research would 
not be obligated to follow the Steering Committee’s requirements. Such action, however, 
may sour the relationship between such researchers and the bank in future. ”474 
Therefore, compliance with the Code of Practice to seek approval from the Steering 
Committee to import stem cell lines should be high.
471 Announcement on stem cell lines in the NIH Registry Medical Research Council 
http://www.ukstemcellbank.ore.uk/index.html (accessed 19/6/09)
Stem Cell Catalogue Medical Research Council http://www.ukstemcellbank.org.uk/catalogue.html 
(accessed 19/6/09)
472 Morgan. R., A lack o f foresight? Jurisdictional uncertainties in the regulatory interface between the 
HFEA, the UK Stem Cell Bank and beyond  27(3) Legal Studies 511 at p525
473 Thanks to Soren Holm for raising this point
474 Morgan. R., A lack o f  foresight? Jurisdictional uncertainties in the regulatory interface between the 
HFEA, the UK Stem Cell Bank and beyond  27(3) Legal Studies 511 at p526
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Export of Stem Cell Lines
When considering the exportation of stem cell lines to researchers working 
overseas the requirements which must be fulfilled could be seen to be overly onerous 
upon the researchers wishing to export. Researchers should apply to the Steering 
Committee for approval before exporting stem cell lines, similar to the procedure 
discussed above in respect of importing stem cell lines. However, there are the additional 
requirements that “Research performed overseas shouldfulfil the criteria in Section 8.1.1 
[the permitted research areas as discussed above] and must comply with legislation in 
the UK and in the country where the research is performed and is expected to comply 
with this Code o f Practice. ”475
Whilst it is perhaps admirable of the Stem Cell Bank to try to ensure that any 
human embryonic stem cell lines which are exported from the UK are not used for 
unethical research, and are in fact used for those purposes which the Bank considers to be 
suitable as defined in Section 8.1.1 of the Code of Practice, in reality this could be very 
difficult to ensure. The onus is upon the researcher who wishes to export the human 
embryonic stem cell lines to show that any research performed overseas complies with 
not only UK legislation but also the legislation of the country in which the research is 
going to be performed, as well as compliance with the Code of Practice. In reality once 
the stem cell lines pass from one country to another it could be very difficult for the UK 
Stem Cell Bank to enforce the requirements to comply with UK legislation.
The UK Stem Cell Bank or the researcher who exports the stem cell lines will 
have a contractual agreement with the receiving researcher which would include the 
requirements to comply with UK legislation. Should the receiving researcher breach that 
requirement then the Bank or exporting researcher may have a claim for damages for 
breach of contract. Additionally they may also be able to obtain an injunction to stop the 
‘illegal’ research from continuing. The UK researcher or Stem Cell Bank would be able 
to take action either in the UK courts and then pursue the enforcement o f the remedy in 
the receiving country’s courts or, particularly if the receiving country is an EU country, 
sue directly in the receiving country court to enforce English law. It is likely that the
475 Code o f  Practice fo r  the use o f  Human Stem Cell Lines August 2006, Version 3 at Section 8.4, page 14 
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contracts between researchers will contain a condition that should any breach occur, 
English law is to be the presiding law.
Once human embryonic stem cell research progresses to the clinical therapies 
stage the role of the UK Stem Cell Bank in the import and export o f cell lines will be 
reinforced by the EU Tissue and Cells Directive, as mentioned above. The EU Tissue and 
Cell Directive requires a ‘competent authority’ to “...take all necessary measures to 
ensure that all imports [and exports] o f tissues and cells from  third countries are 
undertaken by tissue establishments accredited, designated, authorised or licensedfor the 
purpose o f those activities, and that imported tissues and cells can be traced from  the 
donor to the recipient... ”476 There is no requirement in the EU Tissue and Cells Directive 
that Member States receiving stem cell lines for clinical trials must comply with the 
permitted purposes of the Member State in which the cell lines were derived. So whilst 
the UK Stem Cell Bank is currently attempting to restrict research in other countries upon 
UK derived stem cell lines to those permitted research purposes of the UK, it does not 
seem that this will be possible in respect of clinical trials and applications.
Conclusion
Although there may be concern that embryonic stem cell lines are not regulated 
by an Act of Parliament the establishment of the UK Stem Cell Bank will have allayed 
many people’s fears and concerns about the right of access to those stem cell lines as well 
as worries over the research which occurs.
The establishment of a UK Stem Cell Bank can only be a good thing; it helps 
make the research which is being undertaken more transparent to the public by making 
people aware of the stem cell lines which are available for research and the work which is 
being done upon them. The Bank controls the access to those stem cell lines and 
eventually the collection of stem cell lines may be large enough to warrant a decrease in 
the number o f embryos used for the derivation of embryonic stem cell lines, something 
which may appease those who sit in the middle ground concerning the debate around the 
permissibility of embryo research.
476 Directive 2004/23/EC o f the European Parliament and o f the Council o f  31 March 2004 on setting  
standards o f quality and safety fo r  the donation, procurement, testing, processing, preservation, storage 
and distribution o f  human tissue and cells, [2004] OJ L102/48 Article 9
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The attempt by the Bank to regulate research abroad which is performed upon UK 
stem cell lines is open to criticism due to the difficulties in enforcing guidelines and 
contracts overseas. However, the attempt may well work, it is something that will have to 
be followed closely in the future.
The preceding chapters have discussed and analysed the regulation of human 
embryonic stem cell research -  from the initial application to the local research ethics 
committee to the later application to the HFEA to create and derive the human embryonic 
stem cells, the regulation of the research, and the banking of the cell lines. Whilst the 
legislation has generally worked well in regulating human embryonic stem cell research it 
was in need of reform. The reform process is discussed in the following two chapters.
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Chapter 7 -  Reform
Introduction
The Human Fertilisation and Embryology Act 1990 has overall worked well for 
the duration of its lifetime.477 However, that is not to say that it has been without its legal 
challenges. This factor, along with the rapidity with which science is developing, 
prompted the Government to undertake a review of the HFE Act with a view to replacing 
the existing legislation. New legislation, the Human Fertilisation and Embryology Act 
2008, received Royal Assent on the 13th November 2008 although the majority o f the Act 
including the provisions relating to embryo research will not come into force until 
October 2009.478
The road to reform has been a lengthy process and this chapter covers the period 
from 2003 to 2006. The subsequent Bills and the HFE Act 2008 are discussed and 
analysed in the following chapter. It is necessary to examine the reform process to 
understand how and why the new legislation has been enacted in the manner which it has 
and how this will affect human embryonic stem cell research. It is important to recognise 
the interface between embryo research and human embryonic stem cell research, again 
legislation which governs human embryo research is being used to also regulate human 
embryonic stem cell research.
Historical progression of the Reports
The House of Commons Science and Technology Committee announced their 
intention to review the HFE Act in October 2003 and following the initial Report by the 
House of Commons Science and Technology Committee in 2005 there have been several 
reports and responses to those reports. For the purpose o f this chapter the following 
documents are discussed:
477 Hereafter referred to as the HFE Act
478 Hereafter referred to as the HFE Act 2008
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• Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, 
House of Commons Science and Technology Committee HC 7-1
• Human Reproductive Technologies and the Law: Government Response to the 
Report from the House of Commons Science and Technology Committee (2005) 
CM 6641
• Review o f  the Human Fertilisation and Embryology Act: A Public Consultation 
(2005) Department of Health
• The Human Fertilisation and Embryology Authority Response to the Department 
of Health’s consultation on the Review of the Human Fertilisation and 
Embryology Act, 24th November 2005, 05/33273
• Report on the Consultation on the review o f the Human Fertilisation and 
Embryology Act 1990: Prepared for the Department o f  Health (2006) People 
Science and Policy Ltd
• Review o f  the Human Fertilisation and Embryology Act: Proposals fo r  revised 
legislation (including establishment o f the Regulatory Authority fo r  Tissue and 
Embryos) (2006) Department of Health CM 6989
As the outcome of this reform is a new Act of Parliament this chapter will discuss 
each area individually, how it has been examined by each different body and the 
recommendations which have been made. The two areas which are relevant to this thesis 
are:
• Legislative definitions and regulation of human embryos and gametes
• Research
and as such the relevant parts of each report is discussed under these headings.
A vast amount of time and discussion was spent upon the Government’s desire 
and proposal to merge the HFEA and the HTA to form RATE, the Regulatory Authority 
for Tissue and Embryos, and as such there are numerous references to this body within 
the documents discussed in this chapter, as well as the next. However, following the 
Report from the Joint Committee on the Human Tissue and Embryos (Draft) Bill, which
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is discussed in greater depth in the next chapter, the Government backed down and did 
not push forward with the RATE proposal. Therefore the HFEA will continue to be the 
regulatory body responsible for human embryo research under the HFE Act 2008. Due to 
the Government’s decision not to form RATE this body is not discussed in depth in this 
thesis, interested readers should refer to the relevant sections o f the reform documents 
which are discussed here for further information upon this body if required.
Although the Government has now undertaken and completed a review o f the 
HFE Act (which is discussed in detail below) it was initially slow to take this action. The 
House of Commons Science and Technology Committee decided to undertake its own 
review following evidence provided to it by the outgoing Chair of the Human 
Fertilisation and Embryology Authority, Dame Ruth Deech in April 2002.479 The 
Committee felt that Dame Deech gave a '‘‘...complacent response to developments in [a] 
fast-moving field ...” and equally that the Department of Health’s response that the 
Government was keeping the HFE Act under review was a “limp response. ”480
Therefore the Science and Technology Committee announced its own review on 
the 24th October 2003.481 The Department of Health finally announced its own review of 
the HFE Act on the 21st January 2004 but waited for the publication o f the Science and 
Technology Committee Report to inform its own review 482
The terms of reference of the Inquiry into Human Reproduction and the Law
were:
a) To consider a) the balance between legislation, regulation and
reproductive freedom; b) the role o f  Parliament in the area o f  human 
reproductive technologies; and c) the foundation, adequacy and 
appropriateness o f the ethical framework fo r  legislation on 
reproductive technologies.
b) To consider the provisions o f  the Human Fertilisation and Embryology
Act 1990 in the context o f  other national and international legislation 
and regulation o f  medical practice and research
479 Hereafter referred to as the Science and Technology Committee
480 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, House o f Commons 
Science and Technology Committee HC 7-1 at Para 2, Pg 3
481 New Inquiry: Human Reproductive Technologies and the Law Press Release No. 45, Session 2002-2003, 
House o f  Commons Science and Technology Committee, 24th October 2003
http://www.parliament.uk/parliamentarv committees/science and technology com m ittee/scitech241003.cf 
m (last accessed 30/10/08)
482 Human Reproductive Technologies and the Law Fifth Report o f  Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1 at Para 2, Pg 3
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c) To consider the challenges to the Human Fertilisation and Embryology
Act 1990from a) the development o f  new technologies fo r  research and 
development, and their ethical and societal implications and b) recent 
changes in ethical and societal attitudes
d) To consider the composition, expertise and approach o f  the Human
Fertilisation and Embryology Authority, its code o f  practice, licensing 
arrangements and the provision o f  information to patients, the
483profession and the public.
As can be seen the Science and Technology Committee undertook a thorough and 
comprehensive review of the HFE Act and related areas. It also carried out an on-line 
consultation to try to include as many people as possible from a cross-section o f 
society.484
The Government presented its response to the House o f Commons Science and 
Technology Committee Report on Human Reproductive Technologies and the Law in 
August 2005.485
As previously mentioned the Government had announced its own review of the 
HFE Act on the 21st January 2004 and as such had considered the Science and 
Technology Committee recommendations and conclusions in light o f its own review. The 
Government responded to the recommendations made by the Science and Technology 
Committee by grouping together recommendations by topic rather than responding to 
each recommendation individually. The Government Response is discussed in this 
manner below.
Following the publication of the House of Commons Science and Technology 
Committee Report and the Government Response to that Report, the Department of 
Health released the Review o f the Human Fertilisation and Embryology Act: A Public 
Consultation in August 2005.486 Responses to the Public Consultation had to be received 
by Friday 25th November 2005. The responses were then collated and reported (see 
below).
For the purposes of this thesis there are two sections o f the Public Consultation 
document which are relevant; Section Two: The model and scope o f Regulation and
483 Ibid. at Table 1, Pg 4
484 Hansard Society Online Consultation on Human Reproductive Technologies and the Law, Summary 
Report March 2004 http://tellparliament.net/scitech/documents/sci-tech-report.pdf (last accessed 07/08/08)
485 Human Reproductive Technologies and the Law: Government Response to the Report from the House o f  
Commons Science and Technology Committee (2005) CM 6641
486 (2005) Department o f  Health http://www.dh. gov. uk/en/Consultations/Closedconsultations/DH 4123863  
(last accessed 17/09/08)
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Section 9: Research. Both are discussed in turn. The questions and proposals for 
consultation which the Government laid out in this Public Consultation can be found in 
full in Annex B of the Consultation.
People Science and Policy Ltd were asked to prepare a report which 
“...summarises the landscape o f arguments put forward in response to the DH  
consultation document. ”487 A total of 535 responses were received and the arguments 
submitted are summarised within the Consultation Report.
The Consultation Report is laid out in the same structure as the Consultation 
Document upon which it is summarising. As such only the relevant parts of the 
Consultation Report will be discussed, those which correspond to the areas highlighted 
above in the discussion of the Consultation Document.
The White Paper was published just nine months after the Report on the 
Consultation on the Review o f the Human Fertilisation and Embryology Act 1990. The 
White Paper is a comprehensive account of the proposed revised legislation, giving the 
reader the general scope and purpose of the proposed legislation. As with the HFE Act 
the proposed revised legislation covers a wide range o f issues connected to human 
fertilisation and embryology, nonetheless, there are a large number of issues discussed 
within the White paper which relate to human embryonic stem cell research and these are 
examined below.
The Government recognised that the HFE Act had worked well and largely 
continued to do so, enabling science and medicine to flourish within agreed 
parameters and promoting public confidence...[and] has concluded that the 
foundations o f the current law remain sound, and provide an effective and 
appropriate model o f  regulation fo r  the development and use o f  human 
reproductive technologies.4 8
Although the HFE Act had worked well the Government finally decided that a 
review of the Act was necessary due to a number o f issues, including “possible changes 
in public perceptions and attitude’s on complex ethical issues.”489 These possible changes
487 Report on the Consultation on the review o f  the Human Fertilisation and Em bryology A ct 1990: 
Prepared fo r  the Department o f  Health (2006) People Science and Policy Ltd
http://www.peoplescienceandpolicv.com/downloads/FlNAL HFEA reportDH.pdf (accessed 5/9/07) pg 1 
Review o f  the Human Fertilisation and Embryology Act: Proposals fo r  revised legislation (including 
establishment o f the Regulatory Authority fo r  Tissue and Embryos) (2006) Department o f  Health CM 6989 
at Para 1.2 and 1.8
489 Ibid. at Para 1.3
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are partly due to the rate at which science is progressing and the developments which are 
being made in respect of human embryo research and human embryonic stem cell 
research.
The need to keep legislation up to date was recognised within Paragraph 2.5 
where it was stated that “...regulatory controls need to be responsive to technological 
advances, and to keep pace with significant changes in public attitudes. ” It is for this 
reason that the Government had finally undertaken the review o f the HFE Act and 
published the White Paper with proposals to revise the legislation.
The relevant sections of all the Reports, Responses and Papers are discussed in 
the following sections.
Legislative definitions and regulation of human embryos and gametes 
Human Reproductive Technolo2ies and the Law 
Chapter 4 -  Problems with the HFE Act
The Science and Technology Committee identified a number o f problems with the 
HFE Act including artificial gametes, fertility research and sperm sorting. For this part of 
the thesis the areas which will be considered are; the definition o f an embryo, the 14 day 
rule and embryos created not by fertilisation.
Definition of an embryo and gamete - Recommendations 5 and 99
The first problem which the Science and Technology Committee discussed was 
the definition of an embryo contained in section 1(1) of the HFE Act. The definition 
based upon fertilisation did not cause a problem until researchers at the Roslin Institute in 
Scotland demonstrated the success of the cell nuclear replacement technique. It was noted 
that
While the HFE Act had foreseen cloning, it had assumed that this would require
the replacement o f  an embryonic nucleus rather than an egg and had outlawed
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cloning only in specific terms, which did not include the method used to create 
Dolly.490
The Government however believed that the HFE Act covered such embryos and 
this was upheld by the House of Lords in the Quintavalle case (see discussion in Chapter 
3).491 Although the situation has since been resolved by the Courts, the HFEA in its 
evidence to the Science and Technology Committee suggested that the definition 
contained in the HFE Act was unsatisfactory.
The Science and Technology Committee formulated three different ways in which 
the problem of the definition of an embryo could be addressed:
a) By redefining the embryo, at least defining those types o f  embryo that fa ll 
under legislation, according to the way in which they were created. This has 
the advantage o f clarity but it fails to embrace any future technique that might 
be developed....
b) By defining an embryo by its capabilities. For example, it could embrace any 
diploid (two sets o f  chromosomes) with the potential to differentiate.... danger 
that embryonic stem cells might be swept up by such a definition....
c) A final option would be to avoid any definition, as is the case in the 2001 
Human Reproductive Cloning Act. Using this approach, the term “embryo ” 
would cover the normal usage o f  the word....492
Following this discussion of the possible ways to define an embryo within the 
legislation the Science and Technology Committee recommended that any future 
legislation should not contain a definition:
We are concerned that any legal definitions o f  the embryo based on the way it was 
created or its capabilities would either be open to legal challenge or fa il to 
withstand technological advance. The attempt to define an embryo in the HFE Act 
has proved counter-productive, and we recommend that any future legislation 
should resist the temptation to redefine it. We consider that a better approach 
would be to define the forms o f embryo that can be implanted and under what 
circumstances. Using this approach, only those forms o f  embryo specified in the 
legislation, such as those created by fertilisation, could be implanted in the womb 
and thereby used for reproductive purposes. Other form s o f  embryos would be 
regulated insofar as they are created and used fo r  research purposes 493
490 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1 at Para 51, Pg 25
491 R (on the application o f Quintavalle) v Secretary o f State fo r  Health [2003] 2 All ER 113
492 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1 at Para 52, Pg 26-27
493 Ibid. at Para 53, Pg 27
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This approach would be the simplest to take and would help to avoid any future 
legal challenges to the legislation. The HFE Act and the HFEA have been subjected to 
numerous legal challenges during their short history and as will be seen in the next 
Chapter of this thesis the Government has learned from these legal challenges and has 
tried to avoid definitional problems in the future. One possible problem with the 
suggestion made by the Science and Technology Committee is the development of 
artificial wombs. If the new legislation was to specify the types o f embryos which could 
be implanted into wombs, as is suggested by the Science and Technology Committee, the 
wording of the legislation would have to be clear as to whether this includes artificial 
wombs or not. In this fast moving area of science the new legislation has to be very 
carefully worded, not just in respect of the definition of an embryo, but all associated 
expressions must be very clear. Whilst this would help to prevent legal challenges, the 
drafters of the legislation must be equally clear that the terms used do not in the future 
give the automatic green light for work which may be considered undesirable or unethical 
and that equally the terms do not block ethically acceptable research.
The 14 day Rule -  Recommendation 7
The Wamock Report first recommended a short time limit during which research 
could be performed upon human embryos to protect the special status o f human embryos. 
The Gradualist approach taken resulted in the recommendation that no embryo was to be 
allowed to develop beyond fourteen days, or the appearance o f the primitive streak, 
whichever occurs first, from the moment that the gametes were mixed, not including time 
when it is stored. This was due to the knowledge that the primitive streak develops 
around this time and that “This marks the beginning o f  individual development o f  the 
embryo. ”494
The fourteen day rule, as it is known, was carried through to the HFE Act and the 
Science and Technology Committee considered if the rule was still adequate. While it is 
generally accepted as a good cut off point (although there are some who feel that it is an
494 Report o f  the Committee o f  Inquiry into Human Fertilisation and Embryology (The Warnock Report) 
(1984) DHSS Cmnd 9314 at Para 11.22, Pg 66
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arbitrary cut off point) it was noted that the time limit may need to be re-evaluated in the 
future.
The Science and Technology Committee, in its considerations of the fourteen day 
rule, did not deem that the time limit currently needed to be adjusted. The Science and 
Technology Committee did however continue on to state that:
...if scientists or clinicians were able to provide convincing justification fo r  any
change, this should be determined by Parliament495
This was a sensible recommendation. The fourteen day rule has so far stood the 
test of time with scientists currently extracting stem cells at around five to six days 
development and with no record of an embryo being successfully cultivated in vitro for 
up to fourteen days, there does not appear to be any urgency in readdressing this rule. 
However, as can be seen from the example of the development o f the cell nuclear 
replacement technique and the successful extraction of human embryonic stem cells, 
there is the possibility that there could in the future be cause to review the time limit 
imposed by statute. The recommendation that this be done by Parliament was the most 
appropriate as the alteration of the time limit would no doubt be a controversial one, and 
should be thoroughly debated in Parliament before a free vote.
Embryos not formed through fertilisation
The Science and Technology Committee noted that embryos not formed through 
fertilisation were governed by two pieces of legislation -  the HFE Act and the Human 
Reproductive Cloning Act 2001.
The Science and Technology Committee made a detailed discussion o f the issues 
surrounding human reproductive cloning, the possible advantages and the disadvantages 
of allowing it, yet in respect of human therapeutic cloning in relation to the derivation of 
human embryonic stem cells the Science and Technology Committee took the view that;
495 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1, Para 58, Pg 30
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The issues have been comprehensively addressed by the House o f  Lords Stem Cell 
Research Committee in 2001 and we are unaware o f  any new evidence that would 
require a reassessment o f  that Committee’s conclusions, which we respect496
Their interest in therapeutic cloning related to the adequacy o f the 2001 
Regulations which extended the permitted areas of research, this is discussed later on in 
the Report.
Human Reproductive Technologies and the Law: Government Response 
Definition of an embryo -  Recommendations 5, 99 and 7
The Government welcomed the Science and Technology Committee 
recommendations to avoid defining the embryo in future legislation but to define the 
embryo which may be implanted and in what circumstances. The Government agreed that 
there may be merit in taking this approach in future legislation and intended to consult 
further in its review of the HFE A c t497
The Government also considered the fourteen day rule under this heading. The 
Government agreed with the Science and Technology Committee that there was presently 
no need to alter the fourteen day rule but that if  there came a time when scientists or 
clinicians could justify altering the time limit then this must be determined by 
Parliament.498
Review of the Human Fertilisation and Embryology Act: A Public Consultation 
Definition of an embryo
The definition of an embryo as contained in the HFE Act plays a vital role as it 
underpins many of the basic prohibitions relating to embryos. This definition has been 
subjected to legal challenge and although the Courts have taken a purposive approach to 
interpret the law to follow the will of Parliament, it is not appropriate that such a
496 Ibid. at Para 72, Pg 36
497 Human Reproductive Technologies and the Law: Government Response to the Report from the House o f  
Commons Science and Technology Committee (2005) CM 6641 at Para 13, Pg 9
498 Ibid. at Para 14, Pg 9
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fundamental aspect of the law should be subjected to legal challenge and it is be hoped 
that this could be avoided in the future.
The Government took an all inclusive approach to the definition o f an embryo and 
stated within the Public Consultation document that it:
...believes that legislation should make clear that all human embryos outside the 
body are within the scope o f  regulation and subject to the control o f  the statutory 
licensing authority regardless o f the manner o f  their creation.499
The Government goes on to state that it:
...considers that the best approach is to define the form s o f  embryo which may be 
placed in a woman and in what circumstances, and to regulate other form s o f  
embryo insofar as these are created and usedfor research.500
This approach was the same as that taken by the Science and Technology 
Committee of the House of Commons. It would conform with the position found within 
the Human Reproductive Cloning Act 2001 and would encompass all future forms of 
creating embryos, even if the method of creation was not foreseen, as was the situation 
with the cell nuclear replacement technique.
Also, by defining the embryos which may be implanted it clearly separates those 
embryos upon which only research may be performed and those embryos which may be 
researched upon or implanted.
Definition of gametes, eggs, sperm
The HFE Act does not currently define the terms gametes, eggs or sperm, but with 
the advent of artificial gametes and the possibility of these being used to overcome 
infertility problems, the Government foresaw the need to define those terms. The need to 
include a definition was raised by the Government in the respect that it was seen as 
undesirable to use artificial gametes in treatment due to safety and ethical concerns and a 
definition may be needed in order to effectively prohibit the use o f artificial gametes.
499 Review o f  the Human Fertilisation and Embryology Act: A Public Consultation (2005) Department o f  
Health at Para 2.20, Pg 14
500 Ibid. at Para 2.22, Pg 15
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Importantly though, the Government also proposed that legislation should contain 
a power for Parliament to make regulations. This would have given Parliament the 
flexibility to allow the use of artificial gametes if it wished to do so in the future. This 
could have been very useful and important as the situation may indeed arise whereby 
artificial gametes become a safe option to treat infertility.
Report on the Consultation on the review of the Human Fertilisation and 
Embryology Act 1990 
Regulation of embryos
The majority of the responses agreed with the proposals by the Government that 
firstly new legislation should make it clear that all human embryos outside of the body 
were within the scope of regulation and control of the statutory licensing authority 
regardless of the manner of their creation, that secondly the forms o f embryos and the 
circumstances in which they could be placed into a woman should be defined and thirdly 
to regulate other forms of embryos which are created and used for research. Some 
concerns were raised over the possible restrictiveness of definitions whilst others felt that 
the use of embryos for research purposes was wrong.501
Of course the use of embryos for research will always be a contentious issue to 
which there is no easy answer which will satisfy everyone. Overall it can be said that the 
Government proposals were well received as the majority o f discussants centred their 
responses around how best to regulate embryos rather than outlawing such processes.
Regulation of eggs
There appears to have been an almost unanimous response to the Government’s 
proposal that eggs undergoing processes intended to result in the creation o f embryos 
should continue to be subject to regulation. There was even a suggestion to extend 
regulation to all embryos and gametes intended to partake in in utero development.502 
This suggestion appears to include gametes and embryos held within the human body and
501 Report on the Consultation on the review o f  the Human Fertilisation and Em bryology A ct 1990: 
P reparedfor the Department o f  Health (2006) People Science and Policy Ltd at Para 2.3.1, pg 6-7 
http://www.peoplescienceandpolicv.com/downloads/FlNAL HFEA reportDH.pdf (accessed 5/9/07)
502 Ibid. at Para 2.3.2, pg 7
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would be very difficult to put into practice. Currently embryos which are created outside 
of the body are regulated as are gametes. Previously clinics using fresh gametes for 
gamete intra-fallopian transfer (GIFT) or inter-uterine insemination (IUI) were excluded 
from the need for a licence. This is no longer the case due to the implementation of the 
EU Tissue and Cells Directive and all such clinics were required to have a licence by the 
7th April 2007.503
Artificial gametes
The Government proposal that the use o f artificial gametes for infertility 
treatments should be prohibited for the time being invoked a mixed response but it was 
the proposal by Government that the legislation should contain a regulation-making 
power to allow Parliament to permit the use of artificial gametes in the future if the need 
arose which was not as well met. It was felt that a full Parliamentary debate should be 
required before there was any amendment which would permit the use o f artificial 
gametes for infertility treatment.504
Review of the Human Fertilisation and Embryology Act: Proposals for revised 
legislation 
Embryos and gametes
Within the White Paper there was a continued acceptance that “...activities 
involving the creation, keeping or use o f  embryos outside the body, or the use o f  donated 
gametes, should continue to be subject to licensing by an independent regulator. ”505 O f 
course it was vital that ‘embryo’ and ‘gamete’ were sufficiently defined within the new 
legislation so that all embryos and gametes which the Government wished to regulate 
were covered by the system of licensing. This was vital so as to avoid legal challenges
503 HFEA Consultation on Annual Fees fo r  Centres Licensed under the European Tissue and Cells D irective  
from  7 April 2007  HFEA http://vAvw.hfea.gov.uk/docs/2006-09-25 EUTD Fees Consultation - Final.pdf 
(accessed 07/08/08)
504 Report on the Consultation on the review o f  the Human Fertilisation and Em bryology A ct 1990: 
Prepared fo r  the Department o f  Health (2006) People Science and Policy Ltd at Para 2.4, pg 7-8 
http://www.peoplescienceandDolicv.com/downloads/FINAL HFEA reportDH.pdf (accessed 5/9/07)
505 Review o f the Human Fertilisation and Embryology Act: Proposals fo r  revised legislation (including 
establishment o f the Regulatory Authority fo r  Tissue and Embryos) (2006) Department o f Health CM 6989  
at Para 2.9
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such as the Quintavalle case which challenged the legal definition of an embryo as 
contained within the HFE Act. For further discussion o f this case refer to Chapter 3 of 
this thesis.
The Government proposed a broader definition o f an embryo, as it was the 
intention of Government “ ...that all human embryos outside the body, regardless o f  their 
manner o f creation, will be within the scope o f  regulation. ”506 The proposed approach 
was to define the types o f embryos which may be placed into a woman and to ensure that
• • • 507all embryos which were created for research purposes were subject to licensing.
The need to regulate all embryos regardless o f the manner o f their creation was 
without doubt. To continue public confidence in the area of human embryo research it 
was vital that all work on human embryos and gametes was strictly regulated and 
controlled by the licensing authority. However, by defining the types of embryos which 
can be placed into a woman there was the risk that the legislation could again become 
quickly outdated if  scientists discovered a new method for creating embryos which would 
be acceptable for reproductive means.
Equally, the Government intended to continue to regulate ‘eggs in the process of 
fertilisation’ in the same way as embryos, and to also regulate eggs undergoing other 
processes of embryo creation. This was a sensible idea as it would include eggs 
undergoing the cell nuclear replacement technique, parthenogenesis and any other 
method which scientists may devise in the future.
Whilst ‘gametes’ are not currently defined in the HFE Act it was recognised that 
the previously accepted understanding of human gametes, i.e. naturally produced eggs 
and sperm from the reproductive organs of humans, was no longer universal, particularly 
in light of the developments with artificial gametes. No definition was proposed for 
gametes within the White Paper although it was made clear that the law would apply to 
all cells pertaining to be human gametes (however created). Artificial gametes would also 
be subject to additional controls.
One other point in respect of human embryos is that the Government proposed to 
extend the statutory storage period from five years, to ten years, this being in line with the 
current statutory storage period for gametes.508 This may appear to be o f greater
506 Ibid. at Para 2.11
507 Ibid. at Para 2.11
508 Ib id  at Para 2.37
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relevance in respect of infertility treatment; nevertheless it could also be of use for 
embryo research. The vast majority of embryos upon which research is performed come 
from fertility treatments, embryos which are ‘surplus’ to the fertility requirements of the 
couple undergoing treatment. The current five year statutory storage period is relatively 
short in terms of a couple undergoing treatment, having a child (hopefully) and then 
deciding what to do with the remaining embryos which are in storage. It is the thought of 
the author of this thesis that it is possible that couples are faced with a looming deadline 
to do something with the stored embryos and may not feel ready to donate them to 
research and thereby preferring them to be disposed of. However, if  the statutory storage 
period was extended, there is the possibility that the longer couples have to decide what 
to do with any remaining embryos following fertility treatment, there may be a trend 
towards donation to research if the couple have a longer period to reflect and decide. This 
could result in a greater number of embryos being donated for research and which are 
suitable for research, thereby helping the scientists who need more than are currently 
available for their research.
Research
Human Reproductive Technologies and the Law 
Research
As noted previously, the 2001 Regulations extended the permitted purposes of 
research. The 2001 Regulations allow the use of embryos for therapeutic research, 
including research involving human embryonic stem cells.
Some concerns were raised over the 2001 Regulations. As the Science and 
Technology Committee were told in the evidence submitted to them, the derivation of 
human embryonic stem cells and the creation o f embryos by the cell nuclear replacement 
technique are not easy processes to achieve successfully. Basic research could improve 
the success rates but it was questioned if the 2001 Regulations permitted this basic 
research to be carried out.
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Valuable basic research could be undertaken in perfecting these techniques yet it 
would yield no information on serious disease, nor arguably increase knowledge 
about the development o f  embryos.509
The issue of permitting basic research upon human embryos was an area which 
needed to be addressed clearly within the legislation and the permitted research purposes. 
It was obviously an area of concern for the Science and Technology Committee.
Recommendation 104
The Science and Technology Committee noted that embryo research would have 
to be undertaken in an accredited facility, have been scrutinised by a research ethics 
committee, and been scientifically reviewed. The Science and Technology Committee 
suggested that the Medical Research Council (MRC) guidelines should be adopted to 
ensure that embryo research was of real clinical benefit and also suggested that the MRC 
took on the peer review process for applications involving human embryos even where 
the application did not involve MRC funds.510 There was no specific reason given for the 
MRC to take over the peer review process, one possible reason could be to ensure 
independence from the HFEA so as to guarantee thoroughly independent review of 
proposed research projects.
Human Reproductive Technologies and the Law: Government Response 
Embryo Research -  Recommendations 83 and 104
These two recommendations were made by the Science and Technology 
Committee in relation to Ethical Oversight and Research respectively and are discussed 
under those headings. The Government Response has grouped these two 
recommendations under the heading ‘Embryo Research’ along with recommendations 4, 
59 and 100.
The recommendation to move towards local oversight of research on human 
embryos was not accepted by the Government as serious doubts were expressed over the
509 Human Reproductive Technologies and the Law Fifth Report o f  Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1 at Para 175, Pg 79
510 Ibid. at Para 400, Pg 173-4
207
consistency of decision-making, the expertise available, and the clarity o f responsibilities 
in such a system. The Government believed that the purposes for which research using 
embryos may be undertaken should continue to be determined by Parliament and that 
such research projects should also continue to be approved by a national body to ensure 
compliance with the law, consistency and appropriate ethical oversight.511
Review of the Human Fertilisation and Embryology Act: A Public Consultation 
Cell nuclear replacement
The HFE Act permits the creation of embryos with the cell nuclear replacement 
technique for the purposes of research only. The use of the cell nuclear replacement 
technique on embryos once they have been created is prohibited by law. There are two 
issues upon which the Government invited opinions; the first being that subject to 
licensing the cell nuclear replacement technique should be permitted to be used for the 
purpose of studying mitochondrial diseases, the second that the prohibition of preventing 
“the replacing o f a nucleus o f  a cell o f  an embryo with the nucleus taken from  the cell o f  
any person, another embryo or subsequent development o f  an embryo” should be 
removed for research purposes.512
What is interesting to note is that the cell nuclear replacement technique was 
permitted in the first instance primarily for the research which was desired to be 
undertaken with human embryonic stem cells, and yet there is no further mention of the 
technique being used in conjunction with stem cell research here. To the Government at 
least it seemed to be an open and shut case that stem cell research in conjunction with the 
cell nuclear replacement technique should continue to be permitted under the new 
legislation, and did not need to be put out for public consultation. Whilst the 2001 
Regulations which extended the permitted research purposes received considerable 
parliamentary time for debate, the inclusion of the cell nuclear replacement technique in 
the legislation was not debated in this manner. The inclusion of the cell nuclear 
replacement technique for therapeutic or research purposes has not been fully debated by
511 Human Reproductive Technologies and the Law: Government Response to the Report from the House o f  
Commons Science and Technology Committee (2005) CM 6641 at Para 11 and 12, Pg 8
512 Review o f  the Human Fertilisation and Embryology Act: A Public Consultation (2005) Department o f  
Health at Para’s 9.22-9.23, Pg 63
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Parliament although it is clear that the technique is included in the HFE Act due to the 
House of Lords decision in Quintavalle.513 As discussed in an earlier Chapter the Human 
Reproductive Cloning Act 2001 was enacted as a knee jerk reaction to the decision of the 
High Court in Quintavalle. The debate at the time of the Human Reproductive Cloning 
Act 2001 was more concerned with the possible reproductive uses o f the cell nuclear 
replacement technique, rather than the therapeutic uses. The Government felt that it was 
important to act quickly to outlaw human reproductive cloning and debate the issue o f 
therapeutic cloning at a later date. The actual inclusion o f the technique in the legislation 
for therapeutic purposes has not been fully debated subsequently.
The purposes for which research may be permitted
The Government very briefly dealt with the research purposes contained within 
the HFE Act. The concern which was raised, that the list o f research purposes may not 
allow some basic research to be performed, was dismissed by the Government which 
stated that:
The Government has previously made clear that it is confident that basic research
is permissible under the current list o f legitimate research purposes.514
The Government merely invited opinions on whether the current list o f research 
purposes for research involving embryos was appropriate. It could be foreseen that some 
commentators would still take this opportunity to raise their concerns that basic research 
was not permitted under the legislation. It seemed somewhat naive for the Government to 
think that just because it believed that basic research was permitted, that everyone would 
just accept this. The concern that basic research was not covered by the research purposes 
has been raised several times, most recently by the Science and Technology Committee 
in its Report.515 It was an issue which needed clarification in the legislation as it is a 
fundamental part of the embryo research process.
513 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2003] 2 All ER 113 Refer to 
Chapter 3 for a discussion o f  this case
514 Review o f  the Human Fertilisation and Embryology Act: A Public Consultation (2005) Department o f  
Health at Para 9.37, Pg 69
515 Human Reproductive Technologies and the Law Fifth Report o f Session 2004-05, House o f  Commons 
Science and Technology Committee HC 7-1 at Para 175, Pg 79
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Approval of research projects
The current system of requiring a research proposal to be approved by a local 
research ethics committee before passing to the HFEA for approval and licensing, was 
criticised as bureaucratic and time consuming. Although there was a suggestion for 
approval to lay with the local research ethics committee only, the Government rejected 
this and considered that not only should research purposes continue to be defined by law, 
but also that research projects should continue to be approved by a national body to 
ensure compliance with the law, consistency and ethical oversight.516
There is a definite advantage of a national body overseeing research projects; 
consistency in decisions is the primary one. However, the Government did need to 
seriously reconsider how research projects were approved as the present-day system of 
requiring research ethics committee approval prior to approval from the HFEA duplicates 
work, frustrates the participants, and involves additional costs, resources and time. This 
lack of consideration of the way in which research projects involving human embryos 
receive ethical approval is worrying. The Government wished to see consistency in 
decisions; with the limited number of research ethics committees that have experience of 
dealing with research projects involving human embryos, there should be greater concern 
that there is not consistency at the ethical approval stage o f the process. As discussed 
elsewhere in this thesis, a single central research ethics committee, possibly even forming 
part of the HFEA or the UK Stem Cell Bank, could carry out ethical approval of all 
projects involving human embryos before the application passes to the Licensing 
Committee of the HFEA for scientific approval.
Creation of embryos for therapeutic purposes
One concern which has been raised about the research purposes contained within 
the legislation is that whilst they permit research upon embryos for research purposes, the 
legislation does not allow the creation of embryos for treatment purposes, other than as a 
means to assist a woman to carry children. Effectively this means that embryos can be
516 Review o f  the Human Fertilisation and Embryology Act: A Public Consultation (2005) Department o f  
Health at Para 9.41, Pg 70
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researched upon but once a therapy has been designed, if  the therapy requires the creation 
of embryos this would be prohibited under the Act.
The Government invites comments upon the desirability o f  allowing the creation 
o f embryos fo r the treatment o f  serious diseases (as distinct from  research into 
developing treatments for serious diseases which is already allowed.)517
This was an important consideration and it was logical that the creation of 
embryos for therapeutic purposes should be permitted in the new legislation. It seemed 
somewhat bizarre if the legislation allowed the creation of embryos for research purposes, 
but that any subsequent research could not be therapeutically applied due to a prohibition 
on creating embryos for this purpose.
This would be a controversial step as it is going beyond using surplus embryos for 
research, the issue of creating embryos for personal gain, along with the number of 
embryos involved and the possibility of needing to use the cell nuclear replacement 
technique in conjunction, is for some people a step too far. Although it may at first sight 
seem strange that new legislation may allow the creation o f embryos purely for research 
purposes and not for therapeutic purposes, it was actually politically sensible to take this 
route. It is thought by the author of this thesis that by not yet taking a decision on this 
step it allowed the new legislation to pass through Parliament relatively easily, after all, 
any possible therapies are a long way in the future and are still merely a possibility. 
Politically there was no need to make a decision on this matter before needed.
There are also questions as to how the therapies may occur in the sense that we do 
not know if it will be possible to create a number of ‘general’ stem cell lines for use by 
the majority of people or if any therapy needs to be individually tailored. Two different 
scenarios are foreseeable -  the use of human embryonic stem cells in personalised 
medical treatments, through the derivation of embryonic stem cells from embryos cloned 
using a patients DNA or the ‘general’ application of stem cell lines. These stem cell lines 
would probably be derived from embryos which are surplus to reproductive uses, similar 
to the current situation of using surplus embryos for research. Commercially this would 
be very attractive but the creation of embryos specifically to derive ‘general’ stem cells 
for treatment is prohibited under the current legislation even if it could help thousands of
517 Ibid. at Para 9.47, Pg 71
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people. If the stem cells were initially derived for research purposes but then later found
• 518to have a therapeutic purpose this may be permissible under the current legislation.
Report on the Consultation on the review of the Human Fertilisation and 
Embryology Act 1990
The Consultation Report separated the responses to the use o f the cell nuclear 
replacement technique for mitochondrial diseases and the cell nuclear replacement 
technique on embryos. These two uses of the cell nuclear replacement technique were 
dealt with jointly in the discussion of the Consultation Document but will be dealt with 
separately here in accordance with the layout of the Consultation Report.
Cell nuclear replacement and mitochondrial diseases
Understandably there were mixed views on the Government proposal to allow 
research on embryos created by cell nuclear replacement for the purpose o f studying 
mitochondrial disease. This is still an area where a great deal of research needs to be 
carried out, certainly before possibly using it in treatment, but the need for regulation and 
review has been emphasised in some responses.519
While there is merit in trying to overcome mitochondrial diseases, the 
implications of effectively creating an embryo with three genetic parents needs to be 
carefully examined, particularly if the Government saw fit to include cell nuclear 
replacement embryos created for the purpose of overcoming mitochondrial disease in the 
group of embryos which are permitted to be placed into a woman. (Note that in the end 
the Government chose to include a regulation making power in the HFE Act 2008 which 
would allow an embryo to be a permitted embryo when it had undergone ‘a process 
designed to prevent the transmission of serious mitochondrial disease’ and therefore 
could be implanted for treatment purposes).520
518 Thanks to Soren Holm for raising these points.
519 Report on the Consultation on the review o f the Human Fertilisation and Em bryology A ct 1990: 
Preparedfor the Department o f  Health (2006) People Science and Policy Ltd at Para 29.2.1, pg 67 
http://www.peoplescienceandpolicv.com/downloads/FINAL HFEA reportDH.pdf (accessed 5/9/07)
520 Section 3(5) and 26 Human Fertilisation and Embryology Act 2008
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Cell nuclear replacement on embryos
The proposal to remove the prohibition currently found in Section 3(3)(d) of the 
HFE Act again received a mixed response. Section 3(3)(d) prohibits “replacing the 
nucleus o f a cell o f  an embryo with a nucleus taken from  the cell o f  any person, another 
embryo or a subsequent development o f an embryo.” Views ranged from the complete 
removal of the prohibition to allow for advances in research, to those who felt that the 
lifting of the ban could lead to the eventual cloning of humans. As pointed out by the 
British Medical Association the fears that the removal o f this prohibition could result in 
human reproductive cloning were unjustifiable due to the Human Reproductive Cloning 
Act 2001.521
Whilst public opinion seemed to be divided upon this point it could be predicted 
that the Government would remove the prohibition contained in Section 3(3)(d) o f the 
HFE Act. There did not appear to be a valid reason to retain the prohibition, precisely due 
to the reason raised by the British Medical Association.
The purposes for which research may be permitted
Unsurprisingly, there was again a varied response to the Government question 
whether any changes should occur to the current list o f purposes for which research can 
be undertaken. As commented above, the question of the legislation allowing basic 
research was raised by some respondents. As the Government did not see the specific 
inclusion of basic research as an issue worthy of further consideration it was somewhat 
unlikely at that point in time (2006) that basic research would be mentioned in any future 
legislation. This could have been a problem for the Government if  the issue had been 
raised in the Courts in the future and the issue had not been resolved in the new 
legislation.
From the varied responses, it can be seen the Government opinion that basic 
research was permissible under the current list of research purposes was not unanimously 
supported and if there was to be a legal challenge to this aspect o f the legislation there
521 Report on the Consultation on the review o f  the Human Fertilisation and Em bryology A ct 1990: 
Prepared fo r  the Department o f  Health (2006) People Science and Policy Ltd at Para 9.2.2, pg 
68http://www.peoplescienceandpolicv.com/downloads/FINAL HFEA reportDH.pdf (accessed 5/9/07)
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could have been judges sympathetic to the argument that the list o f research purposes was 
not inclusive of basic research. Of course, based upon previous legal challenges, notably 
Quintavalle,522 it could have been predicted that the Courts would take the Government 
viewpoint and interpret the list of research purposes as permitting basic research. Ideally 
this was an issue which required clarification. As will be seen in the next Chapter this 
issue was resolved and basic research is specifically referred to in the new legislation.
Creation of embryos for therapeutic purposes
As expected, the invitation to comment upon the desirability o f creating embryos 
for treatments of serious diseases invoked many different responses. Many o f those who 
disagreed with creating embryos for treatment also disagreed with creating embryos for 
research purposes. This was unsurprising. As has been commented upon several times by 
the author of this work, the polarisation of views over the use o f embryos for reasons 
other than for treating infertility means that embryo research will always be contentious.
Of those who felt that it was desirable to allow the creation o f embryos for 
treatment purposes, the reasoning seemed to be that it was illogical that embryos could be 
used for research into treatments for diseases, and yet, once we reached the clinical trials 
and treatment stage of the process, the use of embryos for treatments may not have been 
permissible. There were of course calls for such use to be supported by evidence; after all 
there was still the feeling, even amongst the advocates of embryo research, that excessive 
numbers of embryos should not be used where this was not necessary. We would not 
want to see embryos being created for treatment purposes when there is inadequate 
evidence supporting the use of embryos in such treatments.
Review of the Human Fertilisation and Embryology Act: Proposals for revised 
legislation 
Research involving embryos
Within the section of the White Paper concerning the reformation of the sections 
of the HFE Act which deal with research upon human embryos, it was made very clear
522 R (on the application o f  Quintavalle) v Secretary o f  State fo r  Health [2001] 4 All ER 1013, [2002] 2 All 
ER 625 (CA), [2003] 2 All ER 113 (HL) Discussed in Chapter 3
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that the Government did not intend to reopen the debate on “ ...the permissibility o f  the 
creation and use o f  embryos for research... ” as it is one o f the fundamental principles of 
the legislation that such research is permitted to be performed “...within limits and 
subject to regulatory oversight. ”523 Whilst the basic limits will not be altered, such as the 
fourteen day limit on developing embryos in vitro, the Government did propose to make 
some amendments to the Act “...to ensure that legitimate research can continue to 
flourish, and that controls remain up to date. ”524
There were no radical changes suggested to be made to the list o f research 
purposes as contained within the HFE Act, although there was the suggestion that the new 
legislation should make it very clear that basic research as well as applied research was 
permissible, obviously still subject to the controls contained within the legislation. So 
at this point we can see that the Government had listened to the respondents o f the Public 
Consultation and would take steps to ensure that basic research was specifically referred 
to in the new legislation. This was a complete turnabout on the Government position 
which was insistent that basic research was covered by legislation and that there was no 
need to explicitly refer to it in the proposed new legislation.
There was the additional intention to broaden the permitted research purposes 
beyond ‘increasing knowledge about serious disease ’ to also include research into serious
• • 526  •injuries. The term ‘serious disease’ is not defined within the current legislation and 
there was no suggestion that a definition would appear in the revised legislation. It has 
been suggested that the Government could provide a list o f diseases which warrant 
human embryonic stem cell research; this list would not be exhaustive and so would not 
exclude diseases from research but would help to provide guidance for the regulator as to 
the diseases which are ‘serious’ and therefore the regulator could permit human embryo 
research and/or human embryonic stem cell research which specifically looks at these 
diseases.527
523 Review o f the Human Fertilisation and Embryology Act: Proposals fo r  revised legislation (including 
establishment o f  the Regulatory Authority fo r  Tissue and Embryos) (2006) Department o f  Health CM 6989 
at Para 2.72
524 Ibid. at Para 2.72
525 Ibid. at Para 2.74
526 Ibid. at Para 2.74
527 Discussion between Professor Ruth Chadwick, Professor David Miers, Professor Soren Holm and the 
author on the 26th July 2007
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An example of a disease which is considered to be ‘serious’ by the HFEA and
• 528warrant the use of embryos in research is research into mitochondrial DNA disease. 
Other examples of ‘serious’ disease may include Alzheimer’s and diabetes. In 
comparison diseases which may not be considered to be serious would be those which 
already have acceptable and cheap treatments such as an under-active thyroid and 
eczema. If such a list was introduced it would be vital that it was not exhaustive as the 
term ‘serious’ is very difficult to define. Equally a disease which may appear on the ‘non- 
serious’ list could require the HFEA to grant a research licence should a researcher later 
demonstrate the seriousness of it. Definitions and perceptions can change over time as do 
medical opinions and knowledge, therefore should a list o f diseases be provided it must 
be flexible and open to interpretation and alterations. When considering what constitutes 
a ‘serious’ disease or condition that warrants the use of human embryos are we concerned 
with the effect that the disease or condition has upon a person or the number of people 
which are affected by it? Can we only justify the use of human embryos in research when 
the results of that research will potentially benefit thousands or millions of people or is it 
acceptable to use human embryos when only a handful o f people will benefit from such 
research? Arguably it is both types of situations, provided that the effects of the disease 
or condition are sufficiently serious so as to warrant the use human embryos, the number 
of people to benefit from the research is irrelevant.
Creation of embryos for therapeutic use
The creation of embryos for research purposes is permitted under the HFE Act 
and that will continue under the new revised legislation. The situation could arise in the 
future that a therapy may require the creation of embryos which would be used for the 
direct benefit of a patient.529 The use of embryos to directly benefit a patient would take 
this outside of the realm of research into the realm of treatment and the regulator would 
not be able to license such work.
528 Current research projects HFEA http://www.hfea.gov.uk/en/374.html (accessed 23/10/08)
Review o f  the Human Fertilisation and Embryology Act: Proposals fo r  revised legislation (including 
establishment o f  the Regulatory Authority fo r  Tissue and Embryos) (2006) Department o f  Health CM 6989  
at Para 2.79
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There was no immediate resolution to this possible problem within the White 
Paper, the suggested solution was to keep the issue under review and to debate this 
particular question during the passage of the new legislation.
The Government would need to be careful in wording any provision relating to 
embryos for therapeutic use in the new revised legislation. The Government would need 
to ensure that any such provision will allow the legislation to be adapted as the 
Government sees fit when this situation arises. It is not so much a question o f ‘i f  this 
situation arises, but when. This is due to the ongoing human embryonic stem cell research 
work that is being undertaken. There is a high possibility that a situation may arise 
whereby a patient requires human embryonic stem cells for treatment which would 
require the use (and destruction) of embryos to obtain those stem cells for the direct 
benefit of a patient. This is the goal that scientists and researchers are working towards. 
WTiilst some patients may need specific types of embryos to be used to create stem cells 
for their use, other patients may require stem cells more generally, but both types of 
situation will require the creation of embryos for therapeutic use.
As will be seen in the next Chapter the issue of creating embryos for therapeutic 
use was set aside for debate at a later date.
The Human Fertilisation and Embryology Authority Response to the 
Department of Health’s consultation on the Review of the Human 
Fertilisation and Embryology Act
The Human Fertilisation and Embryology Authority responded to the Department 
of Health’s consultation on the Review of the Human Fertilisation and Embryology Act 
1990 on the 24th November 2005.
In respect of the discussion above of the suggestions contained in Section Two: 
Model and Scope o f Regulation, concerning the definition and use o f human embryos, 
gametes, eggs and sperm, the HFEA was in agreement with all o f the Government 
suggestions on these points.
530 Ibid. at Para 2.80
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The HFEA was also in agreement with the Government that research upon
embryos created by the cell nuclear replacement technique should be permitted where
•  • 1that research is for the purpose of studying mitochondrial disease.
The HFEA in its response to the desirability o f creating embryos for the treatment 
of serious diseases, as opposed to the research into serious disease which is already 
permitted, opened this question up for further public debate. The HFEA recognised that it 
can be implied from the explicit permission to create embryos for research that the 
creation of embryos for treatment was also permitted but it equally recognised that this 
was an issue which needed wider public debate, as well as the appropriate regulatory 
framework for these treatments.532
This need for further public debate into the issue of creating embryos to derive 
stem cells for the treatment of patients is an important one. Besides the ethical issues 
which would undoubtedly re-arise in this debate, issues such as access to treatments, 
payment for these treatments and how to separate embryonic from non-embryonic 
treatments is an important debate which needs to happen. It was very interesting to note 
that the HFEA also raised the regulation of these treatments; it specifically recognised in 
the introduction that “The HFEA regulates the generation o f  embryonic stem cell lines 
but does not regulate the use o f  embryonic stem cell lines once established. ”533 This is an 
issue which has been raised and discussed elsewhere in this thesis.
Conclusion
The House of Commons Science and Technology Committee conducted a 
thorough review of the HFE Act and the regulatory body, the HFEA. It can be 
commended for clearly identifying the areas of the law which require reform.
A review of the HFE Act was never going to be an easy task in light of the range 
of different topics that the legislation covers and the advances in science which have been 
made over the last 18 years. A public consultation was a correct first step in this review; 
the public want to be consulted on these matters which it views as fundamental to society.
531 Response by the Human Fertilisation and Embryology Authority to the Department o f  H ealth ’s  
consultation on the Review o f  the Human Fertilisation and Embryology A ct 05/33273 HFEA 24th 
November 2005 at pg 38 Available at:
http://www.hfea.gov.uk/AboutHFEA/HFEAPolicv/ReviewoftheHFEAct (accessed 11/4/06)
532 Ibid. at pg 41
533 Ibid. Introduction, Page 4
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The Consultation Document can be criticised though for not taking into account 
the basic research aspect of the research purposes, regardless of the fact that the 
Government believed that basic research was covered by the legislation. It should have 
sought comments upon this aspect as it was foreseen to be a possible stumbling block in 
future legislation if it was not adequately addressed. Although the Government made an 
about turn in the White Paper concerning the specific inclusion o f basic research in the 
new legislation, it would have been advisable to have sought the public opinion on this 
specific matter in the Public Consultation. It would have been useful so as to help guide 
the Government on how to explicitly approach this matter in the new legislation. The 
Government could also have taken the opportunity to overhaul the licensing system 
which has been criticised as bureaucratic, time consuming and has problems with 
overlap. Although there are some areas which do need further reform at least the 
Government recognised the need to overhaul the definition o f a human embryo and had 
also taken steps to define human gametes. It is to be hoped that the final definition (as 
discussed in the following chapter) will stand the test of time, unlike the current statutory 
definition.
When dealing with the sensitive subject of embryos it was inevitable that such a 
range of responses would have been submitted to the Consultation. In discussing the 
responses at the time of publication of the Report it was difficult to come to any clear 
conclusions as to what direction the Government would take in forming the new 
legislation. There are no conclusions within the Report as it is designed as merely that, a 
Report outlaying the responses which were received by the Department of Health in its 
Consultation on the review of the HFE Act. At the time, how the Government would 
respond was not easy to foresee, the Draft Bill was eagerly awaited following the 
Consultation to see exactly how the Government listened, and responded, to the concerns 
raised.
The speed at which science is progressing particularly in the field of human 
fertilisation and embryology is astounding. Barely ten years after the enactment of 
legislation designed to regulate this new and developing area o f science, the scientific 
leaps forward required the current legislation to be amended (in the form of the 2001 
Regulations) and new legislation to be introduced (the Human Reproductive Cloning Act 
2001).
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There was undoubtedly a need to revise the current legislation so as to continue 
the work started under the Human Fertilisation and Embryology Act 1990, to provide a 
legal framework within which scientific progress was encouraged but controlled. The 
path to complete reformation of the Act was a long one and is only just completed. The 
final stages in the reform process and the new legislation are discussed in the next 
Chapter.
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Chapter 8 - A New Act
Following the extensive reform process which has been undertaken by the UK 
Government, the Human Fertilisation and Embryology Act 1990 has been overhauled by 
the enactment of the new Human Fertilisation and Embryology Act 2008 which will 
come fully into force in October 2009. The legislation has only recently received Royal 
Assent after a lengthy reform process; a Draft Bill was published for pre-legislative 
scrutiny on the 22nd May 2007 and a subsequent report from the Joint Committee on the 
Human Tissue and Embryos (Draft) Bill was published on the 1st August 2007. The 
Government then issued a response to the Joint Committee Report and a new version of
ththe Bill was debated in the Houses of Parliament. This Chapter is up to date as of the 13 
November 2008 following the Royal Assent of the Human Fertilisation and Embryology 
Act 2008 534 Controversially the Third Reading of the Bill in the House of Commons was 
suddenly delayed by four months. Scheduled for the 14th July 2008 the announcement 
was only made on the 11th July that the debate was delayed until October. One reason 
which it was speculated for the delay was an upcoming election in Glasgow. Harriet 
Harman MP however insisted that the Bill had been delayed to allow more time to debate
• 535 •it. The reality was that when the debate was rescheduled for October the Government 
deliberately gave the debate limited time. This was to prevent the Bill from being delayed 
further due to many Members of Parliament wanting greater debate on the provisions 
relating to abortion.536 Finally, following the debate in the House o f Commons and the 
subsequent minor amendments, the Bill received Royal Assent one year after it was 
introduced. Whilst the outcome is now known it is important to examine the last few 
steps in the reform process to understand the content o f the New Act when it comes into 
force and how it will regulate human embryonic stem cell research.
534 Hansard -  House o f  Lords, 13th November 2008, Royal Assent — Human Fertilisation and Embryology 
Act 2008, Vol 705, Col 832 Hereafter referred to as the HFE Act 2008
535 Watt, N and Stratton, A., Health ministers stunned by embryo bill delay 11th July 2008 The Guardian 
http://www.guardian.co.Uk/politics/2008/iul/l 1/health.houseofcommons/print (accessed 11th July 2008)
For example refer to the comments made by Norman Lamb, Hansard -  House o f  Commons, Human 
Fertilisation and Embryology Bill, 22nd October 2008, Volume 480, Column 410
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The Human Tissue and Embryos (Draft) Bill
It is necessary to examine the Human Tissue and Embryos (Draft) Bill in detail in 
order to understand the future regulation of, and consequences for, human embryonic 
stem cell research under the HFE Act 2008.537
As with the HFE Act 1990 the Draft Bill dealt with a broad spectrum of issues 
relating to fertility and embryology. In fact the name of the Draft Bill was somewhat 
misleading as it did not deal specifically with the fine detail o f  regulating human tissue. 
Rather the regulation of human tissue was only referred to in respect o f the proposed 
merger of the HFEA and the HTA which has been mentioned briefly in the preceding 
chapter and was subsequently abandoned. The legislation pertaining to human tissue, 
such as the retention of human organs, remained unaffected.
There are only parts of the Draft Bill which are of relevance to human embryonic 
stem cell research. These included amongst others; the definition of ‘embryo’ and 
‘gamete’, legal prohibitions, activities which may be licensed and the permitted research 
purposes. The Draft Bill also referred to inter-species embryos, those created with a non­
human element, the creation of which could have implications for human embryonic stem 
cell research. Each relevant part is examined and discussed in detail below.
Meaning of ‘embryo’ and ‘gamete’, prohibitions and permissions
The definition of an embryo has been altered to take into account the alternative 
ways o f creating embryos, such as the cell nuclear replacement technique. As such the 
proposed definition o f an embryo was as follows:
(a) embryo means a live human embryo and does not include an inter-species 
embryo...
(b) references to an embryo include an egg in the process o f  fertilisation or is 
undergoing any other process capable o f resulting in an embryo.538
537 Human Tissue and Embryos (Draft) B ill (2007) Department o f  Health CM7087 http://www.official- 
documents.gov.uk/document/cm70/7087/7087.pdf (last accessed 05/07/08) Hereafter referred to as the 
Draft Bill
538 Ibid. at Part 2, Clause 14, sub clause 2
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By not specifically naming the alternative processes by which it may be capable 
of forming an embryo, the Government had potentially avoided the definitional legal 
challenges which have caused problems within the current legislation. The broader 
definition to include ‘any other process capable o f  forming an embryo ’ should cover any 
new process which may arise in the future and which has not yet been discovered by 
scientists or tried with human embryos.
Problems may however arise in respect o f the proposed definition for human 
gametes. The proposed definitions were:
(a) references to eggs are to live human eggs, including cells o f  the female germ 
line at any stage o f maturity, but...not including eggs that are in the process o f  
fertilisation or are undergoing any other process capable o f  resulting in an 
embryo,
(b) references to sperm are to live human sperm, including cells o f  the male germ 
line at any stage o f maturity, ...540
The problem which could potentially arise in respect of the definitions of human 
gametes is the issue of artificial gametes or in vitro derived gametes as they are also 
referred to. Artificial gametes are those which are created from stem cell lines. If the 
proposed definitions were strictly applied then artificial gametes would fall into the 
definitions and could be used to create human embryos. This may be o f particular use for 
further stem cell research or even testing o f drugs or techniques upon embryos. What 
needs to be questioned is the intention o f Parliament. Is it the intention of Parliament that 
artificial gametes, and embryos created from artificial gametes, are used for research 
purposes only or could they also be used for reproductive purposes?
The intention o f Parliament was not clear from the Draft Bill when examined in 
greater depth. To replace the Human Reproductive Cloning Act 2001 the Draft Bill 
proposed to amend the section titled ‘Prohibitions in connection with embryos’ contained 
within the HFE Act to prevent placing in a woman “an embryo other than a permitted
539 For a discussion o f  the different ways o f  creating embryos refer to Hammond, N  and Holm, S.,
Resolving the “egg supply problem  ” in human embryonic stem cell derivation through technical means -  a  
legal and ethical analysis 27(1) Medicine and Law (2008) p g l67
540 Human Tissue and Embryos (Draft) B ill (2007) Department o f  Health CM7087 at Part 2, Clause 14, sub 
clause 4
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embryo...or any gametes other than permitted eggs or sperm ...”541 This appears 
straightforward until one looks at the definitions of permitted egg, sperm and embryo.
A permitted egg is one -
(a) which has been produced by or extractedfrom the ovaries o f  a woman, and
(b) whose nuclear or mitochondrial DNA has not been altered.
Permitted sperm are sperm -
(a) which have been produced by or extractedfrom the testes o f  a man, and
(b) whose nuclear or mitochondrial DNA has not been altered.
An embryo is a permitted embryo i f—
(a) it has been created by the fertilisation o f  a permitted egg by permitted sperm, 
and
(b) no nuclear or mitochondrial DNA o f  any cell o f  the embryo has been 
altered542
This would also appear to be clear at first sight, eggs and sperm must come from 
the reproductive organs o f men and women and embryos which are to be used for 
reproductive purposes can only be created from these permitted gametes. However, the 
argument could be made that as embryonic stem cells are extracted from embryos which 
have been created using ‘permitted’ eggs and sperm i.e. have been extracted from the 
ovaries and testes, and the embryonic stem cells are then differentiated into artificial 
gametes, it could then be argued that these artificial gametes are ‘permitted’ gametes as 
they technically originate from the ovaries and testes o f humans.
This interpretation of the legal definition may be argued for if  the use of artificial 
gametes becomes a realistic treatment for infertile couples. The argument will arise in the 
future that we should allow people to use artificial gametes for reproductive purposes 
where necessary. The use of artificial gametes to create embryos for research does not 
appear to be an issue here as the researchers would not be attempting to implant the 
embryos created by artificial gametes.
This interpretation is not one that the Government is keen upon. In fact in the 
Explanatory Notes to the Draft Bill it was stated that Clause 16 ‘Prohibitions in 
connection with embryos’ “ ...ensures that other form s o f  embryos or gametes including
541 Ibid. at Part 2, Clause 16, sub clause 2
542 Ibid. at Part 2, Clause 16, sub clause 5
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artificial gametes ...cannot be placed into a woman.”543 Should the issue come to the 
Courts it is hard to predict the outcome. The Government made it clear in the Explanatory 
Notes that artificial gametes should only be used for research purposes. The problem is 
that there is no regulation making power contained within the Bill to allow for regulations 
in the future if or when the use o f artificial gametes for treatment purposes becomes 
desirable and safe.544
The derivation o f artificial gametes from non-embryonic stem cell lines for 
reproductive uses, such as those created from induced pluripotent stem cell lines, would 
be prohibited by the Bill in its current wording. Artificial gametes created from non- 
embryonic stem cells could not be used for reproductive uses as the stem cells from 
which they were derived are non-embryonic and so definitely did not use gametes from 
the ovaries or testes o f humans at any point in the process.
Chimera and hybrid embryos
Although not previously discussed in great detail earlier in this thesis it is 
important to note that the Draft Bill included provisions for the creation of hybrid and 
chimera embryos when permitted by a licence. These provisions are briefly mentioned 
here due to the possible implications which these types of embryos may have for human 
embryonic stem cell research. One problem currently afflicting the progress of human 
embryonic stem cell research is the lack of suitable oocytes to enable researchers to 
create embryos, either by IVF or by the cell nuclear replacement technique (note that this 
is permitted under licence where ‘spare’ IVF embryos are not suitable for the purposes of 
the research). A possible solution to this problem is to create embryos using the 
enucleated oocytes of animals, effectively providing a shell for human DNA.
Although the debate about using the resulting stem cells from these human/animal 
embryos is still to fully occur, the creation o f human/animal embryos could be very 
useful for human embryonic stem cell research. The reason for this is that researchers 
could perfect their techniques and skills in creating embryos, extracting stem cells and 
growing them in culture without using or wasting valuable human oocytes. There is no 
question that the debate about using stem cells extracted from human/animal embryos
543 Ibid. at Explanatory Notes, Paragraph 53
544 Thanks to Professor Emily Jackson for raising this point in her paper Artificial Gametes and the Law: 
Legal and Ethical Implications at the SLS conference 15th September 2008
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will be one that will greatly divide people; nonetheless the Government took steps to 
allow the creation of these human/animal embryos in five different forms in a bid to 
allow stem cell research to progress for the foreseeable future. Referred to as inter­
species embryos in the Draft Bill they could be created in the following ways:
(a) an embryo created by using human gametes and the gametes o f  an animal,
(b) an embryo created by replacing the nucleus o f  an animal egg or a cell derived 
from  an animal embryo with a human cell or the nucleus o f  a human cell,
(c) a human embryo that has been altered by the introduction o f  any sequence o f  
nuclear or mitochondrial DNA o f  an animal,
(d) a human embryo that has been altered by the introduction o f  one or more 
animal cells, or
(e) any other embryo that contains both —
(i) any haploid set o f  human chromosomes, and
(ii) any haploid set o f  animal chromosomes or any other sequence o f  
nuclear or mitochondrial DNA o f  an animal.545
According to the Draft Bill these inter-species embryos could only be created in 
pursuance of a licence and could not be implanted into a woman.546 As can be seen the 
Government attempted to cover all o f the possible methods for creating human/animal 
embryos. There was the risk that by taking this approach, as with the HFE Act, that it 
could lead to legal definitional challenges in the future if  scientists were to discover 
another new method for creating embryos not covered within these definitions. The 
appearance of Part (e) was designed to be a catch all provision, to ensure that the 
legislation governed any type o f embryo created with human and animal elements, even 
if the exact method did not correspond to the methods laid out in parts (a) -  (d). Although 
Part (e) was designed to catch all human/animal hybrids there was always the possibility 
of this all encompassing definition not actually including an embryo which may, for 
example, have its chromosomes manipulated, possibly by removing a chromosome or 
fusing two, in such a way as to make it fall out of the definition. Manipulation of the 
mitochondria could also result in an embryo falling outside o f the statutory definitions. 
The definition itself which was used in Part (e) was also hard to understand. As a non­
scientist the author of this thesis was unable to explain or understand clearly the 
definition in Part (e) and, as will be seen in the Joint Committee Report on the Draft Bill,
545 Human Tissue and Embryos (Draft) Bill (2007) Department o f  Health CM7087 at Part 2, Clause 17, sub 
clause 2(5)
546 Ibid. at Part 2, Clause 17, sub clause 2(1 )(b) and 2(2)
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scientists were also unable to explain the meaning of this provision. As noted by 
Professor Holm some of the definition contained in (e)(ii) can be found in part (c) but can 
you say that any of part (c) is found in part (e)(ii)?547 The provision just made no sense.
There was also the risk that by specifically stating that an inter-species embryo 
may not be placed into a woman that a scientist may try to get around this prohibition and 
implant the inter-species embryo into an artificial womb. Although the Draft Bill also 
prohibited “ ...the keeping or using o f an inter-species embryo after... the appearance o f  
the primitive streak, or... after 14 days”548 if a scientist was to attempt to implant an inter­
species embryo into an artificial womb, he may try to do so before the fourteen days had 
expired (or the primitive streak had appeared) and may also have attempted to continue 
any resulting pregnancy in breach o f the law. While it would be hoped that no scientist 
working within the UK would attempt this, and that his or her co-workers would report 
any suspected breach as serious as this, there is the possibility that this could happen. The 
Courts would be likely to take a liberal interpretation of the legislation so as to ensure 
that any scientist who did implant an inter-species embryo into an artificial womb would 
be subject to the Act. While a scientist may argue that they were not ‘keeping or using an 
inter-species embryo after the appearance of the primitive streak or after 14 days’ a judge 
could be persuaded to view an artificial womb as just another container, thereby the 
scientist would be ‘keeping it.’549
The impetus for the inclusion of inter-species embryos into the Human Tissue and  
Embryos (Draft) Bill was two research licence applications to the HFEA by scientists 
working separately at King’s College London and the Newcastle Centre for Life. 
Decisions on the applications were delayed by the HFEA which deferred judgement to 
the Government. Initially the Government did not want to permit the use o f inter-species 
embryos in human embryo research but had a change of perspective following the House 
of Commons Science and Technology Select Committee Report.550 Whilst there is the 
potential o f inter-species embryos to aid the progress and development o f human 
embryonic stem cell research it was felt that this was an area which needed further
547 Raised in a meeting with Soren Holm, 21st November 2007
548 Human Tissue and Embryos (Draft) Bill (2007) Department o f  Health CM 7087 at Part 2, Clause 17, sub 
clause 2(3)
549 Thanks to Soren Holm for raising this point
550 Government Proposals fo r  the regulation o f  hybrid and chimera em bryos Fifth Report o f  Session 2006- 
07, House o f  Commons Science and Technology Select Committee Report HC 272-1 (April 2007) 
http://www.publications.parliament.uk/pa/cm200607/cmselect/cmsctech/272/272i.pdf (accessed 5/9/07)
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discussion and consideration, not least due to the wording contained within the Draft Bill 
which could have led to legal challenges in the future. King’s College London and the 
Newcastle Centre for Life have both recently received licences to carry out research on 
human/animal chimeric embryos and a third centre at the University of Warwick, which 
proposes to use pig eggs but to replace the animal mitochondria as well as the nucleus, 
has just had its licence application approved.551
Permitted research purposes
The requirement that research may only be licensed where it is ‘necessary or 
desirable for a research purpose’ was retained within the Draft Bill although the situations 
in which it may be ‘necessary or desirable’ were increased. The Draft Bill proposed three 
sections which all referred to research being ‘necessary or desirable’. These were:
(1) A licence ...cannot authorise any activity unless the activity appears to the 
Authority -
(a) to be necessary or desirable fo r  any o f the purposes specified in sub- 
paragraph (2) ( uthe principal purposes ”),
(b) to be necessary or desirable fo r  the purpose o f  providing knowledge that, in 
the view o f  the Authority, may be capable o f  being applied fo r  the purposes 
specified in sub-paragraphs (2) (a) or(b), or
(c) to be necessary or desirable fo r  such other purposes as may be specified in 
regulations552
As will be seen in the following discussion the purpose o f part (b) above was to 
ensure that any research into human embryonic stem cell research which may require 
basic research to be performed would be covered by the licensing system. The 
Government had previously stated that the research purposes contained in the HFE Act 
included basic research. This has been one criticism of the current research purposes in
551 HFEA Licence Committee Minutes for R 0179 Newcastle -
http://www.hfea.gov.uk/docs/HFEA Licence Committee minutes for R0179 Newcastle - 
November 2007 and January 2008.pdf 
HFEA Licence Committee Minutes for RO180 Kings
http://www.hfea.gov.uk/docs/HFEA Licence Committee minutes for RO179 Newcastle - 
November 2007 and January 2008.pdf 
University o f  Warwick, Project title: The generation o f  human embryonic stem cells by transferring a  
human cell into recipient p ig  eggs http://www.hfea.gov.uk/en/l 699.html (last accessed 05/07/08)
552 Human Tissue and Embryos (Draft) Bill (2007) Department o f  Health CM 7087 at Schedule 2, paragraph 
6, subparagraph 3A(1)
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that it was not explicitly stated that basic research upon embryos was permitted where 
this research was necessary for the progress of stem cell research.
Part (c) above is a continuation of the current regulation making power contained 
in Schedule 2, paragraph 3(2) of the HFE Act. As evidenced by the necessity of the 
Government to expand the permitted research purposes through the use o f regulations so 
as to include human embryonic stem cell research it was important that this regulation 
making power was continued.553 After all, the scientific progress in the field o f human 
fertilisation and embryology is one that cannot be predicted, the use of regulations would 
have allowed the Government to keep the new legislation up to date, should the need 
have arisen to amend the research purposes.
The purposes for which a research licence may be granted were proposed to be:
(a) increasing knowledge about serious disease or other serious medical 
conditions,
(b) developing treatments fo r  serious disease or other serious medical 
conditions,
(c) increasing knowledge about the causes o f  any congenital disease or any 
congenital medical condition that does not fa ll within paragraph (a),
(d) promoting advances in the treatment o f  infertility,
(e) increasing knowledge about the causes o f  miscarriage,
(f) developing more effective techniques o f  contraception,
(g) developing methods fo r  detecting the presence o f  gene, chromosome or 
mitochondrion abnormalities in embryos before implantation, or
(h) increasing knowledge about the development o f  embryos.554
These were very similar to the current permitted research purposes contained in 
the HFE Act as amended by the 2001 Regulations. The permitted research purposes have 
worked well over the past two decades, they have ensured that valuable research has been 
allowed to continue whilst also ensuring that embryos have not been used unnecessarily 
for research.
Parts (c) -  (g) are basically the reiteration of the original research purposes as 
contained within Schedule 2, paragraph 3(2) of the HFE Act. There was the addition of 
‘mitochondrion’ to part (g), unsurprising considering the increased knowledge about the 
role of mitochondrion in the developing embryo. Although the addition o f mitochondrion
553 Human Fertilisation and Embryology (Research Purposes) Regulations 2001 SI 2001/188
554 Human Tissue and Embryos (Draft) Bill (2007) Department o f  Health CM 7087 at Schedule 2, paragraph 
6, subparagraph 3A(2)
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to part (g) was at first sight unsurprising it is actually superfluous since what is looked for 
is mitochondrion gene abnormalities and would be covered by the ‘gene abnormality’ 
provision which was already contained within part (g).555
Parts (a), (b) and (h) were very similar provisions to those found in the 2001 
Regulations. The 2001 Regulations read as:
(2) A licence may be issued fo r  the purposes o f  -
(a) increasing knowledge about the development o f  embryos;
(b) increasing knowledge about serious disease, or
(c) enabling any such knowledge to be applied in developing treatments fo r
serious disease.556
The provisions have been altered slightly, whereas the 2001 Regulations merely 
refer to ‘serious disease’ the Draft Bill referred to not only ‘serious disease’ but also 
‘other serious medical conditions’. Potentially this greatly broadened the areas into which 
research could be performed using human embryos. There was also the issue as to what 
exactly constituted ‘serious’. The Draft Bill, like the Act before it, did not define ‘serious’ 
thereby giving no guidance to the regulator as to how to judge whether a disease or 
medical condition was serious enough to warrant research using human embryos. It has 
been suggested that a list of appropriate medical diseases and conditions could be 
provided in the new legislation, with the explicit wording that such a list was not 
exhaustive, thereby not excluding research into diseases not on the list.557 Although such 
a list could be possible it would also be very subjective, what one person considers 
serious, another person may not. Does a disease have to afflict a certain number o f people 
before it is considered to be ‘serious’? Is the affliction of two people sufficient? Is it the 
effect that a disease has which needs to be solely considered? Or is it both types of 
situation? This is the risk with not only a list, but also guidelines as to what constitutes 
‘serious’. Some guidance would be advisable, particularly as the permitted research 
purposes now allow research into not only serious disease, but also serious medical 
conditions. Although ‘serious’ was not defined the extension to include ‘other serious 
medical conditions’ was an important one as it permitted research into conditions which 
are not considered to be diseases but which warranted research, for example brain injury.
555 Thanks to Soren Holm for clarifying this point
556 Human Fertilisation and Embryology (Research Purposes) Regulations 2001 SI 2001/188
557 Suggestion from Professor David Miers, meeting 26th July 2007
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It would appear that a licence for research could be given if  only one person was 
suffering from a disease so long as they were affected seriously. The difficulty with using 
a term such as ‘serious’ is that it is open to interpretation; o f course this could be 
deliberate so that the regulator has flexibility in deciding what is serious enough to 
warrant the use of human embryos for research. Whilst ‘serious’ is difficult to define in 
everyday language, within the context of the legislation it could eventually reach a 
particular meaning. An analogy is the term ‘grievous’; this word is difficult to define as
• 558used in everyday language, but within the Criminal Law it has a legal meaning.
Part (b) of the permitted research purposes contained in the Draft Bill repeated 
one of the provisions found in the 2001 Regulations although it was subjected to a slight 
rewording. The current wording of subsection (c) of the 2001 Regulations, if  strictly 
interpreted, appears to allow knowledge to be used to develop treatments for serious 
disease, but not the application of those treatments. By omitting the wording ‘enabling 
any such knowledge to be applied’ the new proposed section appeared to allow the 
development o f treatments, which would include the testing and application o f those 
treatments. While this is a minor change in terms of words, it could possibly be a major 
change in respect of the potential treatments which may arise from human embryonic 
stem cell research.
Part (h) o f the proposed permitted research purposes was identical to that o f Part
(a) o f the 2001 Regulations. Increasing knowledge about the development of embryos is 
vital for human embryonic stem cell research, researchers may discover new ways of 
extracting the stem cells without destroying or damaging the human embryo, they may 
even find that stem cells are best to be extracted at a different time to which they are 
currently extracted (five to six days development). In fact it has been shown that it is 
possible to perform a single cell biopsy of embryos to extract stem cells without the 
destruction of that embryo.559 Other developments may also be found in researching the 
development of human embryos, which may have implications for human embryonic 
stem cell research, infertility treatments or an area not currently in the minds o f 
researchers and legislators alike.
558 Thanks to Soren Holm for raising this point
559 Klimanskaya, I., et a l Human embryonic stem cell lines derivedfrom  single blastom eres 444 Nature 
481-485
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As the current permitted research purposes were generally well received and 
accepted by the public and scientists alike, there was no great impetus to change 
dramatically the research purposes in any new legislation which was forthcoming. It was 
for this reason that the changes made were minor tweaks, explicitly allowing that which 
the Government had said was permitted under the current legislation but which is not 
clearly stated in the wording.
Conclusion
Whilst it was clear that the HFE Act was in need of updating to keep pace with the 
fast moving scientific developments being made, particularly in the field of embryo 
research, the Draft Bill which was put forward by the Government was not without its 
problem areas. Definitional questions and working procedures all required further 
detailed consideration and it was to be hoped that by placing the Draft Bill for legislative 
scrutiny prior to the publication of a Bill for debate, that the Government listened to the 
concerns which were raised, took them on board and adjusted the Bill as required. The 
need for legislative scrutiny was recognised and as such a Joint Committee on the Human 
Tissue and Embryos (Draft) Bill was established. Its findings are discussed below.
Report from the Joint Committee on the Human Tissue and Embryos 
(Draft) Bill
The Joint Committee on the Human Tissue and Embryos (Draft) Bill was 
appointed at the start of May 2007 “to consider and report on any draft Human Tissue 
and Embryos Bill ”560 The Draft Bill was presented to Parliament on the 17th May 2007 
and the Joint Committee published their report on the 1st August 2007.561 The Joint 
Committee had a limited amount of time to complete their inquiry and produce the 
Report and as such concentrated upon the issues which were most likely to cause 
problems if and when the Bill was published in full (note that the Bill under discussion 
here is the Draft Bill which was published for pre-legislative scrutiny in May 2007 to
560 Joint Committee on the Human Tissue and Embryos (Draft) Bill Volume I: Report HL Paper 169-1, HC 
Paper 630-1 at Para 1. Hereafter referred to as the Joint Committee
http://www.publications.parliament.uk/pa/it200607/itselect/itembrvos/169/169.pdf (last accessed 05/07/08)
561 Ibid.
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enable these issues to be discussed and amendments to be made to the Draft Bill as 
necessary prior to publication of the Bill proper).
The Joint Committee Report was not wholly supportive of the Draft Bill; the Joint 
Committee was particularly scathing o f the proposal to establish RATE. RATE has not 
been discussed in any great detail due to the Government decision not the merge the 
HFEA and the HTA. This decision was taken by the Government following this Report 
from the Joint Committee.562 Readers interested in the criticisms raised against RATE 
should refer to the Joint Committee Report.
Definitions 
Embryo and gamete
The Joint Committee was supportive of the broad definitions placed before 
Parliament by the Government as in the view of the Joint Committee, broad definitions 
would “...allow the regulator appropriate flexibility in the exercise o f  its regulatory 
functions, yet [will be] certain enough that both the regulator and the scientific 
community can be reasonably confident about the legal boundaries o f  their actions. ”563
The Joint Committee also noted the concerns which had been raised about the 
definition of ‘embryo’ and ‘gametes’ as contained within the Draft Bill, particularly that 
there was concern that the definitions did not make scientific sense and that the breadth of 
the definitions was unclear. As a solution to this the Joint Committee recommended 
following these definitions but that the detail as to how the definitions were to be applied 
should be left to the regulator.564
The issue of interpretation raised above by the author of this thesis in respect of 
artificial gametes was not addressed by the Joint Committee and so it appeared that this 
would be an issue for the regulator or the Courts to decide as and when the situation 
arises particularly if  the matter was not fully resolved within the new legislation. As will 
be seen in the later discussion of the HFE Act 2008, Parliament believes that it has made
562 Ibid. at Para 92
Government Response to the Report from  the Joint Committee on Human Tissue and Em bryos (Draft) Bill 
(2007) Department o f  Health CM 7209 at Para 16
563 Joint Committee on the Human Tissue and Embryos (Draft) Bill Volume I: Report HL Paper 169-1, HC 
Paper 630-1 at Para 132
564 Ib id  at Para 138
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it clear that artificial gametes cannot be used for treatment purposes under the definitions 
contained within the Act.
Inter-species embryos
The issue of inter-species embryos was “ ...one o f  the most contentious... ” for the 
Joint Committee.565 The Joint Committee noted that in contrast to the wide definitional 
approach taken towards defining ‘embryo’ and ‘gamete’ the Government had listed the 
known methods of creating inter-species embryos and had also provided for the future 
with a catch all provision.566
The Joint Committee was highly critical of the approach taken by the Government 
in outlining the licensable methods of creating inter-species embryos as well as providing 
the catch all provision. Concerns were raised about the prospect of embryos being 
regulated by both the human embryo regulator and the Home Office through the Animal 
(Scientific Procedures) Act 1986 as well as the lack o f clarity as to what makes an 
embryo ‘human’, what is the required level of human genetics which must be apparent in 
the embryo before it is deemed human rather than animal? When considering that an 
embryo must be 50% human, for example, what specifically does the 50% refer to?567
The catch all provision was heavily criticised particularly in light of the fact that 
none of the witnesses could understand or explain what this provision meant!568 As the 
Joint Committee correctly stated "...this is a fundamental flaw  in the Government's 
approach to the definition o f  inter-species embryos. ”569
While it is noted that the Joint Committee could not come to a consensus on the 
use of inter-species embryos for research, and as such the issue should be put to a free 
vote in both Houses o f Parliament, the Joint Committee strongly recommended that 
“ ...the Government should revisit its approach to the definition o f  inter-species embryos 
in the draft Bill with a view to providing a general definition...with authority given to the 
regulator to interpret and apply that definition to individual research applications, based 
on the principles set out in legislation... ”570
565 Ibid. at Para 142
566 Ibid. at Para 144
567 Ibid. Refer to Paragraphs 162-169
568 Ibid. Refer to Paragraphs 162 and 173
569 Ibid. at Para 162
570 Ibid. at Para 178
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A broader definition of an inter-species embryo would bring the definitions 
relating to all embryos and gametes into line with each other (in the sense that the 
approaches would be the same, not that the definitions would be identical). It would also 
avoid possible future legal challenges over the definitions provided for in the legislation, 
as has occurred in the past with the HFE Act, and would give the discretion to the 
regulator to licence research using inter-species embryos where it was considered 
appropriate and necessary. The regulator could look at each research application and 
consider the method of creating the inter-species embryo and then decide if the creation 
of inter-species embryos was desirable and necessary for that research project. This 
would have allowed the regulator to consider each method of creating inter-species 
embryos as and when the question of research arose before them.
Licensable activities -  research licences
It was noted that the Joint Committee had insufficient time to consider in detail 
the licensable activities as proposed in the Draft Bill; however, they had been able to 
concentrate upon a few important issues, including research licences.571
It was noted that significant changes had been made to the current arrangements, 
the extension to allow research into ‘serious medical conditions’ being one.572 The other 
significant change was that the new paragraph 3A(l)(b), which would allow the licensing 
of research “ ...for the purpose o f providing knowledge that...may be capable o f  being 
applied...”573 “...is intended to allow fundamental research...”574 There was clear 
support for the alterations to the research purposes, including “...the clarification that 
fundamental, as well as applied, research is licensable. ”575 In light o f the support for 
these alterations, and the lack o f evidence to the contrary that these alterations were not 
appropriate, the Joint Committee “...consider[s] the extensions to the existing research 
purposes to be sensible and [they] therefore support these provisions. ”576
571 Ibid. at Para 191
572 Ibid. at Para 206
573 Human Tissue and Embryos (Draft) Bill (2007) Department o f  Health CM7087 at Schedule 2, paragraph 
6, subparagraph 3A (l)(b)
574 Joint Committee on the Human Tissue and Embryos (Draft) Bill Volume I: Report HL Paper 169-1, HC 
Paper 630-1 at Para 206
575 Ibid. at Para 207
576 Ibid. at Para 208
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It was reasonable for the Joint Committee to support the extensions which had 
been made to the permitted research purposes, the alterations were relatively minor and 
the current research purposes were generally supported by those who favoured embryo 
research.
Government Response to the Report from the Joint Committee
577The Government issued its response to the Joint Committee in October 2007. 
The Government took on board the concerns raised by the Joint Committee, most notably 
in respect of RATE, as previously mentioned. An in depth discussion of the proposal to 
form RATE is not necessary here precisely due to the Government’s acceptance that 
RATE was opposed by the vast majority of the interested parties.
...the Government accepts the recommendation to reconsider the proposal to 
establish RATE. The Government will therefore amend the Bill to drop the 
proposal fo r  RATE.578
The Government also accepted the Joint Committee recommendations that the 
HFEA and the HTA could work together more effectively;
In accepting the Committee’s recommendation, the Government will be looking at 
the scope, without a fu ll legal merger, fo r  the two authorities to streamline 
regulation, fo r  instance through sharing support functions579
The HFEA and the HTA could work together more effectively and efficiently. It 
is interesting to note though that the Government specifically referred to the sharing of 
support functions as one way to streamline the work of both of the authorities. This move 
would not only streamline the work o f the authorities (or possibly mean the opposite, that 
the administrative staff are more overworked) but due to sharing support staff this would
577 Government Response to the Report from  the Joint Committee on Human Tissue and Em bryos (Draft) 
Bill (2007) Department o f  Health CM 7209
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicvAndGuidance/DH 0791 
27 (last accessed 05/07/08)
578 Ibid. at Para 16
579 Ib id  at Para 17
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reduce the running costs o f the two authorities, thereby still achieving the objective o f the 
Government to reduce the overall running costs o f its arms length bodies.580
O f note is the fact that the Joint Chair o f the HFEA and HTA, Shirley Harrison,
thannounced on the 17 October 2007 that she would step down as Chair o f the HFEA on 
the 1st November 2007 but would remain as Chair of the HTA. Walter Merricks CBE, a 
current HFEA member took over as Interim Chair of the HFEA.581 Professor Lisa Jardine 
was appointed on the 1st April 2008 as the new Chair o f the HFEA.582 Whilst this does 
take into account the fact that the Government would no longer take the necessary steps 
to establish RATE the continuance of a Joint Chair may have been one way to ensure that 
the two bodies worked closer together in the future.
Definitions -  Embryos, gametes and inter-species embryos
In respect o f the definitions appertaining to ‘embryo’ and ‘gamete’ the 
Government recognised the support of the Joint Committee towards the definitions, with 
the regulator deciding how to apply the definitions in practice.583
It then discussed the recommendations made by the Joint Committee to bring the 
definitions of inter-species embryos in line with the definitions used for ‘human embryo’ 
and ‘gametes’, in the sense that a general definition should be provided along with 
authority given to the regulator to interpret and apply those definitions in line with the 
principles set out in the legislation. The Government also considered the recommendation 
to include hybrid embryos specifically within the Bill. As such the Government altered 
the definitions to include hybrid embryos and to remove the catch all provision which no- 
one appeared capable o f understanding. A general definition for inter-species embryos 
was rejected. However, the new definitions along with the power o f the regulator to 
interpret and apply those provisions are an improvement upon the original Draft Bill.584
580 Reconfiguring the Department o f  H ealth’s A rm ’s Length Bodies 40378 (2004) Department o f  Health 
http://www.dh.gov.uk/prod consum dh/groups/dh digitalassets/@dh/@en/documents/digitalasset/dh 4098 
136.pdf (accessed 1/12/08)
581 Statement on HFEA Chair HFEA 17th October 2007 http://www.hfea.gov.uk/en/1601 .html (accessed  
30/01/08)
582 New Chair appoin tedfor HFEA HFEA 23rd January 2008 http://www.hfea.gov.uk/en/! 641 .html 
(accessed 26/06/08)
583 Government Response to the Report from  the Joint Committee on Human Tissue and Embryos (Draft) 
Bill (2007) Department o f  Health CM 7209 at Para 24
584 Ib id  at Para 25-35
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Licensable activities -  research licences
As the Joint Committee was supportive o f the amendments made to the licensable 
activities, or at least the relevant parts for this thesis, the Government made no further 
comment on this particular part of the Joint Committee Report.
The Human Fertilisation and Embryology Bill
The Human Fertilisation and Embryology Bill was published on the 8th November 
20 07 . 585 The New Bill was debated in Parliament for some time due to all the 
amendments. Three amended versions of the New Bill appeared during the process, one
thfollowing debate in the House of Lords (on the 29 January 2008) and two following 
debate in the House of Commons (on the 6th February and the 13th June 2008).586 On the 
23rd October 2008 the House o f Commons published a list o f amendments which were 
accepted by the House of Lords before the New Bill (as amended) was passed and 
received Royal Assent on the 13 November 2008. While this thesis is principally 
concerned with embryo research and the implications for human embryonic stem cell 
research the New Bill, as with the HFE Act 1990, deals with many contentious areas such 
as the need for a father in respect o f infertility treatment, provisions relating to surrogacy 
and confidentiality provisions. All o f these provisions took many hours of debate before 
the Bill was passed into legislation.
The provisions of the New Bill and amendments where appropriate will be 
discussed under the same headings as those in the Draft Bill: Meaning of ‘embryo’ and 
‘gamete’, prohibitions and permissions, chimera and hybrid embryos and the permitted 
research purposes.
585 Human Fertilisation and Embryology Bill [HLJ HL Bill 6, 54/3
http://www.publications.parliament.uk/pa/ld200708/ldbills/006/2008006.pdf (accessed 9/11/07) Hereafter 
referred to as the New Bill
586 Human Fertilisation and Embryology Bill [H L] HL Bill 25, 54/3
http://www.publications.parliament.uk/pa/ld200708/ldbills/025/2008025.pdf (accessed 30/01/08)
HL Bill 70, 54/3 http://www.publications.parliament.uk/pa/cm200708/cmbills/070/2008070.pdf (accessed  
08/02/08) HL Bill 120, 54/3 http://www.publications.parliament.uk/pa/cm200708/cmbills/120/2008120.pdf 
(accessed 04/07/08) Hereafter referred to as the January, February and June Bills respectively or Am ended  
Bills when referred to jointly
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Meaning of ‘embryo’ and ‘gamete’, prohibitions and permissions
The definitions of ‘embryo’ and ‘gamete’ which appeared in the Draft Bill appear 
in the same wording in the New Bill. However, in the January Bill the term ‘inter-species 
embryo’ has been replaced with the term ‘human admixed embryo’. Throughout the 
Amended Bills reference is made to the term ‘human admixed embryo’ which was 
previously referred to as an ‘inter-species embryo’. It was felt that the term ‘human 
admixed embryo’ was preferable to that of ‘inter-species embryo’ for the following 
reason:
It was fe lt that the word “human” should be used to indicate that these entities 
are at the human end o f the spectrum o f  this research.... The term “admixed” is 
preferable as it...is used in the chemical sciences to refer to a substance where 
two or more components are mixed in to each other ....This term... allows fo r  more 
focused debate on the research issues addressed in the Bill.581
Another amendment which was made was in respect of the definition of a 
‘permitted embryo’. The New Bill added a subsection so the definition included:
An embryo is a permitted embryo i f —
(c) no cell has been added to it other than by division o f  the embryo’s own 
cells588
This amendment was made as the Members of Parliament did not want to allow 
embryos to be implanted whose cellular makeup had been added to.
The New Bill retained the prohibition that No person shall place in a woman an 
embryo other than a permitted embryo or gametes other than permitted eggs or permitted 
sperm ’ (Proposed Section 3(2)(a) and (b)). There was no provision prohibiting the 
placing of an embryo (permitted or otherwise) from being implanted into an artificial 
womb. Whilst a scientist would in all likelihood be deemed to be ‘keeping’ an embryo 
beyond fourteen days if he was to do this, an express prohibition against the use of
587 Report Stage Human Fertilisation and Embryology Bill [HL] 15th January 2008, Volume 697, Column 
1183, Lords Hansard http://wvyw.publications.parliament.uk/pa/ld200708/ldhansrd/text/80115-0002.htm  
(accessed 29/01/08)
588 Human Fertilisation and Embryology Bill [H L] HL Bill 6, 54/3 Proposed Section 3ZA (4) 
http://www.publications.parliament.uk/pa/ld200708/ldbills/006/2008006.pdf (accessed 9/11/07)
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artificial wombs would have made this clear to all concerned that this is currently 
undesirable.
Interestingly the Government proposal within the Public Consultation to include a 
regulation making power in respect of the use of artificial gametes in treatment was not 
included in the New Bill probably due to the mixed response this suggestion received. If 
or when the use of artificial gametes becomes safe and desirable to use in treatment new 
primary legislation will need to be made.
Chimera and hybrid embryos
Additional amendments were made in the New Bill in respect o f the definitions o f 
inter-species embryos. The previous definitions were added to and expanded and Part (e) 
as contained in the Draft Bill was fortunately deleted altogether, showing that the
Government had listened to the many criticisms made about Part (e) mainly that no-one
understood what it meant. The section now reads as:
For the purpose o f  this Act an inter-species embryo is -
(a) an embryo created by using —
i. human gametes and animal gametes, or
ii. one human pronucleus and one animal pronucleus,
(b) an embryo created by replacing the nucleus o f  an animal egg or o f  an 
animal cell, or two animal pronuclei with -
i. two human pronuclei,
ii. one nucleus o f  a human cell, or
iii. one human cell,
(c) a human embryo that has been altered by the introduction o f  any
sequence o f  nuclear or mitochondrial DNA o f  an animal into one or
more cells o f  the embryo,
(d) a human embryo that has been altered by the introduction o f  one or 
more animal cells, or
(e) such other thing (sic) as may be specified in regulations.589
The inclusion of a section allowing for regulations to be made was a sensible one 
to add due to the rapidity with which science is progressing in this field, the 
permissibility of using regulations would have allowed the Government to keep the 
legislation up to date should new methods of creating inter-species embryos have arisen 
in the future.
589 Ibid. Proposed Section 4A (5)
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The definitions were again altered within the January Bill. Part (a) has become 
Part (b) in the January Bill, although the wording remained the same, as it did for Parts
(c)-(e). A change can be found in Part (a) of the January Bill definition o f a human 
admixed embryo (previously Part (b) in the New Bill). The section reads as:
For the purpose o f  this Act a human admixed embryo is -
(a) an embryo created by replacing the nucleus o f  an animal egg or o f  an animal 
cell, or two animal pronuclei, with -
i. two human pronuclei,
ii. one nucleus o f a human gamete or o f  any other human cell, or
Hi. one human gamete or other human cell,
590
Whilst the author of this thesis admits that these definitions are very technical and 
scientific it was important to see that the Government was taking seriously the proposals 
by scientists to undertake research with human and animal gametes, embryos and cells in 
a bid to push forward human embryonic stem cell research. The ethical debate 
surrounding the use o f these embryos for research was being debated in Parliament with 
concerns raised about the use of any resulting embryos or cells being used in therapeutic 
applications.591 While it may be useful for scientists to perfect extraction techniques and 
help them to understand embryo development, to name just a couple of reasons why this
research is being pursued, it was obviously a contentious area which needed to be
carefully regulated.
The definitions of a human admixed embryo are the same in the February and 
June Bills but there was an amendment to Part (e) in the June Bill. Whereas the section 
had read as ‘such other thing as may be specified in regulations ’ Part (e) o f the June Bill 
reads as:
590 Human Fertilisation and Embryology Bill [HLJ HL Bill 25, 54/3 Proposed Section 4A  (5), 
http://www.publications.parliament.uk/pa/ld200708/ldbills/025/2008025.pdf (accessed 30/01/08)
591 For example refer to Lord Rea, Report Stage Human Fertilisation and Em bryology Bill [H L] 15th 
January 2008, Volume 697, Column 1215, Lords Hansard http://www.publications.parliament.uk/cgi- 
bin/newhtml hl?DB=semukparl&STEMMER=en&WORDS:=human%20admix%20embrvo%20therapeut 
%20applic&ALL=human%20admixed%20embrvos%20therapeutic%20application&ANY=&PHRASE:=&
CATEGORiES=&SIMPLE=&SPEAKER=&COLOUR=red&STYLE=s& ANCH Q R=80115-
0007.htm spnew2&URL=/pa/ld200708/ldhansrd/text/80115-0007.htm#80115-0007.htm spnew2 (accessed
07/08/08)
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(e) any embryo not falling within paragraphs (a) to (d) which contains both
nuclear or mitochondrial DNA o f a human and nuclear or mitochondrial DNA o f
592an animal ( “animal DNA ”) but in which the animal DNA is not predominant.
Previously Part (e) would have allowed Parliament to issue regulations to cover 
any type of human admixed embryo which may have arisen in the future but which was 
not covered by the definitions in (a) to (d). By removing this provision and trying to write 
a catch all provision to encompass all future types and methods of creating human 
admixed embryos there is the very real risk that a new type of human admixed embryo 
may not fall within this definition. The use of the word ‘predominant’ is also very 
subjective. What percentage of the human admixed embryo must be human for it to be 
the dominant species? What one person would see as predominant others may not agree. 
Is 51% sufficient? Or is it somewhere closer to 100%? At least with the regulation 
making power Parliament could have amended the legislation once in force as it saw fit 
and as the need arose. Without this regulation making power there is a real risk that the 
new HFE Act 2008 will need a complete rewrite very soon in the future, much as the 
HFE Act 1990 has required. It is not clear from the Parliamentary debate as to why Part
(e) was altered in this way. Part (e) was subsequently enacted in this wording.
Although there is no specific part of the definitions concerning human admixed 
embryos which gives a more general catch all definition or provides for regulations 
allowing Parliament to amend the definitions if the need arose, there is a power which 
allows the Secretary of State to amend the definitions:
I f  it appears to the Secretary o f  State necessary or desirable to do so in light o f
developments in science or medicine, regulations may -
(a) amend (but not repeal) paragraphs (a) to (e) o f  subsection (6);
(b) provide that in this section “embryo ”, “eggs ”, or “gametes ” include things 
specified in the regulations which would not otherwise fa ll within the 
definitions.593
This section first appeared in the January Bill and as will be seen below was 
carried through to the new HFE Act 2008. The problem with this regulation making 
power is two fold; first o f all it is the Secretary of State who has the power to amend the
592 June Bill, Human Fertilisation and Embryology Bill [HL] Bill 120, 54/3 Proposed section 4A(6)(e) 
http://www.publications.parliament.uk/pa/cm200708/cmbills/120/2008120.pdf (accessed 04/07/08)
593 Ibid. Proposed section 4A (11)
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definitions without full Parliamentary debate, secondly there is only a power to ‘amend’ 
the definitions. It is surprising that the Secretary of State has the power to amend the 
definitions o f human admixed embryos due to the particularly controversial nature of 
these embryos. It is recognised that the regulations which the Secretary o f State may 
decide to make are subject to the affirmative resolution procedure within Parliament 
(Section 45 of the HFE Act as amended by section 30(5)(4A) of the HFE Act 2008) but 
this does not allow Parliament to alter any suggested regulations, merely to approve them. 
Additionally the fact that the definitions can only be amended means that there is a 
possibility that a new method of creating human admixed embryos may soon be 
discovered which does not fall into the current definitions and also find that an 
amendment to the definitions is not suitable; in such a situation an amendment would not 
bring that particular embryo within the scope o f the new legislation and new primary 
legislation will be needed. The retention of Part (e) ‘such other thing as may be provided  
fo r  in regulations’ would have been preferable as it would have given Parliament as a 
whole greater scope to deal with any new methods of creation.
One regulation making power that was introduced in the Commons Amendments 
was the introduction o f a new regulation making power which could be used “to enable 
the circumstances in which a human admixed embryo can be kept or used to be 
restricted. ”594 The Commons Amendments introduced into Clause 4 of the New Bill the 
provision that:
A licence cannot authorise keeping or using a human admixed embryo in any
circumstances in which regulations prohibit its keeping or use.595
The House o f Lords agreed with this amendment. It is interesting to note that this 
regulation making power could only be used to further restrict the use of human admixed 
embryos and not widen their use in research if it was shown to be necessary or desirable. 
The fact that regulations could only be used to further restrict the uses o f human admixed 
embryos is possibly due to the fact that any regulations made under this provision are also 
subject to the affirmative resolution procedure in Parliament; due to their controversial
594 Human Fertilisation and Embryology Bill [HL], Explanatory Notes on Commons Amendments HL Bill 
83-EN, 54/3 at Para 6 http://www.publications.parliament.uk/pa/ld200708/ldbills/083/en/2008083en.pdf 
(accessed 10/06/09)
595 Human Fertilisation and Embryology Bill [HL] HL Bill 83, 54/3 at Amendment 2 
http://www.publications.parliament.uk/pa/ld200708/ldbills/083/2008083.pdf (accessed 10/06/09)
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nature it was not desirable to allow regulations to be used to extend the permitted uses o f 
human admixed embryos through the use of affirmative resolution procedures and 
without full Parliamentary debate and free votes.
Permitted research purposes
Apart from the fact that the Amended Bills used the term ‘human admixed 
embryo’ instead of ‘inter-species embryo’ as is found in the New Bill, the different 
versions of the New Bill are identical. There was no alteration to the research purposes 
since they were first put forward in the Draft Bill. Importantly there was still the 
requirement that research should be necessary and desirable to fulfil any of the research
596purposes.
Human Fertilisation and Embryology Act 2008
As previously mentioned the HFE Act 2008 received Royal Assent on the 13th 
November 2008. The majority of the provisions are to come into force in October 2009. It 
is important to note that the entirety o f the HFE Act 1990 has not been repealed, the HFE 
Act 2008 has amended Part 1 and Schedules 1 to 5 of the HFE Act 1990 and so the two 
Acts need to be read together.597 In summary the main points relating to human 
embryonic stem cell research which have been raised in the discussion of the reform 
process and o f the Bill passing through Parliament to finally receive Royal Assent are: 
the definition of an embryo, gamete, human admixed embryos and the permitted research 
purposes.
Definition of an embryo, permitted embryo and gamete
The definition of an embryo in Section 1(2) if the HFE Act 2008 is very broad; it 
defines an embryo as a ‘live human embryo’ but without reference to any specific method 
of creation. The provision which prohibits the placing into a woman o f ‘an embryo other
596 For the latest version refer to Human Fertilisation and Embryology Bill [H L] Bill 120, 54/3 Proposed 
Schedule 2, paragraph 3A (l)(a)
http://www.publications.parliament.uk/pa/cm200708/cmbills/120/2008120.pdf (accessed 04/07/08)
597 Human Fertilisation and Embryology Act 2008 Explanatory Notes at Paragraph 12 
http://www.opsi.gov.uk/acts/acts2008/en/ukpgaen 20080022 en.pdf (accessed 22/06/09)
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than a permitted embryo’ has been implemented without reference to placing or keeping
• •  598  •embryos in any other way, such as placing an embryo into an artificial womb. There is 
also no regulation making power which would allow the use o f artificial gametes in 
treatment should that purpose become safe and desirable. Therefore it is possible that in 
the near future new primary legislation will be needed concerning the use o f artificial 
gametes in treatment and the use of artificial wombs (for treatment or research) as and 
when the science progresses to this point.
Human admixed embryos
In contrast with the broad definition in Section 1(2) o f the HFE Act 2008 for 
human embryos, the definitions of human admixed embryos are very precise and 
scientific. As previously discussed within Section 4A(6) o f the HFE Act 2008 there is no 
regulation making power which could be used to expand the accepted list o f human 
admixed embryos should the need arise in the future. As noted above the Secretary o f 
State does have the power to amend (but not repeal) the definitions subject to the 
affirmative resolution procedure. It has been questioned how appropriate this is 
considering the particularly controversial nature of human admixed embryos and the 
possibility that amendments still may not bring all such embryos within the statutory 
definitions.
It is good to see that human admixed embryos are specifically referred to in the 
legislation as the creation of these types of embryos has implications for human 
embryonic stem cell research. The use of human admixed embryos in human embryonic 
stem cell research could speed up the research which is being carried out. Nonetheless the 
use of stem cells derived from human admixed embryos needs to be debated fully and 
legislated upon or referred to the UK Stem Cell Bank for regulation. Although the UK 
Stem Cell Bank would be highly likely to carefully regulate stem cells derived from 
human admixed embryos this is a matter which ideally needs further Parliamentary 
debate due to the contentious issue o f using such stem cells in clinical trials and therapies.
598 Section 3(2) Human Fertilisation and Embryology Act 2008
246
Permitted research purposes
The permitted research purposes passed through Parliament relatively easily 
compared to many of the other provisions contained within the HFE Act 2008. Any 
research activity involving embryos can only be authorised where the activity appears to 
the HFE A to be ‘necessary or desirable’ for one of the permitted purposes found in 
Schedule 2, paragraph 3A HFE Act 2008. This can be found originally in the HFE Act 
1990 and has worked well to ensure that embryos are not used frivolously for research. 
Basic research is now explicitly provided for in Schedule 2, Paragraph 3A(l)(b) and the 
requirement that no licence “...is to be granted unless the Authority is satisfied that any 
proposed use o f  embryos or human admixed embryos is necessary fo r  the purposes o f  the 
research ” has been retained and expanded to include human admixed embryos.599 Also 
as previously discussed the permitted research purposes have been expanded to include 
research into ‘serious medical conditions’ potentially opening up the field of research.
The provisions of the HFE Act 2008 are important for human embryo research 
generally and human embryonic stem cell research more specifically. The legislation now 
applies to all human embryos regardless o f the method of creation and also applies to 
human admixed embryos. Therefore where it is desirable to use a particular method to 
create an embryo to extract stem cells this can be done provided o f course that it falls 
within one of the permitted research purposes. The inclusion of basic as well as applied 
research is also very important for human embryonic stem cell research as there is still 
much basic research to be done before human embryonic stem cell research moves onto 
clinical trials and applications of therapies on a large scale.
The extension to the permitted research purposes to include ‘other serious medical 
conditions’ is likely to not only expand the areas in which embryos are being used for 
research but also the research uses o f the extracted stem cells. This is due to the 
likelihood that the UK Stem Cell Bank will change its Code o f Practice to follow the 
research purposes of the HFE Act 2008 as it had done with the research purposes o f the 
HFE Act 1990. The range of research and potential uses of stem cells has been greatly 
increased by the inclusion o f ‘serious medical condition’ as well as disease in the 
permitted research purposes.
599 Ibid. at Schedule 2, Paragraph 3(5)
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The debate surrounding the creation of embryos for treatment purposes, whereby 
it is desirable to create an embryo to extract stem cells for subsequent treatment, was set 
aside after the White Paper and will not be discussed by Parliament until it is necessary to 
do so. It was likely that had the Government included a provision in the New Bill which 
would have allowed the creation of embryos for treatment purposes then the New Bill 
would have been defeated. We do not yet know if we will need to create embryos 
specifically to derive stem cells for subsequent treatment or if we will be able to use 
‘general’ stem cells which have been derived during research, while this matter is still 
being researched into it was important not to delay the new HFE Act 2008 as there was a 
need for the legislation to be updated.
Conclusion
It was encouraging to see that the Government fully took on board the 
recommendations made by the Joint Committee before writing and publishing a Bill for 
debate. This was very important due to the very strong opposition to the establishment of 
RATE. The strong opposition towards the establishment of RATE was unsurprising and 
yet the Government wanted to push this provision despite the lack o f support for this 
measure. The establishment of RATE could have dealt a major blow to the reputation 
which the UK has established in the field of human fertilisation and embryology. 
Although the Government backed down over the merger of the HFE A and the HTA to 
form RATE, there does still appear to be attempts to save money in respect of these two 
authorities. While the harmonisation of these two bodies is to be encouraged, where 
possible, it should not come for the sake o f saving a few pounds.
The new ‘embryo’ definition should be better than the definition found in the 
HFE Act 1990 which is scientifically out o f date, however, the author has concerns about 
the definition of a ‘permitted embryo’ and why the Act does not contain a regulation 
making power so as to allow fertility treatment with embryos that have been created with 
artificial gametes if and when this is shown to be safe and desirable. It is foreseeable that 
without regulation making powers new primary legislation will be needed in the near 
future.
The inclusion of human admixed embryos could be beneficial to human 
embryonic stem cell research as there is a distinct lack o f suitable oocytes to be used in
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the process. The use o f human admixed embryos in combination with human embryonic 
stem cell research could for example allow researchers to perfect their extraction 
techniques without wasting valuable ‘pure’ human embryos. Nevertheless the inclusion 
of such embryos was not without controversy and there is now the problem that the 
definitions contained within the HFE Act 2008 are so scientifically precise that they may 
become out of date in the near future. The inability o f Parliament to debate and introduce 
Regulations as it sees fit could mean that primary legislation is again needed in the near 
future. The usefulness of the Secretary o f State being able to amend the definitions 
through the affirmative resolution procedure remains to be seen.
Finally, the alterations to the permitted research purposes are sensible, 
unproblematic and of benefit to human embryonic stem cell research as they greatly 
increase the potential areas of research and future clinical trials and therapies.
Previous chapters of this thesis have been a detailed critical look at the United 
Kingdom’s current regulation o f human embryonic stem cell research as well as a critical 
analysis of the reform process and the new HFE Act 2008. The UK was the first country 
to regulate permissively on human embryo research and human embryonic stem cell 
research but it is no longer the only country to do so. By way of comparison the 
following chapter examines the regulation of human embryonic stem cell research in the 
State of California in the United States of America.
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Chapter 9 - California and Proposition 71
Introduction
In November 2004 the Californian public voted to allow State funds to be used for 
stem cell research. This was to be done by raising a bond, not through paying more taxes. 
Whilst this may not at first sight appear to be groundbreaking, when compared to the 
stance taken for many years in the United Kingdom, in actuality this was a major step in 
the United States. At the time of completing this thesis in November 2008 and as will be 
discussed, the United States prohibits the use of Federal (national) funds to create new 
embryonic stem cell lines and greatly limits the funding of embryo research more 
generally. It needs to be noted that on the 4th November 2008 Barack Obama was elected 
as the next President o f the United States. One o f the policies which he said he would 
overturn was the prohibition on the Federal funding of human embryonic stem cell 
research. As the ban was contained within a Presidential Executive Order this would be 
easy to do.600 President Obama subsequently overturned the Bush Executive Order on the 
9th March 2009 and the National Institutes of Health is now devising new guidelines.601 
Although President Obama has now reversed the Federal position regarding the funding 
of human embryonic stem cell research, it is still important to understand how and why 
the Federal funding of embryo research and human embryonic stem cell research has 
generally been prohibited over the years and why this led to California adopting a 
contrary position. Additionally the new Federal rules and NIH guidelines will take some 
time to come into force and to start to have an effect upon human embryonic stem cell 
research within the United States. California will want to maintain the head start which it 
has over the Federal Government.
600 Zeleny, J., Obama Weighs Quick Undoing o f  Bush Policy NY Times 9th November 2008 
http://www.nvtimes.eom/2008/11 /10/us/politics/10obama.html? _r= 1 &scp=2&sq=barack%20obama%20em  
brvonic%20stem%20cells&st=cse (accessed 23/11/08) Editorial, Stem-cell futures 456 Nature 282 (20th 
November 2008) http://www.nature.com/nature/ioumal/v456/n7220/pdf/456282a.pdf (accessed 23/11/08)
601 Executive Order no. 13505 o f  March 9, 2009: Removing Barriers to Responsible Scientific Research  
Involving Human Stem Cells http://edocket.access.gpo. gov/2009/pdfZE9-5441.pdf (accessed 13/03/09) 
Hereafter referred to as the NIH
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It will be seen that the issue of human embryonic stem cell research in the United 
States is not primarily a question o f legislation and regulation, but one o f funding at the 
Federal and State level.
This Chapter seeks to discuss the historical context of stem cell research in the 
United States, discuss the legislation and policies of the State of California and where 
appropriate draw comparisons between the legal position adopted in California and that 
which has been adopted in the United Kingdom.
History of the regulation of embryo research in the United States
Historically the United States has taken a very limited approach towards the 
regulation o f human embryo research. Looking over the last few decades we can see that 
human embryo research and the Federal funding of such research were not condoned.
In the late 1970’s Congress issued a moratorium on the Federal funding o f human 
IVF research until regulations were adopted by the Department o f Health and Human 
Services. The Federal regulations, which were adopted in 1978, recommended that no 
human embryo research should receive Federal funding until the application had been 
approved by an Ethical Advisory Board (EAB).602 The first such EAB was appointed in 
1978 and a year later the EAB recommended the Federal funding of IVF research 
provided that alternative methods were not available and that the embryos were not kept 
beyond fourteen days development. Although the EAB had recommended the Federal 
funding of human IVF research the Department of Health and Human Services did not 
move forward and allowed the EAB to expire in 1980. This effectively prohibited all 
embryo research from occurring (where Federal funds were required) as no such research 
could proceed without EAB approval.
The lack o f Federal funding for embryo research continued with Presidents 
Reagan and Bush Snr as the pro-life lobby were successful in persuading the Presidents 
not to appoint a new EAB, effectively resulting in a moratorium of embryo research.
602 45 CFR 46 (Title 45, Public Welfare, Department o f  Health and Human Services, Part 46, Protection o f  
Human Subjects) The most recent version (2005) is available online: 
http://www.hhs.gov/ohrp/humansubiects/guidance/45cfr46.htm (Accessed 7/6/07)
603 Refer to Belew, K., Comment: Stem Cell Division: Abortion Law and its Influence on the Adoption o f  
Radically Different Embryonic Stem Cell Legislation in the United States, the United Kingdom and  
Germany (2004) 39 Tex. Int'l L.J. 479 for a detailed and clear discussion o f  the historical regulation o f  
embryo research in the United States
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However, the election of President Clinton was to see a reversal in the Federal funding 
fortunes o f embryo research.
President Clinton introduced the National Institute o f  Health Revitalization Act o f  
1993 which was passed by Congress. This Act eliminated the need for EAB approval 
prior to conducting research upon human embryos.604 As the NIH started to receive 
applications for funding of embryo research, the NIH responded by assembling the 
Human Embryo Research Panel, an ethics board which was required to consider the 
ethics o f human embryo research and provide advice accordingly.605
In September 1994 the Human Embryo Research Panel published its report, Report o f  
the Human Embryo Research Panel, which recommended that the Federal funding of 
embryo research was ethical provided that certain conditions were met.606 This included
fiC\lnot permitting research on embryos past fourteen days development. Surprisingly, in 
light of the fact that absolutely no embryo research, irrelevant of the sources o f the 
embryos, up to this point had been federally funded, the Report also recommended 
allowing embryos to be created specifically for research purposes. The Report notes that 
this was one area which was the most difficult to consider amongst its panel members but 
felt that the fertilisation of oocytes specifically for research should be permitted and 
federally funded but only when two conditions were met.608 These were:
• When the research by its very nature cannot otherwise be validly conducted. ...
• When the fertilization o f oocytes is necessary fo r  the validity o f  a study that is 
potentially o f  outstanding scientific and therapeutic value. ...6 9
It is also worth noting that the Report recommended a further three guidelines in 
respect o f the procurement o f oocytes for the specific purpose o f research. This included 
only obtaining oocytes from women who were already undergoing gynaecological 
surgery such as IVF treatment.610 Therefore women could not altruistically donate
604 National Institutes o f  Health Revitalization A ct o f 1993 Public Law 103-43, section 121(c)
605 The National Institutes o f  Health (NIH), a part o f  the U.S. Department o f  Health and Human Services, is 
the primary federal funding agency for conducting and supporting medical research About NIH  NIH  
http://www.nih.gov/about (Accessed 11/6/07)
606 Report o f  the Human Embryo Research Panel, Volume /  National Institutes o f  Health, Sept 1994 
http://www.bioethics.gov/reports/past commissions/human embryo vol l.p d f (accessed 4/6/07)
607 Ibid. at p g51
608 Ib id  at pg 41
609 Ib id  at pg 44-45
610 Ibid. at pg 57
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oocytes unless they were already undergoing related medical treatment. This is different 
to the situation in the United Kingdom where women can donate oocytes altruistically if 
they desire. This also differs to the US position of allowing payment for oocytes for 
infertility treatments. Allowing payment for donation of oocytes for treatment but not for 
research can perhaps be explained by the fact that in the US the donation o f oocytes for 
infertility treatment is considered to be a worthy cause by helping the childless to achieve 
the goal of having a child, whereas donation of oocytes to research is still seen as 
ethically contentious and to many people is not a worthy reason for which to donate 
oocytes. The donation (and payment) of oocytes for infertility treatment may be 
encouraged in the US due to the fact that any resulting embryos have the possibility of 
their potential to become persons to be fulfilled (even if this is theoretical depending 
upon the number of embryos produced and needed) whereas the donation of oocytes for 
research will result in embryos that cannot and will not fulfil their potential due to 
restrictions upon their implantation. Allowing payments to be made to egg donors for 
treatment is perhaps meant to encourage donors to participate whereas prohibiting 
payments for donations to research is another method of signalling (even subconsciously) 
disapproval for embryo research.
Considering the restrictions which the Human Embryo Research Panel placed upon 
the fertilisation of oocytes for research purposes it is somewhat surprising, to the British 
observer at least, that President Clinton was not willing to accept the recommendation of 
the Human Embryo Research Panel to allow embryos to be created specifically for 
research purposes. Whilst not corresponding to the British legislative position it is 
consistent with the stance taken by many other countries. As such President Clinton 
issued “ .. .a directive barring the use o f  federal funds to create human embryos fo r  
experimentation.” 611 The directive did not however prohibit the Federal funding of 
research using ‘spare’ IVF embryos, those which had been created for reproductive 
purposes but which were no longer required for that purpose and had been donated to 
research by the gamete donors.
Before the NIH could make any funding decisions on applications for research 
involving these spare embryos, an amendment was introduced in 1995 to the Department
611 Belew, K., Comment: Stem Cell Division: Abortion Law and its Influence on the Adoption o f  Radically 
Different Embryonic Stem Cell Legislation in the United States, the United Kingdom and Germany (2004) 
39 Tex. Int'l L.J. 479 at page 501
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o f Health and Human Services Appropriations Bill. Called the ‘Dickey Amendment’ after 
the Republican who introduced it, the Amendment prevents the Federal funding of any 
research which involves:
(1) the creation o f  a human embryo or embryos for research purposes; or
(2) research in which a human embryo or embryos are destroyed, discarded, or 
knowingly subjected to risk o f  injury or death greater than that allowed fo r  
research on fetuses in utero under 45 CFR 46.208(a)(2) a n d ... [42 U.S.C. 289gm
For purposes o f  this section, the phrase "human embryo or embryos" shall 
include any organism, not protected as a human subject under 45 CFR 46 as o f  
the date o f  enactment o f  this Act, that is derived by fertilization, parthenogenesis, 
cloning, or any other means from  one or more human gametes.61
This Amendment has been passed in all successive years and as such controls the 
access to Federal funds for all human embryo research.
When Professor Thomson at the University of Wisconsin announced his work 
with human embryonic stem cells in 1998 the question arose if  work on the derived stem 
cell lines could be federally funded without breaching the Dickey Amendment. The 
actual research undertaken by Professor Thomson and his team had been privately funded 
by the Geron Corporation o f Menlo Park, California.613 Within the same month John 
Gearhart also announced work involving the derivation of human embryonic germ cells, 
derived from aborted foetuses of between 5 and 9 weeks gestation.614 This work had also 
been privately funded by the Geron Corporation.
On the 14th November 1998 President Clinton wrote to the National Bioethics 
Advisory Commission to request that it conduct a review of the ethical issues associated 
with human embryonic stem cell research.615 The Director o f the NIH, Harold Varmus,
612 ‘Dickey Amendment’ Balanced Budget Downpayment Act o f 1996  Pub. L. No. 104-99, §128, 110 Stat. 
26, 34 (1996)
613 Korobkin, R., Stem Cell Century, Law and Policy fo r  a Breakthrough Technology (2007) Yale 
University Press at pg 51 (Ch 2 Embryo Wars) and pg 96-98 (Ch 4 Stem Cell Patents)
614 M.J. Shamblott et al., Derivation o f  Pluripotent Stem Cells from  Cultured Human Prim ordial Germ  
Cells 95 Proceeding Nat’1 Acad. Sci. 1 3 7 2 6 -  13731 (1998)
615 Ethical Issues in Human Stem C ell Research, Vol I, Report and Recommendations o f  the National 
Bioethics Advisory Commission September 1999 Letter to the President 
http://www.bioethics.gov/reports/past commissions/nbac stemcell 1 .pdf (accessed 4/6/07)
The National Bioethics Advisory Commission was set up for the purpose o f  “Advising the President on 
ethical issues related to advances in biomedical science and technology.” http://www.bioethics.gov 
(accessed 11/6/07)
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also sought the legal opinion of the General Counsel o f the Department o f Health and 
Human Services, Harriet Raab. In Harriet Raab’s memorandum to Harold Varmus it was 
established that in her legal opinion the NIH could provide Federal funding for research 
involving human embryonic stem cell lines as the cells did not constitute an embryo 
within the statutory definition.616
In September of 1999 the National Bioethics Advisory Commission also 
concluded in its Report, Ethical Issues in Human Stem Cell Research, that it was ethical 
for research upon the derived stem cell lines to proceed with Federal funding and that a 
statutory exception to the Dickey Amendment should be permitted to allow the Federal 
funding of such research. However, the National Bioethics Advisory Commission did not 
agree with the recommendation made by the Human Embryo Research Panel five years 
earlier that the creation of embryos specifically for research purposes should be 
permitted.617
Recommendation 2:
Research involving the derivation and use o f  human ES cells from  embryos 
remaining after infertility treatments should be eligible fo r  federal funding. An  
exception should be made to the present statutory ban on federal funding o f  
embryo research to permit federal agencies to fund  research involving the 
derivation o f human ES cells from  this source under appropriate regulation that 
includes public oversight and review.
Recommendation 3:
Federal agencies should not fund  research involving the derivation or use o f  
human ES cells from embryos made solely fo r  research purposes using IVF.618
The call for national oversight and public review of stem cell research, including 
the recommendation to create a National Stem Cell Oversight and Review Panel, has 
been subsequently ignored by the Federal Government, as evidenced by the lack o f a 
national oversight panel nearly a decade after its recommendation by the National 
Bioethics Advisory Commission.619
516 Federal Funding fo r  Research Involving Human Pluripotent Stem Cells Memorandum from Harriet S. 
Raab, General Counsel o f  the DHHS, to Harold Varmus, Director o f  the NIH (Jan. 15, 1999)
617 Ethical Issues in Human Stem Cell Research, Vol I, Report and Recommendations o f  the National 
Bioethics Advisory Commission September 1999 at pg 61-62, Summary 
http://www.bioethics.gov/reports/past commissions/nbac stemcell 1 .pdf (accessed 4/6/07)
618 Ibid. at pg 70-71
619 Ibid. Refer to Recommendation 8, Page 76 for a discussion o f  the National Stem Cell Oversight and 
Review Panel
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Considering that the National Bioethics Advisory Commission viewed national 
oversight as crucial “ ...to ensure strict adherence to guidelines and standards across the 
country” it is strange that an issue as sensitive and divisive as human embryonic stem cell 
research has not resulted in the panel which was called for in 1999. When a subject is 
as divisive as human embryonic stem cell research, particularly in a country as politically 
sensitive as the United States, it would be thought that a system of national oversight 
would be one way in which the Federal Government could show that it is taking an active 
interest in this area of research.
In light of the favourable Report from the National Bioethics Advisory 
Commission, the NIH went ahead with adopting guidelines for research on human 
pluripotent stem cells. On a side note, the term ‘human pluripotent stem cell’ is used in 
the American literature when referring to human embryonic stem cells and human 
embryonic germ cells and the discussions centre around these two sources of stem cells, 
along with those created by somatic cell nuclear transfer. This is compared to the UK 
literature which generally separates human embryonic stem cells from ‘adult’ stem cells, 
of which germ cells are part of, and also refers to somatic cell nuclear transfer as 
therapeutic cloning. As such, the NIH guidelines refer to all human pluripotent stem cells, 
not specifically to human embryonic stem cells.
Although the National Bioethics Advisory Commission had called for a statutory 
exception to the Dickey Amendment to allow research involving the derivation o f human 
embryonic stem cells, this was not forthcoming and so the NIH guidelines which were 
being adopted only referred to work on stem cell lines which had already been derived. 
The Federal funding of the actual derivation process was still outlawed and so could not 
be funded by the NIH but the subsequent research upon the stem cells themselves could 
be federally funded.
The NIH adopted guidelines on human pluripotent stem cells in August 2000 and 
started to receive grant applications for this type of research. One condition of the 
guidelines was that for all research involving human pluripotent stem cell lines the 
research application had to be reviewed by the NIH Human Pluripotent Stem Cell Review
620 Ibid. at pg 76
621 For a US discussion o f  the three sources o f  human pluripotent stem cells refer to Capron, A.M ., Stem  
Cells: Ethics, Law and Politics (2001) 20(5) Biotechnology Law Report 678 at page 682
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Group (HPSCRG) for compliance with the guidelines.622 However, before any funding 
could be allocated and distributed President Clinton’s term in office came to an end and 
President George W. Bush was elected. In spring 2001, “In order to prevent the N IH  from  
funding stem cell research under the Clinton administration's policies, ...the Bush 
administration froze federal funding o f  stem cell research and postponed the first 
scheduled meeting o f  the HPSCRG in anticipation o f  the announcement o f  his
fcyxadministration's own funding guidelines.”
On the 9th August 2001 President George W. Bush announced the Federal policy 
in relation to human pluripotent stem cells.624 In essence it can be summarised as 
permitting the Federal funding of research using human pluripotent stem cell lines which 
had been derived prior to the 9th August 2001. The reason for this was that those embryos 
which had been destroyed prior to that date were effectively beyond help and that 
valuable work could be done upon the cell lines for which they were sacrificed. However, 
President Bush did not want to be seen to be encouraging the future destruction of 
embryos, hence the ban on Federal funding o f any stem cell lines created after the date o f 
his announcement.
The adoption of this policy was criticised from all sides, from those who felt that 
the President should have completely outlawed all embryo research where it involves the 
destruction of embryos, to those who felt that the policy did not go far enough and that 
the limited research which was being permitted was inadequate.625
In reality this approach adopted by President Bush is absurd as embryos will 
continue to be destroyed in the United States for embryo research and for the derivation 
o f stem cell lines but that such research will be privately funded, as was the situation with 
Professor Thomson’s original groundbreaking work. By not moving to completely outlaw 
embryo research where embryos are destroyed, but preferring to see it as an issue o f 
funding, the President has put the United States in the strange position o f not condoning
622 National Institutes o f  Health Guidelines fo r  Research Using Human P luripotent Stem Cells, Effective as 
o f  25th August 2000, Section IV (A) NIH
http://stemcells.nih.gov/news/newsArchives/stemcel 1 guidelines.asp (accessed 4/6/07)
623 Belew, K., Comment: Stem Cell Division: Abortion Law and its Influence on the Adoption o f  Radically 
Different Embryonic Stem Cell Legislation in the United States, the U nited Kingdom  and Germ any (2004) 
39 Tex. Int'l L.J. 479 at page 503
624 Remarks by the President on Stem Cell Research President Bush 9th August 2001 The full transcript o f  
President Bush’s speech can be found on the Whitehouse website at: 
http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html (accessed 11/6/07)
625 For a summary o f  some o f  the criticisms aimed at the Bush policy refer to Sax, J.K., The States “Race ” 
with the Federal Government fo r  Stem Cell Research  (2006) 15 Annals Health L. 1 at pg 18
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embryo research and yet not prohibiting it. It appears that the private investors will be left 
to pursue human embryonic stem cell research without any national oversight or 
regulation. An analogous situation in the UK is in respect of lap dancing. The UK 
Government does not like lap dancing and yet has not outlawed it. If  moves were made to 
outlaw this practice it is unlikely that such a law would pass through Parliament. 
Interestingly the industry itself is calling for stricter regulation (though still permitting the 
practice).626
Although the situation that the Bush policy has created is bizarre to the outside 
observer, upon reflection it is perhaps not that surprising that human embryonic stem cell 
research has been regulated, not through legislation but by funding bodies and through a 
Presidential Executive Order. It is typical o f the United States to regulate sensitive issues 
through funding rather than legislation as it is an easier route by which to regulate and is 
less open to legal challenges. With the Federal body, the NIH as the principal funder of 
medical research this effectively means that research is adequately controlled. 
Additionally, not only is the Bush Executive Order the easiest way to regulate human 
embryonic stem cell research it is also the only immediately effective option. Had 
President Bush tried to regulate human embryonic stem cell research through the 
introduction of prohibitive legislation the debate may still be ongoing in Congress.627
Due to the complete change in direction which the Bush administration had taken 
towards human embryonic stem cell research compared to the approach taken by the 
Clinton administration, the NIH was forced to redraft the guidelines concerning the 
Federal funding of human pluripotent research. As Daar notes, “The specific funding  
parameters o f  the Bush Administration policy are set out by the National Institutes o f  
Health.. . ” 628 The guidelines state that:
On August 9, 2001, at 9:00 p.m. EDT, the President announced his decision to 
allow Federal funds to be used fo r research on existing human embryonic stem 
cell lines as long as prior to his announcement (1) the derivation process (which 
commences with the removal o f  the inner cell mass from  the blastocyst) had 
already been initiated and (2) the embryo from  which the stem cell line was 
derived no longer had the possibility o f  development as a human being.
626 Lewis, P., Lap dance firm s call fo r  tighter regulation  28th April 2008 The Guardian 
http://www.guardian.co.Uk/uk/2008/apr/28/3 (accessed 6/11/08)
627 Thanks to Soren Holm for his comments on this point
628 Daar, J.F., Reproductive Technologies and The Law (2006) LexisNexis at Page 783
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In addition, the President established the following criteria that must be met:
• The stem cells must have been derived from  an embryo that was created for 
reproductive purposes;
• The embryo was no longer needed fo r these purposes;
• Informed consent must have been obtained fo r  the donation o f the embryo;
• No financial inducements were provided fo r  donation o f  the embryo.
In order to facilitate research using human embryonic stem cells, the NIH  is 
creating a Human Embryonic Stem Cell Registry that will list the human 
embryonic stem cells that meet the eligibility criteria...629
The establishment of an NIH Human Embryonic Stem Cell Registry was 
necessary to enable the NIH to list the eligible and available stem cell lines for Federal 
research. At the time of President Bush’s announcement this was anticipated to number 
“...more than 60 genetically diverse stem cell lines... ” and that research upon these stem 
cell lines would allow the United States “...to explore the promise and potential o f  stem 
cell research without crossing a fundamental moral line... ”630 The reality is that o f these 
60 stem cell lines only 21 (as of November 2008) have so far been registered as suitable 
for research with the NIH Human Embryonic Stem Cell Registry.631 O f the remaining 
stem cell lines referred to by President Bush, many are not suitable for research due to 
problems in retaining them in their undifferentiated state or have developed mutations.632
Recently (June 2008) it has come to light that the 21 cell lines which are available 
for funding and distribution by the NIH may not fulfil the informed consent requirements 
which President Bush specifically referred to in his 9th August speech. Streiffer requested 
from the NIH copies of the consent forms used for the cell lines available for distribution 
and has analysed eleven forms from the six providers o f the cell lines.633 Two of the 
consent forms, from Cellartis and BresaGen, are considered to be the most problematic 
whilst the others are adequate to cover many research uses although the research will be
629 Notice o f  Criteria fo r  the Federal Funding o f  Research on Existing Human Embryonic Stem Cells and  
Establishment o f  NIH Human Embryonic Stem Cell Registry NIH 7th November 2001 
http://grants.nih.gov/grants/guide/notice-files/not-od-02-005.html (accessed 4/6/07)
630 Remarks by the President on Stem Cell Research  President Bush 9th August 2001 
http://www.whitehouse.gov/news/releases/2001/08/200108Q9-2.html (accessed 4/6/07)
631 Information on Eligibility Criteria fo r  Federal Funding o f  Research on Human Embryonic Stem Cells 
National Institutes o f  Health http://stemcells.nih.gov/research/registrv/eligibilitvCriteria.asp (last accessed 
2/11/08)
632 For example refer to Time to expand US funding fo r  stem-cell research  (2007) 6 The Lancet Neurology 
469
633 Streiffer, R., Informed Consent and Federal Funding fo r  Stem Cell Research  (2008) 38 Hastings Cent. 
Rep. 40-47 at pg 42
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restricted. Streiffer argues that federal funding should be used to derive new cell lines 
which comply with informed consent guidelines and then subsequent research would not 
be restricted.634
Stanford University is considering taking steps to prevent its researchers working 
upon the two most problematic lines and other research institutions may also follow 
suit.635 This also has implications for the UK Stem Cell Bank which will normally allow 
researchers to access stem cell lines from the NIH Stem Cell Registry without the need to 
prove that the cell lines were ethically sourced:
“Information in relation to the ethical sourcing o f  human embryonic stem cell 
lines does not need to be provided fo r  human embryonic stem cell lines that ...b) 
are listed on the National Institute o f  Health (NIH) registry (as ethical sourcing 
has been confirmed by NIH)... ”636
The Steering Committee o f the UK Stem Cell Bank has also approved four stem
f.'in #
cell lines from Cellartis although these are not yet accessioned by the Bank. This was 
to be reviewed by the Steering Committee in September 2008.638
The original number of 60 was criticised by some for not being representative or 
suitable for research. As the number has since been shown to be much smaller there were 
calls for President Bush to review his policy.639 There is also the issue o f the suitability of 
these stem cell lines to be used in therapeutic applications. Although it will occur 
sometime into the future there is the possibility that these stem cell lines could lead to 
therapies or cures. However, it is unlikely that these particular stem cell lines could be 
used for human therapies due to the fact that they have all been grown on cultures which 
include mouse feeder cells. The possibility of animal to human infection and
Ibid. at pg 47
635 Baker, M., Consent issues restrict stem-cell use 28th July 2008 Nature news 
http://www.nature.com/news/2008/080728/full/454556a.html (accessed 30/07/08)
Baker, M., The Niche Stem Cell Blog: Some NIH Registry Lines Fall Outside Informed Consent Guidelines 
http://blogs.nature.com/reports/theniche/2008/07/some nih registry lines fall o.html (accessed 05/09/08)
636 Code o f  Practice fo r  the use o f  Human Stem Cell Lines Version 3, August 2006 at Section 8.3 
http.7/www.ukstemcellbank.org.uk/documents/Code%20of%20Practice%20for%20the%20Use%20of%20 
Human%20Stem%20Cell%20Lines.pdf (accessed 30/04/08)
637 Accepted by the Steering Committee UK Stem Cell Bank 
http://www.ukstemcellbank.org.uk/accepted.html (accessed 12/08/08)
638 Electronic communication from Soren Holm 8th July 2008, member o f  the UK Stem Cell Bank Steering 
Committee. Confirmed 17th July 2009 in meeting with Soren Holm that one Cellartis line was okay as new 
consent had been sought
639 For example refer to Time to expand US funding fo r  stem-cell research  (2007) 6 The Lancet Neurology 
469 and Rao, M.S., Embryonic Stem Cell Research and U.S. Policy (2006) 24 Stem Cells 1412
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contamination is one which everyone wishes to avoid. If scientists were able to find a 
way to purify these cell lines of the mouse feeder cells then there is the possibility of 
these cell lines being used in future therapies. Until such work is undertaken and proven, 
these cell lines will remain unsuitable for use in humans.
President Bush’s speech on the 9th August pronouncing the Federal Government 
policy in respect o f human embryonic stem cell research was not the end o f the matter at 
Federal level. There are many supporters of human embryonic stem cell research within 
the Government, some o f whom have taken steps to introduce legislation which would 
override the current Federal position. The latest o f these is the Stem Cell Research 
Enhancement Act o f 2007. This Act would have amended Part H o f Title IV o f the Public 
Health Act by inserting wording after section 498C. The amendment would have 
permitted the Federal Government to “...conduct and support research that utilizes 
human embryonic stem cells ...(regardless o f the date on which the stem cells were 
derived from  the human embryo). ”640 First introduced on the 4th January 2007 it was 
passed by the Senate on the 11th April, and was finally passed by the House of 
Representatives on the 7th June. However, less than two weeks later President Bush 
vetoed the Bill. The Presidential veto can be overridden if two thirds o f each chamber, 
starting with the Senate, were to vote in favour of the Act. No attempt was made to do 
this.641 The Presidential veto was not a surprise as President Bush had vetoed an identical 
Bill the previous year and the attempt to override the Presidential veto failed.642 How 
successful the Act would have been has been debated elsewhere, all that is left to say is 
that the divisive voting and subsequent Presidential veto shows the continued problems 
which human embryonic stem cell research raises and the difficulty o f finding a middle 
ground upon which everyone can agree, at least to some extent.643 Due to the Bush policy 
in force at the time California took steps to actively fund human embryonic stem cell 
research.
640 §2 Stem Cell Research Enhancement Act o f 2005  H.R. 810, 109th Cong.
641 The passage o f  the Stem Cell Research Enhancement Act o f 2007  can be located at: 
http://www.govtrack.us/congress/bill.xpd?bill=s 110-5 (accessed 12/7/07)
642 The passage o f  the Stem C ell Research Enhancement Act o f 2005  can be located at: 
http://www.govtrack.us/congress/bill.xpd7bilHhl09-810 (accessed 29/5/07)
643 For a useful discussion o f  the shortcomings o f  the Stem Cell Research Enhancement A ct o f 2005  refer to 
Korobkin, R., Stem Cell Century, Law and Policy fo r  a Breakthrough Technology (2007) Yale University 
Press at pg 41-48 (Ch 2 Embryo Wars subheading ‘The Stem Cell Research Enhancement Act and 
Limitations o f  the SCREA’)
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California and Proposition 71
It is necessary to consider California’s stance on stem cell research in light of the 
above discussion concerning Federal funding and lack of regulation of human embryonic 
stem cell research. It was the dissatisfaction with the Federal Government policy on stem 
cell research which lead to the introduction o f Proposition 71 by the California 
legislature.
Proposition 71 was sold to the general public as an opportunity to keep California 
at the forefront of global biotechnology whilst also providing revenue to the State of 
California in the future. The public was asked to vote for the State to provide $3 billion 
over 10 years to Californian scientists to continue work with human pluripotent stem 
cells. The debate over this proposed legislation was fierce, as can be imagined over such 
a divisive issue, however, when the ‘yes’ campaign group had campaign funds o f $35 
million whereas the ‘no’ campaign group had a mere $200,000 it is in some respect 
hardly surprising that 59% of the general public voted ‘yes’ to Proposition 71 and 41% 
voted no.644
The initiative was voted on in November 2004, with the idea that the regulatory 
body established by Proposition 71, the California Institute for Regenerative Medicine, 
would start to distribute funds as soon as suitable policies had been formulated. However, 
the distribution of funds was delayed by various legal challenges from groups which 
challenged the constitutionality of Proposition 71.
The legal challenges
Various groups challenged the legality of Proposition 71, including the California 
Family Bioethics Council and the People’s Advocate. One legal challenge by the 
People’s Advocate fell at the first hurdle, 645 whilst the decision of Judge Bonnie 
Lewman-Sabraw in the Superior Court o f Alameda County,646 in favour o f the California
644 Fox, C., Cell o f  Cells: The Global Race to Capture and Control the Stem Cell (2007) W.W.Norton at pg 
413
645 P eop le’s Advocate et al. v. Independent Citizen's Oversight Committee et al. S I31655 (Supreme Court 
o f  California) 23rd March 2005
646 P eo p le’s Advocate and National Tax Limitation Foundation v. Independent Citizen's Oversight 
Committee et al. Superior Court o f  Alameda County N o’s HG05206766 and HG05235177 — Judge Bonnie 
Lewman-Sabraw
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Institute for Regenerative Medicine and the Independent Citizen's Oversight Committee, 
lead to an appeal first to the Court of Appeal of California and then finally to the 
Supreme Court o f California.
Court of Appeal of California
The Court of Appeal o f California consolidated two cases, one involving the 
California Family Bioethics Council against the California Institute for Regenerative 
Medicine, the other involving the People’s Advocate against the Independent Citizen's 
Oversight Committee.647 Both groups were challenging the legality o f Proposition 71 on 
a number of bases. This included an alleged violation o f the Californian Constitution 
concerning the appropriation o f funds for the benefit o f private entities, an alleged 
violation of the single-subject rule contained in the Californian Constitution and possible 
conflicts of interest.648
After detailed and lengthy analysis of all the issues the Court of Appeal of 
California followed the trial court decision and unanimously held that Proposition 71 was 
valid.
The legal challenges in California differs greatly to those seen in the United 
Kingdom concerning the Human Fertilisation and Embryology Act 1990 as the 
Californian cases concerned the actual validity of the legislation and as such the 
challenges were initiated within a very short time of the public vote on Proposition 71. In 
comparison, the cases challenging the HFE Act have occurred sometime after the 
enactment o f the Act and mainly concern definitions contained in the Act and whether the 
Act stood up to modem day techniques.649
647 California Family Bioethics Council v. California Institute fo r  Regenerative Medicine, P eo p le ’s 
Advocate v. Independent Citizen's O versight Committee 26th February 2007, 147 Cal. App. 4th 1319
648 Refer to the case headnote for a full discussion o f  all the issues which were challenged
649 For example refer to the discussion o f  R (on the application o f  Quintavalle) v. the Human Fertilisation  
and Embryology Authority in Chapter 3 o f  this thesis
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The Supreme Court of California
In a final bid to overturn the legality of Proposition 71 the groups appealed to the 
Supreme Court of California, the final arbiter. The request for an appeal hearing was met 
with a resounding ‘no’ on the 16th May 2007.650
With this decision the California Institute for Regenerative Medicine and its 
governing body, the Independent Citizen's Oversight Committee, could move forward 
obtaining and distributing funds to the scientists o f California to continue work on human 
pluripotent stem cells.
The Fundamentals of Proposition 71
When Proposition 71 was enacted following the positive 59% vote by the 
Californian public, it created the California Stem Cell Research and Cures Bond Act 
which was inserted into the Californian Health and Safety Code (Division 106, Part 5, 
Chapter 3, sections 125290-125292). Additionally it took the unusual step o f introducing 
a new article into the Californian Constitution.
The California Constitution
Article XXXV of the Californian Constitution establishes the California Institute 
for Regenerative Medicine,651 outlaws the funding by the CIRM of human reproductive 
cloning and most interestingly of all, establishes
...a right to conduct stem cell research, which includes research involving adult 
stem cells, cord blood cells, pluripotent stem cells, and/or progenitor 
cells... Pluripotent stem cells may de derived from somatic cell nuclear transfer or 
from  surplus products o f  in vitro fertilization treatments. . ,652
It should be noted that while Article XXXV of the Californian Constitution 
specifically prohibits the funding of human reproductive cloning by the CIRM, it does
650 California Family Bioethics Council v. California Institute fo r  Regenerative Medicine et a l and  
companion case 16th May 2007 SI 51574, Supreme Court o f  California
651 Hereafter referred to as the CIRM
652 California Constitution, Section 5, Article XXXV, M edical Research  
http://www.leginfo.ca.gOv/.const/.article 35 (accessed 4/6/07)
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not mean that private investors can freely pursue human reproductive cloning in 
California. Sections 24185-24187 o f the California Health and Safety Code specifically 
outlaw human reproductive cloning irrespective o f the funding source:
(a) No person shall clone a human being or engage in human reproductive 
cloning.
(b) No person shall purchase or sell an ovum, zygote, embryo, or fetus fo r  the 
purpose o f  cloning a human being.653
These sections also apply administrative penalties in terms o f pecuniary fines, the 
amount is dependant upon who has breached this section i.e. an individual or a 
corporation.654
This particular section o f the California Constitution is perhaps the most 
interesting due to establishing a ‘right to conduct stem cell research ’. Whereas the United 
Kingdom establishes a system o f licensing for those people who are correctly qualified 
and who desire to perform stem cell research within the limited and restrictive range of 
permissible purposes, the Californian approach appears, at first sight, to be one of 
uncontrolled permissiveness. By establishing a ‘right to conduct stem cell research ’ it 
appears that anyone can claim a right to do this research, without the need to approach a 
regulatory body for permission or oversight. The ‘right to conduct stem cell research ’ is 
not dependant upon funding for the research being allocated by the CIRM, thereby 
implying a right to perform stem cell research irrelevant of the funding source. This is a 
problem with the system of controls with which the United States has chosen to regulate 
stem cell research. Rather than implement a nationwide regulatory system it has chosen 
to regulate stem cell research on the basis o f who is funding the research and when the 
stem cell lines were established. However, this is where the new article of the California 
Constitution fails. It does not establish a right to conduct research only when the 
researcher is funded by the State agency, the CIRM, rather it establishes a right to 
conduct research full stop. This could have serious implications for privately funded stem 
cell research occurring in California. As with the rest o f the United States privately 
funded stem cell research is left unregulated thereby allowing any type o f research to be
653 §24185 (Division 20, Chapter 1.4) California Health and Safety Code http://www.leginfo.ca.gov/cgi- 
bin/displavcode?section:::=hsc&group:=24001-25000& file=24185-24187 (accessed 7/6/07)
654 Ibid. at §24187
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performed and potentially extending the acceptable moral limits (i.e. the twelve day 
development rule as established by Proposition 71). The only way in which privately 
funded research will be regulated by individual States is where the research is prohibited, 
regardless of the funding source, and this has not yet happened anywhere in the United 
States. This issue of regulation through funding controls will be revisited throughout this 
Chapter.
It should also be noted that although there is a ‘right to conduct stem cell 
research ’ there is no corresponding right for the Californian public to receive the benefits 
of the research. There is the potential that the therapies resulting from stem cell research 
funded by the CIRM may for a long time be very costly, thereby excluding access to 
those therapies for many citizens of California.655
One final point to note in consideration of the ‘right to conduct stem cell 
research ’ in California is in respect o f the types of embryos upon which this research can 
be conducted. Section 5 o f  Article XXXV o f the California Constitution continues on to 
state that:
Pluripotent stem cells may be derived from somatic cell nuclear transfer or from
surplus products o f  in vitro fertilization treatments...
This section therefore means that researchers in California are only able to 
conduct stem cell research upon embryos which are left over from IVF treatments and are 
no longer required for reproductive purposes, or can create embryos specifically for 
research, but only through using the therapeutic cloning method, somatic cell nuclear 
transfer. Researchers are not able to create embryos specifically for stem cell research 
either through normal in vitro fertilisation, or through any other method o f creation. 
Considering that the Medical and Ethical Standards Regulations, which are discussed 
below, specifically prohibits keeping human embryos or “any product o f  SCNT, 
parthenogenesis or androgenesis” in culture beyond twelve days, it is difficult to resolve 
these two sections as the California Constitution does not appear to allow the creation of
655 For further discussion o f  the failure to grant a right to receive the benefits o f  CIRM funded stem cell 
research refer Greenfield, D., Impatient Proponents: W hat’s Wrong with the California Stem C ell and  
Cures Act? (2004) 34(5) The Hasting Center Report 32 at pg 34
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human embryos in any manner apart from SCNT and IVF for stem cell research
656anyway.
The California Institute for Regenerative Medicine
As mentioned above, the CIRM is established by Section 1 o f Article XXXV of the 
California Constitution. Section 2 goes further and outlines the purposes o f the CIRM:
(a) To make grants and loans fo r  stem cell research, fo r  research facilities, and fo r  
other vital research opportunities to realize therapies, protocols, and/or medical 
procedures that will result in, as speedily as possible, the cure for, and/or 
substantial mitigation o f major diseases, injuries, and orphan diseases.
(b) To support all stages o f  the process o f  developing cures, from  laboratory research 
through successful clinical trials.
(c) To establish the appropriate regulatory standards and oversight bodies fo r  
research andfacilities development.
The California Stem Cell Research Cures and Bonds Act, which is added to Division 
106, Part 5 of the Health and Safety Code, expands upon the powers, role and mission o f 
the CIRM and gives the substance to the otherwise brief but ground breaking Article 
XXXV of the California Constitution.
However, the CIRM is merely the name of the body which controls access to State 
funds for human pluripotent stem cell research. In actuality it is the governing board o f 
the CIRM which makes the decisions and guidelines governing this type o f research.
The Independent Citizen’s Oversight Committee
The CIRM is governed by the Independent Citizen’s Oversight Committee which 
has “ ...full power, authority, and jurisdiction over the institute” and must oversee the 
operations of the institute.657
The ICOC is composed of 29 members drawn from Californian Universities (9), 
non-profit academic and research institutes (4), commercial life science institutes (which
656 For the full list o f  activities which are ineligible for CIRM funding refer to §100030 The CIRM M edical 
and Ethical Standards Regulations CIRM (2006)
http://CIRM.ca.gov/laws/pdf/Compiled Regulations 2.pdf (accessed 11/4/07)
657 Hereafter referred to as the ICOC.
§ 125290.15 and § 125290.40 (a) California Health and Safety Code, California Stem Cell Research and  
Cures Bond Act http://www.cirm.ca.gov/prop71 /pdf/prop71 .pdf (accessed 4/6/07)
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are not actively involved in stem cell research) (4), various advocacy groups (10) and
• 658finally the chairperson and vice chairperson (2).
The advocacy groups which have members on the ICOC represent the following 
diseases:
• Spinal cord injury
• Alzheimer’s disease
• Type II diabetes
• Multiple sclerosis or amyotrophic lateral sclerosis
• Type I diabetes
• Heart disease
• Cancer
• Parkinson’s disease
• Mental health disease
• HIV/Aids659
Whilst it is admirable to include representatives o f advocacy groups it can be 
questioned if these representatives will be able to remain neutral when considering 
research applications which do not directly benefit the disease which they represent. As 
will be seen representatives of the disease advocacy groups are required to sit on the 
various working groups of the ICOC, including the Research Funding Working Group. 
Whilst the ICOC is required to hold some public meetings every year, the Research 
Funding Working Group meetings could be held in closed sessions, although the award 
of grants will be made in public meetings.660
Californian Universities are also highly represented on the ICOC, with a 
representative from the University of California at San Francisco, Davis, San Diego, Los 
Angeles and Irvine.661 The remaining Californian University representatives can come 
from any other Californian University “...that has demonstrated success and leadership
658 Ibid. at §125290.20
659 Ib id  at §125290.20 (a)(3)-(5)
660 Ib id  at §125290.30 (d)(l)-(3)
661 Ib id  at §125290.20 (a)(1)
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in stem cell research. ”662 There are also additional qualifying requirements for these 
Universities to have representatives on the ICOC (refer to §125290.20 (a)(2)(A)(i)-(iii) 
California Health and Safety Code, California Stem Cell Research and Cures Bond Act).
Looking at the membership of the ICOC it is obvious that no-one can be a member 
without either representing a body with an established record in stem cell research or 
representing a group who has a vested interest in the success o f stem cell research. This 
includes the Chairperson and Vice Chairperson who must have a “Documented history in 
successful stem cell research advocacy. ” 663 In retrospect this weighting towards 
supporters of stem cell research is hardly surprising, after all this is the body designed to 
award grants to support such work. However, it is a criticism which has also been 
levelled at the UK’s regulatory body, the HFEA that bodies which oversee stem cell 
research should have members who are opposed to such work to provide a contrary 
viewpoint and to ensure that the research which is being undertaken is strictly necessary. 
By including members who are opposed to human embryonic stem cell research upon 
such regulatory bodies both sides o f the argument would be heard before decisions were 
reached upon the funding of such controversial research. In all likelihood though this 
would result in deadlock and the repetition of arguments slowing or preventing decisions 
from being made and progress occurring in this area of science. Once an area o f research 
has been governed upon as acceptable, as has been the case in both California and the 
UK, it is important that progress is made and not hindered at every turn.
The functions of the ICOC
The ICOC has a number of specific functions which are laid out in §125290.40 of 
the California Health and Safety Code. These include:
(d) Ensure the completion o f an annual financial audit o f  the institute’s operations.
(e) Issue public reports on activities o f  the institute.
(f) Establish policies regarding intellectual property rights arising from  research 
funded by the institute.
662 Ibid. at §125290.20 (a)(2)(A)
663 Ibid. at §125290.20 (a)(6)(A)(i)
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(m)May annually modify its funding and finance programs to optimize the institute’s 
ability to achieve the objective that its activities be revenue-positive fo r  the State 
o f  California during its first five years o f  operation without jeopardizing the 
progress o f  its core medical and scientific research program.
(n) ...accept additional revenue and real and personal property... that may be used to 
supplement annual research grant funding and the operations o f  the institute.
The requirement to complete an annual financial audit and to issue public reports on 
the activities of the CIRM is hardly surprising in light o f the fact that it is taxpayers’ 
money which is funding this research. What is interesting to note is that the ICOC is 
under an obligation to ensure that the CIRM is returning a profit within five years of 
starting its operations. It is without doubt that the CIRM must make a profit so as to be 
able to repay the $3 billion which the taxpayers are providing through the sale of general 
obligation bonds, however, the fact that the CIRM must start to be revenue-positive 
within five years is interesting. The promise of stem cell research, particularly human 
embryonic stem cell research, is that it will provide therapies and cures for a large 
number of diseases. However, at present it is just that, a promise. Scientists are predicting 
that it will be many years before any therapies come to market. However, the pressure is 
on California and the CIRM to show that not only are these therapies and cures within 
reach but to also make a profit upon the discoveries.
It should be noted that due to the intellectual property policy which the ICOC has 
created, the CIRM will see a return in a number of different situations. The policy o f the 
CIRM for non-profit organisations states that the policy
...is intended to meet the dual goals o f  academic openness and the need to bring 
scientific advances to the public via commercialization. ...[the policy] aims to provide 
a financial benefit to the State o f  California through revenue sharing in the event that 
CIRM-funded discoveries lead to valuable diagnostics and/or medical therapies.664
The intellectual property policy requires that any revenue on CIRM-funded patented 
inventions exceeding $500,000 the grantee organisation must pay 25% of its profits to the 
CIRM (25% on the portion exceeding $500,000).665 An invention is defined according to 
the Bayh-Dole Act (which along with the US Patent Code governs intellectual property in 
the United States) as “...a discovery that is or may be patentable (novel, useful and
664 Intellectual Property Policy fo r  Non-Profit Organizations CIRM approved by the ICOC 2/10/06 at Pg 4- 
5 http://www.cirm.ca.gov/policies/pdf/IPPNPO.pdf (Accessed 11/4/07)
665 Ibid. at Section H(f)(2), Page 19
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obvious) or otherwise protectable under Title 35 o f  the United States Code.1,666 Therefore 
the ‘invention’ upon which the funded bodies need to repay the CIRM are not defined in 
terms of therapies and cures; rather it is a ‘discovery’. This could include scientific 
processes, culture mediums or new stem cell lines (as was the case in the Thomson
patents).667 Therefore the potential for the CIRM to start to make a profit within five
668years of starting its operations may not be as unrealistic as it first appears.
ICOC Working Groups
The ICOC also has functions in respect of its working groups.
(g) Establish rules and guidelines fo r  the operation o f the ICOC and its working 
groups.
(i) Select members o f  the working groups.669
The CIRM is required to have three different scientific and medical working groups, 
these are:
1. The Scientific and Medical Research Funding Working Group
2. The Scientific and Medical Accountability Standards Working Group
3. The Scientific and Medical Research Facilities Working Group670
These Working Groups are purely advisory and have no final decision making 
authority, therefore the recommendations which the Working Groups make can be 
considered by the ICOC and potentially ignored in reaching the final decision.671 The 
possibility of this occurring is slim though due to the presence of ICOC members on each
666 Ibid. at Glossary, Section D, Page 7
667 For a full discussion o f  the scope, range and problems with stem cell patents refer to Korobkin, R., Stem  
Cell Century, Law and Policy fo r  a Breakthrough Technology (2007) Yale University Press at Ch 4 Stem  
Cell Patents
668 For a detailed critique o f  the financial benefits which may accrue to California and how these w ill be 
assessed refer to Longaker, M.T., Baker, L.C. and Greely, H.T., Proposition 71 and CIRM -  assessing the 
return on investment (2007) 25(5) Nature Biotechnology 513
669 §125290.40 ICOC Functions, California Health and Safety Code, California Stem Cell Research and  
Cures Bond Act http://www.cirm.ca.gov/prop717pdf/prop71 .pdf (accessed 4/6/07)
670 Ibid. at §125290.50
671 Ibid. at §125290.50 (e)(3)
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of the Working Groups, thereby helping to ensure that the recommendations of each 
Working Group are fairly considered, even if they are not followed to the letter.
The Accountability Standards Group is composed o f 19 members, five of the ICOC 
disease advocacy members, nine scientists nationally recognised in the field of stem cell 
research, four medical ethicists and the Chairperson o f the ICOC.672 The role of this 
Working Group is to recommend to the ICOC scientific, medical and ethical standards, 
standards for all medical, socioeconomic and financial aspects o f clinical trials and 
therapy delivery to patients, the modification of those standards, recommend appropriate 
oversight by the ICOC of funded research to ensure compliance with the standards and to 
advise on an ongoing basis about relevant ethical and regulatory issues.
The use of ‘nationally recognised’ scientists in this Working Group provides an 
opportunity for any standards which are recommended to the ICOC to reflect, consider 
and possibly incorporate the standards which are being used elsewhere in the United 
States (where this type of work is permitted and being performed). The incorporation of 
medical ethicists is also vital as this ensures that the standards which are recommended 
have passed ethical review and consideration and should reach the highest ethical 
standards.
In contrast the role of the Research Funding Working Group is to recommend to the 
ICOC standards and requirements for the consideration of funding applications and for 
awarding research grants and to recommend standards for the medical and scientific 
oversight of funding awards. It is also required to review those grant applications and 
make recommendations to the ICOC whether to award funding, conduct progress 
oversight reviews of grantees and to recommend to the ICOC standards for evaluating 
grantees to ensure that they comply with all requirements.674 The membership quota of 
this group is also higher than that of the Accountability Standards Working Group. The 
Research Funding Working Group is composed of 23 members, seven ICOC members 
from the disease advocacy groups, fifteen scientists nationally recognised in stem cell 
research and the Chairperson of the ICOC.675
As mentioned previously the high number o f ICOC disease advocacy members is of 
slight concern here. As noted, the Research Funding Working Group has the role of
672 Ibid. at § 125290.55(a)
673 Ibid. at §125290.55 (b)(l)-(5)
674 Ibid. at §125290.60 (b)(l)-(6)
675 Ibid. at §125290.60 (a)
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reviewing grant applications and making recommendations to the ICOC for the award of 
funding. Whilst the ICOC has the final decision making power in all situations it is to be 
thought that the ICOC will generally follow the recommendations o f its Working Groups, 
otherwise what is the point of these groups? Even if the ICOC disease advocacy members 
try to take a position of neutrality concerning the review o f funding applications it is 
almost inevitable that should there be disagreement over recommending the award of 
funding to an application, if the application is considering the disease o f which that 
member is representing, he will almost undoubtedly be in favour o f this research, with the 
possibility o f overlooking some fundamental aspect.
O f course, an alternative view to look at this situation with the ICOC disease 
advocacy members is to bear in mind that although there are seven such members sitting 
on the Research Funding Working Group, each member is representing a different 
disease. Additionally, there is the presence of fifteen scientists who are the only members
f n f tof this group permitted to evaluate the scientific merit o f the research application. 
Therefore, even if one ICOC disease advocacy member strongly supports a research 
application, possibly because it is specific to the disease which they are representing, 
there are 22 other members o f the groups whose opinions have to be taken into 
consideration before a final recommendation can be made to the ICOC.
At this point, it is important to note that
Recommendations o f each o f  the working groups may be forwarded to the ICOC only 
by a vote o f  a majority o f  a quorum o f  the members o f  each working group. I f  35 per  
cent o f  the members o f  any working group jo in  together in a minority position, a 
minority report may be submitted to the ICOC...677
A quorum consists of at least 65% of the members who are eligible to vote.678 
Therefore there should be a very small risk of one persuasive ICOC disease advocacy 
member controlling the research funding to the favour of his particular disease. The 
possible conflict of interest though should always be borne in mind.
The final Working Group for consideration is the Facilities Working Group. The role 
of the Facilities Working Group is self-explanatory; it makes recommendations to the 
ICOC standards for applications for, and awarding of, grants for buildings and
676 Ibid. at §125290.60 (c)(1)
677 Ibid. at §125290.50 (d)
678 Ibid  at §125292.10 (s)
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equipment.679 This is necessary due to the fact that Federal money has been used in many 
research laboratories in the past for various different research projects. However, the 
Federal funding rules governing human embryonic stem cell research prohibits Federal 
funds being used in any manner in relation to human embryonic stem cell research which 
is not permitted under President Bush’s policy. Therefore the situation has arisen 
whereby equipment such as microscopes, Petri dishes and laboratories which have been 
previously paid for with Federal funds cannot be used for human embryonic stem cell 
research in California (or elsewhere in the United States) where those stem cell lines have 
been created after the 9th August 2001. The reason for this is that “The complicated 
bookkeeping required by federal policy, along with fear o f  political repercussions should 
errors be made, has caused some universities to take even more extreme precautions to
/ C O S )
prevent intermingling o f  funds than the government actually requires. ” It has resulted 
in the ridiculous situation where laboratories have been physically separated with barriers 
or new laboratories have been or are being built alongside already perfectly useable 
facilities.681
Therefore it can be seen that the ICOC, along with the three Working Groups, 
controls the access to the CIRM funds as well as setting the appropriate standards for 
applications to be considered.
The funding story so far...
The California Institute for Regenerative Medicine is charged with distributing 
$295 million dollars a year over a ten year period to fund stem cell research and 
dedicated facilities in a bid to “Improve the California health care system and reduce the 
long-term health care cost burden on California through the development o f  therapies 
that treat diseases and injuries with the ultimate goal to cure them.”682
This level of funding has not been seen anywhere else in the world. In 
comparison, the Stem Cell Initiative in the United Kingdom has secured a total o f up to 
£100 million o f public sector funding for stem cell research from 2006 until 2008 and the
679 Ibid. at §125290.65 (b)
680 Korobkin, R., Stem Cell Century, Law and Policy fo r  a Breakthrough Technology (2007) Yale 
University Press at pg 55 (Ch 2 Embryo Wars)
681 Ibid. Refer to the situations at Harvard and Stanford at pg 55 (Ch2 Embryo Wars)
682 Section 3, Purpose and Intent California Stem Cell Research and Cures Initiative 
http://wvyw.cirm.ca.gov/prop71/pdf/prop71.pdf (accessed 4/6/07)
275
National Institutes of Health allocates around $40 million a year to human embryonic 
stem cell research.
Although the legality o f Proposition 71 was being challenged in the courts, with 
the effect that the bond issuance necessary to support the research programme was halted 
before it even started, the CIRM was still able to start work on formulating its policies for 
the regulation o f stem cell research and was even able to distribute some grants.
“On April 10, 2006, CIRM officially became a State funding agency when it 
announced that the first stem cell grants were awarded.”684 The CIRM was able to 
announce the first stem cell grants due to “ ...the sale o f  $14 million o f  bond anticipation 
notes (BANs) from  six leading California philanthropic individuals and foundations. ”685 
These initial grants to 16 Californian non-profit institutions were to train new stem cell 
researchers and a total of 169 training fellowship grants were awarded to the tune of 
$12.1 million. In August 2006 the Californian Governor, Arnold Schwarzenegger decided 
to loan the CIRM $150 million from the State’s general fund and in November 2006 an 
additional $31 million in BANs was announced.686
Following these initial training grants the CIRM called for applications for a further 
three different types o f grant. This new grant programme Innovation in Human 
Embryonic Stem Cell Research is designed to focus upon human embryonic stem cell 
research 687 These grants are:
• The Leon J. Thai SEED Grants
• Comprehensive Research Grants
• Shared Research Laboratories Grants
683 For the UK Government funding refer to the Government Response to the U K Stem Cell Initiative 
Report and Recommendations
http://www.dh.gov.uk/en/Policvandguidance/Healthandsocialcaretopics/Stemcell/Stemcellgeneralinformati 
on/DH 4124082 (accessed 28/6/07, last updated 8th February 2007) and for the US NIH funding refer to 
NIH -  Estimates o f  Funding fo r  Various Diseases, Conditions, Research Areas
http://www.nih.gov/news/fundingresearchareas.htm (accessed 12/08/08) The table provides actual figures 
for 2004-2007, estimates for 2008-2009, last updated 5th Feb 2008
684 Scientific Strategic Plan December 2006 CIRM at pg 17
http://www.cirm.ca.gov/meetings/pdF2006/12/1207Q6 item 7.pdf (accessed 4/6/07)
685 Ibid. at pg 17
686 Ib id  at pg 17
687 Ibid. Refer to Page 17 and 61 to 63
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On the 16th February 2007 the CIRM distributed $45 million across 72 grants to 20
• 688 Californian institutions for human embryonic stem cell research. SEED grants
(Scientific Excellence through Exploration and Development) “...are intended to bring
new ideas and new investigators into the fie ld  o f  hESC research and offer an opportunity
for investigators to carry out studies that may yield preliminary data or proof-of-
principle results that could then be extended to fu ll scale investigations. ”689
On the 16th March 2007 the CIRM approved 29 Comprehensive Research Grants
which resulted in the award o f $75 million over 4 years to 12 academic and non-profit
research centres.690 “Comprehensive Research Grants will support mature, ongoing
studies on hESCs by scientists with a record o f accomplishment in the field. ”691 The work
which is being funded covers a broad range of projects including studies “to develop
neural cellular models o f  Parkinson’s Disease", “development o f  new ways to derive
human embryonic stem cells ” and “building better tools to isolate heart and blood cells
from  differentiated populations o f  human embryonic stem cells. ”692
The final stage of this grant programme was the award o f the Shared Research
Laboratories Grants. These were announced on the 5th June 2007. These grants are to
fund dedicated laboratory space for the culture of human embryonic stem cells,
particularly those which are outside o f the Federal funding guidelines. They are to be
used to develop core laboratories for use by multiple investigators and are to be shared by
multiple institutions, providing an environment for the unrestricted conduct o f scientific
research on human embryonic stem cells.693 The terminology used within the Scientific
Strategic Plan to describe the objectives of the Shared Research Laboratory Grant
Programs is very worrying as it specifically says that these Grants are “...to provide an
environment...for the unrestricted conduct o f  scientific research on hESCs.” 694
Considering that Proposition 71 and the Medical and Ethical Standards Regulations do
688 CIRM press release 16th February 2007 ‘$45 MILLION FOR STEM CELL RESEARCH IN 
CALIFORNIA’ http://www.cirm.ca.gov/press/pdf/2007/02-16-07.pdf (last accessed 11/08/08)
689 Page 17, Scientific Strategic Plan December 2006 CIRM 
http://www.cirm.ca.gov/meetings/pdF2006/12/1207Q6 item 7.pdf (accessed 4/6/07)
690 CIRM press release 16th March 2007 ‘$75 MILLION BOOST FOR CALIFORNIA STEM CELL 
SCIENTISTS’ http://www.cirm.ca.gov/pressreleases/pdf/2007/Q3-16-07icoc.pdf (accessed 20/3/07)
691 Scientific Strategic Plan  December 2006 CIRM at pg 17 
http://www.cirm.ca.gOv/meetings/pdf/2006/12/l 20706 item 7.pdf (accessed 4/6/07)
692 Page 2, CIRM press release 16^ March 2007 ‘$75 MILLION BOOST FOR CALIFORNIA STEM 
CELL SCIENTISTS’ http://www.cirm.ca.gov/pressreleases/pdF2007/03-16-07icoc.pdf (accessed 20/3/07)
693 Scientific Strategic Plan, December 2006 CIRM at pg 62
http://www.cirm.ca.gov/meetings/pdf/2006/12/120706 item 7.pdf (accessed 4/6/07)
694 Ibid. at pg 62
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impose some research limits upon stem cell research (although limited) this wording 
stands out almost as an attempt to override those rules. In reality it is to be hoped that this 
wording was a careless slip in the drafting of the Scientific Strategic Plan and that at most 
it is a reference to the very restricted research which is permitted under Federal 
guidelines and funding. In total $50 million has been distributed to 17 academic and non­
profit institutions under the Shared Research Laboratories Grants.695
In the interim, between the award of the Comprehensive Research Grants and the 
Shared Research Laboratories Grants, the legal challenges to Proposition 71 were finally 
ended with the Supreme Court of California refusing leave to appeal (as discussed 
above). With this announcement the CIRM now needs to repay the State o f California the 
$150 million loan which it was given in August 2006 and to also repay the philanthropists 
who made loans to enable the CIRM to get up and running whilst the cases were 
ongoing.696
In the last year (June 2007-2008) the CIRM has distributed a further $349 million. 
$54 million was awarded for 22 New Faculty Awards “...to encourage and support the 
next generation o f  clinical and scientific leaders in stem cell research. ”697 $271 million 
was awarded to 12 different institutions under the Major Facilities Grant Program. These 
grants are awarded so as to enable institutions to fund and build new facilities “...that are 
free o f  any federal funding so as to allow research and development o f  therapies based 
on human embryonic stem cell (hESC) and other stem cell approaches to proceed in 
California without restrictions imposed by the federal government ...bring stem cell- 
related researchers together in a collaborative setting. ”698
Additionally, $23 million has been awarded to 25 institutions under the New Cell 
Lines Awards “...to support the derivation and propagation o f  new lines o f  pluripotent 
human stem cells with important research and clinical application fo r  understanding,
695 CIRM press release 5th June 2007 ‘FIRST STEM CELL RESEARCH FACILITIES GRANTS 
APPROVED’ http://www.cirm.ca.gov/pressreleases/pdF2007/06-05-Q7.pdf (accessed 7/6/07)
696 CIRM press release 16th May 2007 ‘LITIGATION AGAINST CALIFORNIA STEM CELL PROJECT 
ENDS’ http://www.cirm.ca.gov/pressreleases/Ddf/2007/05-16-07.pdf (accessed 4/6/07)
697 A pproved CIRM Grants as o f  June 2008  CIRM http://www.crim.ca.gov/info/grants.asp (accessed 
10/08/08)
698 CIRM press release 7th May 2008 Page 4 ‘CALIFORNIA STEM CELL AGENCY, DONORS AND 12 
CALIFORNIAN INSTITUTIONS COMMIT $1.1 BILLION TO INCREASE THE CAPACITY FOR 
STEM CELL RESEARCH IN CALIFORNIA’ http://www.cirm.ca.gov/press/pdf/2008/Q5-07-08.pdf 
(accessed 12/08/08)
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diagnosing and treating serious injury and disease. ”699 What is particularly interesting 
about this award is that not only are the awards for the derivation of new human 
embryonic stem cell lines from excess or rejected human embryos created by IVF, but 
they have also been awarded for the derivation o f pluripotent human stem cell lines from 
other sources such as SCNT and induced pluripotent stem cells.700 So the CIRM is 
actively engaged in pluripotent stem cell research generally, although the focus still 
remains upon human embryonic stem cells.
Finally, $1 million was awarded across 22 Disease Team Planning grants which are 
designed “...to support multi-disciplinary teams o f scientists in pursuits o f  therapies fo r
701  • •specific disease. ” These are preliminary awards to teams who will prepare proposals to 
an upcoming request from the CIRM for proposals for major grants to support 
translational research that could lead to clinical trials. These proposals are to be 
considered by the ICOC in June 2009 and the award of these grants should be a major 
step towards the CIRM realising its goal of proving therapies and cures for disease and 
injury.702
With these grants being awarded between April 2006 and June 2008 and totalling 
nearly $555 million the CIRM is already on its way to fulfilling its obligation to distribute 
$295 million a year for the next ten years. This level of funding is immense and yet it 
remains to be seen if the Californian public will be repaid, not only financially but also 
health wise in the much hoped for therapies and cures which stem cell research 
potentially offers.
699 CIRM press release 27th June 2008 Pg 1 ‘$24 MILLION IN NEW STEM CELL RESEARCH  
FUNDING AWARDED TO 25 CALIFORNIA INSTITUTIONS’ 
http://www.cirm.ca.gov/press/pdF2008/06-27-Q8.pdf (accessed 12/08/08)
700 Ibid. at Pg 1
701 Ibid. at Pg 2
702 Ib id  at Pg 2
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Oversight and Regulation of Stem Cell Research by the California
Institute for Regenerative Medicine
...the institute will develop its own scientific and medical standards to carry out 
the specific controls and intent o f  the act... The ICOC, its working committees, 
and its grantees shall be governed solely by the provisions o f  this act in the 
establishment o f  standards, the award o f  grants, and the conduct o f  grants 
awarded pursuant to this act.703
The CIRM took time to formulate, finalise and approve many o f its policies.704 
However, the CIRM did manage to formulate and approve the Medical and Ethical 
Standards Regulations and the Scientific Strategic Plan promptly which were vital for the 
running of the CIRM’s operations.
The CIRM Medical and Ethical Standards Regulations
The CIRM Medical and Ethical Standards Regulations became effective as o f the 
22nd November 2006.705 The Regulations were brought into force prior to the first grants 
for human embryonic stem cell research on the 16th February 2007.
The CIRM Medical and Ethical Standards Regulations are effectively the 
equivalent of the sections o f the UK’s HFE Act which deal with the prohibited activities 
in respect of embryo research, the oversight of that research and donor consent.
The first point to note is that the CIRM Medical and Ethical Standards 
Regulations apply only to CIRM-funded research.706 Again the issue of regulating stem 
cell research falls to the funding bodies; rather than produce comprehensive ethical 
guidelines which apply to all forms and stages of human embryonic stem cell research 
regardless o f the source of funding, the issue is left to each body to regulate. Whilst the 
CIRM may well become the main source of funding for stem cell research in California 
there will still be some privately funded work occurring in California. It can be
703 §125290.35 (a) Medical Standards, California Health and Safety Code, California Stem C ell Research  
and Cures Bond A ct http://www.cirm.ca.gov/prop71/pdf/prop71.pdf (accessed 4/6/07)
704 Refer to CIRM Regulations web page for policies under discussion: 
http://www.cirm.ca.gov/laws/default.asp (accessed 7/6/07)
705 Introduction, The CIRM M edical and Ethical Standards Regulations CIRM (2006) 
http://ClRM.ca.gov/laws/pdf/Compiled Regulations 2 .p d f(accessed 11/4/07)
706 Ibid. Refer to Introduction and §100010
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questioned why the State Government did not also take the opportunity to introduce State 
wide regulation of stem cell research at the time o f introducing Proposition 71.
Prohibited activities
The CIRM Medical and Ethical Standards Regulations lay out the activities which 
are not eligible for CIRM funding. These are:
(a) Human reproductive cloning
(b) The culture in vitro o f
(i) any intact human embryo or
(ii) any product o f  SCNT, parthenogenesis or androgenesis, after the appearance 
o f the primitive streak or after 12 days whichever is earlier. The 12 day 
prohibition does not count any time during which the embryos and/or cells have 
been frozen
(c) The introduction o f  stem cells from a stem cell line into non-human primates
(d) The introduction o f  any stem cells, human or non-human, into human embryos
(e) Breeding any animal into which stem cells from  a stem cell line have been 
introduced
(f) The transfer to a uterus o f  a genetically modified human embryo707
The first point to note is that the language used to refer to the time limit for the 
culture in vitro o f a human embryo, regardless of the manner of the embryos creation, 
contained in the Medical and Ethical Standards Regulations differs to the California 
Stem Cell Research Cures and Bonds Act. Within the Act the time limit refers to 
obtaining cells, not the culture of embryos in vitro. The Act states that:
Standards setting a limit on the time during which cells may be extracted from  
blastocysts, which shall initially be 8 to 12 days after cell division begins, not 
counting any time during which the blastocysts and/or cells have been stored 
frozen.7 8
The Medical and Ethical Standards Regulations places a time limit on keeping 
human embryos in culture but does this without reference to a starting point. Whilst the 
section refers to '‘human embryos and any product o f  SCNT, parthenogenesis or 
androgensis\ these are the final products after the creation process has started. Whilst
707 Ibid. at §100030
708 § 125290.35 (b)(6) California Health and Safety Code, California Stem Cell Research and Cures Bonds 
Act http://www.cirm.ca.gov/prop71/pdf/prop71.pdf (accessed 4/6/07)
281
both the Act and the Regulations have the same moral and legal cut off point of 12 days 
(cell extraction within 12 days of cell division compared to 12 days culture in vitro) it 
does need to be asked why the Regulations were phrased differently to the wording found 
within the Act, particularly as the Act is the legal basis upon which the CIRM can fund 
stem cell research.
Another issue is that by specifically stating the alternative processes to create 
embryos, other than by in vitro fertilisation, the Regulations are already running the risk 
that they will become outdated and inapplicable if and when scientists find other ways to 
create human embryos. One possible advantage o f not referring to human embryos 
created by fertilisation is that it may incorporate all future methods o f creation. This is 
dubious as the specific reference to other methods of creation implies that the Regulations 
are designed to deal with these processes specifically and not apply to other creation 
processes. The final decision would probably lie with the Court, if  the CIRM did not alter 
its Regulations immediately that a new creation method was discovered. However the 
CIRM can and would in all likelihood change the Regulations very quickly should such a 
situation arise.
An additional problem with the prohibition of the CIRM funding the retention o f 
human embryos ‘or any other product o f  SCNT, parthenogenesis or androgenesis’ in 
culture beyond twelve days has already been noted above (see the Section on the 
California Constitution). That is to say that the California Constitution only permits 
human embryonic stem cell research upon spare IVF embryos and those created 
specifically for research through SCNT. It can be questioned again why the Medical and 
Ethical Standards Regulations specifically refers to creation methods other than IVF or 
SCNT when it seems that any other method of creating embryos for stem cell research 
could not be funded by the CIRM anyway.
The other activities which are prohibited for CIRM funding are not as 
problematic. The main issue is that the Regulations have not incorporated what could be 
termed a ‘dustbin clause’. This could be a sentence such as ‘Any other activities which 
the CIRM deems ineligible for funding.’ Such a clause would allow the CIRM to 
incorporate all future creation methods, the problem identified above, as well as any other 
activities which may be felt to be unethical and not desirable to pursue (at least with State 
funding).
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Compliance
The next point to note is the issue o f compliance with the Medical and Ethical 
Standards Regulations. It is the responsibility o f the institutions which receive CIRM 
funding to provide “...written assurance satisfactory to CIRM  that CIRM-funded 
research complies with the requirements set forth in [these regulations]. ”709 This method 
of providing written assurance of compliance is common in the US. It is also the 
responsibility of the grantees to report to CIRM “...any failure to comply with the terms 
and conditions o f  an award.” 110 As it is the CIRM which reviews the research 
applications and provides funding accordingly, it would have been thought that the CIRM 
would be the only body responsible for ensuring compliance with its Regulations. 
However, the addition of institutional compliance provides an extra level o f security, 
helping to ensure compliance with the requirements set by the CIRM.
Oversight
The Medical and Ethical Standards Regulations also require all research 
institutions to designate one or more Institutional Review Boards (IRB) as well as one or 
more Stem Cell Research Oversight Committees (SCRO committee).711 The function o f 
the SCRO Committee is to “...provide scientific and ethical review o f  CIRM-funded 
research” and “...may provide oversight fo r  two or more funded research
712institutions. ”
It can be questioned why the CIRM does not have one central SCRO Committee 
which could conduct the scientific and ethical review o f CIRM-funded research, 
particularly as one SCRO Committee may be used by more than one institution. One 
advantage o f this would be that all applications for CIRM funding would receive the 
same review treatment and the central SCRO Committee would rapidly build up 
experience o f dealing with stem cell research funding applications.
709 §100040 (a) The CIRM M edical and Ethical Standards Regulations CIRM (2006) 
http://CIRM.ca.gov/laws/pdf/Compiled Regulations 2.pdf (accessed 11/4/07)
7,0 Ibid. at §100050
711 Ibid. at §100040 (b)(2) and (3)
712 Ibid. at §100060 (c) and (e)
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The Research Funding Working Group already recommends to the ICOC 
standards and requirements for considering funding applications and for awarding 
research grants. It also reviews all research funding applications, including the scientific 
merit o f those applications. It is therefore apparent that all research funding applications 
are not only reviewed for scientific and ethical merit by the institutional SCRO 
Committee but are also subject to the same review by the Research Funding Working 
Group before making recommendations of awarding grants to the ICOC for the final 
decision. With the Accountability Standards Working Group also recommending to the 
ICOC the scientific, medical and ethical standards it is unclear why the CIRM has 
established the SCRO Committees within the institutions requesting funding. It seems 
that all research funding applications are in fact subject to a double review, first by the 
institutional SCRO Committee then by the Research Funding Working Group, before the 
final decision by the ICOC. The usefulness of this double review can be questioned. 
Research institutions already have departments and personnel who can advise research 
applicants if  their proposed research complies with all the necessary rules and guidelines, 
why require the institutions to also undertake scientific and ethical review when that will 
be completed by the Research Funding Working Group? This central Working Group 
will rapidly build up the experience which it needs to review research applications, 
whereas the local institutional SCRO Committees will see far fewer applications in 
comparison and so will take far longer to build up comparative experience.
A similar comment has been made in Chapter 4 of this thesis in respect of the role 
played in the United Kingdom by Research Ethics Committees in their ethical review role 
o f licence applications and following up progress of research. Research Ethics Committee 
scrutiny is only legally required for research which involves NHS patients or facilities 
and yet the HFEA normally requires research ethics committee approval for all research 
licence applications. This is very similar to the CIRM requirement that a SCRO 
Committee reviews CIRM funded research as well as the involvement o f an IRB. It is the 
CIRM which has chosen to impose this additional level o f scrutiny.
At first sight there appears to also be the risk that these SCRO Committees will be 
biased towards approval of all applications. After all the SCRO Committee is set up 
within the very institution from which it is receiving applications for scientific and ethical 
review. As Winickoff notes
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SCRO members are likely to be...from the research institution itself. Such 
members would be likely to appreciate the value o f  these investments to the 
institution, and may be influenced by the desire to protect the overall fiscal health
711o f the entity.
However, upon closer examination o f the Medical and Ethical Standards 
Regulations an attempt has been made to negate the possible conflict o f interest. The 
membership of an SCRO Committee must include, at a minimum, people with expertise 
in developmental biology, stem cell research, molecular biology, assisted reproduction 
and ethical issues in stem cell research as well as at least one patient advocate. Whilst 
these members may be employees of the institution which has established the SCRO 
Committee there is the additional requirement that a SCRO Committee shall include at 
least one non-scientist member of the public who is not paid by the institution.714
The inclusion of a member with expertise in ethical issues o f stem cell research is 
important as without this member there could be a serious risk o f the members merely 
considering the scientific issues, and neglecting to give full consideration o f the ethical 
issues connected with this type of research such as appropriate donor consent, protection 
of women who donate their eggs to research as well as considering the actual use of 
embryos in research. It is to be hoped that the balance of expertise, along with at least one 
member who is not reimbursed by the institution where the SCRO Committee is based, 
will result in fair and balanced consideration of applications for and ongoing review of, 
CIRM funded research. However, “There is a danger that the SCRO system o f  oversight 
could create the perception that crucial ethical decisions are being made in the dark back 
rooms o f  the very institutions that stand to gain from large CIRM grants. ”715 Until these 
SCRO Committees are convened and their actions scrutinised there is no way o f knowing 
which of the two possible routes discussed above the committees may go down.
The SCRO Committees not only have a role to play in reviewing research prior to 
an application being submitted to the CIRM, they also play a role in research which has 
been awarded CIRM funding and is ongoing. The SCRO Committee approvals are to be 
reviewed at least once per year and “The renewal review shall confirm compliance with
713 Winickoff, D.E., Bioethics and Stem Cell Banking in California (2006) 21 Berkeley Tech. L.J 1067 at 
pg 1089
714 §100060 (a) The CIRM M edical and Ethical Standards Regulations CIRM (2006) 
http://CIRM.ca.gov/laws/pdf/Compiled Regulations 2.pdf (Accessed 11/4/07)
715 Winickoff, D.E., Bioethics and Stem Cell Banking in California  (2006) 21 Berkeley Tech. L.J 1067 at 
pg 1090
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all applicable rules and regulations. The SCRO Committee may establish guidelines and 
procedures fo r  expedited review o f  renewals so that review by the entire SCRO 
Committee is not required. ”716 Whilst it is to be congratulated that the approval is to be 
reviewed at least once per year, the possibility o f the review being completed by an 
incomplete SCRO Committee is somewhat worrying. There is a possibility that new 
ethical or scientific issues may have arisen since the research was approved for funding. 
If the full complement o f the SCRO Committee membership is not involved in the review 
process, how can these issues be reviewed and resolved? Upon closer inspection o f the 
wording used in relation to SCRO Committee ongoing review, it becomes obvious why it 
may be possible to review approvals without the full membership. This is due to the fact 
that the review is merely required to ensure compliance with all applicable rules and 
regulations. The SCRO Committee is not required to look again at the scientific and 
ethical issues of the funded research, even where issues may have arisen subsequent to 
the research receiving funding. Therefore the role of the SCRO Committee in reviewing 
ongoing research is merely to ensure compliance, not to thoroughly review the research.
The SCRO Committee is required to review and approve in writing specified research 
projects, as defined by the Medical and Ethical Standards Regulations and funded by the 
CIRM. These research projects are:
1) Research involving the procurement or use of human oocytes -  the researcher 
must justify the use o f oocytes, the numbers needed and justify SCNT if the 
process is to be used
2) Research involving the use of human embryos -  the researcher must justify the 
use o f embryos and the numbers required
3) Research with the aim to derive or create a covered stem cell line717 -  the 
researcher must justify why there is a need to derive the stem cell line, the use o f 
SCNT if proposed, and show how the stem cell lines will be stored, distributed, 
validated and characterised to ensure the confidentiality o f donors
4) Research introducing covered stem cell lines into non-human animals -  the 
researcher must provide justification for undertaking this process and show that 
the stem cell lines have been acceptably derived. The reader should be reminded 
o f the prohibitions in §100030 (c) and (e) which prohibit the introduction of stem 
cells into primate embryos and the prohibition to breed any animal into which 
stem cells have been introduced
716 §100070 (h) The CIRM M edical and Ethical Standards Regulations CIRM (2006) 
http://CIRM.ca.gov/laws/pdPCompiled Regulations 2.pdf (accessed 11/4/07)
7,7 Ibid. at §100020 (c) Defined in the Regulations as: “...a  culture derived, human pluripotent stem cell 
population that is capable of: (1) sustained propagation in culture; and (2) self-renewal to produce  
daughter cells with equivalent developmental potential. ”
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5) Research introducing stem cells from covered stem cell lines into a live bom 
human -  the researcher must provide justification for introducing stem cells into 
humans and show that the stem cell lines have been acceptably derived718
Furthermore, the SCRO Committee must be notified in writing where there is 
“...purely in vitro research utilizing covered stem cell lines. ”719 Researchers must show 
that the stem cell lines have been acceptably derived along with proof o f compliance with 
and required review of the proposed research by an IRB.
This mere notification requirement for work upon stem cell lines could lead to 
problems in the future. For a start, as there is no SCRO Committee making scientific or 
ethical review of the type of work which is being undertaken upon these stem cell lines, 
there is the risk that the work being undertaken suffers from ethical issues which should 
be addressed prior to starting the research. There is also a risk o f work being repeated, 
possibly within the same institution but certainly within all o f the Californian institutions 
eligible for CIRM funding for this type of research. This is another problem with the 
SCRO Committees being localised rather than centralised. Whilst the CIRM reviews all 
research applications and it would be hoped is able to distinguish between research 
applications, this really is the work of the SCRO Committees, to review the scientific 
merit of the research proposed.
Additionally, as one commentator has noted, “Furthermore, i f  researchers in 
California send cells out to non-CIRM funded researchers, then any subsequent SCRO  
oversight would be purely voluntary. No formal legal requirement would exist that 
research funded outside o f  CIRM, but on CIRM-derived lines, be subject to any 
institutional oversight. ”720 When the CIRM has worked hard to ensure that there is 
oversight o f stem cell research (whether this is adequate or appropriate is open to debate 
as above) it is somewhat strange that there is no additional requirement for SCRO 
Committee oversight when CIRM-derived cell lines are being used for research and 
worked upon by non-CIRM funded researchers. This is a major flaw with stem cell 
research in the United States, not just at State level in California, and is yet another 
reason why there should be national oversight of stem cell research. This would be 
possible, even though the 52 States of America have all taken different approaches
718 Ibid. at §100070 (a)-(c) and (e)-(f)
719 Ibid. at §100070 (d)
720 Winickoff, D.E., Bioethics and Stem Cell Banking in California (2006) 21 Berkeley Tech. L.J 1067 at 
pg 1092
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towards human embryonic stem cell research. There could be national regulation of stem 
cell research in those States which permit such research which requires not only SCRO 
Committee oversight of the research, but also lays out clearly the permitted and 
prohibited areas of research and would ensure consistency between the States. I believe 
that this would not contravene the popular view that the human embryo should be 
protected from the moment of its conception (which ever method that may be), which is a 
widely held belief within the United States, hence the current Federal position on stem 
cell research. I believe that this widely held belief would not be contravened by 
introducing national regulation as each State still has the option whether or not to allow 
such research to occur within its borders, just as the Californian public chose in 
November 2004 with the approval o f Proposition 71. Those who strongly and fervently 
believe that human embryos should be protected at all times will not be involved in the 
research, either as researchers, donors of gametes or as patients o f the therapies which 
may be developed from human embryonic stem cell research.
A final point to note in relation to the different research areas that require SCRO 
Committee written approval prior to starting the research application process with the 
CIRM, is that within the section governing SCRO Committee review, there is nothing 
which would allow the CIRM to easily add in or alter the research areas which would 
require SCRO Committee approval. Overall, this is another major flaw with the Medical 
and Ethical Standards Regulations. The Regulations do not contain any provisions which 
would allow the CIRM to easily alter the Regulations should it be required. That is not to 
say that the Regulations should not be fully debated prior to alteration, but with science 
rapidly advancing the ability to alter the Regulations at relatively short notice could be 
invaluable. One only needs to look to the United Kingdom’s 2001 Regulations which 
introduced three new research purposes into the HFE A ct to specifically allow stem cell 
research, to see the value of alteration provisions such as these.
Amendments to Proposition 71
Although the CIRM has been established under the California Stem Cell Research 
and Cures Bond Act to distribute funds over 10 years for stem cell research, there is a 
possibility that the California Stem Cell Research and Cures Bond Act may need to be 
amended or altered before these ten years expire.
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The process for amending the statutory provisions o f the Act is contained in the 
final paragraph:
The statutory provisions o f  this measure, except the bond provisions, may be 
amended to enhance the ability o f  the institute to further the purposes o f  the grant 
and loan programs created by the measure, by a bill introduced and passed no 
earlier than the third fu ll calendar year follow ing adoption, by 70 percent o f  the 
membership o f  both houses o f  the Legislature and signed by the Governor, 
provided that at least 14 days prior to passage in each house, copies o f  the bill in 
fina l form  shall be made available by the clerk o f  each house to the public and 
news media.721
The first point to note is that action to amend the Act cannot be taken until three
722  •years after the measure has been adopted, in this situation not until January 2008. This 
three year period of allowing the legislation to sit on the books without alteration allows 
the CIRM to formulate and implement the many policies which it needs to devise. It also 
allows a period of reflection, permitting the CIRM the time to identify problems which 
may need to be rectified by amendment at a later date. Importantly, for the supporters of 
the Act, this three year period prevents unnecessary legal challenges to the Act through 
introducing amendments which would or could dramatically alter how the Act works. 
Any amendments introduced in this manner would be time consuming and costly and in 
light o f the fact that there was a public referendum which passed the Act, a waste o f 
taxpayers money.
Interestingly the amendment provision of the Act requires 70% o f both Houses of 
the Legislature to approve any proposed amendments. This is a very high percentage to 
require and it can be questioned if this will result in no amendments ever passing the 
Houses for approval. Considering that only 59% of the public voted in favour o f 
Proposition 71 it is unlikely that there will be 70% support for stem cell research and 
amendments to the very Act supporting that type o f research in both Houses. It is possible 
of course that the approval percentage was deliberately set that high in an attempt to 
prevent all future amendments, if  this was the reasoning behind it this would be very 
strange as legislation needs to adapt and be adapted as needs arise. In an area o f science 
developing as fast as stem cell research it is vital that legislation governing this area of
721 Article 3, Section 8 California Stem Cell Research and Cures Initiative 
http://www.cirm.ca.gov/prop71/pdf/prop71.pdf (accessed 4/6/07)
722 Confirmed in personal communication with CIRM on 11th July 2007
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work is able to keep up to date with current developments. There is the risk that the 
California Stem Cell Research and Cures Bond Act will fail to do this if  amendments are 
not able to be passed.
A final point to note in respect of the ability to amend the California Stem Cell 
Research and Cures Bond Act is the requirement that any amendment which is approved 
by 70% o f both Houses of the Legislature must be approved by the State Governor. This 
is similar to the role which the President has concerning Federal legislation. The current 
Californian Governor, Arnold Schwarzenegger, is supportive o f stem cell research and so 
would be likely to approve any amendments which continued the supportive work being 
undertaken under the Act. However, there is always the possibility that a new Californian 
Governor would not be so supportive of stem cell research and may take steps to hinder 
or prevent such research from occurring in California by refusing to sign any 
amendments to the Act. This would be the same action as President Bush has taken 
recently by vetoing a new Stem Cell Research Enhancement Act o f  2007.723 President 
Bush had never before vetoed legislation but has done so now in respect o f legislation 
which would have allowed the Federal funding of human embryonic stem cell research.
So whilst it is important to have the methods to amend legislation it remains to be 
seen how easily or successfully amendments are introduced and passed by the Californian 
Legislature and Governor.
723 Details o f  the progress o f  the Stem Cell Research Enhancement A c t 2007  can be found at: 
http://vyww.govtrack.us/congress/bill.xpd7bill—si 10-5 (accessed 12th July 2007)
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Research funding application process
If approved by SCRO Committee funding application is sent to the CIRM 
Research Funding Working Group -  reviews applications and makes 
recommendations to the ICOC for the award o f  research, therapy and trial
erants
Funding application reviewed by institutional SCRO Committee for scientific
and ethical review
Recommendations sent to the ICOC -  makes final decisions on the award o f  
research, therapy and trial grants. If receive CJRM funding, the SCRO 
Committee reviews its approval o f the research at least once per 
confirms comnlianee with rules and regulationsh i in .....
review
Conclusion
It is the CIRM, as controlled by the ICOC and receiving recommendations from 
its three Working Groups, which is charged with the job o f funding, facilitating and 
overseeing human stem cell research in California. The issue o f conflicts o f interest is one 
which the CIRM is keen to avoid, as evidenced by its many ‘Conflict o f Interest’ 
policies.724 It will be interesting to see how successful the ‘separation o f powers’ will be 
within this State body. With ICOC members from many of the Universities which will be 
requesting funding, there is a high risk of a conflict of interest, along with the fact that the 
CIRM is not only regulating but also funding such research, which implies that there is a 
possibility that the CIRM will be seen as a bank, to be approached for grants and loans to 
do as one wishes with. Without greater regulatory controls there is a risk that the CIRM 
will go in the opposite direction of the Federal Government and permit grants for a wide 
range of research purposes, some of which may not be entirely ethically acceptable.
724 CIRM policies http://wvyw.cirm.ca.gov/policies/ (accessed 7/06/07)
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Beyond the restrictions specifically included in Proposition 71, including human 
reproductive cloning and not keeping an embryo in culture beyond twelve days or the 
appearance of the primitive streak, there are very few restrictions upon the type of 
research which can be performed. This contrasts greatly to the regulatory situation in the 
United Kingdom which specifically lays out the permitted areas o f research, thereby 
avoiding unnecessary or undesirable research. The United Kingdom’s governing body, 
the HFEA, regulates all human embryonic stem cell research regardless o f who is funding 
the research, it has a strict set o f guidelines as to what type o f research is permissible, and 
what is prohibited, along with criminal sanctions for those who attempt to break the rules. 
Additionally the UK Stem Cell Bank reinforces the permitted research purposes within its 
own Code of Practice. California regulates human embryonic stem cell research on the 
basis of who is funding the research; it is not a question o f licensing the research. There 
also appears to be no criminal sanctions for those who conduct research other than that 
for which the CIRM funds were awarded. The exception is human reproductive cloning 
which is specifically outlawed irrelevant of the sources of funding and also carries 
pecuniary penalties within the California Health and Safety Code.
The CIRM appears to be prepared for its role of funding stem cell research, 
however, the regulation contained within Proposition 71 and the CIRM policy documents 
do not appear to be sufficient to regulate this highly sensitive area of research. Whilst the 
principal role o f the CIRM is to fund such research, it cannot shirk its responsibility of 
also overseeing and regulating the very research which it is funding. It is to be hoped that 
the CIRM will rapidly develop and refine its policies to ensure that the research which it 
is funding is safely overseen and regulated.
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Thesis Conclusion
The science o f human embryonic stem cell research is fast moving, with rapid 
developments made on an almost daily basis. In order to regulate this field o f research, 
and hopefully clinical applications, the legislation needs to be flexible so as to keep up to 
date with the progress which is being made. The legislation needs to be flexible to allow 
Parliament to adapt and regulate as it sees fit but also so as to allow scientific freedom 
and progress.
The ability to keep up to speed with the scientific progress in human embryonic 
stem cell research is necessary to keep the United Kingdom at the forefront o f stem cell 
science. It is also necessary so as to retain public confidence in this controversial field o f 
work. The regulatory framework in the United Kingdom works both ways, legislation 
cannot develop without the input o f the science which it seeks to regulate, and equally 
this contentious area o f science cannot progress successfully without the support o f the 
regulatory regime.
Ethically, the Gradualist status afforded to the human embryo by the United 
Kingdom’s legislature is accepted by the majority o f the public and commentators alike. 
The law enshrines a form of Step Gradualism — in vitro embryos are protected by the law, 
research is only permitted up until the fourteenth day of development or the appearance 
o f the primitive streak, whichever occurs first. The type o f research is also limited, human 
embryos cannot be used unnecessarily or frivolously. After fourteen days development 
post-creation the human embryo takes a step up the ‘respect ladder’ as it were. After 
fourteen days the human embryo can no longer be experimented upon as the moral status 
o f the embryo increases at this point.
When this is combined with the approach taken in the Abortion Act 1967 it can be 
seen that the human embryo/foetus takes another step up the ‘respect ladder’ at 24 weeks 
gestation when it becomes morally and legally unacceptable to abort due to ‘social’ 
reasons. The human embryo/foetus does not attain full legal status until birth, even after 
24 weeks gestation abortion is permitted in limited circumstances. Further steps up the 
‘respect ladder’ are taken after birth, with the development o f self-consciousness, 
rationality, speech skills and so on. The point at which a human foetus/child attains full 
moral status and reaches the top of the ‘respect ladder’ will depend upon ones own moral
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compass. Most lay Gradualists would be likely to afford full respect to the human 
embryo/foetus/child upon birth, as does the law. Academic commentators tend to debate 
the merits o f rationality, self-awareness and so on as necessary for full moral status.
As was seen in the discussion upon the morality o f human embryo research, it is 
unlikely that a time will ever be reached when everyone is in agreement as to when the 
human embryo reaches a point at which it is to be afforded full moral status. However, 
the Human Fertilisation and Embryology Act 1990 as well as its successor the Human 
Fertilisation and Embryology Act 2008 have made it clear that the law approaches the 
human embryo in a Gradualist manner. This approach was first advocated by the 
Warnock Committee in 1984 and once enacted has generally been well received.
Whilst the ethical issue of allowing human embryo research and human 
embryonic stem cell research appears to be resolved, in the sense that the law has taken a 
permissive but controlled stance, the regulation o f such research is not without its faults. 
The use o f legislation that governs human embryo research to also regulate human 
embryonic stem cell research was bound to lead to some problems, although it was a 
novel and innovative approach which has allowed human embryonic stem cell research to 
progress, with the confidence o f the public.
The involvement o f research ethics committees can be both criticised and praised. 
The need for ethical review o f human embryonic stem cell research licence applications 
is necessary and instils confidence in the work being performed. At first sight, it would 
appear that the use o f research ethics committees to undertake this ethical review is ideal. 
Upon closer inspection of the process involved it is shown that the situation is 
burdensome and time consuming.
The process is far from satisfactory due to the two stage process that research 
licence applications must go through, first applying to a research ethics committee for 
ethical approval and then to the HFEA for the legal approval. If  the ethical and legal 
approval were clearly separate there may be no issue, but as the situation currently stands, 
research ethics committees undertake ethical and scientific review o f an application prior 
to the application going to the HFEA for scientific, ethical and legal review before a 
licence is granted. There is also the problem that few research ethics committees will 
have the necessary knowledge or expertise to deal with applications for human 
embryonic stem cell research in a timely or suitable manner. This is time consuming for 
all involved.
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I would not advocate losing the ethical review although I have suggested the 
creation of a single central research ethics committee, to deal solely with human 
embryonic stem cell research applications, or possibly all research applications concerned 
with stem cell research more generally. This single central research ethics committee 
could be attached to either the HFEA or the UK Stem Cell Bank and therefore deal with 
applications prior to submission to either body. If this system was put in place, the HFEA 
should be content that appropriate ethical review had occurred prior to applying to it for 
the legal approval and would then only be concerned with the scientific and legal issues. 
As the central research ethics committee would be working closely with the HFEA and 
the UK Stem Cell Bank, action could be taken so as to ensure that one set o f forms would 
be appropriate for both stages o f the process. This would help to speed up the time taken 
for applications.
Another area where a central research ethics committee would help is in the 
reporting o f research after a licence has been granted. Research ethics committees and the 
HFEA require regular progress reports once work is underway. This double reporting 
requirement is again burdensome for the researcher who is often duplicating information 
on two different sets o f forms. There is also the problem that following submission o f the 
progress report either body could revoke its approval. Whilst the HFEA has the 
experience and knowledge as to when it is appropriate to revoke, suspend or vary its 
approval, local research ethics committees have far less experience with the field o f 
human embryonic stem cell research and so may take action when it is unnecessary. The 
HFEA has made it clear that if  research ethics committee approval is withdrawn all 
research will have to stop until a resolution is found. This seems an unnecessary strain 
upon the researcher when there may actually be no ethical problem as far as the HFEA is 
concerned. A central research ethics committee would be able to work closely with the 
HFEA so as to discuss progress reports jointly and ensure that the situation does not arise 
whereby one body approves and the other disapproves of a research project. Additionally, 
one set of progress report forms could be devised, again saving time and work for those 
involved.
Overall, the HFEA has worked well to implement the will o f Parliament. It has 
approved research licence applications in many different research areas, not just human 
embryonic stem cell research. All research licence applications must comply with the 
permitted research purposes as contained in the Human Fertilisation and Embryology Act
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1990 (and from October 2009 those contained in the Human Fertilisation and 
Embryology Act 2008) as well as demonstrating that the use o f embryos is ‘necessary’; 
the HFEA has been a good final arbiter in deciding if  an application fulfils the legal 
requirements. The double approval requirement as mentioned above is an area o f concern 
and although this has been highlighted it does not appear that it will be resolved soon. 
Within the Human Fertilisation and Embryology Act 2008 there is no section which 
provides for the establishment o f a central research ethics committee for human embryo 
research and human embryonic stem cell research, it is a shame that the Government has 
not taken the opportunity to do this.
The formation of the UK Stem Cell Bank solves a regulatory problem within the 
UK. The EU required a ‘competent authority’ to oversee human tissue and cells and the 
UK decided that the UK Stem Cell Bank was appropriate for this task in respect o f stem 
cells. Not many other European countries have a Stem Cell Bank; others have used 
existing bodies to be the ‘competent authority’. 725 The Human Fertilisation and 
Embryology Act 1990 and the Human Fertilisation and Embryology Act 2008 (from 
October 2009) only govern human embryonic stem cell research where human embryos 
are needed to derive the stem cells. Post-extraction the stem cells fall outside o f statutory 
regulation. The formation of the UK Stem Cell Bank, along with the legal requirement 
made by the HFEA to bank human embryonic stem cell lines with the UK Stem Cell 
Bank, ensures that research upon human embryonic stem cell lines is overseen and 
regulated. The implementation o f the EU Tissue and Cells Directive also requires there to 
be a ‘competent authority’ which is responsible for overseeing clinical trials where 
human tissue and cells are used. Although human embryonic stem cell research is still at 
the research stage, clinical trials are not far off. The use of the UK Stem Cell Bank to 
oversee research and future clinical trials helps to ensure continuity in the regulation o f 
work involving human embryonic stem cells.
725 Whilst Spain has created a National Stem Cell Bank (established by Ley 45/2003, de 21 de noviembre, 
por la que se modifica la Ley 35/1988, de 22 de noviembre, sobre Tecnicas de Reproduction Asistida) it 
has designated its Organization Nacional de Transplantes (National Transplant Organisation) as its 
competent authority. Other countries have also utilised pre-existing bodies such as the Federal Agency for 
Medicines and Health Products in Belgium and the Irish Medicines Board in Ireland. Summary Table o f  
Responses from  Competent Authorities: Questionnaire on the transposition and implementation o f  the 
European Tissue and Cells regulatory fram ew ork  European Commission, Health and Consumer Protection 
Directorate-General, 2008 (Oct)
http://ec.europa.eu/health/ph threats/human substance/summary table questionnaire-responses from ca- 
october2008.pdf (last accessed 23/11/08)
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The need for the UK Stem Cell Bank to continue the permitted research purposes 
found in the HFE Act in its Code of Practice can be questioned, although understandable. 
Once extracted, human embryonic stem cells no longer form part o f the human embryo 
and are not capable o f developing into an embryo (at least not in their undifferentiated 
state and then only if differentiated into gametes and fertilisation occurs). Why then the 
need to only permit research on human embryonic stem cells when it is for one o f the 
permitted research purposes as found in the legislation? One possible explanation that 
springs to mind is that this is the easiest and the least controversial approach. Some 
people are unable to differentiate between human embryos and embryonic stem cells; 
therefore, there is a need for the UK Stem Cell Bank to reinforce the permitted research 
purposes within its own Code of Practice. O f course, further debate and disagreement 
about the UK Stem Cell Bank reinforcing the permitted research purposes may soon 
occur. Another explanation is that by reinforcing the permitted research purposes found 
within the HFE Act it prevents researchers and scientists from circumventing the 
statutory provisions. For example, a researcher may decide that human embryonic stem 
cells are a good source upon which to test cosmetics. If this was permitted then human 
embryonic stem cell research could become very difficult within the UK, the public 
would quickly lose confidence in the fact that scientists only use human embryos for 
research where it is necessary and desirable. It is for this reason that the use o f  human 
embryonic stem cell lines needs to be controlled and overseen.
Finally, in respect of the UK Stem Cell Bank and the permitted research purposes 
criticism was made of the Bank’s attempt to enforce the permitted research purposes 
upon researchers working overseas with UK stem cell lines. Whilst admirable to attempt 
continuity in this manner, it is foreseen that someone soon will import UK stem cell lines 
and go beyond the permitted research purposes. A long protracted legal battle could then 
occur.
The UK Stem Cell Bank is still in its infancy; there is undoubtedly a need for such 
a bank and the UK Stem Cell Bank is taking steps in the right direction in overseeing 
research upon human embryonic stem cells and hopefully soon clinical trials with these 
cells.
It was recognised that, due to the pace o f scientific developments, the Human 
Fertilisation and Embryology Act 1990 was in need of reform. The reform process has 
been long, drawn out, and only recently reached its conclusion.
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The reform process has been ongoing since 2004 when the House o f Commons 
Science and Technology Committee undertook a review o f the Act. Following several 
reports, a consultation, White Paper and Draft Bill the Government finally debated the 
Human Fertilisation and Embryology Bill. Throughout the parliamentary process three 
amended versions o f the Bill were published along with a document laying out 
amendments from the House o f Commons which were accepted by the House o f Lords 
before the Bill received Royal Assent on the 13th November 2008. This thesis is up to 
date as o f the 13th November 2008.
The debate surrounding the legal definitions o f ‘embryo’, ‘gamete’ and ‘human 
admixed embryo’ have all been interesting and resulted in both broad and precise 
technical definitions. The need for flexibility has been turned down by Parliament in 
some respects. The precise scientific definitions for human admixed embryos, as well as 
the lack o f regulation making powers in respect o f both human admixed embryos and the 
permitted research purposes, has resulted in inflexible and rigid legislation. This could 
lead to scientific developments being made in the near future with the result that the 
Government is unable to amend the legislation appropriately. A need for new primary 
legislation could soon arise. In respect of the legal definition o f an embryo the 
Government has in contrast taken a broad sweeping approach which should encompass 
all forms o f creating embryos, including any methods not yet discovered or applied to 
human embryos. As the HFE Act 2008 does not deal solely with human embryo research 
but also includes issues such as who are legal mothers/fathers and surrogacy matters, 
there was much that needed to be discussed, hence the lengthy and protracted debates that 
occurred during its passage through Parliament. The Bill spent one year passing through 
Parliament before Royal Assent was given.
Finally, comment needs to be made upon the regulation o f human embryonic stem 
cell research in the State of California, USA. Comparisons with California show that 
regulation is made through the funding o f research rather than restricting the type o f 
research which can be undertaken or imposing criminal sanctions. The State o f California 
has taken this approach as this is how the Federal Government has also chosen to regulate 
human embryo research more generally.
It is recognised that regulation through funding has occurred in California due to 
the Federal stance on this issue, although it is equally recognised that the Federal position 
has now changed but it will take some time for the effects o f that change to be seen. It is
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of concern that California has not sought to regulate in finer detail human embryonic 
stem cell research (besides the time limits o f keeping embryos in vitro). For example, the 
Californian legislation is apparently more concerned with making clear what is prohibited 
(very little) and how money can be made from the research. Unlike the UK legislation, 
there is no restriction upon the type of research which can be undertaken, possibly 
leading to funding of relatively frivolous research involving human embryos and 
embryonic stem cells. Whilst I have queried the need to limit the research done upon 
extracted embryonic stem cells, the complete lack o f guidance in the Californian 
legislation is o f concern.
Equally, the use of multiple Institutional Review Boards and Stem Cell Research 
Oversight Committees along with the CIRM leads to comparisons with research ethics 
committees and the HFEA. The ethical review and subsequent oversight o f research 
funded by the CIRM is complicated and inadequate. The CIRM should take responsibility 
for the research which it is funding and take action for greater oversight and control. A 
central SCRO Committee could be established to oversee the necessary scrutiny o f all 
funding applications before going to the CIRM for discussion and possibly subsequent 
approval. This has parallels with the suggestion of a central research ethics committee to 
provide ethical review o f stem cell research applications prior to passing to the HFEA for 
scientific and legal approval.
The State o f California has taken steps to ensure that it is at the forefront o f stem 
cell research by pumping $3 billion into such research over 10 years. While I cannot 
criticise California for taking positive action, I am concerned that it is pushing research 
forward without seriously overseeing the work which is occurring. There is also the issue 
that the Californian tax payers are funding this venture and yet there is no guarantee of 
the money being returned or that Californians will benefit either financially or physically 
from any scientific developments which occur. The forward thinking o f California is 
admirable; however, greater thought into regulating this field o f research is needed.
This thesis has been an in depth look at the interface between embryo research 
and human embryonic stem cell research primarily through examining the regulation o f 
human embryonic stem cell research in the United Kingdom, from the early steps towards 
regulation, the current legislation and the licensing process, through to the reform which 
has occurred and the new legislation which will soon come into force. Comparison has
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been made with California, the system of regulating through funding throws into 
highlight the careful system of regulating through licensing that occurs in the United 
Kingdom. Whilst human embryonic stem cell research is still at an early stage, it is 
important to know why and how we regulate this area o f science, as well as looking at 
faults in the system and looking for improvements in the future. When all o f the 
provisions o f the Human Fertilisation and Embryology Act 2008 come into force the Act 
will continue to allow human embryonic stem cell research as well as maintaining the 
system o f licensing which we have currently; it is the legal definitions and permitted 
research purposes that will change. Human embryonic stem cell research is here to stay.
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Annex A
DECISION TREE FOR APPLICATION 
FOR A RESEARCH LICENCE
STAGE 1
Identify the activity or activities to be activities to be authorised by Licence
If yes, reject
application <—
giving
reasons
STAGE 2
Are any of the activities prohibited under the Act?
Prohibition includes:
• Keeping or using an embryo after the appearance of the primitive streak,
• Placing an embryo in any animal,
• Keeping or using an embryo in any circumstances in which regulations prohibit its 
keeping or use, or
• Replacing a nucleus of a cell of any embryo with a nucleus taken from a cell of
any person, embryo or subsequent development of an embryo.
• Altering the genetic structure of any cell while it forms part of an embryo
If no, reject 
application 
giving 
reasons
__________________________________I  No______________________________
STAGE 3
Consider whether each activity appears to be necessary or desirable for one of the 
specified purposed, namely:
Schedule 2 to the HF&E Act 1990
3(2)(a) Promoting advances in the treatment of infertility,
(b) Increasing knowledge about the causes of congenital disease,
(c) Increasing knowledge about the causes of miscarriages,
(d) Developing more effective techniques of contraception,
(e) Developing methods for detecting the presence of gene or chromosome 
abnormalities in embryos before implantation,
HF&E (Research Purposes) Regulations 2001
2(2)(a) Increasing knowledge about the development of embryos,
(b) Increasing knowledge about serious disease, or
(c) Enabling any such knowledge to be applied in developing treatments for 
serious disease. ___________
If not, reject 
application 
giving 
reasons
__________________________________4, Yes___________________________
STAGE 4
Is the Committee satisfied that the proposed creation and / or use of embryos is 
necessary for the purpose of the research?
If not, reject 
application 
giving 
reasons
__________________________________-I Yes_______________________
STAGE 5
Is the Committee satisfied with the Patient Information and Consent Forms?
If not, reject 
application 
giving 
reasons
>, Yes ___________________
STAGE 6
Does the Committee consider that it is appropriate to grant a Licence (whether 
conditionally or unconditionally)?
Yes
6
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If yes, give STAGE 7
condition(s) * Should additional conditions be attached to the grant of the Licence and, if so, what
and move conditions?
to Stage 8
If no to any 
question, 
refuse 
application 
giving 
reasons
No
STAGE 8
Are the requirements for the grant of a Licence under Section 16 satisfied? Namely:
• Has the application fee been paid?
• Is the Committee satisfied that the Nominal Licensee is a suitable person to hold 
a Licence?
• Is the Committee satisfied that the character, qualifications and experience of 
proposed Person Responsible are such as are required for the supervision of the 
activities and that he/she will discharge their duty under Section 17 of the Act?
• Is the Licence Committee satisfied that the premises in respect of which the 
Licence is to be granted are suitable for the activities?
IF YES TO ALL 
QUESTIONS IN STAGE 8, 
GRANT LICENCE
CfiS
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